data_2kkg_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2kkg _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.361 0 N-CA-C 112.561 -0.216 . . . . 0.0 112.561 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 73' ' ' TRP . . . . . 0.481 ' CD1' ' N ' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -146.76 -78.9 0.16 Allowed 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 120.97 0.415 . . . . 0.0 110.746 -179.573 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -114.39 13.23 21.13 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.843 -0.694 . . . . 0.0 112.54 179.83 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 23.9 pt20 -97.38 154.48 38.02 Favored Pre-proline 0 C--N 1.332 -0.192 0 CA-C-O 120.722 0.296 . . . . 0.0 110.888 179.983 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 39.4 Cg_endo -67.29 147.3 78.0 Favored 'Trans proline' 0 C--N 1.344 0.303 0 C-N-CA 122.543 2.162 . . . . 0.0 112.27 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 8.4 t-160 -97.26 -30.62 12.87 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.865 179.893 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -113.17 -27.95 3.5 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.893 -0.67 . . . . 0.0 112.565 179.941 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 179.37 -54.52 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.596 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -145.71 -158.64 7.79 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.521 -179.924 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 81' ' ' TRP . . . . . 0.478 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -147.56 -77.11 0.17 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.97 0.414 . . . . 0.0 110.698 -179.556 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -106.85 -20.93 8.47 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.903 -0.665 . . . . 0.0 112.473 179.868 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 17.8 pt20 -60.18 154.45 51.54 Favored Pre-proline 0 C--N 1.331 -0.216 0 CA-C-O 120.735 0.302 . . . . 0.0 110.856 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_endo -68.72 140.53 47.05 Favored 'Trans proline' 0 C--N 1.345 0.378 0 C-N-CA 122.525 2.15 . . . . 0.0 112.251 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 7.5 m170 -94.89 -30.99 13.89 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.846 -179.956 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -125.22 -40.79 0.39 Allowed Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.496 179.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -177.18 96.9 0.11 Allowed Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.468 179.942 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 59.59 -170.71 6.01 Favored Glycine 0 N--CA 1.452 -0.268 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.55 179.947 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 89' ' ' TRP . . . . . 0.478 ' CD1' ' N ' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -147.52 -77.78 0.17 Allowed 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.919 0.39 . . . . 0.0 110.795 -179.638 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -134.69 18.32 4.1 Favored Glycine 0 N--CA 1.449 -0.445 0 C-N-CA 120.894 -0.669 . . . . 0.0 112.504 179.843 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 7.2 pt20 . . . . . 0 C--O 1.249 1.052 0 CA-C-O 118.173 -0.918 . . . . 0.0 110.864 -179.944 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.268 0 N-CA-C 112.56 -0.216 . . . . 0.0 112.56 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 73' ' ' TRP . . . . . 0.467 ' CD1' ' N ' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -147.69 -78.02 0.16 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.927 0.394 . . . . 0.0 110.799 -179.598 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -111.34 -15.26 10.66 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.883 -0.675 . . . . 0.0 112.632 179.917 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 18.9 pt20 -56.74 154.08 19.49 Favored Pre-proline 0 C--N 1.331 -0.201 0 CA-C-O 120.699 0.285 . . . . 0.0 111.028 -179.974 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 41.2 Cg_endo -67.32 161.29 43.76 Favored 'Trans proline' 0 C--N 1.343 0.28 0 C-N-CA 122.597 2.198 . . . . 0.0 112.314 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 12.6 t60 -109.32 -30.5 7.96 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.966 179.865 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -135.16 27.09 3.18 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.468 179.982 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 106.28 92.9 2.29 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.476 179.939 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 58.92 -170.88 4.98 Favored Glycine 0 N--CA 1.452 -0.268 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.535 179.936 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 81' ' ' TRP . . . . . 0.489 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -146.81 -78.88 0.16 Allowed 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.832 0.348 . . . . 0.0 110.76 -179.604 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -119.98 15.89 10.22 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.863 -0.684 . . . . 0.0 112.547 179.733 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 8.2 pt20 -82.11 154.2 69.65 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-O 120.723 0.297 . . . . 0.0 110.903 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 27.6 Cg_endo -62.72 156.47 53.03 Favored 'Trans proline' 0 C--N 1.345 0.365 0 C-N-CA 122.535 2.156 . . . . 0.0 112.273 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 0.7 OUTLIER -109.38 -31.08 7.67 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.815 179.94 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -108.26 -61.71 0.55 Allowed Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.436 -179.984 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -165.77 30.1 0.21 Allowed Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.709 -0.757 . . . . 0.0 112.523 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 136.1 -164.33 25.04 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.581 -179.971 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 89' ' ' TRP . . . . . 0.491 ' CD1' ' N ' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -146.85 -77.92 0.17 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.897 0.379 . . . . 0.0 110.735 -179.634 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -133.04 18.69 4.45 Favored Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.907 -0.663 . . . . 0.0 112.511 179.793 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 15.3 pt20 . . . . . 0 C--O 1.249 1.056 0 CA-C-O 118.203 -0.903 . . . . 0.0 110.89 -179.968 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.329 0 N-CA-C 112.561 -0.216 . . . . 0.0 112.561 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 73' ' ' TRP . . . . . 0.496 ' CD1' ' N ' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -146.31 -78.6 0.17 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.857 0.36 . . . . 0.0 110.76 -179.616 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -116.64 13.72 15.1 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.953 -0.641 . . . . 0.0 112.599 179.73 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 3.9 pt20 -91.02 154.13 45.05 Favored Pre-proline 0 C--N 1.331 -0.238 0 CA-C-O 120.708 0.289 . . . . 0.0 110.942 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 36.0 Cg_endo -65.33 151.01 86.56 Favored 'Trans proline' 0 C--N 1.344 0.324 0 C-N-CA 122.495 2.13 . . . . 0.0 112.27 179.971 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 17.2 t-160 -101.07 -30.72 11.44 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.796 179.916 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -109.17 -27.77 4.67 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.528 179.95 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 168.11 -31.38 0.18 Allowed Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.598 179.953 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -162.3 -162.17 13.05 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.555 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 81' ' ' TRP . . . . . 0.49 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -146.28 -78.54 0.17 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.92 0.391 . . . . 0.0 110.748 -179.657 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -116.99 13.25 14.3 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.903 -0.665 . . . . 0.0 112.555 179.806 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 13.9 pt20 -86.09 154.29 57.58 Favored Pre-proline 0 C--N 1.332 -0.193 0 CA-C-O 120.628 0.251 . . . . 0.0 110.917 179.966 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_endo -66.12 157.41 59.85 Favored 'Trans proline' 0 C--N 1.344 0.296 0 C-N-CA 122.538 2.159 . . . . 0.0 112.32 179.914 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 3.5 t-80 -98.95 -30.79 12.16 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.854 179.861 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -113.03 -27.73 3.61 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.481 -179.995 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 169.91 -32.39 0.16 Allowed Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.711 -0.756 . . . . 0.0 112.551 179.979 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -159.08 -161.48 11.18 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.509 -179.966 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 89' ' ' TRP . . . . . 0.485 ' CD1' ' N ' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -147.14 -77.98 0.17 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.826 0.346 . . . . 0.0 110.826 -179.669 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -134.71 17.76 4.15 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.921 -0.657 . . . . 0.0 112.523 179.863 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 7.6 pt20 . . . . . 0 C--O 1.248 1.023 0 CA-C-O 118.242 -0.885 . . . . 0.0 110.944 -180.0 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.349 0 N-CA-C 112.56 -0.216 . . . . 0.0 112.56 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 73' ' ' TRP . . . . . 0.485 ' CD1' ' N ' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -147.82 -77.25 0.17 Allowed 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.936 0.398 . . . . 0.0 110.787 -179.603 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -105.39 -21.67 8.67 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.888 -0.672 . . . . 0.0 112.446 179.832 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 16.3 pt20 -63.66 154.48 80.04 Favored Pre-proline 0 C--N 1.331 -0.2 0 CA-C-O 120.677 0.275 . . . . 0.0 110.879 -180.0 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 41.6 Cg_endo -67.7 142.06 56.9 Favored 'Trans proline' 0 C--N 1.344 0.311 0 C-N-CA 122.518 2.145 . . . . 0.0 112.239 -179.998 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 3.5 t-80 -96.05 -31.0 13.25 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.918 179.994 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -124.78 -41.77 0.37 Allowed Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.463 -179.986 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -177.02 94.58 0.1 OUTLIER Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.531 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 62.84 -170.66 13.08 Favored Glycine 0 N--CA 1.45 -0.416 0 C-N-CA 120.667 -0.778 . . . . 0.0 112.607 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 81' ' ' TRP . . . . . 0.477 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -148.24 -75.59 0.18 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.942 0.401 . . . . 0.0 110.742 -179.634 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -107.45 -22.09 7.61 Favored Glycine 0 N--CA 1.449 -0.436 0 C-N-CA 120.869 -0.682 . . . . 0.0 112.463 179.831 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 14.6 pt20 -60.17 154.11 53.32 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-O 120.646 0.26 . . . . 0.0 110.876 179.961 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 34.8 Cg_endo -65.35 153.46 78.15 Favored 'Trans proline' 0 C--N 1.344 0.308 0 C-N-CA 122.515 2.143 . . . . 0.0 112.255 179.963 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 57.5 m80 -100.63 -31.74 11.09 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.672 179.831 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -116.69 -31.65 1.74 Allowed Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.834 -0.698 . . . . 0.0 112.447 179.971 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -165.87 -69.25 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.59 -180.0 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -135.66 -147.84 5.51 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.616 179.98 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 89' ' ' TRP . . . . . 0.423 ' CH2' ' HB3' ' A' ' 91' ' ' GLN . 0.4 OUTLIER -161.11 23.57 0.13 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.765 0.317 . . . . 0.0 111.119 -179.342 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 103.03 -14.34 55.77 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.668 -0.777 . . . . 0.0 112.402 -179.644 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 91' ' ' GLN . . . . . 0.423 ' HB3' ' CH2' ' A' ' 89' ' ' TRP . 4.3 pt20 . . . . . 0 C--O 1.249 1.074 0 CA-C-O 118.229 -0.891 . . . . 0.0 110.919 -179.984 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.453 -0.229 0 N-CA-C 112.57 -0.212 . . . . 0.0 112.57 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 73' ' ' TRP . . . . . 0.557 ' CD1' ' N ' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -136.21 -78.33 0.42 Allowed 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.954 0.407 . . . . 0.0 110.629 -179.654 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -113.33 -9.09 18.34 Favored Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 120.907 -0.663 . . . . 0.0 112.625 179.758 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 14.3 pt20 -58.37 154.22 33.79 Favored Pre-proline 0 C--N 1.331 -0.237 0 CA-C-O 120.751 0.31 . . . . 0.0 110.957 179.933 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 55.0 Cg_endo -70.58 137.9 34.06 Favored 'Trans proline' 0 C--N 1.344 0.32 0 C-N-CA 122.431 2.088 . . . . 0.0 112.199 179.796 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 18.4 m-70 -107.66 105.38 15.21 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.985 0.421 . . . . 0.0 110.709 179.657 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 104.74 -31.5 8.53 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.868 -0.682 . . . . 0.0 112.433 -179.886 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 152.04 93.28 0.1 OUTLIER Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.576 -179.986 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 52.8 -161.79 2.54 Favored Glycine 0 C--N 1.33 0.229 0 C-N-CA 120.883 -0.675 . . . . 0.0 112.781 179.983 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 81' ' ' TRP . . . . . 0.549 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -137.09 -78.27 0.4 Allowed 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.935 0.398 . . . . 0.0 110.694 -179.665 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -107.33 -20.28 8.76 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.89 -0.672 . . . . 0.0 112.483 179.853 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 15.6 pt20 -59.9 154.42 48.66 Favored Pre-proline 0 C--N 1.331 -0.223 0 CA-C-O 120.631 0.253 . . . . 0.0 110.923 -179.946 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 44.0 Cg_endo -68.04 141.39 52.85 Favored 'Trans proline' 0 C--N 1.344 0.306 0 C-N-CA 122.558 2.172 . . . . 0.0 112.277 179.912 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 4.7 t-160 -95.5 -31.07 13.52 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.886 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -120.55 -41.37 0.53 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.518 179.966 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 179.22 96.13 0.1 Allowed Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.68 -0.772 . . . . 0.0 112.434 179.958 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 59.7 -170.07 6.55 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.542 -179.998 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 89' ' ' TRP . . . . . 0.482 ' CD1' ' N ' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -148.31 -76.18 0.17 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.998 0.428 . . . . 0.0 110.828 -179.634 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -112.89 -22.22 5.74 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.86 -0.686 . . . . 0.0 112.435 179.879 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 2.8 pp0? . . . . . 0 C--O 1.249 1.03 0 CA-C-O 118.257 -0.877 . . . . 0.0 110.904 -179.914 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.27 0 N-CA-C 112.517 -0.233 . . . . 0.0 112.517 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 73' ' ' TRP . . . . . 0.454 ' CD1' ' N ' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -148.04 -79.36 0.15 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.885 0.374 . . . . 0.0 110.845 -179.667 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -115.99 -2.82 20.2 Favored Glycine 0 CA--C 1.519 0.311 0 C-N-CA 120.815 -0.707 . . . . 0.0 112.663 179.911 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 9.7 pt20 -58.04 154.41 29.58 Favored Pre-proline 0 C--N 1.33 -0.263 0 CA-C-O 120.728 0.299 . . . . 0.0 110.942 179.985 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -66.32 153.47 77.91 Favored 'Trans proline' 0 C--N 1.344 0.318 0 C-N-CA 122.553 2.169 . . . . 0.0 112.287 179.991 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 22.9 t-160 -100.23 -30.33 11.97 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.785 179.896 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -151.04 27.46 1.01 Allowed Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.478 -179.99 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 165.49 -109.59 0.37 Allowed Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.541 -179.932 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -123.7 -158.94 10.3 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.829 -0.701 . . . . 0.0 112.518 -179.945 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 81' ' ' TRP . . . . . 0.481 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -147.42 -78.6 0.16 Allowed 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.971 0.415 . . . . 0.0 110.873 -179.637 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -111.9 -15.22 10.23 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.959 -0.639 . . . . 0.0 112.577 179.898 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 16.2 pt20 -56.36 154.33 16.68 Favored Pre-proline 0 C--N 1.331 -0.211 0 CA-C-O 120.706 0.288 . . . . 0.0 111.006 179.969 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 40.9 Cg_endo -67.35 169.22 15.91 Favored 'Trans proline' 0 C--N 1.344 0.299 0 C-N-CA 122.604 2.202 . . . . 0.0 112.287 179.936 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 3.6 m-70 -110.15 -31.34 7.38 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.898 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -136.75 27.93 2.89 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.556 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 105.22 98.4 2.54 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.46 179.928 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 59.09 -170.81 5.24 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.511 179.925 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 89' ' ' TRP . . . . . 0.475 ' CD1' ' N ' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -147.92 -77.51 0.16 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.936 0.398 . . . . 0.0 110.88 -179.605 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -113.56 -22.06 5.57 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.87 -0.681 . . . . 0.0 112.486 179.823 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.249 1.034 0 CA-C-O 118.173 -0.918 . . . . 0.0 110.939 -179.993 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.267 0 N-CA-C 112.56 -0.216 . . . . 0.0 112.56 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 73' ' ' TRP . . . . . 0.528 ' CD1' ' N ' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -141.31 -79.08 0.26 Allowed 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.928 0.394 . . . . 0.0 110.627 -179.601 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -116.99 13.93 14.09 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.83 -0.7 . . . . 0.0 112.47 179.842 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 21.2 pt20 -89.55 154.52 48.46 Favored Pre-proline 0 C--N 1.331 -0.197 0 CA-C-O 120.661 0.267 . . . . 0.0 110.881 -179.966 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 39.8 Cg_endo -67.06 148.38 81.33 Favored 'Trans proline' 0 C--N 1.344 0.319 0 C-N-CA 122.485 2.123 . . . . 0.0 112.26 179.921 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 77' ' ' HIS . . . . . 0.4 ' CD2' ' O ' ' A' ' 77' ' ' HIS . 9.5 t-160 -97.54 6.22 48.42 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.379 179.956 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 150.81 44.57 0.02 OUTLIER Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.524 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 168.37 -82.92 0.1 OUTLIER Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.52 -179.973 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -169.64 -160.8 18.77 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.516 -179.941 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 81' ' ' TRP . . . . . 0.472 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -147.53 -77.96 0.16 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.901 0.381 . . . . 0.0 110.747 -179.613 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -105.86 -20.9 8.97 Favored Glycine 0 N--CA 1.45 -0.398 0 C-N-CA 120.915 -0.66 . . . . 0.0 112.46 179.807 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 20.8 pt20 -63.98 154.2 82.45 Favored Pre-proline 0 C--N 1.33 -0.25 0 CA-C-O 120.71 0.29 . . . . 0.0 110.887 179.935 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo -66.27 177.58 3.08 Favored 'Trans proline' 0 C--N 1.344 0.338 0 C-N-CA 122.62 2.213 . . . . 0.0 112.293 179.9 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 27.4 p-80 -99.96 -30.99 11.69 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.887 179.93 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -162.66 28.78 0.26 Allowed Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.461 179.949 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 170.12 -92.3 0.1 OUTLIER Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.599 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -138.74 -156.5 7.05 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.589 179.953 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 89' ' ' TRP . . . . . 0.478 ' CD1' ' N ' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -147.8 -78.01 0.16 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.908 0.385 . . . . 0.0 110.707 -179.576 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -134.98 16.92 4.17 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.904 -0.665 . . . . 0.0 112.59 179.849 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 7.0 pt20 . . . . . 0 C--O 1.249 1.069 0 CA-C-O 118.238 -0.887 . . . . 0.0 110.93 -179.991 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.326 0 N-CA-C 112.599 -0.201 . . . . 0.0 112.599 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 73' ' ' TRP . . . . . 0.499 ' CD1' ' N ' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -144.78 -77.79 0.2 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.921 0.391 . . . . 0.0 110.8 -179.607 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -103.39 -23.06 8.64 Favored Glycine 0 N--CA 1.449 -0.437 0 C-N-CA 120.954 -0.641 . . . . 0.0 112.517 179.884 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 3.1 pt20 -62.35 151.29 82.76 Favored Pre-proline 0 C--N 1.33 -0.249 0 CA-C-O 120.717 0.294 . . . . 0.0 110.907 -179.986 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 23.9 Cg_endo -62.36 155.48 57.11 Favored 'Trans proline' 0 C--N 1.344 0.337 0 C-N-CA 122.587 2.191 . . . . 0.0 112.386 179.939 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 8.3 p80 -109.55 -29.92 8.16 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.84 179.817 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -112.35 -57.06 0.44 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.8 -0.715 . . . . 0.0 112.488 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -169.86 32.16 0.16 Allowed Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.649 179.965 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 138.75 -169.3 24.44 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.646 -0.788 . . . . 0.0 112.611 -179.973 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 81' ' ' TRP . . . . . 0.491 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -145.65 -77.98 0.19 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.919 0.39 . . . . 0.0 110.781 -179.681 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -102.69 -20.3 11.99 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.87 -0.681 . . . . 0.0 112.558 179.927 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 12.5 pt20 -58.71 153.78 39.68 Favored Pre-proline 0 C--N 1.332 -0.195 0 CA-C-O 120.784 0.326 . . . . 0.0 110.952 -179.963 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 30.5 Cg_endo -64.2 154.13 72.55 Favored 'Trans proline' 0 C--N 1.345 0.361 0 C-N-CA 122.542 2.162 . . . . 0.0 112.267 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 1.6 t-80 -108.96 -29.82 8.4 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.82 179.872 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -108.5 -61.46 0.54 Allowed Glycine 0 N--CA 1.45 -0.406 0 C-N-CA 120.821 -0.704 . . . . 0.0 112.469 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -166.75 30.6 0.19 Allowed Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.569 179.946 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 135.31 -165.78 24.62 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.586 179.919 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 89' ' ' TRP . . . . . 0.489 ' CD1' ' N ' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -146.1 -79.36 0.17 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.902 0.382 . . . . 0.0 110.727 -179.626 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -139.13 22.67 2.92 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.99 -0.624 . . . . 0.0 112.175 179.779 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 20.2 mt-30 . . . . . 0 C--O 1.249 1.03 0 CA-C-O 118.223 -0.894 . . . . 0.0 110.933 -179.923 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.284 0 N-CA-C 112.584 -0.206 . . . . 0.0 112.584 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 73' ' ' TRP . . . . . 0.494 ' CD1' ' N ' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -146.25 -79.72 0.16 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.867 0.365 . . . . 0.0 110.791 -179.624 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -120.0 16.96 10.05 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.936 -0.649 . . . . 0.0 112.467 179.714 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 6.6 pt20 -77.29 154.79 82.12 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 120.734 0.302 . . . . 0.0 110.801 -179.965 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 32.7 Cg_endo -64.57 154.56 71.42 Favored 'Trans proline' 0 C--N 1.344 0.32 0 C-N-CA 122.465 2.11 . . . . 0.0 112.264 179.879 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 23.1 t-160 -102.85 -30.38 10.88 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.829 179.871 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -148.98 27.74 1.27 Allowed Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.431 179.991 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 162.48 -108.64 0.35 Allowed Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.487 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -123.26 -158.44 10.18 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.561 179.975 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 81' ' ' TRP . . . . . 0.477 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -147.7 -78.36 0.16 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.847 0.356 . . . . 0.0 110.748 -179.574 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -111.2 -18.36 8.24 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.928 -0.653 . . . . 0.0 112.523 179.908 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 4.6 pt20 -58.03 154.0 31.59 Favored Pre-proline 0 C--N 1.331 -0.232 0 CA-C-O 120.732 0.301 . . . . 0.0 110.931 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 28.1 Cg_endo -63.47 161.44 31.35 Favored 'Trans proline' 0 C--N 1.344 0.329 0 C-N-CA 122.581 2.188 . . . . 0.0 112.335 179.942 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 85' ' ' HIS . . . . . 0.401 ' CD2' ' N ' ' A' ' 85' ' ' HIS . 3.5 m-70 -118.32 106.15 12.47 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.674 179.694 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 94.43 -26.51 17.37 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.452 -179.801 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 150.06 92.43 0.1 OUTLIER Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.51 -179.98 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 59.1 -156.78 24.36 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.591 -179.968 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 89' ' ' TRP . . . . . 0.501 ' CD1' ' N ' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -142.58 -78.5 0.24 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.959 0.409 . . . . 0.0 110.666 -179.656 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -134.84 16.53 4.24 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.907 -0.663 . . . . 0.0 112.54 179.902 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 3.6 pt20 . . . . . 0 C--O 1.249 1.063 0 CA-C-O 118.2 -0.905 . . . . 0.0 110.927 179.996 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.306 0 N-CA-C 112.496 -0.241 . . . . 0.0 112.496 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 73' ' ' TRP . . . . . 0.493 ' CD1' ' N ' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -146.2 -77.97 0.18 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.939 0.399 . . . . 0.0 110.794 -179.672 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -104.74 -21.17 9.32 Favored Glycine 0 N--CA 1.45 -0.416 0 C-N-CA 120.888 -0.673 . . . . 0.0 112.485 179.755 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 17.6 pt20 -65.74 154.0 89.74 Favored Pre-proline 0 C--N 1.331 -0.225 0 CA-C-O 120.751 0.31 . . . . 0.0 110.861 179.971 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . 0.413 ' HD3' ' CD1' ' A' ' 81' ' ' TRP . 33.7 Cg_endo -65.32 149.04 88.8 Favored 'Trans proline' 0 C--N 1.345 0.342 0 C-N-CA 122.535 2.156 . . . . 0.0 112.227 179.951 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 4.2 t-160 -102.82 6.56 39.31 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.369 179.93 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 158.39 -26.43 0.41 Allowed Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.64 -0.791 . . . . 0.0 112.536 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -113.64 -82.1 1.09 Allowed Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.545 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -171.16 -157.86 13.94 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.673 -0.775 . . . . 0.0 112.504 -179.961 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 81' ' ' TRP . . . . . 0.498 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -145.18 -78.6 0.19 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.949 0.404 . . . . 0.0 110.682 -179.574 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -112.85 10.87 25.24 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.87 -0.681 . . . . 0.0 112.574 179.829 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 19.0 pt20 -96.32 154.56 38.66 Favored Pre-proline 0 C--N 1.332 -0.164 0 CA-C-O 120.747 0.308 . . . . 0.0 110.878 179.933 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 42.3 Cg_endo -67.71 141.39 54.48 Favored 'Trans proline' 0 C--N 1.345 0.364 0 C-N-CA 122.486 2.124 . . . . 0.0 112.244 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 45.5 m-70 -95.89 -30.65 13.53 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.853 -179.973 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -118.92 -52.19 0.29 Allowed Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.515 -179.939 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -172.38 88.63 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.539 179.973 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 69.55 -170.68 42.22 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.604 -179.961 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 89' ' ' TRP . . . . . 0.482 ' CD1' ' N ' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -147.3 -78.74 0.16 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.946 0.403 . . . . 0.0 110.735 -179.641 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -138.49 22.19 3.04 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.96 -0.638 . . . . 0.0 112.194 179.749 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 6.2 mt-30 . . . . . 0 C--O 1.25 1.087 0 CA-C-O 118.19 -0.91 . . . . 0.0 110.911 -179.85 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.254 0 N-CA-C 112.464 -0.254 . . . . 0.0 112.464 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 73' ' ' TRP . . . . . 0.492 ' CD1' ' N ' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -146.75 -78.53 0.17 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.917 0.389 . . . . 0.0 110.77 -179.601 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -103.93 -20.65 10.37 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.927 -0.654 . . . . 0.0 112.477 179.823 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 17.9 pt20 -65.1 153.91 88.09 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-O 120.682 0.277 . . . . 0.0 110.852 -179.984 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_endo -69.69 140.09 42.07 Favored 'Trans proline' 0 C--N 1.343 0.283 0 C-N-CA 122.502 2.134 . . . . 0.0 112.414 179.947 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 25.3 p80 -92.23 -31.43 15.44 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.653 179.757 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -120.6 -35.69 0.83 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.845 -0.693 . . . . 0.0 112.411 179.981 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -155.12 -78.0 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.5 -179.952 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -130.62 -157.67 9.03 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.575 -179.951 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 81' ' ' TRP . . . . . 0.48 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -146.75 -78.06 0.17 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.857 0.36 . . . . 0.0 110.731 -179.646 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -105.96 -20.06 9.65 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.886 -0.673 . . . . 0.0 112.532 179.898 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 11.1 pt20 -59.72 154.2 48.0 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-O 120.699 0.285 . . . . 0.0 110.895 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.9 140.57 42.47 Favored 'Trans proline' 0 C--N 1.343 0.263 0 C-N-CA 122.551 2.167 . . . . 0.0 112.314 179.913 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 7.8 m-70 -93.53 -30.46 14.99 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.892 179.925 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -147.38 27.8 1.52 Allowed Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.522 -179.97 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 163.25 -102.27 0.2 Allowed Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.53 179.933 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -130.93 -156.89 8.7 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.552 -179.934 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 89' ' ' TRP . . . . . 0.479 ' CD1' ' N ' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -147.18 -77.99 0.17 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.934 0.397 . . . . 0.0 110.779 -179.65 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -134.78 17.67 4.14 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.923 -0.656 . . . . 0.0 112.528 179.823 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 5.9 pt20 . . . . . 0 C--O 1.249 1.074 0 CA-C-O 118.193 -0.908 . . . . 0.0 110.849 -179.964 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.254 0 N-CA-C 112.495 -0.242 . . . . 0.0 112.495 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 73' ' ' TRP . . . . . 0.488 ' CD1' ' N ' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -146.86 -78.89 0.16 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.942 0.401 . . . . 0.0 110.811 -179.648 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -117.79 14.43 12.83 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.964 -0.636 . . . . 0.0 112.585 179.782 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 8.6 pt20 -84.21 154.36 63.3 Favored Pre-proline 0 C--N 1.331 -0.2 0 CA-C-O 120.684 0.278 . . . . 0.0 110.847 -179.972 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -66.43 146.88 81.64 Favored 'Trans proline' 0 C--N 1.344 0.317 0 C-N-CA 122.557 2.171 . . . . 0.0 112.253 179.89 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 7.8 t60 -98.68 -31.01 12.14 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.917 179.902 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -128.38 -42.18 0.26 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.435 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -172.76 94.15 0.1 OUTLIER Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.556 -179.967 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 62.01 -170.29 11.48 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.545 -179.926 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 81' ' ' TRP . . . . . 0.491 ' CD1' ' N ' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -147.16 -78.65 0.16 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.93 0.395 . . . . 0.0 110.713 -179.552 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -117.85 14.03 12.85 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.86 -0.686 . . . . 0.0 112.505 179.857 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 21.5 pt20 -81.34 154.62 71.86 Favored Pre-proline 0 C--N 1.331 -0.214 0 CA-C-O 120.736 0.303 . . . . 0.0 110.857 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 40.3 Cg_endo -67.12 143.39 65.03 Favored 'Trans proline' 0 C--N 1.344 0.322 0 C-N-CA 122.541 2.161 . . . . 0.0 112.265 179.967 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 45.2 m-70 -97.43 -30.84 12.68 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.882 179.983 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -126.31 -41.49 0.32 Allowed Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.457 -179.947 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -175.23 96.18 0.1 Allowed Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.672 -0.775 . . . . 0.0 112.471 179.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 59.64 -169.51 6.82 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.557 -179.982 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 89' ' ' TRP . . . . . 0.481 ' CD1' ' N ' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -148.26 -76.62 0.17 Allowed 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.961 0.41 . . . . 0.0 110.763 -179.632 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -112.88 -22.12 5.78 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.92 -0.657 . . . . 0.0 112.537 179.88 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 1.1 pt20 . . . . . 0 C--O 1.248 1.008 0 CA-C-O 118.27 -0.871 . . . . 0.0 110.9 179.991 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.3 0 N-CA-C 112.533 -0.227 . . . . 0.0 112.533 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 73' ' ' TRP . . . . . 0.483 ' CD1' ' N ' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -146.46 -78.96 0.17 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.92 0.39 . . . . 0.0 110.705 -179.628 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -113.96 10.61 22.9 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.845 -0.693 . . . . 0.0 112.662 179.845 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 13.6 pt20 -93.16 153.35 41.68 Favored Pre-proline 0 C--N 1.331 -0.216 0 CA-C-O 120.704 0.288 . . . . 0.0 110.889 179.973 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . 0.413 ' HD3' ' CD1' ' A' ' 81' ' ' TRP . 28.8 Cg_endo -64.08 151.96 83.06 Favored 'Trans proline' 0 C--N 1.344 0.322 0 C-N-CA 122.529 2.153 . . . . 0.0 112.31 -179.989 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 15.7 t-160 -107.68 -28.62 9.61 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.821 179.902 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -157.02 25.6 0.49 Allowed Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.552 -179.998 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 134.86 89.32 0.31 Allowed Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.664 -0.779 . . . . 0.0 112.595 179.867 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 56.92 -176.34 1.17 Allowed Glycine 0 N--CA 1.452 -0.237 0 C-N-CA 120.807 -0.711 . . . . 0.0 112.645 179.888 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 81' ' ' TRP . . . . . 0.527 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -142.14 -79.22 0.24 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.908 0.385 . . . . 0.0 110.819 -179.48 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -118.45 19.28 10.72 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.834 -0.698 . . . . 0.0 112.551 179.797 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 24.4 pt20 -85.08 154.38 60.47 Favored Pre-proline 0 C--N 1.331 -0.228 0 CA-C-O 120.702 0.287 . . . . 0.0 110.827 179.977 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -66.54 158.55 55.07 Favored 'Trans proline' 0 C--N 1.344 0.31 0 C-N-CA 122.56 2.174 . . . . 0.0 112.329 179.903 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 29.1 m80 -107.99 -30.79 8.26 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.916 179.968 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -133.72 27.7 3.32 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.72 -0.753 . . . . 0.0 112.503 -179.999 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 104.5 93.56 2.3 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.523 179.921 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 59.36 -169.86 6.16 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.547 179.938 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 89' ' ' TRP . . . . . 0.484 ' CD1' ' N ' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -147.5 -77.79 0.17 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.942 0.401 . . . . 0.0 110.751 -179.626 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -134.8 17.99 4.11 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.918 -0.658 . . . . 0.0 112.574 179.871 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 2.0 pt20 . . . . . 0 C--O 1.248 1.017 0 CA-C-O 118.233 -0.889 . . . . 0.0 110.868 -179.97 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.31 0 N-CA-C 112.507 -0.237 . . . . 0.0 112.507 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 73' ' ' TRP . . . . . 0.6 ' CD1' ' N ' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -123.06 -78.42 0.6 Allowed 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.896 0.379 . . . . 0.0 110.709 -179.639 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -109.86 -19.15 8.35 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.947 -0.644 . . . . 0.0 112.457 179.799 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 13.8 pt20 -59.34 153.87 45.83 Favored Pre-proline 0 C--N 1.33 -0.249 0 CA-C-O 120.722 0.296 . . . . 0.0 110.894 -179.99 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 30.6 Cg_endo -64.07 153.55 75.49 Favored 'Trans proline' 0 C--N 1.344 0.334 0 C-N-CA 122.568 2.179 . . . . 0.0 112.321 179.956 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 13.2 p80 -107.25 -30.66 8.6 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.817 179.931 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -108.09 -62.83 0.56 Allowed Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.51 179.949 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -164.41 29.26 0.22 Allowed Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.564 -179.981 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 136.16 -164.52 25.04 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.575 179.984 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 81' ' ' TRP . . . . . 0.497 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -146.1 -78.69 0.17 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.941 0.401 . . . . 0.0 110.788 -179.621 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -116.74 13.89 14.78 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.851 -0.69 . . . . 0.0 112.573 179.807 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 18.8 pt20 -86.21 154.31 57.26 Favored Pre-proline 0 C--N 1.331 -0.204 0 CA-C-O 120.688 0.28 . . . . 0.0 110.879 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 38.9 Cg_endo -66.89 153.4 78.04 Favored 'Trans proline' 0 C--N 1.344 0.301 0 C-N-CA 122.565 2.177 . . . . 0.0 112.277 -179.995 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 3.5 t-80 -107.76 -31.1 8.19 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.9 179.928 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -129.61 27.91 4.08 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.51 179.949 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 101.33 96.02 2.25 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.55 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 59.51 -169.45 6.64 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.548 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 89' ' ' TRP . . . . . 0.47 ' CD1' ' N ' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -147.38 -77.61 0.17 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.938 0.399 . . . . 0.0 110.82 -179.612 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -134.69 18.19 4.11 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.907 -0.663 . . . . 0.0 112.556 179.872 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 2.9 pt20 . . . . . 0 C--O 1.249 1.065 0 CA-C-O 118.282 -0.866 . . . . 0.0 110.92 179.995 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.341 0 N-CA-C 112.472 -0.251 . . . . 0.0 112.472 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 73' ' ' TRP . . . . . 0.487 ' CD1' ' N ' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -147.71 -77.95 0.16 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.993 0.425 . . . . 0.0 110.708 -179.583 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -105.53 -20.48 9.51 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.912 -0.661 . . . . 0.0 112.347 179.861 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 13.5 pt20 -65.47 154.43 87.97 Favored Pre-proline 0 C--N 1.33 -0.241 0 CA-C-O 120.652 0.263 . . . . 0.0 110.898 -179.954 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 40.1 Cg_endo -67.14 154.8 73.22 Favored 'Trans proline' 0 C--N 1.343 0.257 0 C-N-CA 122.536 2.157 . . . . 0.0 112.256 179.937 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 5.3 p-80 -100.55 -31.67 11.15 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.912 179.99 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -125.24 -47.36 0.22 Allowed Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.457 179.985 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -171.82 87.38 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.459 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 72.67 -169.54 52.12 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.546 179.987 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 81' ' ' TRP . . . . . 0.482 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -148.12 -76.14 0.17 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.921 0.391 . . . . 0.0 110.785 -179.649 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -107.05 -21.73 7.94 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.935 -0.65 . . . . 0.0 112.455 179.833 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 15.6 pt20 -60.1 154.4 50.99 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 120.677 0.275 . . . . 0.0 110.865 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 44.5 Cg_endo -68.34 141.13 50.58 Favored 'Trans proline' 0 C--N 1.344 0.331 0 C-N-CA 122.539 2.159 . . . . 0.0 112.248 179.958 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 13.7 m-70 -95.17 -31.14 13.67 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.934 179.966 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -125.2 -40.99 0.38 Allowed Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.821 -0.704 . . . . 0.0 112.437 -179.959 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -176.92 96.55 0.1 Allowed Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.509 -179.946 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 59.64 -170.36 6.3 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.55 -179.986 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 89' ' ' TRP . . . . . 0.483 ' CD1' ' N ' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -147.58 -77.82 0.16 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.901 0.381 . . . . 0.0 110.831 -179.664 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -133.66 18.55 4.32 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.853 -0.689 . . . . 0.0 112.514 179.776 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 6.5 pt20 . . . . . 0 C--O 1.249 1.052 0 CA-C-O 118.179 -0.915 . . . . 0.0 110.949 -179.998 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.353 0 N-CA-C 112.5 -0.24 . . . . 0.0 112.5 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 73' ' ' TRP . . . . . 0.486 ' CD1' ' N ' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -147.38 -77.66 0.17 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.931 0.396 . . . . 0.0 110.715 -179.563 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -107.89 -20.15 8.62 Favored Glycine 0 N--CA 1.45 -0.413 0 C-N-CA 120.901 -0.666 . . . . 0.0 112.463 179.856 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 11.6 pt20 -59.62 154.32 46.2 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-O 120.701 0.286 . . . . 0.0 110.904 -179.988 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 40.9 Cg_endo -67.33 152.76 78.67 Favored 'Trans proline' 0 C--N 1.345 0.356 0 C-N-CA 122.564 2.176 . . . . 0.0 112.26 179.941 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 6.0 t-160 -105.72 -31.24 8.97 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.875 179.967 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -128.57 29.36 4.04 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.453 -179.996 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 97.48 94.71 1.92 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.467 179.959 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 61.64 -170.07 10.66 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.505 179.966 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 81' ' ' TRP . . . . . 0.488 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -147.02 -78.29 0.17 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.901 0.381 . . . . 0.0 110.736 -179.558 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -115.17 12.97 19.38 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.907 -0.663 . . . . 0.0 112.618 179.748 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 13.1 pt20 -93.43 154.17 41.33 Favored Pre-proline 0 C--N 1.332 -0.186 0 CA-C-O 120.649 0.262 . . . . 0.0 110.889 179.973 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -65.93 148.89 86.5 Favored 'Trans proline' 0 C--N 1.343 0.268 0 C-N-CA 122.629 2.22 . . . . 0.0 112.274 179.944 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 7.7 m170 -100.33 -30.57 11.79 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.776 179.877 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -110.63 -27.93 4.18 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.489 179.935 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 173.91 -43.28 0.15 Allowed Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.641 179.997 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -154.39 -160.12 9.64 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.61 179.985 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 89' ' ' TRP . . . . . 0.488 ' CD1' ' N ' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -146.89 -78.84 0.16 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.879 0.371 . . . . 0.0 110.644 -179.541 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -138.48 22.04 3.05 Favored Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.946 -0.645 . . . . 0.0 112.211 179.764 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 6.0 mt-30 . . . . . 0 C--O 1.25 1.118 0 CA-C-O 118.209 -0.9 . . . . 0.0 110.929 -179.875 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.345 0 N-CA-C 112.6 -0.2 . . . . 0.0 112.6 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 73' ' ' TRP . . . . . 0.493 ' CD1' ' N ' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -147.4 -77.49 0.17 Allowed 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.903 0.382 . . . . 0.0 110.696 -179.53 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -101.84 -19.67 14.73 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.964 -0.636 . . . . 0.0 112.522 179.851 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 4.7 pt20 -59.03 153.97 41.91 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 120.734 0.302 . . . . 0.0 110.891 179.983 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -66.64 154.06 75.77 Favored 'Trans proline' 0 C--N 1.345 0.369 0 C-N-CA 122.524 2.149 . . . . 0.0 112.329 179.992 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 19.8 p-80 -109.51 -30.31 8.0 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.867 -179.933 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -132.13 27.07 3.67 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.545 -179.982 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 104.5 96.45 2.42 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.668 -0.777 . . . . 0.0 112.563 179.925 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 58.84 -170.85 4.9 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.824 -0.703 . . . . 0.0 112.615 179.968 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 81' ' ' TRP . . . . . 0.49 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -147.03 -77.02 0.18 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.884 0.373 . . . . 0.0 110.71 -179.563 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -104.18 -20.86 9.94 Favored Glycine 0 N--CA 1.452 -0.248 0 C-N-CA 120.861 -0.685 . . . . 0.0 112.548 179.86 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 8.3 pt20 -58.84 153.84 40.74 Favored Pre-proline 0 C--N 1.331 -0.221 0 CA-C-O 120.686 0.279 . . . . 0.0 110.917 179.997 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_endo -59.77 160.75 20.26 Favored 'Trans proline' 0 C--N 1.343 0.283 0 C-N-CA 122.584 2.189 . . . . 0.0 112.352 -179.979 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 7.8 p-80 -113.15 -30.87 6.82 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.822 179.873 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -116.8 20.81 11.64 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.648 179.93 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 102.56 9.72 40.17 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.939 179.847 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 161.67 -170.75 37.47 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.633 -0.794 . . . . 0.0 112.635 -179.987 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 89' ' ' TRP . . . . . 0.522 ' CD1' ' N ' ' A' ' 89' ' ' TRP . 0.1 OUTLIER -150.78 -60.05 0.18 Allowed 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 121.278 0.561 . . . . 0.0 110.559 -179.256 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -153.18 -44.86 0.02 OUTLIER Glycine 0 N--CA 1.45 -0.433 0 CA-C-N 115.264 -0.88 . . . . 0.0 111.499 179.636 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 4.6 mt-30 . . . . . 0 C--O 1.248 1.004 0 CA-C-O 118.22 -0.895 . . . . 0.0 111.363 179.326 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.324 0 N-CA-C 112.539 -0.224 . . . . 0.0 112.539 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 73' ' ' TRP . . . . . 0.485 ' CD1' ' N ' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -147.16 -77.04 0.18 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.956 0.408 . . . . 0.0 110.785 -179.555 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -106.76 -21.26 8.32 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.805 -0.712 . . . . 0.0 112.5 179.867 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 3.0 pt20 -59.94 153.84 52.38 Favored Pre-proline 0 C--N 1.331 -0.223 0 CA-C-O 120.663 0.268 . . . . 0.0 110.915 179.947 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_endo -66.06 153.93 76.11 Favored 'Trans proline' 0 C--N 1.344 0.321 0 C-N-CA 122.481 2.121 . . . . 0.0 112.389 179.938 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 23.3 t-160 -109.7 -29.76 8.19 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.811 179.956 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -134.39 26.7 3.33 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.549 179.952 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 106.88 97.63 2.52 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.53 179.888 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 58.45 -172.7 3.59 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.58 179.909 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 81' ' ' TRP . . . . . 0.486 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -146.21 -77.84 0.18 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.96 0.41 . . . . 0.0 110.845 -179.603 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -106.46 -20.81 8.76 Favored Glycine 0 N--CA 1.45 -0.419 0 C-N-CA 120.848 -0.692 . . . . 0.0 112.553 179.895 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 12.5 pt20 -58.89 153.68 42.17 Favored Pre-proline 0 C--N 1.33 -0.254 0 CA-C-O 120.694 0.283 . . . . 0.0 110.933 179.966 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 30.3 Cg_endo -64.37 159.99 41.29 Favored 'Trans proline' 0 C--N 1.344 0.326 0 C-N-CA 122.522 2.148 . . . . 0.0 112.321 -179.977 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 4.1 m-70 -117.72 106.34 12.95 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.092 -0.503 . . . . 0.0 110.645 179.665 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 94.93 -26.85 16.7 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.444 -179.797 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 150.01 92.8 0.1 Allowed Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.549 -179.966 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 58.46 -157.5 19.53 Favored Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.593 179.988 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 89' ' ' TRP . . . . . 0.509 ' CD1' ' N ' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -142.02 -78.46 0.25 Allowed 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.981 0.42 . . . . 0.0 110.701 -179.636 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -134.68 17.29 4.21 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.908 -0.663 . . . . 0.0 112.507 179.816 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 6.0 pt20 . . . . . 0 C--O 1.249 1.072 0 CA-C-O 118.228 -0.891 . . . . 0.0 110.943 179.963 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.394 0 N-CA-C 112.571 -0.212 . . . . 0.0 112.571 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 73' ' ' TRP . . . . . 0.489 ' CD1' ' N ' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -145.62 -78.83 0.18 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.872 0.368 . . . . 0.0 110.804 -179.606 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -105.93 -20.93 8.91 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.868 -0.682 . . . . 0.0 112.446 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 16.7 pt20 -59.81 154.16 49.2 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 120.742 0.306 . . . . 0.0 110.891 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo -69.31 139.75 42.59 Favored 'Trans proline' 0 C--N 1.344 0.326 0 C-N-CA 122.548 2.165 . . . . 0.0 112.333 179.965 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 19.9 t-160 -93.73 -31.22 14.51 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.86 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -125.89 -40.82 0.36 Allowed Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.801 -0.714 . . . . 0.0 112.485 -180.0 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -176.48 97.16 0.11 Allowed Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.567 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 59.91 -171.82 5.78 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.563 179.971 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 81' ' ' TRP . . . . . 0.474 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -147.09 -77.34 0.17 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.902 0.382 . . . . 0.0 110.757 -179.66 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -106.6 -21.63 8.18 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.919 -0.658 . . . . 0.0 112.493 179.934 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 20.7 pt20 -59.96 154.03 51.52 Favored Pre-proline 0 C--N 1.33 -0.24 0 CA-C-O 120.702 0.287 . . . . 0.0 110.902 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 39.0 Cg_endo -67.13 158.1 58.52 Favored 'Trans proline' 0 C--N 1.344 0.335 0 C-N-CA 122.567 2.178 . . . . 0.0 112.296 179.955 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 8.8 m170 -97.67 -30.94 12.54 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.774 179.986 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -113.75 -29.09 2.97 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.506 179.97 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 172.38 -33.6 0.13 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.524 179.991 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -157.85 -161.2 10.74 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.68 -0.771 . . . . 0.0 112.558 -179.968 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 89' ' ' TRP . . . . . 0.489 ' CD1' ' N ' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -147.17 -77.98 0.17 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.969 0.414 . . . . 0.0 110.756 -179.636 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -133.79 17.87 4.36 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.909 -0.662 . . . . 0.0 112.484 179.816 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 13.8 pt20 . . . . . 0 C--O 1.25 1.095 0 CA-C-O 118.164 -0.922 . . . . 0.0 110.896 179.982 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.267 0 N-CA-C 112.469 -0.252 . . . . 0.0 112.469 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 73' ' ' TRP . . . . . 0.509 ' CD1' ' N ' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -144.61 -79.79 0.18 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.944 0.402 . . . . 0.0 110.72 -179.546 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -112.27 15.16 25.4 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.81 -0.71 . . . . 0.0 112.436 179.706 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 3.5 pt20 -107.39 154.07 40.86 Favored Pre-proline 0 C--N 1.33 -0.252 0 CA-C-O 120.713 0.292 . . . . 0.0 110.901 179.989 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_endo -66.0 146.73 83.26 Favored 'Trans proline' 0 C--N 1.344 0.299 0 C-N-CA 122.481 2.121 . . . . 0.0 112.305 179.988 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 6.3 t-160 -100.03 -31.16 11.58 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.794 179.813 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -118.83 -34.59 1.04 Allowed Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.812 -0.709 . . . . 0.0 112.436 179.907 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -161.53 -64.96 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.558 -179.996 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -138.57 -158.95 7.9 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.599 -179.957 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 81' ' ' TRP . . . . . 0.501 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -145.94 -77.99 0.18 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.9 0.381 . . . . 0.0 110.778 -179.594 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -104.18 -21.88 9.14 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.903 -0.665 . . . . 0.0 112.54 179.896 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 16.9 pt20 -61.13 151.7 74.48 Favored Pre-proline 0 C--N 1.331 -0.224 0 CA-C-O 120.719 0.295 . . . . 0.0 110.93 -179.98 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 30.7 Cg_endo -64.63 160.82 38.23 Favored 'Trans proline' 0 C--N 1.344 0.328 0 C-N-CA 122.511 2.141 . . . . 0.0 112.358 179.968 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 16.6 p-80 -118.47 106.57 12.82 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.599 179.644 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 94.42 -26.08 19.52 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.513 -179.797 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 149.29 92.53 0.1 Allowed Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.498 179.937 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 58.93 -157.37 22.33 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.548 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 89' ' ' TRP . . . . . 0.511 ' CD1' ' N ' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -142.55 -78.7 0.24 Allowed 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 121.002 0.429 . . . . 0.0 110.829 -179.676 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -113.15 -20.71 6.2 Favored Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 120.904 -0.665 . . . . 0.0 112.473 179.888 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 2.0 pt20 . . . . . 0 C--O 1.248 1.024 0 CA-C-O 118.333 -0.841 . . . . 0.0 110.862 -179.982 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' TRP . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.489 1.478 0 CA-C-O 120.831 0.348 . . . . 0.0 111.316 . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -166.08 30.61 0.21 Allowed Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.535 -179.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 13.0 pt20 -71.12 154.21 94.1 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 120.789 0.328 . . . . 0.0 110.837 -179.954 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 44.7 Cg_endo -68.14 153.79 73.94 Favored 'Trans proline' 0 C--N 1.345 0.345 0 C-N-CA 122.518 2.145 . . . . 0.0 112.314 179.945 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' HIS . . . . . . . . . . . . . 16.6 p-80 -101.89 -31.17 10.84 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.885 179.934 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -126.54 -41.53 0.32 Allowed Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.462 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -176.38 90.26 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.441 179.963 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 62.31 -170.81 11.31 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.679 -0.772 . . . . 0.0 112.603 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' TRP . . . . . 0.492 ' N ' ' CD1' ' A' ' 65' ' ' TRP . 0.0 OUTLIER -147.06 -78.6 0.16 Allowed 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.864 0.364 . . . . 0.0 110.823 -179.673 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -118.5 14.67 11.82 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.941 -0.647 . . . . 0.0 112.538 179.732 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 20.6 pt20 -80.32 154.5 74.4 Favored Pre-proline 0 C--N 1.33 -0.241 0 CA-C-O 120.656 0.265 . . . . 0.0 110.91 -179.988 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -66.35 160.26 46.26 Favored 'Trans proline' 0 C--N 1.344 0.312 0 C-N-CA 122.56 2.173 . . . . 0.0 112.291 179.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 27.8 p-80 -106.76 -31.36 8.44 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.828 -179.897 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . -135.14 28.07 3.08 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.515 -179.964 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 105.04 93.48 2.31 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.512 -179.952 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 59.39 -171.12 5.49 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.561 179.967 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' TRP . . . . . 0.481 ' CD1' ' N ' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -146.76 -78.9 0.16 Allowed 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 120.97 0.415 . . . . 0.0 110.746 -179.573 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -114.39 13.23 21.13 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.843 -0.694 . . . . 0.0 112.54 179.83 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 23.9 pt20 -97.38 154.48 38.02 Favored Pre-proline 0 C--N 1.332 -0.192 0 CA-C-O 120.722 0.296 . . . . 0.0 110.888 179.983 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 39.4 Cg_endo -67.29 147.3 78.0 Favored 'Trans proline' 0 C--N 1.344 0.303 0 C-N-CA 122.543 2.162 . . . . 0.0 112.27 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 8.4 t-160 -97.26 -30.62 12.87 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.865 179.893 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -113.17 -27.95 3.5 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.893 -0.67 . . . . 0.0 112.565 179.941 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 179.37 -54.52 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.596 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -145.71 -158.64 7.79 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.521 -179.924 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' TRP . . . . . 0.478 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -147.56 -77.11 0.17 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.97 0.414 . . . . 0.0 110.698 -179.556 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -106.85 -20.93 8.47 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.903 -0.665 . . . . 0.0 112.473 179.868 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 17.8 pt20 -60.18 154.45 51.54 Favored Pre-proline 0 C--N 1.331 -0.216 0 CA-C-O 120.735 0.302 . . . . 0.0 110.856 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_endo -68.72 140.53 47.05 Favored 'Trans proline' 0 C--N 1.345 0.378 0 C-N-CA 122.525 2.15 . . . . 0.0 112.251 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 7.5 m170 -94.89 -30.99 13.89 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.846 -179.956 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -125.22 -40.79 0.39 Allowed Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.496 179.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -177.18 96.9 0.11 Allowed Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.468 179.942 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 59.59 -170.71 6.01 Favored Glycine 0 N--CA 1.452 -0.268 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.55 179.947 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' TRP . . . . . 0.478 ' CD1' ' N ' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -147.52 -77.78 0.17 Allowed 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.919 0.39 . . . . 0.0 110.795 -179.638 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -134.69 18.32 4.1 Favored Glycine 0 N--CA 1.449 -0.445 0 C-N-CA 120.894 -0.669 . . . . 0.0 112.504 179.843 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 7.2 pt20 . . . . . 0 C--O 1.249 1.052 0 CA-C-O 118.173 -0.918 . . . . 0.0 110.864 -179.944 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' TRP . . . . . . . . . . . . . 30.1 t-105 . . . . . 0 N--CA 1.486 1.367 0 CA-C-O 120.709 0.29 . . . . 0.0 111.207 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . 0.465 ' O ' ' CG ' ' A' ' 59' ' ' GLN . . . -60.31 -40.7 97.81 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.541 179.948 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.465 ' CG ' ' O ' ' A' ' 58' ' ' GLY . 2.6 pt20 54.74 155.08 0.05 OUTLIER Pre-proline 0 N--CA 1.464 0.256 0 CA-C-O 120.948 0.404 . . . . 0.0 111.527 179.958 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 58.5 Cg_endo -72.01 142.4 38.46 Favored 'Trans proline' 0 C--N 1.344 0.328 0 C-N-CA 122.556 2.171 . . . . 0.0 112.302 -179.891 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' HIS . . . . . . . . . . . . . 8.7 t-160 -90.29 -31.11 17.09 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.937 179.924 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -126.22 -42.14 0.31 Allowed Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.41 -179.951 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -176.14 97.81 0.12 Allowed Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.501 -179.899 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 59.61 -170.86 5.94 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.541 179.94 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' TRP . . . . . 0.474 ' CD1' ' N ' ' A' ' 65' ' ' TRP . 0.0 OUTLIER -147.91 -76.82 0.17 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.934 0.397 . . . . 0.0 110.751 -179.621 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -108.23 -19.72 8.75 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.937 -0.649 . . . . 0.0 112.574 179.9 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 18.1 pt20 -58.56 154.14 36.2 Favored Pre-proline 0 C--N 1.33 -0.246 0 CA-C-O 120.682 0.277 . . . . 0.0 110.95 -179.99 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo -69.06 151.39 73.08 Favored 'Trans proline' 0 C--N 1.343 0.287 0 C-N-CA 122.591 2.194 . . . . 0.0 112.309 179.967 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 27.6 p-80 -95.38 -31.01 13.61 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.83 179.933 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . -151.87 27.66 0.92 Allowed Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.502 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 167.41 -107.97 0.3 Allowed Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.524 -179.995 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -126.46 -158.08 9.76 Favored Glycine 0 N--CA 1.452 -0.268 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.56 -179.968 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' TRP . . . . . 0.467 ' CD1' ' N ' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -147.69 -78.02 0.16 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.927 0.394 . . . . 0.0 110.799 -179.598 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -111.34 -15.26 10.66 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.883 -0.675 . . . . 0.0 112.632 179.917 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 18.9 pt20 -56.74 154.08 19.49 Favored Pre-proline 0 C--N 1.331 -0.201 0 CA-C-O 120.699 0.285 . . . . 0.0 111.028 -179.974 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 41.2 Cg_endo -67.32 161.29 43.76 Favored 'Trans proline' 0 C--N 1.343 0.28 0 C-N-CA 122.597 2.198 . . . . 0.0 112.314 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 12.6 t60 -109.32 -30.5 7.96 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.966 179.865 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -135.16 27.09 3.18 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.468 179.982 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 106.28 92.9 2.29 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.476 179.939 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 58.92 -170.88 4.98 Favored Glycine 0 N--CA 1.452 -0.268 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.535 179.936 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' TRP . . . . . 0.489 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -146.81 -78.88 0.16 Allowed 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.832 0.348 . . . . 0.0 110.76 -179.604 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -119.98 15.89 10.22 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.863 -0.684 . . . . 0.0 112.547 179.733 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 8.2 pt20 -82.11 154.2 69.65 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-O 120.723 0.297 . . . . 0.0 110.903 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 27.6 Cg_endo -62.72 156.47 53.03 Favored 'Trans proline' 0 C--N 1.345 0.365 0 C-N-CA 122.535 2.156 . . . . 0.0 112.273 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 0.7 OUTLIER -109.38 -31.08 7.67 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.815 179.94 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -108.26 -61.71 0.55 Allowed Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.436 -179.984 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -165.77 30.1 0.21 Allowed Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.709 -0.757 . . . . 0.0 112.523 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 136.1 -164.33 25.04 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.581 -179.971 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' TRP . . . . . 0.491 ' CD1' ' N ' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -146.85 -77.92 0.17 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.897 0.379 . . . . 0.0 110.735 -179.634 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -133.04 18.69 4.45 Favored Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.907 -0.663 . . . . 0.0 112.511 179.793 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 15.3 pt20 . . . . . 0 C--O 1.249 1.056 0 CA-C-O 118.203 -0.903 . . . . 0.0 110.89 -179.968 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' TRP . . . . . . . . . . . . . 31.0 t-105 . . . . . 0 N--CA 1.487 1.387 0 CA-C-O 120.848 0.356 . . . . 0.0 111.21 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . 0.468 ' O ' ' CG ' ' A' ' 59' ' ' GLN . . . -60.85 -50.83 63.25 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.512 -179.983 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.468 ' CG ' ' O ' ' A' ' 58' ' ' GLY . 5.4 pt20 54.62 155.55 0.05 OUTLIER Pre-proline 0 CA--C 1.531 0.213 0 CA-C-O 121.01 0.433 . . . . 0.0 111.517 179.949 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 60.5 Cg_endo -73.52 147.39 40.83 Favored 'Trans proline' 0 C--N 1.346 0.418 0 C-N-CA 122.446 2.098 . . . . 0.0 112.335 -179.867 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' HIS . . . . . . . . . . . . . 23.8 t-160 -89.33 -30.63 18.28 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.905 179.97 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -165.77 31.45 0.22 Allowed Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.527 179.941 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -178.37 -91.22 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.458 179.965 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -155.56 -158.52 8.82 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.62 -179.964 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' TRP . . . . . 0.476 ' N ' ' CD1' ' A' ' 65' ' ' TRP . 0.0 OUTLIER -147.13 -77.61 0.17 Allowed 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 120.973 0.416 . . . . 0.0 110.826 -179.584 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -108.18 -21.07 7.9 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.901 -0.666 . . . . 0.0 112.455 179.827 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 3.2 pt20 -60.05 153.95 53.0 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 120.639 0.257 . . . . 0.0 110.868 -179.969 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 30.2 Cg_endo -64.01 154.13 72.04 Favored 'Trans proline' 0 C--N 1.343 0.289 0 C-N-CA 122.478 2.118 . . . . 0.0 112.304 179.952 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 12.1 t-160 -107.78 -30.6 8.45 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.87 179.923 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . -108.28 -62.69 0.55 Allowed Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.454 -179.976 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -164.28 29.29 0.23 Allowed Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.57 -179.975 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 135.82 -164.02 24.98 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.561 -180.0 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' TRP . . . . . 0.496 ' CD1' ' N ' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -146.31 -78.6 0.17 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.857 0.36 . . . . 0.0 110.76 -179.616 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -116.64 13.72 15.1 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.953 -0.641 . . . . 0.0 112.599 179.73 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 3.9 pt20 -91.02 154.13 45.05 Favored Pre-proline 0 C--N 1.331 -0.238 0 CA-C-O 120.708 0.289 . . . . 0.0 110.942 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 36.0 Cg_endo -65.33 151.01 86.56 Favored 'Trans proline' 0 C--N 1.344 0.324 0 C-N-CA 122.495 2.13 . . . . 0.0 112.27 179.971 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 17.2 t-160 -101.07 -30.72 11.44 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.796 179.916 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -109.17 -27.77 4.67 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.528 179.95 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 168.11 -31.38 0.18 Allowed Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.598 179.953 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -162.3 -162.17 13.05 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.555 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' TRP . . . . . 0.49 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -146.28 -78.54 0.17 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.92 0.391 . . . . 0.0 110.748 -179.657 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -116.99 13.25 14.3 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.903 -0.665 . . . . 0.0 112.555 179.806 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 13.9 pt20 -86.09 154.29 57.58 Favored Pre-proline 0 C--N 1.332 -0.193 0 CA-C-O 120.628 0.251 . . . . 0.0 110.917 179.966 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_endo -66.12 157.41 59.85 Favored 'Trans proline' 0 C--N 1.344 0.296 0 C-N-CA 122.538 2.159 . . . . 0.0 112.32 179.914 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 3.5 t-80 -98.95 -30.79 12.16 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.854 179.861 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -113.03 -27.73 3.61 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.481 -179.995 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 169.91 -32.39 0.16 Allowed Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.711 -0.756 . . . . 0.0 112.551 179.979 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -159.08 -161.48 11.18 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.509 -179.966 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' TRP . . . . . 0.485 ' CD1' ' N ' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -147.14 -77.98 0.17 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.826 0.346 . . . . 0.0 110.826 -179.669 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -134.71 17.76 4.15 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.921 -0.657 . . . . 0.0 112.523 179.863 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 7.6 pt20 . . . . . 0 C--O 1.248 1.023 0 CA-C-O 118.242 -0.885 . . . . 0.0 110.944 -180.0 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' TRP . . . . . . . . . . . . . 6.1 t90 . . . . . 0 N--CA 1.487 1.412 0 CA-C-O 120.797 0.332 . . . . 0.0 111.197 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -59.87 -75.23 0.29 Allowed Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.545 -179.996 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 9.1 pt20 -87.54 153.79 53.27 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 120.714 0.292 . . . . 0.0 110.922 179.969 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 32.5 Cg_endo -64.62 150.56 87.99 Favored 'Trans proline' 0 C--N 1.344 0.337 0 C-N-CA 122.566 2.178 . . . . 0.0 112.342 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' HIS . . . . . . . . . . . . . 9.0 t-160 -103.18 6.27 38.23 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.221 179.931 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 137.68 43.76 0.09 OUTLIER Glycine 0 C--N 1.331 0.298 0 C-N-CA 120.617 -0.802 . . . . 0.0 112.522 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 158.74 42.53 0.02 OUTLIER Glycine 0 N--CA 1.45 -0.419 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.681 179.882 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 56.0 -157.35 9.48 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.748 179.893 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' TRP . . . . . 0.488 ' N ' ' CD1' ' A' ' 65' ' ' TRP . 0.0 OUTLIER -147.33 -77.68 0.17 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.911 0.386 . . . . 0.0 110.743 -179.623 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -109.08 -19.17 8.68 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.869 -0.681 . . . . 0.0 112.483 179.901 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 9.1 pt20 -58.55 154.19 35.84 Favored Pre-proline 0 C--N 1.331 -0.208 0 CA-C-O 120.674 0.273 . . . . 0.0 110.954 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo -66.02 157.83 57.44 Favored 'Trans proline' 0 C--N 1.344 0.309 0 C-N-CA 122.572 2.182 . . . . 0.0 112.28 179.913 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 3.7 p-80 -108.09 -31.18 8.04 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.899 179.948 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . -130.57 28.55 3.75 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.456 -179.955 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 100.19 95.93 2.17 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.559 179.988 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 60.37 -169.61 7.93 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.56 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' TRP . . . . . 0.485 ' CD1' ' N ' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -147.82 -77.25 0.17 Allowed 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.936 0.398 . . . . 0.0 110.787 -179.603 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -105.39 -21.67 8.67 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.888 -0.672 . . . . 0.0 112.446 179.832 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 16.3 pt20 -63.66 154.48 80.04 Favored Pre-proline 0 C--N 1.331 -0.2 0 CA-C-O 120.677 0.275 . . . . 0.0 110.879 -180.0 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 41.6 Cg_endo -67.7 142.06 56.9 Favored 'Trans proline' 0 C--N 1.344 0.311 0 C-N-CA 122.518 2.145 . . . . 0.0 112.239 -179.998 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 3.5 t-80 -96.05 -31.0 13.25 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.918 179.994 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -124.78 -41.77 0.37 Allowed Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.463 -179.986 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -177.02 94.58 0.1 OUTLIER Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.531 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 62.84 -170.66 13.08 Favored Glycine 0 N--CA 1.45 -0.416 0 C-N-CA 120.667 -0.778 . . . . 0.0 112.607 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' TRP . . . . . 0.477 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -148.24 -75.59 0.18 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.942 0.401 . . . . 0.0 110.742 -179.634 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -107.45 -22.09 7.61 Favored Glycine 0 N--CA 1.449 -0.436 0 C-N-CA 120.869 -0.682 . . . . 0.0 112.463 179.831 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 14.6 pt20 -60.17 154.11 53.32 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-O 120.646 0.26 . . . . 0.0 110.876 179.961 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 34.8 Cg_endo -65.35 153.46 78.15 Favored 'Trans proline' 0 C--N 1.344 0.308 0 C-N-CA 122.515 2.143 . . . . 0.0 112.255 179.963 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 57.5 m80 -100.63 -31.74 11.09 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.672 179.831 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -116.69 -31.65 1.74 Allowed Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.834 -0.698 . . . . 0.0 112.447 179.971 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -165.87 -69.25 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.59 -180.0 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -135.66 -147.84 5.51 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.616 179.98 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' TRP . . . . . 0.423 ' CH2' ' HB3' ' A' ' 91' ' ' GLN . 0.4 OUTLIER -161.11 23.57 0.13 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.765 0.317 . . . . 0.0 111.119 -179.342 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 103.03 -14.34 55.77 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.668 -0.777 . . . . 0.0 112.402 -179.644 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 91' ' ' GLN . . . . . 0.423 ' HB3' ' CH2' ' A' ' 89' ' ' TRP . 4.3 pt20 . . . . . 0 C--O 1.249 1.074 0 CA-C-O 118.229 -0.891 . . . . 0.0 110.919 -179.984 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' TRP . . . . . 0.427 ' CZ2' ' HG2' ' A' ' 59' ' ' GLN . 3.5 p-90 . . . . . 0 N--CA 1.488 1.429 0 CA-C-O 120.493 0.187 . . . . 0.0 111.021 . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -43.68 -75.46 0.15 Allowed Glycine 0 C--N 1.332 0.319 0 C-N-CA 121.094 -0.574 . . . . 0.0 113.194 -179.567 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.427 ' HG2' ' CZ2' ' A' ' 57' ' ' TRP . 5.6 pt20 -96.48 154.6 38.53 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 120.705 0.288 . . . . 0.0 110.95 -179.934 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -66.1 151.02 84.81 Favored 'Trans proline' 0 C--N 1.344 0.321 0 C-N-CA 122.527 2.151 . . . . 0.0 112.32 179.968 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' HIS . . . . . . . . . . . . . 17.9 t-160 -104.79 -31.18 9.44 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.871 179.983 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -125.32 -40.85 0.38 Allowed Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.543 179.946 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -176.54 91.06 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.652 -0.785 . . . . 0.0 112.445 179.94 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 59.63 -169.0 7.12 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.51 179.961 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' TRP . . . . . 0.467 ' CD1' ' N ' ' A' ' 65' ' ' TRP . 0.0 OUTLIER -148.46 -75.88 0.17 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.905 0.383 . . . . 0.0 110.794 -179.643 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -110.22 -19.55 7.97 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.9 -0.667 . . . . 0.0 112.496 179.932 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 11.2 pt20 -58.4 153.74 36.77 Favored Pre-proline 0 C--N 1.331 -0.2 0 CA-C-O 120.744 0.307 . . . . 0.0 110.956 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 27.6 Cg_endo -63.25 157.86 47.6 Favored 'Trans proline' 0 C--N 1.344 0.329 0 C-N-CA 122.601 2.201 . . . . 0.0 112.355 179.977 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 15.2 p-80 -116.6 105.28 12.27 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.6 179.556 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 94.29 -25.92 20.05 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.531 -179.728 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -172.17 -92.77 0.08 OUTLIER Glycine 0 N--CA 1.453 -0.216 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.612 -179.983 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -133.55 -146.45 5.52 Favored Glycine 0 N--CA 1.453 -0.229 0 C-N-CA 120.85 -0.69 . . . . 0.0 112.57 -179.876 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' TRP . . . . . 0.557 ' CD1' ' N ' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -136.21 -78.33 0.42 Allowed 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.954 0.407 . . . . 0.0 110.629 -179.654 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -113.33 -9.09 18.34 Favored Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 120.907 -0.663 . . . . 0.0 112.625 179.758 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 14.3 pt20 -58.37 154.22 33.79 Favored Pre-proline 0 C--N 1.331 -0.237 0 CA-C-O 120.751 0.31 . . . . 0.0 110.957 179.933 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 55.0 Cg_endo -70.58 137.9 34.06 Favored 'Trans proline' 0 C--N 1.344 0.32 0 C-N-CA 122.431 2.088 . . . . 0.0 112.199 179.796 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 18.4 m-70 -107.66 105.38 15.21 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.985 0.421 . . . . 0.0 110.709 179.657 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 104.74 -31.5 8.53 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.868 -0.682 . . . . 0.0 112.433 -179.886 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 152.04 93.28 0.1 OUTLIER Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.576 -179.986 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 52.8 -161.79 2.54 Favored Glycine 0 C--N 1.33 0.229 0 C-N-CA 120.883 -0.675 . . . . 0.0 112.781 179.983 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' TRP . . . . . 0.549 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -137.09 -78.27 0.4 Allowed 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.935 0.398 . . . . 0.0 110.694 -179.665 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -107.33 -20.28 8.76 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.89 -0.672 . . . . 0.0 112.483 179.853 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 15.6 pt20 -59.9 154.42 48.66 Favored Pre-proline 0 C--N 1.331 -0.223 0 CA-C-O 120.631 0.253 . . . . 0.0 110.923 -179.946 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 44.0 Cg_endo -68.04 141.39 52.85 Favored 'Trans proline' 0 C--N 1.344 0.306 0 C-N-CA 122.558 2.172 . . . . 0.0 112.277 179.912 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 4.7 t-160 -95.5 -31.07 13.52 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.886 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -120.55 -41.37 0.53 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.518 179.966 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 179.22 96.13 0.1 Allowed Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.68 -0.772 . . . . 0.0 112.434 179.958 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 59.7 -170.07 6.55 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.542 -179.998 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' TRP . . . . . 0.482 ' CD1' ' N ' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -148.31 -76.18 0.17 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.998 0.428 . . . . 0.0 110.828 -179.634 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -112.89 -22.22 5.74 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.86 -0.686 . . . . 0.0 112.435 179.879 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 2.8 pp0? . . . . . 0 C--O 1.249 1.03 0 CA-C-O 118.257 -0.877 . . . . 0.0 110.904 -179.914 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' TRP . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.486 1.357 0 CA-C-O 120.815 0.34 . . . . 0.0 111.254 . . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 161.24 -28.24 0.29 Allowed Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.493 179.97 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 14.1 pt20 -69.35 154.08 95.26 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 120.7 0.286 . . . . 0.0 110.92 179.999 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_endo -68.21 147.52 72.77 Favored 'Trans proline' 0 C--N 1.344 0.33 0 C-N-CA 122.54 2.16 . . . . 0.0 112.317 179.961 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' HIS . . . . . . . . . . . . . 21.9 t-160 -96.04 -31.02 13.25 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.858 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -127.66 -41.79 0.28 Allowed Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.848 -0.691 . . . . 0.0 112.516 179.928 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -174.52 94.91 0.1 Allowed Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.686 -0.768 . . . . 0.0 112.507 179.969 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 59.37 -169.32 6.49 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.535 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' TRP . . . . . 0.46 ' CD1' ' N ' ' A' ' 65' ' ' TRP . 0.0 OUTLIER -148.69 -75.97 0.17 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.876 0.369 . . . . 0.0 110.786 -179.683 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -111.86 -13.72 12.17 Favored Glycine 0 N--CA 1.452 -0.248 0 C-N-CA 120.886 -0.674 . . . . 0.0 112.698 -179.99 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 6.6 pt20 -56.68 154.32 18.25 Favored Pre-proline 0 C--N 1.332 -0.157 0 CA-C-O 120.708 0.29 . . . . 0.0 110.958 -179.943 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -70.72 152.48 64.36 Favored 'Trans proline' 0 C--N 1.343 0.254 0 C-N-CA 122.57 2.18 . . . . 0.0 112.313 179.878 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 23.7 t-160 -97.02 -29.8 13.43 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.853 179.894 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . -151.21 27.56 0.99 Allowed Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.569 179.931 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 165.86 -107.04 0.28 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.542 179.958 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -126.9 -156.63 9.24 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.805 -0.712 . . . . 0.0 112.517 179.982 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' TRP . . . . . 0.454 ' CD1' ' N ' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -148.04 -79.36 0.15 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.885 0.374 . . . . 0.0 110.845 -179.667 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -115.99 -2.82 20.2 Favored Glycine 0 CA--C 1.519 0.311 0 C-N-CA 120.815 -0.707 . . . . 0.0 112.663 179.911 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 9.7 pt20 -58.04 154.41 29.58 Favored Pre-proline 0 C--N 1.33 -0.263 0 CA-C-O 120.728 0.299 . . . . 0.0 110.942 179.985 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -66.32 153.47 77.91 Favored 'Trans proline' 0 C--N 1.344 0.318 0 C-N-CA 122.553 2.169 . . . . 0.0 112.287 179.991 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 22.9 t-160 -100.23 -30.33 11.97 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.785 179.896 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -151.04 27.46 1.01 Allowed Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.478 -179.99 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 165.49 -109.59 0.37 Allowed Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.541 -179.932 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -123.7 -158.94 10.3 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.829 -0.701 . . . . 0.0 112.518 -179.945 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' TRP . . . . . 0.481 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -147.42 -78.6 0.16 Allowed 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.971 0.415 . . . . 0.0 110.873 -179.637 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -111.9 -15.22 10.23 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.959 -0.639 . . . . 0.0 112.577 179.898 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 16.2 pt20 -56.36 154.33 16.68 Favored Pre-proline 0 C--N 1.331 -0.211 0 CA-C-O 120.706 0.288 . . . . 0.0 111.006 179.969 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 40.9 Cg_endo -67.35 169.22 15.91 Favored 'Trans proline' 0 C--N 1.344 0.299 0 C-N-CA 122.604 2.202 . . . . 0.0 112.287 179.936 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 3.6 m-70 -110.15 -31.34 7.38 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.898 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -136.75 27.93 2.89 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.556 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 105.22 98.4 2.54 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.46 179.928 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 59.09 -170.81 5.24 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.511 179.925 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' TRP . . . . . 0.475 ' CD1' ' N ' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -147.92 -77.51 0.16 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.936 0.398 . . . . 0.0 110.88 -179.605 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -113.56 -22.06 5.57 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.87 -0.681 . . . . 0.0 112.486 179.823 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.249 1.034 0 CA-C-O 118.173 -0.918 . . . . 0.0 110.939 -179.993 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' TRP . . . . . . . . . . . . . 2.2 t90 . . . . . 0 N--CA 1.487 1.376 0 CA-C-O 120.847 0.356 . . . . 0.0 111.208 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -59.75 -51.18 60.53 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.492 179.981 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER 57.53 165.03 0.07 OUTLIER Pre-proline 0 C--N 1.33 -0.271 0 CA-C-O 120.755 0.312 . . . . 0.0 111.005 -179.928 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -70.05 126.2 12.85 Favored 'Trans proline' 0 C--N 1.344 0.317 0 C-N-CA 122.548 2.166 . . . . 0.0 112.267 -179.928 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' HIS . . . . . . . . . . . . . 5.4 m170 -89.81 6.05 43.42 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.377 179.908 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 173.25 39.37 0.04 OUTLIER Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.515 -179.993 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 151.47 -102.41 0.23 Allowed Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.68 -0.772 . . . . 0.0 112.48 179.929 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -139.54 -159.22 7.91 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.511 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' TRP . . . . . 0.488 ' N ' ' CD1' ' A' ' 65' ' ' TRP . 0.0 OUTLIER -146.88 -78.62 0.16 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.889 0.376 . . . . 0.0 110.725 -179.573 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -119.12 14.01 11.18 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.907 -0.663 . . . . 0.0 112.56 179.77 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 17.9 pt20 -78.56 154.19 78.75 Favored Pre-proline 0 C--N 1.331 -0.198 0 CA-C-O 120.75 0.31 . . . . 0.0 110.906 179.932 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 29.3 Cg_endo -63.83 160.68 35.88 Favored 'Trans proline' 0 C--N 1.345 0.378 0 C-N-CA 122.541 2.161 . . . . 0.0 112.31 -179.972 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 6.1 p80 -117.9 106.34 12.87 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.649 179.707 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 94.46 -26.52 17.36 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.452 -179.812 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 149.69 92.7 0.1 Allowed Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.497 179.99 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 58.88 -158.43 20.0 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.676 -0.773 . . . . 0.0 112.56 179.965 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' TRP . . . . . 0.528 ' CD1' ' N ' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -141.31 -79.08 0.26 Allowed 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.928 0.394 . . . . 0.0 110.627 -179.601 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -116.99 13.93 14.09 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.83 -0.7 . . . . 0.0 112.47 179.842 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 21.2 pt20 -89.55 154.52 48.46 Favored Pre-proline 0 C--N 1.331 -0.197 0 CA-C-O 120.661 0.267 . . . . 0.0 110.881 -179.966 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 39.8 Cg_endo -67.06 148.38 81.33 Favored 'Trans proline' 0 C--N 1.344 0.319 0 C-N-CA 122.485 2.123 . . . . 0.0 112.26 179.921 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' HIS . . . . . 0.4 ' CD2' ' O ' ' A' ' 77' ' ' HIS . 9.5 t-160 -97.54 6.22 48.42 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.379 179.956 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 150.81 44.57 0.02 OUTLIER Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.524 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 168.37 -82.92 0.1 OUTLIER Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.52 -179.973 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -169.64 -160.8 18.77 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.516 -179.941 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' TRP . . . . . 0.472 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -147.53 -77.96 0.16 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.901 0.381 . . . . 0.0 110.747 -179.613 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -105.86 -20.9 8.97 Favored Glycine 0 N--CA 1.45 -0.398 0 C-N-CA 120.915 -0.66 . . . . 0.0 112.46 179.807 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 20.8 pt20 -63.98 154.2 82.45 Favored Pre-proline 0 C--N 1.33 -0.25 0 CA-C-O 120.71 0.29 . . . . 0.0 110.887 179.935 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo -66.27 177.58 3.08 Favored 'Trans proline' 0 C--N 1.344 0.338 0 C-N-CA 122.62 2.213 . . . . 0.0 112.293 179.9 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 27.4 p-80 -99.96 -30.99 11.69 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.887 179.93 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -162.66 28.78 0.26 Allowed Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.461 179.949 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 170.12 -92.3 0.1 OUTLIER Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.599 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -138.74 -156.5 7.05 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.589 179.953 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' TRP . . . . . 0.478 ' CD1' ' N ' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -147.8 -78.01 0.16 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.908 0.385 . . . . 0.0 110.707 -179.576 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -134.98 16.92 4.17 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.904 -0.665 . . . . 0.0 112.59 179.849 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 7.0 pt20 . . . . . 0 C--O 1.249 1.069 0 CA-C-O 118.238 -0.887 . . . . 0.0 110.93 -179.991 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' TRP . . . . . . . . . . . . . 6.9 t90 . . . . . 0 N--CA 1.487 1.394 0 CA-C-O 120.771 0.32 . . . . 0.0 111.214 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . 0.473 ' O ' ' CG ' ' A' ' 59' ' ' GLN . . . -58.45 -28.31 62.02 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.586 179.977 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.473 ' CG ' ' O ' ' A' ' 58' ' ' GLY . 3.0 pt20 54.92 154.32 0.05 OUTLIER Pre-proline 0 N--CA 1.463 0.206 0 CA-C-O 121.01 0.433 . . . . 0.0 111.558 179.994 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_endo -64.36 155.83 63.56 Favored 'Trans proline' 0 C--N 1.345 0.376 0 C-N-CA 122.55 2.166 . . . . 0.0 112.295 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' HIS . . . . . . . . . . . . . 23.8 t-160 -103.07 -30.2 10.89 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.859 179.944 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 175.27 38.33 0.05 OUTLIER Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.665 -0.779 . . . . 0.0 112.54 179.988 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 170.02 39.73 0.03 OUTLIER Glycine 0 N--CA 1.452 -0.248 0 C-N-CA 120.604 -0.808 . . . . 0.0 112.576 179.918 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 56.37 -154.15 16.66 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.674 179.856 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' TRP . . . . . 0.475 ' CD1' ' N ' ' A' ' 65' ' ' TRP . 0.0 OUTLIER -147.39 -77.94 0.17 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.959 0.409 . . . . 0.0 110.676 -179.613 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -108.91 -19.61 8.5 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.953 -0.642 . . . . 0.0 112.425 179.866 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 14.5 pt20 -61.42 152.91 71.72 Favored Pre-proline 0 C--N 1.33 -0.258 0 CA-C-O 120.728 0.299 . . . . 0.0 110.908 -179.965 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 21.4 Cg_endo -62.06 137.76 68.75 Favored 'Trans proline' 0 C--N 1.345 0.367 0 C-N-CA 122.599 2.199 . . . . 0.0 112.343 -179.948 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 3.2 t-80 -113.46 6.15 17.02 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.281 179.883 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . -174.45 33.87 0.11 Allowed Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.566 -179.982 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 105.39 88.09 2.03 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.578 179.906 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 58.31 -170.85 4.32 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.599 179.881 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' TRP . . . . . 0.499 ' CD1' ' N ' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -144.78 -77.79 0.2 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.921 0.391 . . . . 0.0 110.8 -179.607 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -103.39 -23.06 8.64 Favored Glycine 0 N--CA 1.449 -0.437 0 C-N-CA 120.954 -0.641 . . . . 0.0 112.517 179.884 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 3.1 pt20 -62.35 151.29 82.76 Favored Pre-proline 0 C--N 1.33 -0.249 0 CA-C-O 120.717 0.294 . . . . 0.0 110.907 -179.986 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 23.9 Cg_endo -62.36 155.48 57.11 Favored 'Trans proline' 0 C--N 1.344 0.337 0 C-N-CA 122.587 2.191 . . . . 0.0 112.386 179.939 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 8.3 p80 -109.55 -29.92 8.16 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.84 179.817 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -112.35 -57.06 0.44 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.8 -0.715 . . . . 0.0 112.488 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -169.86 32.16 0.16 Allowed Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.649 179.965 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 138.75 -169.3 24.44 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.646 -0.788 . . . . 0.0 112.611 -179.973 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' TRP . . . . . 0.491 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -145.65 -77.98 0.19 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.919 0.39 . . . . 0.0 110.781 -179.681 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -102.69 -20.3 11.99 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.87 -0.681 . . . . 0.0 112.558 179.927 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 12.5 pt20 -58.71 153.78 39.68 Favored Pre-proline 0 C--N 1.332 -0.195 0 CA-C-O 120.784 0.326 . . . . 0.0 110.952 -179.963 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 30.5 Cg_endo -64.2 154.13 72.55 Favored 'Trans proline' 0 C--N 1.345 0.361 0 C-N-CA 122.542 2.162 . . . . 0.0 112.267 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 1.6 t-80 -108.96 -29.82 8.4 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.82 179.872 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -108.5 -61.46 0.54 Allowed Glycine 0 N--CA 1.45 -0.406 0 C-N-CA 120.821 -0.704 . . . . 0.0 112.469 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -166.75 30.6 0.19 Allowed Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.569 179.946 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 135.31 -165.78 24.62 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.586 179.919 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' TRP . . . . . 0.489 ' CD1' ' N ' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -146.1 -79.36 0.17 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.902 0.382 . . . . 0.0 110.727 -179.626 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -139.13 22.67 2.92 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.99 -0.624 . . . . 0.0 112.175 179.779 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 20.2 mt-30 . . . . . 0 C--O 1.249 1.03 0 CA-C-O 118.223 -0.894 . . . . 0.0 110.933 -179.923 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' TRP . . . . . . . . . . . . . 5.4 t-105 . . . . . 0 N--CA 1.487 1.383 0 CA-C-O 120.896 0.379 . . . . 0.0 111.169 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -160.57 28.51 0.32 Allowed Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.496 179.972 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 4.2 pt20 -168.03 154.4 7.26 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 120.691 0.281 . . . . 0.0 110.878 179.969 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo -68.84 142.58 52.54 Favored 'Trans proline' 0 C--N 1.344 0.309 0 C-N-CA 122.57 2.18 . . . . 0.0 112.295 179.933 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' HIS . . . . . . . . . . . . . 1.2 t-160 -94.82 6.42 49.03 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.322 179.966 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 156.39 43.68 0.02 OUTLIER Glycine 0 C--N 1.332 0.327 0 C-N-CA 120.619 -0.8 . . . . 0.0 112.474 -179.973 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 163.79 -92.94 0.11 Allowed Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.613 -0.803 . . . . 0.0 112.475 -179.994 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -156.23 -162.34 11.35 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.816 -0.707 . . . . 0.0 112.581 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' TRP . . . . . 0.498 ' N ' ' CD1' ' A' ' 65' ' ' TRP . 0.0 OUTLIER -146.33 -79.04 0.17 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.898 0.38 . . . . 0.0 110.795 -179.665 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -119.28 15.14 10.88 Favored Glycine 0 N--CA 1.452 -0.268 0 C-N-CA 120.857 -0.687 . . . . 0.0 112.468 179.761 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 14.3 pt20 -76.57 154.16 83.64 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-O 120.645 0.26 . . . . 0.0 110.907 179.975 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 28.7 Cg_endo -63.32 158.13 46.49 Favored 'Trans proline' 0 C--N 1.343 0.244 0 C-N-CA 122.629 2.219 . . . . 0.0 112.307 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 23.7 t-160 -109.59 -30.55 7.86 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.82 179.902 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . -139.08 26.45 2.72 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.573 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 111.75 94.41 2.2 Favored Glycine 0 N--CA 1.453 -0.232 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.519 179.967 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 57.99 -174.19 2.58 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.584 179.879 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' TRP . . . . . 0.494 ' CD1' ' N ' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -146.25 -79.72 0.16 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.867 0.365 . . . . 0.0 110.791 -179.624 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -120.0 16.96 10.05 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.936 -0.649 . . . . 0.0 112.467 179.714 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 6.6 pt20 -77.29 154.79 82.12 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 120.734 0.302 . . . . 0.0 110.801 -179.965 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 32.7 Cg_endo -64.57 154.56 71.42 Favored 'Trans proline' 0 C--N 1.344 0.32 0 C-N-CA 122.465 2.11 . . . . 0.0 112.264 179.879 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 23.1 t-160 -102.85 -30.38 10.88 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.829 179.871 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -148.98 27.74 1.27 Allowed Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.431 179.991 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 162.48 -108.64 0.35 Allowed Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.487 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -123.26 -158.44 10.18 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.561 179.975 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' TRP . . . . . 0.477 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -147.7 -78.36 0.16 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.847 0.356 . . . . 0.0 110.748 -179.574 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -111.2 -18.36 8.24 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.928 -0.653 . . . . 0.0 112.523 179.908 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 4.6 pt20 -58.03 154.0 31.59 Favored Pre-proline 0 C--N 1.331 -0.232 0 CA-C-O 120.732 0.301 . . . . 0.0 110.931 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 28.1 Cg_endo -63.47 161.44 31.35 Favored 'Trans proline' 0 C--N 1.344 0.329 0 C-N-CA 122.581 2.188 . . . . 0.0 112.335 179.942 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' HIS . . . . . 0.401 ' CD2' ' N ' ' A' ' 85' ' ' HIS . 3.5 m-70 -118.32 106.15 12.47 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.674 179.694 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 94.43 -26.51 17.37 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.452 -179.801 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 150.06 92.43 0.1 OUTLIER Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.51 -179.98 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 59.1 -156.78 24.36 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.591 -179.968 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' TRP . . . . . 0.501 ' CD1' ' N ' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -142.58 -78.5 0.24 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.959 0.409 . . . . 0.0 110.666 -179.656 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -134.84 16.53 4.24 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.907 -0.663 . . . . 0.0 112.54 179.902 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 3.6 pt20 . . . . . 0 C--O 1.249 1.063 0 CA-C-O 118.2 -0.905 . . . . 0.0 110.927 179.996 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.487 1.402 0 CA-C-O 120.884 0.373 . . . . 0.0 111.134 . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 150.21 -32.04 1.05 Allowed Glycine 0 N--CA 1.452 -0.254 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.455 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 14.2 pt20 -132.36 153.58 81.28 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 120.668 0.271 . . . . 0.0 110.854 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -70.69 138.22 34.39 Favored 'Trans proline' 0 C--N 1.343 0.284 0 C-N-CA 122.44 2.093 . . . . 0.0 112.224 179.829 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' HIS . . . . . . . . . . . . . 5.4 m170 -107.97 105.43 15.21 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.728 179.643 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 104.58 -30.92 9.24 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.455 -179.848 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 151.24 93.4 0.1 Allowed Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.609 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 52.93 -162.11 2.53 Favored Glycine 0 CA--C 1.518 0.226 0 C-N-CA 120.854 -0.689 . . . . 0.0 112.732 179.979 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' TRP . . . . . 0.539 ' N ' ' CD1' ' A' ' 65' ' ' TRP . 0.0 OUTLIER -137.41 -78.61 0.39 Allowed 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 120.912 0.387 . . . . 0.0 110.718 -179.691 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -106.48 -21.88 8.09 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.945 -0.645 . . . . 0.0 112.404 179.87 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 16.8 pt20 -61.17 154.07 63.85 Favored Pre-proline 0 C--N 1.33 -0.251 0 CA-C-O 120.626 0.251 . . . . 0.0 110.896 -179.996 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 34.7 Cg_endo -65.58 153.13 79.55 Favored 'Trans proline' 0 C--N 1.344 0.311 0 C-N-CA 122.504 2.136 . . . . 0.0 112.272 179.997 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 19.9 p-80 -101.72 -30.5 11.28 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.825 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . -178.23 36.14 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.468 -179.931 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -171.74 -65.03 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.559 179.989 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 167.34 -159.67 33.08 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.496 -179.946 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' TRP . . . . . 0.493 ' CD1' ' N ' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -146.2 -77.97 0.18 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.939 0.399 . . . . 0.0 110.794 -179.672 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -104.74 -21.17 9.32 Favored Glycine 0 N--CA 1.45 -0.416 0 C-N-CA 120.888 -0.673 . . . . 0.0 112.485 179.755 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 17.6 pt20 -65.74 154.0 89.74 Favored Pre-proline 0 C--N 1.331 -0.225 0 CA-C-O 120.751 0.31 . . . . 0.0 110.861 179.971 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . 0.413 ' HD3' ' CD1' ' A' ' 81' ' ' TRP . 33.7 Cg_endo -65.32 149.04 88.8 Favored 'Trans proline' 0 C--N 1.345 0.342 0 C-N-CA 122.535 2.156 . . . . 0.0 112.227 179.951 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 4.2 t-160 -102.82 6.56 39.31 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.369 179.93 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 158.39 -26.43 0.41 Allowed Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.64 -0.791 . . . . 0.0 112.536 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -113.64 -82.1 1.09 Allowed Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.545 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -171.16 -157.86 13.94 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.673 -0.775 . . . . 0.0 112.504 -179.961 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' TRP . . . . . 0.498 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -145.18 -78.6 0.19 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.949 0.404 . . . . 0.0 110.682 -179.574 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -112.85 10.87 25.24 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.87 -0.681 . . . . 0.0 112.574 179.829 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 19.0 pt20 -96.32 154.56 38.66 Favored Pre-proline 0 C--N 1.332 -0.164 0 CA-C-O 120.747 0.308 . . . . 0.0 110.878 179.933 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 42.3 Cg_endo -67.71 141.39 54.48 Favored 'Trans proline' 0 C--N 1.345 0.364 0 C-N-CA 122.486 2.124 . . . . 0.0 112.244 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 45.5 m-70 -95.89 -30.65 13.53 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.853 -179.973 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -118.92 -52.19 0.29 Allowed Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.515 -179.939 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -172.38 88.63 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.539 179.973 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 69.55 -170.68 42.22 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.604 -179.961 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' TRP . . . . . 0.482 ' CD1' ' N ' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -147.3 -78.74 0.16 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.946 0.403 . . . . 0.0 110.735 -179.641 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -138.49 22.19 3.04 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.96 -0.638 . . . . 0.0 112.194 179.749 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 6.2 mt-30 . . . . . 0 C--O 1.25 1.087 0 CA-C-O 118.19 -0.91 . . . . 0.0 110.911 -179.85 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' TRP . . . . . . . . . . . . . 30.8 t-105 . . . . . 0 N--CA 1.486 1.342 0 CA-C-O 120.798 0.333 . . . . 0.0 111.2 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -69.09 -61.51 4.53 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.481 -179.989 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 10.1 pt20 -176.57 154.34 1.26 Allowed Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 120.766 0.317 . . . . 0.0 110.834 179.941 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -68.91 123.86 10.83 Favored 'Trans proline' 0 C--N 1.344 0.301 0 C-N-CA 122.525 2.15 . . . . 0.0 112.355 179.908 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' HIS . . . . . . . . . . . . . 8.2 m170 -89.94 6.18 43.22 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.34 179.977 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 179.29 37.04 0.07 OUTLIER Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.69 -0.766 . . . . 0.0 112.511 179.968 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 146.71 -101.85 0.24 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.5 -179.933 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -136.38 -157.43 7.76 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.506 -179.93 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' TRP . . . . . 0.475 ' CD1' ' N ' ' A' ' 65' ' ' TRP . 0.0 OUTLIER -147.52 -78.09 0.16 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.912 0.387 . . . . 0.0 110.725 -179.597 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -108.17 -19.88 8.68 Favored Glycine 0 N--CA 1.45 -0.419 0 C-N-CA 120.905 -0.664 . . . . 0.0 112.524 179.766 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 13.6 pt20 -60.07 154.2 51.71 Favored Pre-proline 0 C--N 1.331 -0.237 0 CA-C-O 120.661 0.267 . . . . 0.0 110.902 -179.993 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 42.3 Cg_endo -68.32 150.34 76.15 Favored 'Trans proline' 0 C--N 1.343 0.262 0 C-N-CA 122.478 2.119 . . . . 0.0 112.338 179.935 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 23.8 t-160 -96.29 -29.92 13.73 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.803 179.902 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . -152.41 26.83 0.87 Allowed Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.504 179.864 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 166.33 -94.11 0.11 Allowed Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.682 -0.77 . . . . 0.0 112.519 -179.957 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -133.91 -158.69 8.68 Favored Glycine 0 N--CA 1.452 -0.254 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.464 -179.904 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' TRP . . . . . 0.492 ' CD1' ' N ' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -146.75 -78.53 0.17 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.917 0.389 . . . . 0.0 110.77 -179.601 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -103.93 -20.65 10.37 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.927 -0.654 . . . . 0.0 112.477 179.823 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 17.9 pt20 -65.1 153.91 88.09 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-O 120.682 0.277 . . . . 0.0 110.852 -179.984 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_endo -69.69 140.09 42.07 Favored 'Trans proline' 0 C--N 1.343 0.283 0 C-N-CA 122.502 2.134 . . . . 0.0 112.414 179.947 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 25.3 p80 -92.23 -31.43 15.44 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.653 179.757 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -120.6 -35.69 0.83 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.845 -0.693 . . . . 0.0 112.411 179.981 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -155.12 -78.0 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.5 -179.952 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -130.62 -157.67 9.03 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.575 -179.951 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 81' ' ' TRP . . . . . 0.48 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -146.75 -78.06 0.17 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.857 0.36 . . . . 0.0 110.731 -179.646 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -105.96 -20.06 9.65 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.886 -0.673 . . . . 0.0 112.532 179.898 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 11.1 pt20 -59.72 154.2 48.0 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-O 120.699 0.285 . . . . 0.0 110.895 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.9 140.57 42.47 Favored 'Trans proline' 0 C--N 1.343 0.263 0 C-N-CA 122.551 2.167 . . . . 0.0 112.314 179.913 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 7.8 m-70 -93.53 -30.46 14.99 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.892 179.925 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -147.38 27.8 1.52 Allowed Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.522 -179.97 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 163.25 -102.27 0.2 Allowed Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.53 179.933 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -130.93 -156.89 8.7 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.552 -179.934 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 89' ' ' TRP . . . . . 0.479 ' CD1' ' N ' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -147.18 -77.99 0.17 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.934 0.397 . . . . 0.0 110.779 -179.65 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -134.78 17.67 4.14 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.923 -0.656 . . . . 0.0 112.528 179.823 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 5.9 pt20 . . . . . 0 C--O 1.249 1.074 0 CA-C-O 118.193 -0.908 . . . . 0.0 110.849 -179.964 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' TRP . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 N--CA 1.489 1.5 0 CA-C-O 120.75 0.309 . . . . 0.0 111.421 . . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . 0.403 ' O ' ' CG ' ' A' ' 59' ' ' GLN . . . -95.0 -29.17 9.27 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.543 179.997 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.403 ' CG ' ' O ' ' A' ' 58' ' ' GLY . 0.0 OUTLIER 56.19 156.42 0.07 OUTLIER Pre-proline 0 CA--C 1.53 0.201 0 CA-C-O 120.776 0.322 . . . . 0.0 111.48 -179.947 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -72.57 128.77 13.85 Favored 'Trans proline' 0 C--N 1.343 0.265 0 C-N-CA 122.62 2.213 . . . . 0.0 112.212 -179.851 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' HIS . . . . . . . . . . . . . 8.8 m170 -90.06 6.06 44.0 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.408 179.897 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 164.28 42.26 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.579 -0.819 . . . . 0.0 112.462 179.98 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 160.14 -96.52 0.15 Allowed Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.472 179.966 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -152.2 -159.78 9.17 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.558 -179.947 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' TRP . . . . . 0.486 ' N ' ' CD1' ' A' ' 65' ' ' TRP . 0.0 OUTLIER -147.13 -77.6 0.17 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.947 0.403 . . . . 0.0 110.734 -179.617 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -108.98 -19.01 8.83 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.978 -0.63 . . . . 0.0 112.582 179.908 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 15.0 pt20 -58.61 154.37 35.44 Favored Pre-proline 0 C--N 1.331 -0.209 0 CA-C-O 120.659 0.266 . . . . 0.0 110.891 -179.931 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 41.8 Cg_endo -67.76 154.02 74.28 Favored 'Trans proline' 0 C--N 1.343 0.271 0 C-N-CA 122.576 2.184 . . . . 0.0 112.249 179.925 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 23.1 t-160 -101.3 -31.33 11.02 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.85 179.994 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . -124.11 -40.16 0.46 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.822 -0.704 . . . . 0.0 112.54 179.949 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -179.29 92.47 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.583 -179.979 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 60.93 -170.71 7.93 Favored Glycine 0 N--CA 1.452 -0.254 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.495 179.999 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' TRP . . . . . 0.488 ' CD1' ' N ' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -146.86 -78.89 0.16 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.942 0.401 . . . . 0.0 110.811 -179.648 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -117.79 14.43 12.83 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.964 -0.636 . . . . 0.0 112.585 179.782 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 8.6 pt20 -84.21 154.36 63.3 Favored Pre-proline 0 C--N 1.331 -0.2 0 CA-C-O 120.684 0.278 . . . . 0.0 110.847 -179.972 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -66.43 146.88 81.64 Favored 'Trans proline' 0 C--N 1.344 0.317 0 C-N-CA 122.557 2.171 . . . . 0.0 112.253 179.89 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 7.8 t60 -98.68 -31.01 12.14 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.917 179.902 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -128.38 -42.18 0.26 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.435 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -172.76 94.15 0.1 OUTLIER Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.556 -179.967 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 62.01 -170.29 11.48 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.545 -179.926 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 81' ' ' TRP . . . . . 0.491 ' CD1' ' N ' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -147.16 -78.65 0.16 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.93 0.395 . . . . 0.0 110.713 -179.552 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -117.85 14.03 12.85 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.86 -0.686 . . . . 0.0 112.505 179.857 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 21.5 pt20 -81.34 154.62 71.86 Favored Pre-proline 0 C--N 1.331 -0.214 0 CA-C-O 120.736 0.303 . . . . 0.0 110.857 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 40.3 Cg_endo -67.12 143.39 65.03 Favored 'Trans proline' 0 C--N 1.344 0.322 0 C-N-CA 122.541 2.161 . . . . 0.0 112.265 179.967 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 45.2 m-70 -97.43 -30.84 12.68 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.882 179.983 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -126.31 -41.49 0.32 Allowed Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.457 -179.947 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -175.23 96.18 0.1 Allowed Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.672 -0.775 . . . . 0.0 112.471 179.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 59.64 -169.51 6.82 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.557 -179.982 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 89' ' ' TRP . . . . . 0.481 ' CD1' ' N ' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -148.26 -76.62 0.17 Allowed 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.961 0.41 . . . . 0.0 110.763 -179.632 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -112.88 -22.12 5.78 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.92 -0.657 . . . . 0.0 112.537 179.88 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 1.1 pt20 . . . . . 0 C--O 1.248 1.008 0 CA-C-O 118.27 -0.871 . . . . 0.0 110.9 179.991 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.486 1.354 0 CA-C-O 120.864 0.364 . . . . 0.0 111.134 . . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . 0.465 ' O ' ' CG ' ' A' ' 59' ' ' GLN . . . 167.22 -31.62 0.19 Allowed Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.496 179.974 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.465 ' CG ' ' O ' ' A' ' 58' ' ' GLY . 7.1 pt20 54.74 154.83 0.05 OUTLIER Pre-proline 0 CA--C 1.53 0.208 0 CA-C-O 120.94 0.4 . . . . 0.0 111.586 -179.994 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -70.98 148.84 58.06 Favored 'Trans proline' 0 C--N 1.345 0.348 0 C-N-CA 122.459 2.106 . . . . 0.0 112.307 -179.835 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' HIS . . . . . . . . . . . . . 23.7 t-160 -92.11 -30.79 15.79 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.803 179.915 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -113.26 -28.04 3.45 Favored Glycine 0 N--CA 1.45 -0.39 0 C-N-CA 120.806 -0.711 . . . . 0.0 112.453 179.961 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 175.3 -47.62 0.13 Allowed Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.529 179.987 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -148.14 -161.53 9.61 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.502 -179.896 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' TRP . . . . . 0.491 ' N ' ' CD1' ' A' ' 65' ' ' TRP . 0.0 OUTLIER -145.97 -79.33 0.17 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.93 0.395 . . . . 0.0 110.755 -179.614 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -111.77 12.3 27.44 Favored Glycine 0 N--CA 1.45 -0.417 0 C-N-CA 120.887 -0.673 . . . . 0.0 112.585 179.785 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 14.9 pt20 -101.39 154.19 37.38 Favored Pre-proline 0 C--N 1.332 -0.19 0 CA-C-O 120.657 0.265 . . . . 0.0 110.836 -179.932 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 39.6 Cg_endo -67.45 152.33 78.84 Favored 'Trans proline' 0 C--N 1.343 0.275 0 C-N-CA 122.531 2.154 . . . . 0.0 112.289 179.934 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 15.8 p80 -97.28 -30.08 13.18 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.776 179.881 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . -152.67 26.69 0.84 Allowed Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.81 -0.709 . . . . 0.0 112.485 179.948 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 166.09 -92.87 0.11 Allowed Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.459 179.965 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -133.98 -158.82 8.71 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.533 -179.897 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 73' ' ' TRP . . . . . 0.483 ' CD1' ' N ' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -146.46 -78.96 0.17 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.92 0.39 . . . . 0.0 110.705 -179.628 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -113.96 10.61 22.9 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.845 -0.693 . . . . 0.0 112.662 179.845 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 13.6 pt20 -93.16 153.35 41.68 Favored Pre-proline 0 C--N 1.331 -0.216 0 CA-C-O 120.704 0.288 . . . . 0.0 110.889 179.973 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . 0.413 ' HD3' ' CD1' ' A' ' 81' ' ' TRP . 28.8 Cg_endo -64.08 151.96 83.06 Favored 'Trans proline' 0 C--N 1.344 0.322 0 C-N-CA 122.529 2.153 . . . . 0.0 112.31 -179.989 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 15.7 t-160 -107.68 -28.62 9.61 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.821 179.902 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -157.02 25.6 0.49 Allowed Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.552 -179.998 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 134.86 89.32 0.31 Allowed Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.664 -0.779 . . . . 0.0 112.595 179.867 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 56.92 -176.34 1.17 Allowed Glycine 0 N--CA 1.452 -0.237 0 C-N-CA 120.807 -0.711 . . . . 0.0 112.645 179.888 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 81' ' ' TRP . . . . . 0.527 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -142.14 -79.22 0.24 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.908 0.385 . . . . 0.0 110.819 -179.48 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -118.45 19.28 10.72 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.834 -0.698 . . . . 0.0 112.551 179.797 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 24.4 pt20 -85.08 154.38 60.47 Favored Pre-proline 0 C--N 1.331 -0.228 0 CA-C-O 120.702 0.287 . . . . 0.0 110.827 179.977 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -66.54 158.55 55.07 Favored 'Trans proline' 0 C--N 1.344 0.31 0 C-N-CA 122.56 2.174 . . . . 0.0 112.329 179.903 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 29.1 m80 -107.99 -30.79 8.26 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.916 179.968 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -133.72 27.7 3.32 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.72 -0.753 . . . . 0.0 112.503 -179.999 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 104.5 93.56 2.3 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.523 179.921 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 59.36 -169.86 6.16 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.547 179.938 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 89' ' ' TRP . . . . . 0.484 ' CD1' ' N ' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -147.5 -77.79 0.17 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.942 0.401 . . . . 0.0 110.751 -179.626 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -134.8 17.99 4.11 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.918 -0.658 . . . . 0.0 112.574 179.871 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 2.0 pt20 . . . . . 0 C--O 1.248 1.017 0 CA-C-O 118.233 -0.889 . . . . 0.0 110.868 -179.97 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' TRP . . . . . 0.412 ' CE2' ' HB3' ' A' ' 59' ' ' GLN . 30.4 t-105 . . . . . 0 N--CA 1.487 1.383 0 CA-C-O 120.828 0.346 . . . . 0.0 111.209 . . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -158.07 61.1 0.32 Allowed Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.45 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.412 ' HB3' ' CE2' ' A' ' 57' ' ' TRP . 6.6 pm0 -58.66 154.38 35.85 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 120.729 0.3 . . . . 0.0 111.011 179.897 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 38.5 Cg_endo -66.67 128.06 18.31 Favored 'Trans proline' 0 C--N 1.345 0.351 0 C-N-CA 122.527 2.151 . . . . 0.0 112.264 179.938 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' HIS . . . . . . . . . . . . . 3.8 t-160 -94.93 6.51 48.84 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.323 179.878 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -154.83 -43.81 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.448 179.956 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -150.06 -70.28 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.57 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -147.16 -157.53 7.43 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.544 -179.961 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' TRP . . . . . 0.493 ' N ' ' CD1' ' A' ' 65' ' ' TRP . 0.0 OUTLIER -147.05 -78.68 0.16 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.872 0.367 . . . . 0.0 110.714 -179.588 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -115.18 10.9 20.09 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.894 -0.67 . . . . 0.0 112.586 179.821 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 21.2 pt20 -82.03 157.01 69.29 Favored Pre-proline 0 C--N 1.332 -0.175 0 CA-C-O 120.636 0.255 . . . . 0.0 110.899 179.994 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . 0.469 ' HB3' ' CD1' ' A' ' 73' ' ' TRP . 73.2 Cg_endo -77.76 147.79 24.92 Favored 'Trans proline' 0 C--N 1.343 0.288 0 C-N-CA 122.45 2.1 . . . . 0.0 112.313 179.954 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 16.6 p-80 -114.02 108.39 16.95 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.0 -179.964 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 57.73 28.93 60.8 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.8 -0.714 . . . . 0.0 112.614 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 161.14 -109.63 0.4 Allowed Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.523 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . 0.433 ' HA2' ' HB3' ' A' ' 68' ' ' PRO . . . -151.68 -178.8 26.79 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.68 -0.772 . . . . 0.0 112.507 -179.854 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 73' ' ' TRP . . . . . 0.6 ' CD1' ' N ' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -123.06 -78.42 0.6 Allowed 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.896 0.379 . . . . 0.0 110.709 -179.639 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -109.86 -19.15 8.35 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.947 -0.644 . . . . 0.0 112.457 179.799 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 13.8 pt20 -59.34 153.87 45.83 Favored Pre-proline 0 C--N 1.33 -0.249 0 CA-C-O 120.722 0.296 . . . . 0.0 110.894 -179.99 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 30.6 Cg_endo -64.07 153.55 75.49 Favored 'Trans proline' 0 C--N 1.344 0.334 0 C-N-CA 122.568 2.179 . . . . 0.0 112.321 179.956 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 13.2 p80 -107.25 -30.66 8.6 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.817 179.931 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -108.09 -62.83 0.56 Allowed Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.51 179.949 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -164.41 29.26 0.22 Allowed Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.564 -179.981 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 136.16 -164.52 25.04 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.575 179.984 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 81' ' ' TRP . . . . . 0.497 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -146.1 -78.69 0.17 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.941 0.401 . . . . 0.0 110.788 -179.621 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -116.74 13.89 14.78 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.851 -0.69 . . . . 0.0 112.573 179.807 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 18.8 pt20 -86.21 154.31 57.26 Favored Pre-proline 0 C--N 1.331 -0.204 0 CA-C-O 120.688 0.28 . . . . 0.0 110.879 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 38.9 Cg_endo -66.89 153.4 78.04 Favored 'Trans proline' 0 C--N 1.344 0.301 0 C-N-CA 122.565 2.177 . . . . 0.0 112.277 -179.995 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 3.5 t-80 -107.76 -31.1 8.19 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.9 179.928 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -129.61 27.91 4.08 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.51 179.949 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 101.33 96.02 2.25 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.55 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 59.51 -169.45 6.64 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.548 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 89' ' ' TRP . . . . . 0.47 ' CD1' ' N ' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -147.38 -77.61 0.17 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.938 0.399 . . . . 0.0 110.82 -179.612 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -134.69 18.19 4.11 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.907 -0.663 . . . . 0.0 112.556 179.872 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 2.9 pt20 . . . . . 0 C--O 1.249 1.065 0 CA-C-O 118.282 -0.866 . . . . 0.0 110.92 179.995 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' TRP . . . . . . . . . . . . . 1.2 t90 . . . . . 0 N--CA 1.485 1.319 0 CA-C-O 120.788 0.328 . . . . 0.0 111.244 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -177.62 48.55 0.1 OUTLIER Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.718 -0.754 . . . . 0.0 112.507 -179.987 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 3.2 pt20 -171.96 154.33 3.45 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 120.68 0.276 . . . . 0.0 110.883 -179.956 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo -68.88 149.86 72.84 Favored 'Trans proline' 0 C--N 1.344 0.299 0 C-N-CA 122.528 2.152 . . . . 0.0 112.284 179.892 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' HIS . . . . . . . . . . . . . 23.8 t-160 -95.51 -30.5 13.81 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.871 -179.988 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -170.83 36.29 0.17 Allowed Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.503 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -178.67 -81.24 0.06 OUTLIER Glycine 0 N--CA 1.452 -0.247 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.58 -179.998 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -170.4 -158.76 14.84 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.536 -180.0 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' TRP . . . . . 0.494 ' N ' ' CD1' ' A' ' 65' ' ' TRP . 0.0 OUTLIER -146.45 -78.41 0.17 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.921 0.391 . . . . 0.0 110.745 -179.655 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -118.25 13.11 12.5 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.88 -0.676 . . . . 0.0 112.554 179.797 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -78.85 154.59 78.07 Favored Pre-proline 0 C--N 1.332 -0.193 0 CA-C-O 120.709 0.29 . . . . 0.0 110.878 -179.98 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -66.43 149.15 84.77 Favored 'Trans proline' 0 C--N 1.344 0.316 0 C-N-CA 122.493 2.129 . . . . 0.0 112.255 179.94 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 12.6 t-160 -98.33 6.16 47.59 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.335 179.956 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 172.38 39.61 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.626 -0.797 . . . . 0.0 112.491 179.945 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 148.12 -97.79 0.18 Allowed Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.67 -0.776 . . . . 0.0 112.501 179.958 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -139.2 -157.18 7.22 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.472 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 73' ' ' TRP . . . . . 0.487 ' CD1' ' N ' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -147.71 -77.95 0.16 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.993 0.425 . . . . 0.0 110.708 -179.583 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -105.53 -20.48 9.51 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.912 -0.661 . . . . 0.0 112.347 179.861 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 13.5 pt20 -65.47 154.43 87.97 Favored Pre-proline 0 C--N 1.33 -0.241 0 CA-C-O 120.652 0.263 . . . . 0.0 110.898 -179.954 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 40.1 Cg_endo -67.14 154.8 73.22 Favored 'Trans proline' 0 C--N 1.343 0.257 0 C-N-CA 122.536 2.157 . . . . 0.0 112.256 179.937 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 5.3 p-80 -100.55 -31.67 11.15 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.912 179.99 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -125.24 -47.36 0.22 Allowed Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.457 179.985 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -171.82 87.38 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.459 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 72.67 -169.54 52.12 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.546 179.987 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 81' ' ' TRP . . . . . 0.482 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -148.12 -76.14 0.17 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.921 0.391 . . . . 0.0 110.785 -179.649 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -107.05 -21.73 7.94 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.935 -0.65 . . . . 0.0 112.455 179.833 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 15.6 pt20 -60.1 154.4 50.99 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 120.677 0.275 . . . . 0.0 110.865 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 44.5 Cg_endo -68.34 141.13 50.58 Favored 'Trans proline' 0 C--N 1.344 0.331 0 C-N-CA 122.539 2.159 . . . . 0.0 112.248 179.958 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 13.7 m-70 -95.17 -31.14 13.67 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.934 179.966 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -125.2 -40.99 0.38 Allowed Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.821 -0.704 . . . . 0.0 112.437 -179.959 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -176.92 96.55 0.1 Allowed Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.509 -179.946 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 59.64 -170.36 6.3 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.55 -179.986 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 89' ' ' TRP . . . . . 0.483 ' CD1' ' N ' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -147.58 -77.82 0.16 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.901 0.381 . . . . 0.0 110.831 -179.664 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -133.66 18.55 4.32 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.853 -0.689 . . . . 0.0 112.514 179.776 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 6.5 pt20 . . . . . 0 C--O 1.249 1.052 0 CA-C-O 118.179 -0.915 . . . . 0.0 110.949 -179.998 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' TRP . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.485 1.312 0 CA-C-O 120.782 0.325 . . . . 0.0 111.245 . . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -172.71 45.39 0.17 Allowed Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.501 -179.956 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 12.2 pt20 -160.72 154.4 18.83 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-O 120.716 0.293 . . . . 0.0 110.91 -179.971 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_endo -69.56 150.5 69.52 Favored 'Trans proline' 0 C--N 1.344 0.329 0 C-N-CA 122.529 2.153 . . . . 0.0 112.243 179.934 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' HIS . . . . . . . . . . . . . 14.2 p80 -94.17 -30.97 14.34 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.865 179.963 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -169.27 33.84 0.18 Allowed Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.808 -0.711 . . . . 0.0 112.542 179.943 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -177.01 -84.0 0.06 OUTLIER Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.496 -179.978 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -166.2 -158.71 11.22 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.53 -179.879 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 65' ' ' TRP . . . . . 0.488 ' N ' ' CD1' ' A' ' 65' ' ' TRP . 0.0 OUTLIER -146.72 -78.95 0.16 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.853 0.359 . . . . 0.0 110.75 -179.629 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -117.53 13.19 13.54 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.877 -0.678 . . . . 0.0 112.482 179.765 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 3.9 pt20 -79.69 154.49 75.98 Favored Pre-proline 0 C--N 1.331 -0.226 0 CA-C-O 120.711 0.291 . . . . 0.0 110.872 -179.968 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_endo -68.48 150.86 75.8 Favored 'Trans proline' 0 C--N 1.344 0.31 0 C-N-CA 122.552 2.168 . . . . 0.0 112.228 179.852 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 23.8 t-160 -95.96 -30.18 13.75 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.927 179.884 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . -170.27 37.8 0.19 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.499 -179.963 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 178.36 -82.11 0.06 OUTLIER Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.505 179.984 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -168.74 -157.65 11.74 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.5 -179.927 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 73' ' ' TRP . . . . . 0.486 ' CD1' ' N ' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -147.38 -77.66 0.17 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.931 0.396 . . . . 0.0 110.715 -179.563 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -107.89 -20.15 8.62 Favored Glycine 0 N--CA 1.45 -0.413 0 C-N-CA 120.901 -0.666 . . . . 0.0 112.463 179.856 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 11.6 pt20 -59.62 154.32 46.2 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-O 120.701 0.286 . . . . 0.0 110.904 -179.988 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 40.9 Cg_endo -67.33 152.76 78.67 Favored 'Trans proline' 0 C--N 1.345 0.356 0 C-N-CA 122.564 2.176 . . . . 0.0 112.26 179.941 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 6.0 t-160 -105.72 -31.24 8.97 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.875 179.967 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -128.57 29.36 4.04 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.453 -179.996 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 97.48 94.71 1.92 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.467 179.959 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 61.64 -170.07 10.66 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.505 179.966 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 81' ' ' TRP . . . . . 0.488 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -147.02 -78.29 0.17 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.901 0.381 . . . . 0.0 110.736 -179.558 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -115.17 12.97 19.38 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.907 -0.663 . . . . 0.0 112.618 179.748 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 13.1 pt20 -93.43 154.17 41.33 Favored Pre-proline 0 C--N 1.332 -0.186 0 CA-C-O 120.649 0.262 . . . . 0.0 110.889 179.973 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -65.93 148.89 86.5 Favored 'Trans proline' 0 C--N 1.343 0.268 0 C-N-CA 122.629 2.22 . . . . 0.0 112.274 179.944 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 7.7 m170 -100.33 -30.57 11.79 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.776 179.877 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -110.63 -27.93 4.18 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.489 179.935 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 173.91 -43.28 0.15 Allowed Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.641 179.997 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -154.39 -160.12 9.64 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.61 179.985 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 89' ' ' TRP . . . . . 0.488 ' CD1' ' N ' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -146.89 -78.84 0.16 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.879 0.371 . . . . 0.0 110.644 -179.541 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -138.48 22.04 3.05 Favored Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.946 -0.645 . . . . 0.0 112.211 179.764 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 6.0 mt-30 . . . . . 0 C--O 1.25 1.118 0 CA-C-O 118.209 -0.9 . . . . 0.0 110.929 -179.875 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 57' ' ' TRP . . . . . . . . . . . . . 1.8 t-105 . . . . . 0 N--CA 1.486 1.351 0 CA-C-O 120.764 0.316 . . . . 0.0 111.199 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -119.04 -35.62 0.94 Allowed Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.522 -179.956 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 22.7 pt20 -145.9 154.23 50.92 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 120.691 0.281 . . . . 0.0 110.874 -179.909 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_endo -67.56 152.7 78.0 Favored 'Trans proline' 0 C--N 1.344 0.322 0 C-N-CA 122.501 2.134 . . . . 0.0 112.276 179.907 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 61' ' ' HIS . . . . . . . . . . . . . 13.8 p80 -98.06 -30.74 12.51 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.837 -179.982 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -174.08 34.72 0.11 Allowed Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.508 -179.98 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -173.84 -74.52 0.05 OUTLIER Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.697 -0.764 . . . . 0.0 112.555 -179.949 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -179.23 -159.18 22.91 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.515 -179.948 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 65' ' ' TRP . . . . . 0.487 ' CD1' ' N ' ' A' ' 65' ' ' TRP . 0.0 OUTLIER -146.56 -77.81 0.18 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.905 0.383 . . . . 0.0 110.748 -179.68 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -103.85 -21.22 9.81 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.853 -0.689 . . . . 0.0 112.459 179.794 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 13.0 pt20 -64.81 154.28 86.04 Favored Pre-proline 0 C--N 1.331 -0.219 0 CA-C-O 120.727 0.298 . . . . 0.0 110.865 -179.934 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -69.1 136.88 35.95 Favored 'Trans proline' 0 C--N 1.345 0.349 0 C-N-CA 122.603 2.202 . . . . 0.0 112.309 179.992 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 14.6 p80 -92.73 -30.17 15.67 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.766 179.839 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . -123.02 -38.6 0.56 Allowed Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.849 -0.691 . . . . 0.0 112.515 179.974 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -147.17 -85.96 0.06 OUTLIER Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.633 -0.794 . . . . 0.0 112.541 179.987 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -130.68 -155.68 8.34 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.6 -179.887 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 73' ' ' TRP . . . . . 0.493 ' CD1' ' N ' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -147.4 -77.49 0.17 Allowed 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.903 0.382 . . . . 0.0 110.696 -179.53 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -101.84 -19.67 14.73 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.964 -0.636 . . . . 0.0 112.522 179.851 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 4.7 pt20 -59.03 153.97 41.91 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 120.734 0.302 . . . . 0.0 110.891 179.983 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -66.64 154.06 75.77 Favored 'Trans proline' 0 C--N 1.345 0.369 0 C-N-CA 122.524 2.149 . . . . 0.0 112.329 179.992 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 19.8 p-80 -109.51 -30.31 8.0 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.867 -179.933 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -132.13 27.07 3.67 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.545 -179.982 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 104.5 96.45 2.42 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.668 -0.777 . . . . 0.0 112.563 179.925 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 58.84 -170.85 4.9 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.824 -0.703 . . . . 0.0 112.615 179.968 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 81' ' ' TRP . . . . . 0.49 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -147.03 -77.02 0.18 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.884 0.373 . . . . 0.0 110.71 -179.563 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -104.18 -20.86 9.94 Favored Glycine 0 N--CA 1.452 -0.248 0 C-N-CA 120.861 -0.685 . . . . 0.0 112.548 179.86 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 8.3 pt20 -58.84 153.84 40.74 Favored Pre-proline 0 C--N 1.331 -0.221 0 CA-C-O 120.686 0.279 . . . . 0.0 110.917 179.997 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_endo -59.77 160.75 20.26 Favored 'Trans proline' 0 C--N 1.343 0.283 0 C-N-CA 122.584 2.189 . . . . 0.0 112.352 -179.979 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 7.8 p-80 -113.15 -30.87 6.82 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.822 179.873 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -116.8 20.81 11.64 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.648 179.93 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 102.56 9.72 40.17 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.939 179.847 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 161.67 -170.75 37.47 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.633 -0.794 . . . . 0.0 112.635 -179.987 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 89' ' ' TRP . . . . . 0.522 ' CD1' ' N ' ' A' ' 89' ' ' TRP . 0.1 OUTLIER -150.78 -60.05 0.18 Allowed 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 121.278 0.561 . . . . 0.0 110.559 -179.256 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -153.18 -44.86 0.02 OUTLIER Glycine 0 N--CA 1.45 -0.433 0 CA-C-N 115.264 -0.88 . . . . 0.0 111.499 179.636 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 4.6 mt-30 . . . . . 0 C--O 1.248 1.004 0 CA-C-O 118.22 -0.895 . . . . 0.0 111.363 179.326 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 57' ' ' TRP . . . . . . . . . . . . . 10.2 t-105 . . . . . 0 N--CA 1.486 1.371 0 CA-C-O 120.826 0.346 . . . . 0.0 111.186 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -104.41 -44.92 1.51 Allowed Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.545 -179.981 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 19.5 pt20 -169.67 154.32 5.39 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 120.75 0.309 . . . . 0.0 110.906 -179.99 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -67.8 154.87 71.96 Favored 'Trans proline' 0 C--N 1.344 0.311 0 C-N-CA 122.57 2.18 . . . . 0.0 112.263 179.971 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 61' ' ' HIS . . . . . . . . . . . . . 23.8 t-160 -103.5 -31.32 10.02 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.903 179.99 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -123.89 -43.29 0.34 Allowed Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.426 179.974 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -177.32 94.98 0.1 OUTLIER Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.514 179.993 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 62.3 -170.2 12.54 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.452 179.926 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 65' ' ' TRP . . . . . 0.481 ' N ' ' CD1' ' A' ' 65' ' ' TRP . 0.0 OUTLIER -148.32 -76.1 0.17 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.955 0.407 . . . . 0.0 110.753 -179.542 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -107.15 -21.7 7.92 Favored Glycine 0 N--CA 1.45 -0.414 0 C-N-CA 120.89 -0.672 . . . . 0.0 112.473 179.904 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 18.0 pt20 -60.05 154.19 51.55 Favored Pre-proline 0 C--N 1.33 -0.253 0 CA-C-O 120.726 0.298 . . . . 0.0 110.9 179.984 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 42.2 Cg_endo -68.0 151.76 77.4 Favored 'Trans proline' 0 C--N 1.343 0.282 0 C-N-CA 122.571 2.18 . . . . 0.0 112.257 179.968 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 3.9 p-80 -96.65 -30.85 13.02 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.835 179.894 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . -153.46 27.6 0.77 Allowed Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.491 179.968 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 168.94 -102.11 0.18 Allowed Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.524 179.985 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -131.7 -158.94 9.26 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.539 -179.996 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 73' ' ' TRP . . . . . 0.485 ' CD1' ' N ' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -147.16 -77.04 0.18 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.956 0.408 . . . . 0.0 110.785 -179.555 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -106.76 -21.26 8.32 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.805 -0.712 . . . . 0.0 112.5 179.867 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 3.0 pt20 -59.94 153.84 52.38 Favored Pre-proline 0 C--N 1.331 -0.223 0 CA-C-O 120.663 0.268 . . . . 0.0 110.915 179.947 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_endo -66.06 153.93 76.11 Favored 'Trans proline' 0 C--N 1.344 0.321 0 C-N-CA 122.481 2.121 . . . . 0.0 112.389 179.938 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 23.3 t-160 -109.7 -29.76 8.19 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.811 179.956 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -134.39 26.7 3.33 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.549 179.952 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 106.88 97.63 2.52 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.53 179.888 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 58.45 -172.7 3.59 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.58 179.909 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 81' ' ' TRP . . . . . 0.486 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -146.21 -77.84 0.18 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.96 0.41 . . . . 0.0 110.845 -179.603 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -106.46 -20.81 8.76 Favored Glycine 0 N--CA 1.45 -0.419 0 C-N-CA 120.848 -0.692 . . . . 0.0 112.553 179.895 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 12.5 pt20 -58.89 153.68 42.17 Favored Pre-proline 0 C--N 1.33 -0.254 0 CA-C-O 120.694 0.283 . . . . 0.0 110.933 179.966 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 30.3 Cg_endo -64.37 159.99 41.29 Favored 'Trans proline' 0 C--N 1.344 0.326 0 C-N-CA 122.522 2.148 . . . . 0.0 112.321 -179.977 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 4.1 m-70 -117.72 106.34 12.95 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.092 -0.503 . . . . 0.0 110.645 179.665 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 94.93 -26.85 16.7 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.444 -179.797 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 150.01 92.8 0.1 Allowed Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.549 -179.966 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 58.46 -157.5 19.53 Favored Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.593 179.988 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 89' ' ' TRP . . . . . 0.509 ' CD1' ' N ' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -142.02 -78.46 0.25 Allowed 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.981 0.42 . . . . 0.0 110.701 -179.636 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -134.68 17.29 4.21 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.908 -0.663 . . . . 0.0 112.507 179.816 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 6.0 pt20 . . . . . 0 C--O 1.249 1.072 0 CA-C-O 118.228 -0.891 . . . . 0.0 110.943 179.963 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 57' ' ' TRP . . . . . . . . . . . . . 21.3 t-105 . . . . . 0 N--CA 1.485 1.299 0 CA-C-O 120.766 0.317 . . . . 0.0 111.223 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . 0.47 ' O ' ' CG ' ' A' ' 59' ' ' GLN . . . -67.33 -30.78 75.74 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.532 179.986 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.47 ' CG ' ' O ' ' A' ' 58' ' ' GLY . 3.2 pt20 54.76 154.92 0.05 OUTLIER Pre-proline 0 N--CA 1.463 0.205 0 CA-C-O 120.951 0.405 . . . . 0.0 111.515 -179.954 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -70.97 142.36 42.42 Favored 'Trans proline' 0 C--N 1.345 0.379 0 C-N-CA 122.513 2.142 . . . . 0.0 112.288 -179.869 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 61' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -100.15 -28.89 12.79 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.933 179.921 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -128.98 27.55 4.28 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.688 -0.768 . . . . 0.0 112.472 -179.995 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 99.42 97.0 2.12 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.55 -179.996 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 57.86 -170.88 3.81 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.812 -0.708 . . . . 0.0 112.554 179.96 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 65' ' ' TRP . . . . . 0.491 ' N ' ' CD1' ' A' ' 65' ' ' TRP . 0.0 OUTLIER -146.51 -78.96 0.17 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.905 0.383 . . . . 0.0 110.791 -179.628 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -113.19 12.49 24.07 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.883 -0.675 . . . . 0.0 112.559 179.757 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 21.7 pt20 -98.63 153.94 37.71 Favored Pre-proline 0 C--N 1.331 -0.214 0 CA-C-O 120.777 0.322 . . . . 0.0 110.888 179.955 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_endo -65.58 155.13 70.6 Favored 'Trans proline' 0 C--N 1.344 0.337 0 C-N-CA 122.523 2.149 . . . . 0.0 112.272 179.95 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 3.5 t-80 -109.59 -30.68 7.8 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.862 179.899 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . -134.44 26.55 3.34 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.557 -179.996 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 107.37 98.24 2.55 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.55 179.924 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 58.75 -173.76 3.38 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.82 -0.705 . . . . 0.0 112.571 179.961 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 73' ' ' TRP . . . . . 0.489 ' CD1' ' N ' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -145.62 -78.83 0.18 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.872 0.368 . . . . 0.0 110.804 -179.606 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -105.93 -20.93 8.91 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.868 -0.682 . . . . 0.0 112.446 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 16.7 pt20 -59.81 154.16 49.2 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 120.742 0.306 . . . . 0.0 110.891 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo -69.31 139.75 42.59 Favored 'Trans proline' 0 C--N 1.344 0.326 0 C-N-CA 122.548 2.165 . . . . 0.0 112.333 179.965 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 19.9 t-160 -93.73 -31.22 14.51 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.86 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -125.89 -40.82 0.36 Allowed Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.801 -0.714 . . . . 0.0 112.485 -180.0 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -176.48 97.16 0.11 Allowed Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.567 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 59.91 -171.82 5.78 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.563 179.971 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 81' ' ' TRP . . . . . 0.474 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -147.09 -77.34 0.17 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.902 0.382 . . . . 0.0 110.757 -179.66 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -106.6 -21.63 8.18 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.919 -0.658 . . . . 0.0 112.493 179.934 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 20.7 pt20 -59.96 154.03 51.52 Favored Pre-proline 0 C--N 1.33 -0.24 0 CA-C-O 120.702 0.287 . . . . 0.0 110.902 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 39.0 Cg_endo -67.13 158.1 58.52 Favored 'Trans proline' 0 C--N 1.344 0.335 0 C-N-CA 122.567 2.178 . . . . 0.0 112.296 179.955 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 8.8 m170 -97.67 -30.94 12.54 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.774 179.986 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -113.75 -29.09 2.97 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.506 179.97 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 172.38 -33.6 0.13 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.524 179.991 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -157.85 -161.2 10.74 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.68 -0.771 . . . . 0.0 112.558 -179.968 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 89' ' ' TRP . . . . . 0.489 ' CD1' ' N ' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -147.17 -77.98 0.17 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.969 0.414 . . . . 0.0 110.756 -179.636 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -133.79 17.87 4.36 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.909 -0.662 . . . . 0.0 112.484 179.816 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 13.8 pt20 . . . . . 0 C--O 1.25 1.095 0 CA-C-O 118.164 -0.922 . . . . 0.0 110.896 179.982 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 57' ' ' TRP . . . . . 0.422 ' CD1' ' HG2' ' A' ' 59' ' ' GLN . 26.3 t-105 . . . . . 0 N--CA 1.487 1.381 0 CA-C-O 120.753 0.311 . . . . 0.0 111.191 . . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -56.49 -27.14 53.54 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.629 -179.998 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.422 ' HG2' ' CD1' ' A' ' 57' ' ' TRP . 9.6 pt20 -133.62 154.31 80.63 Favored Pre-proline 0 C--N 1.33 -0.251 0 CA-C-O 120.828 0.346 . . . . 0.0 110.838 179.971 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 39.0 Cg_endo -67.15 149.47 81.96 Favored 'Trans proline' 0 C--N 1.346 0.417 0 C-N-CA 122.519 2.146 . . . . 0.0 112.302 -179.997 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 61' ' ' HIS . . . . . . . . . . . . . 7.9 t60 -97.85 -30.67 12.63 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.806 179.941 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -113.46 -28.07 3.39 Favored Glycine 0 N--CA 1.45 -0.398 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.495 179.988 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 178.85 -52.24 0.09 OUTLIER Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.585 179.952 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -147.53 -158.84 8.07 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.563 -179.957 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 65' ' ' TRP . . . . . 0.481 ' N ' ' CD1' ' A' ' 65' ' ' TRP . 0.0 OUTLIER -147.37 -78.03 0.17 Allowed 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.903 0.382 . . . . 0.0 110.712 -179.604 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -110.39 -21.15 7.04 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.908 -0.663 . . . . 0.0 112.446 179.832 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 9.4 pt20 -61.02 153.79 64.21 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 120.782 0.325 . . . . 0.0 110.9 179.976 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 12.8 Cg_endo -57.06 150.73 54.61 Favored 'Trans proline' 0 C--N 1.344 0.334 0 C-N-CA 122.727 2.285 . . . . 0.0 112.219 179.97 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 19.5 t-160 -128.75 6.0 5.55 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.351 179.942 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . -147.88 25.48 1.46 Allowed Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.64 -0.791 . . . . 0.0 112.6 179.933 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 96.77 24.53 13.22 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.636 179.95 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 127.35 -161.98 21.41 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.469 179.889 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 73' ' ' TRP . . . . . 0.509 ' CD1' ' N ' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -144.61 -79.79 0.18 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.944 0.402 . . . . 0.0 110.72 -179.546 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -112.27 15.16 25.4 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.81 -0.71 . . . . 0.0 112.436 179.706 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 3.5 pt20 -107.39 154.07 40.86 Favored Pre-proline 0 C--N 1.33 -0.252 0 CA-C-O 120.713 0.292 . . . . 0.0 110.901 179.989 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_endo -66.0 146.73 83.26 Favored 'Trans proline' 0 C--N 1.344 0.299 0 C-N-CA 122.481 2.121 . . . . 0.0 112.305 179.988 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 6.3 t-160 -100.03 -31.16 11.58 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.794 179.813 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -118.83 -34.59 1.04 Allowed Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.812 -0.709 . . . . 0.0 112.436 179.907 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -161.53 -64.96 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.558 -179.996 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -138.57 -158.95 7.9 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.599 -179.957 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 81' ' ' TRP . . . . . 0.501 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -145.94 -77.99 0.18 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.9 0.381 . . . . 0.0 110.778 -179.594 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -104.18 -21.88 9.14 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.903 -0.665 . . . . 0.0 112.54 179.896 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 16.9 pt20 -61.13 151.7 74.48 Favored Pre-proline 0 C--N 1.331 -0.224 0 CA-C-O 120.719 0.295 . . . . 0.0 110.93 -179.98 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 30.7 Cg_endo -64.63 160.82 38.23 Favored 'Trans proline' 0 C--N 1.344 0.328 0 C-N-CA 122.511 2.141 . . . . 0.0 112.358 179.968 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 16.6 p-80 -118.47 106.57 12.82 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.599 179.644 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 94.42 -26.08 19.52 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.513 -179.797 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 149.29 92.53 0.1 Allowed Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.498 179.937 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 58.93 -157.37 22.33 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.548 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 89' ' ' TRP . . . . . 0.511 ' CD1' ' N ' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -142.55 -78.7 0.24 Allowed 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 121.002 0.429 . . . . 0.0 110.829 -179.676 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -113.15 -20.71 6.2 Favored Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 120.904 -0.665 . . . . 0.0 112.473 179.888 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 2.0 pt20 . . . . . 0 C--O 1.248 1.024 0 CA-C-O 118.333 -0.841 . . . . 0.0 110.862 -179.982 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.361 0 N-CA-C 112.561 -0.216 . . . . 0.0 112.561 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 73' ' ' TRP . . . . . 0.481 ' N ' ' CD1' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -146.76 -78.9 0.16 Allowed 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 120.97 0.415 . . . . 0.0 110.746 -179.573 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -114.39 13.23 21.13 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.843 -0.694 . . . . 0.0 112.54 179.83 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 23.9 pt20 -97.38 154.48 38.02 Favored Pre-proline 0 C--N 1.332 -0.192 0 CA-C-O 120.722 0.296 . . . . 0.0 110.888 179.983 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 39.4 Cg_endo -67.29 147.3 78.0 Favored 'Trans proline' 0 C--N 1.344 0.303 0 C-N-CA 122.543 2.162 . . . . 0.0 112.27 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 8.4 t-160 -97.26 -30.62 12.87 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.865 179.893 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -113.17 -27.95 3.5 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.893 -0.67 . . . . 0.0 112.565 179.941 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 179.37 -54.52 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.596 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -145.71 -158.64 7.79 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.521 -179.924 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 81' ' ' TRP . . . . . 0.478 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -147.56 -77.11 0.17 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.97 0.414 . . . . 0.0 110.698 -179.556 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -106.85 -20.93 8.47 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.903 -0.665 . . . . 0.0 112.473 179.868 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 17.8 pt20 -60.18 154.45 51.54 Favored Pre-proline 0 C--N 1.331 -0.216 0 CA-C-O 120.735 0.302 . . . . 0.0 110.856 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_endo -68.72 140.53 47.05 Favored 'Trans proline' 0 C--N 1.345 0.378 0 C-N-CA 122.525 2.15 . . . . 0.0 112.251 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 7.5 m170 -94.89 -30.99 13.89 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.846 -179.956 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -125.22 -40.79 0.39 Allowed Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.496 179.98 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -177.18 96.9 0.11 Allowed Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.468 179.942 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 59.59 -170.71 6.01 Favored Glycine 0 N--CA 1.452 -0.268 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.55 179.947 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 89' ' ' TRP . . . . . 0.478 ' CD1' ' N ' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -147.52 -77.78 0.17 Allowed 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.919 0.39 . . . . 0.0 110.795 -179.638 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -134.69 18.32 4.1 Favored Glycine 0 N--CA 1.449 -0.445 0 C-N-CA 120.894 -0.669 . . . . 0.0 112.504 179.843 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 7.2 pt20 . . . . . 0 C--O 1.249 1.052 0 CA-C-O 118.173 -0.918 . . . . 0.0 110.864 -179.944 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.268 0 N-CA-C 112.56 -0.216 . . . . 0.0 112.56 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 73' ' ' TRP . . . . . 0.467 ' CD1' ' N ' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -147.69 -78.02 0.16 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.927 0.394 . . . . 0.0 110.799 -179.598 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -111.34 -15.26 10.66 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.883 -0.675 . . . . 0.0 112.632 179.917 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 18.9 pt20 -56.74 154.08 19.49 Favored Pre-proline 0 C--N 1.331 -0.201 0 CA-C-O 120.699 0.285 . . . . 0.0 111.028 -179.974 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 41.2 Cg_endo -67.32 161.29 43.76 Favored 'Trans proline' 0 C--N 1.343 0.28 0 C-N-CA 122.597 2.198 . . . . 0.0 112.314 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 48.8 t-80 -109.32 -30.5 7.96 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.966 179.865 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -135.16 27.09 3.18 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.468 179.982 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 106.28 92.9 2.29 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.476 179.939 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 58.92 -170.88 4.98 Favored Glycine 0 N--CA 1.452 -0.268 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.535 179.936 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 81' ' ' TRP . . . . . 0.489 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -146.81 -78.88 0.16 Allowed 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.832 0.348 . . . . 0.0 110.76 -179.604 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -119.98 15.89 10.22 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.863 -0.684 . . . . 0.0 112.547 179.733 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 8.2 pt20 -82.11 154.2 69.65 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-O 120.723 0.297 . . . . 0.0 110.903 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 27.6 Cg_endo -62.72 156.47 53.03 Favored 'Trans proline' 0 C--N 1.345 0.365 0 C-N-CA 122.535 2.156 . . . . 0.0 112.273 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 0.7 OUTLIER -109.38 -31.08 7.67 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.815 179.94 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -108.26 -61.71 0.55 Allowed Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.436 -179.984 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -165.77 30.1 0.21 Allowed Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.709 -0.757 . . . . 0.0 112.523 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 136.1 -164.33 25.04 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.581 -179.971 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 89' ' ' TRP . . . . . 0.491 ' CD1' ' N ' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -146.85 -77.92 0.17 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.897 0.379 . . . . 0.0 110.735 -179.634 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -133.04 18.69 4.45 Favored Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.907 -0.663 . . . . 0.0 112.511 179.793 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 15.3 pt20 . . . . . 0 C--O 1.249 1.056 0 CA-C-O 118.203 -0.903 . . . . 0.0 110.89 -179.968 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.329 0 N-CA-C 112.561 -0.216 . . . . 0.0 112.561 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 73' ' ' TRP . . . . . 0.496 ' CD1' ' N ' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -146.31 -78.6 0.17 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.857 0.36 . . . . 0.0 110.76 -179.616 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -116.64 13.72 15.1 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.953 -0.641 . . . . 0.0 112.599 179.73 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 3.9 pt20 -91.02 154.13 45.05 Favored Pre-proline 0 C--N 1.331 -0.238 0 CA-C-O 120.708 0.289 . . . . 0.0 110.942 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 76' ' ' PRO . . . . . 0.403 ' HB3' ' CA ' ' A' ' 80' ' ' GLY . 36.0 Cg_endo -65.33 151.01 86.56 Favored 'Trans proline' 0 C--N 1.344 0.324 0 C-N-CA 122.495 2.13 . . . . 0.0 112.27 179.971 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 17.2 t-160 -101.07 -30.72 11.44 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.796 179.916 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -109.17 -27.77 4.67 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.528 179.95 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 168.11 -31.38 0.18 Allowed Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.598 179.953 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 80' ' ' GLY . . . . . 0.403 ' CA ' ' HB3' ' A' ' 76' ' ' PRO . . . -162.3 -162.17 13.05 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.555 -179.987 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 81' ' ' TRP . . . . . 0.49 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -146.28 -78.54 0.17 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.92 0.391 . . . . 0.0 110.748 -179.657 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -116.99 13.25 14.3 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.903 -0.665 . . . . 0.0 112.555 179.806 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 13.9 pt20 -86.09 154.29 57.58 Favored Pre-proline 0 C--N 1.332 -0.193 0 CA-C-O 120.628 0.251 . . . . 0.0 110.917 179.966 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 84' ' ' PRO . . . . . 0.401 ' HB3' ' CA ' ' A' ' 88' ' ' GLY . 37.3 Cg_endo -66.12 157.41 59.85 Favored 'Trans proline' 0 C--N 1.344 0.296 0 C-N-CA 122.538 2.159 . . . . 0.0 112.32 179.914 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 3.5 t-80 -98.95 -30.79 12.16 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.854 179.861 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -113.03 -27.73 3.61 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.481 -179.995 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 169.91 -32.39 0.16 Allowed Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.711 -0.756 . . . . 0.0 112.551 179.979 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 88' ' ' GLY . . . . . 0.401 ' CA ' ' HB3' ' A' ' 84' ' ' PRO . . . -159.08 -161.48 11.18 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.509 -179.966 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 89' ' ' TRP . . . . . 0.485 ' CD1' ' N ' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -147.14 -77.98 0.17 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.826 0.346 . . . . 0.0 110.826 -179.669 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -134.71 17.76 4.15 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.921 -0.657 . . . . 0.0 112.523 179.863 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 7.6 pt20 . . . . . 0 C--O 1.248 1.023 0 CA-C-O 118.242 -0.885 . . . . 0.0 110.944 -180.0 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.349 0 N-CA-C 112.56 -0.216 . . . . 0.0 112.56 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 73' ' ' TRP . . . . . 0.485 ' N ' ' CD1' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -147.82 -77.25 0.17 Allowed 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.936 0.398 . . . . 0.0 110.787 -179.603 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -105.39 -21.67 8.67 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.888 -0.672 . . . . 0.0 112.446 179.832 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 16.3 pt20 -63.66 154.48 80.04 Favored Pre-proline 0 C--N 1.331 -0.2 0 CA-C-O 120.677 0.275 . . . . 0.0 110.879 -180.0 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 41.6 Cg_endo -67.7 142.06 56.9 Favored 'Trans proline' 0 C--N 1.344 0.311 0 C-N-CA 122.518 2.145 . . . . 0.0 112.239 -179.998 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 3.5 t-80 -96.05 -31.0 13.25 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.918 179.994 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -124.78 -41.77 0.37 Allowed Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.463 -179.986 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -177.02 94.58 0.1 OUTLIER Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.531 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 62.84 -170.66 13.08 Favored Glycine 0 N--CA 1.45 -0.416 0 C-N-CA 120.667 -0.778 . . . . 0.0 112.607 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 81' ' ' TRP . . . . . 0.477 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -148.24 -75.59 0.18 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.942 0.401 . . . . 0.0 110.742 -179.634 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -107.45 -22.09 7.61 Favored Glycine 0 N--CA 1.449 -0.436 0 C-N-CA 120.869 -0.682 . . . . 0.0 112.463 179.831 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 14.6 pt20 -60.17 154.11 53.32 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-O 120.646 0.26 . . . . 0.0 110.876 179.961 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 34.8 Cg_endo -65.35 153.46 78.15 Favored 'Trans proline' 0 C--N 1.344 0.308 0 C-N-CA 122.515 2.143 . . . . 0.0 112.255 179.963 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 57.5 m80 -100.63 -31.74 11.09 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.672 179.831 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -116.69 -31.65 1.74 Allowed Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.834 -0.698 . . . . 0.0 112.447 179.971 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -165.87 -69.25 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.59 -180.0 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -135.66 -147.84 5.51 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.616 179.98 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 89' ' ' TRP . . . . . 0.432 ' CH2' ' HB3' ' A' ' 91' ' ' GLN . 0.4 OUTLIER -161.11 23.57 0.13 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.765 0.317 . . . . 0.0 111.119 -179.342 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 103.03 -14.34 55.77 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.668 -0.777 . . . . 0.0 112.402 -179.644 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 91' ' ' GLN . . . . . 0.432 ' HB3' ' CH2' ' A' ' 89' ' ' TRP . 4.3 pt20 . . . . . 0 C--O 1.249 1.074 0 CA-C-O 118.229 -0.891 . . . . 0.0 110.919 -179.984 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.453 -0.229 0 N-CA-C 112.57 -0.212 . . . . 0.0 112.57 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 73' ' ' TRP . . . . . 0.557 ' N ' ' CD1' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -136.21 -78.33 0.42 Allowed 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.954 0.407 . . . . 0.0 110.629 -179.654 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -113.33 -9.09 18.34 Favored Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 120.907 -0.663 . . . . 0.0 112.625 179.758 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 14.3 pt20 -58.37 154.22 33.79 Favored Pre-proline 0 C--N 1.331 -0.237 0 CA-C-O 120.751 0.31 . . . . 0.0 110.957 179.933 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 76' ' ' PRO . . . . . 0.426 ' HB2' ' N ' ' A' ' 80' ' ' GLY . 55.0 Cg_endo -70.58 137.9 34.06 Favored 'Trans proline' 0 C--N 1.344 0.32 0 C-N-CA 122.431 2.088 . . . . 0.0 112.199 179.796 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 18.4 m-70 -107.66 105.38 15.21 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.985 0.421 . . . . 0.0 110.709 179.657 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 104.74 -31.5 8.53 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.868 -0.682 . . . . 0.0 112.433 -179.886 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 152.04 93.28 0.1 OUTLIER Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.576 -179.986 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 80' ' ' GLY . . . . . 0.426 ' N ' ' HB2' ' A' ' 76' ' ' PRO . . . 52.8 -161.79 2.54 Favored Glycine 0 C--N 1.33 0.229 0 C-N-CA 120.883 -0.675 . . . . 0.0 112.781 179.983 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 81' ' ' TRP . . . . . 0.549 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -137.09 -78.27 0.4 Allowed 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.935 0.398 . . . . 0.0 110.694 -179.665 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -107.33 -20.28 8.76 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.89 -0.672 . . . . 0.0 112.483 179.853 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 15.6 pt20 -59.9 154.42 48.66 Favored Pre-proline 0 C--N 1.331 -0.223 0 CA-C-O 120.631 0.253 . . . . 0.0 110.923 -179.946 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 44.0 Cg_endo -68.04 141.39 52.85 Favored 'Trans proline' 0 C--N 1.344 0.306 0 C-N-CA 122.558 2.172 . . . . 0.0 112.277 179.912 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 4.7 t-160 -95.5 -31.07 13.52 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.886 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -120.55 -41.37 0.53 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.518 179.966 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 179.22 96.13 0.1 Allowed Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.68 -0.772 . . . . 0.0 112.434 179.958 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 59.7 -170.07 6.55 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.542 -179.998 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 89' ' ' TRP . . . . . 0.482 ' N ' ' CD1' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -148.31 -76.18 0.17 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.998 0.428 . . . . 0.0 110.828 -179.634 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -112.89 -22.22 5.74 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.86 -0.686 . . . . 0.0 112.435 179.879 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 2.8 pp0? . . . . . 0 C--O 1.249 1.03 0 CA-C-O 118.257 -0.877 . . . . 0.0 110.904 -179.914 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.27 0 N-CA-C 112.517 -0.233 . . . . 0.0 112.517 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 73' ' ' TRP . . . . . 0.454 ' CD1' ' N ' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -148.04 -79.36 0.15 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.885 0.374 . . . . 0.0 110.845 -179.667 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -115.99 -2.82 20.2 Favored Glycine 0 CA--C 1.519 0.311 0 C-N-CA 120.815 -0.707 . . . . 0.0 112.663 179.911 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 9.7 pt20 -58.04 154.41 29.58 Favored Pre-proline 0 C--N 1.33 -0.263 0 CA-C-O 120.728 0.299 . . . . 0.0 110.942 179.985 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -66.32 153.47 77.91 Favored 'Trans proline' 0 C--N 1.344 0.318 0 C-N-CA 122.553 2.169 . . . . 0.0 112.287 179.991 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 2.2 t60 -100.23 -30.33 11.97 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.785 179.896 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -151.04 27.46 1.01 Allowed Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.478 -179.99 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 165.49 -109.59 0.37 Allowed Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.541 -179.932 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -123.7 -158.94 10.3 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.829 -0.701 . . . . 0.0 112.518 -179.945 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 81' ' ' TRP . . . . . 0.481 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -147.42 -78.6 0.16 Allowed 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.971 0.415 . . . . 0.0 110.873 -179.637 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -111.9 -15.22 10.23 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.959 -0.639 . . . . 0.0 112.577 179.898 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 16.2 pt20 -56.36 154.33 16.68 Favored Pre-proline 0 C--N 1.331 -0.211 0 CA-C-O 120.706 0.288 . . . . 0.0 111.006 179.969 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 40.9 Cg_endo -67.35 169.22 15.91 Favored 'Trans proline' 0 C--N 1.344 0.299 0 C-N-CA 122.604 2.202 . . . . 0.0 112.287 179.936 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 3.6 m-70 -110.15 -31.34 7.38 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.898 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -136.75 27.93 2.89 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.556 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 105.22 98.4 2.54 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.46 179.928 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 59.09 -170.81 5.24 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.511 179.925 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 89' ' ' TRP . . . . . 0.475 ' CD1' ' N ' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -147.92 -77.51 0.16 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.936 0.398 . . . . 0.0 110.88 -179.605 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -113.56 -22.06 5.57 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.87 -0.681 . . . . 0.0 112.486 179.823 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.249 1.034 0 CA-C-O 118.173 -0.918 . . . . 0.0 110.939 -179.993 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.267 0 N-CA-C 112.56 -0.216 . . . . 0.0 112.56 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 73' ' ' TRP . . . . . 0.528 ' N ' ' CD1' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -141.31 -79.08 0.26 Allowed 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.928 0.394 . . . . 0.0 110.627 -179.601 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -116.99 13.93 14.09 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.83 -0.7 . . . . 0.0 112.47 179.842 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 21.2 pt20 -89.55 154.52 48.46 Favored Pre-proline 0 C--N 1.331 -0.197 0 CA-C-O 120.661 0.267 . . . . 0.0 110.881 -179.966 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 39.8 Cg_endo -67.06 148.38 81.33 Favored 'Trans proline' 0 C--N 1.344 0.319 0 C-N-CA 122.485 2.123 . . . . 0.0 112.26 179.921 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 0.8 OUTLIER -97.54 6.22 48.42 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.379 179.956 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 150.81 44.57 0.02 OUTLIER Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.524 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 168.37 -82.92 0.1 OUTLIER Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.52 -179.973 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -169.64 -160.8 18.77 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.516 -179.941 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 81' ' ' TRP . . . . . 0.472 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -147.53 -77.96 0.16 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.901 0.381 . . . . 0.0 110.747 -179.613 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -105.86 -20.9 8.97 Favored Glycine 0 N--CA 1.45 -0.398 0 C-N-CA 120.915 -0.66 . . . . 0.0 112.46 179.807 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 20.8 pt20 -63.98 154.2 82.45 Favored Pre-proline 0 C--N 1.33 -0.25 0 CA-C-O 120.71 0.29 . . . . 0.0 110.887 179.935 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo -66.27 177.58 3.08 Favored 'Trans proline' 0 C--N 1.344 0.338 0 C-N-CA 122.62 2.213 . . . . 0.0 112.293 179.9 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 27.4 p-80 -99.96 -30.99 11.69 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.887 179.93 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -162.66 28.78 0.26 Allowed Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.461 179.949 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 170.12 -92.3 0.1 OUTLIER Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.599 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -138.74 -156.5 7.05 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.589 179.953 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 89' ' ' TRP . . . . . 0.478 ' N ' ' CD1' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -147.8 -78.01 0.16 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.908 0.385 . . . . 0.0 110.707 -179.576 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -134.98 16.92 4.17 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.904 -0.665 . . . . 0.0 112.59 179.849 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 7.0 pt20 . . . . . 0 C--O 1.249 1.069 0 CA-C-O 118.238 -0.887 . . . . 0.0 110.93 -179.991 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.326 0 N-CA-C 112.599 -0.201 . . . . 0.0 112.599 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 73' ' ' TRP . . . . . 0.499 ' N ' ' CD1' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -144.78 -77.79 0.2 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.921 0.391 . . . . 0.0 110.8 -179.607 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -103.39 -23.06 8.64 Favored Glycine 0 N--CA 1.449 -0.437 0 C-N-CA 120.954 -0.641 . . . . 0.0 112.517 179.884 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 3.1 pt20 -62.35 151.29 82.76 Favored Pre-proline 0 C--N 1.33 -0.249 0 CA-C-O 120.717 0.294 . . . . 0.0 110.907 -179.986 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 76' ' ' PRO . . . . . 0.405 ' HB3' ' CA ' ' A' ' 80' ' ' GLY . 23.9 Cg_endo -62.36 155.48 57.11 Favored 'Trans proline' 0 C--N 1.344 0.337 0 C-N-CA 122.587 2.191 . . . . 0.0 112.386 179.939 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 8.3 p80 -109.55 -29.92 8.16 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.84 179.817 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -112.35 -57.06 0.44 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.8 -0.715 . . . . 0.0 112.488 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -169.86 32.16 0.16 Allowed Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.649 179.965 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 80' ' ' GLY . . . . . 0.405 ' CA ' ' HB3' ' A' ' 76' ' ' PRO . . . 138.75 -169.3 24.44 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.646 -0.788 . . . . 0.0 112.611 -179.973 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 81' ' ' TRP . . . . . 0.491 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -145.65 -77.98 0.19 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.919 0.39 . . . . 0.0 110.781 -179.681 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -102.69 -20.3 11.99 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.87 -0.681 . . . . 0.0 112.558 179.927 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 13.2 pt20 -58.71 153.78 39.68 Favored Pre-proline 0 C--N 1.332 -0.195 0 CA-C-O 120.784 0.326 . . . . 0.0 110.952 -179.963 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 30.5 Cg_endo -64.2 154.13 72.55 Favored 'Trans proline' 0 C--N 1.345 0.361 0 C-N-CA 122.542 2.162 . . . . 0.0 112.267 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 1.6 t-80 -108.96 -29.82 8.4 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.82 179.872 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -108.5 -61.46 0.54 Allowed Glycine 0 N--CA 1.45 -0.406 0 C-N-CA 120.821 -0.704 . . . . 0.0 112.469 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -166.75 30.6 0.19 Allowed Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.569 179.946 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 135.31 -165.78 24.62 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.586 179.919 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 89' ' ' TRP . . . . . 0.489 ' N ' ' CD1' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -146.1 -79.36 0.17 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.902 0.382 . . . . 0.0 110.727 -179.626 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -139.13 22.67 2.92 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.99 -0.624 . . . . 0.0 112.175 179.779 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 20.2 mt-30 . . . . . 0 C--O 1.249 1.03 0 CA-C-O 118.223 -0.894 . . . . 0.0 110.933 -179.923 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.284 0 N-CA-C 112.584 -0.206 . . . . 0.0 112.584 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 73' ' ' TRP . . . . . 0.494 ' CD1' ' N ' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -146.25 -79.72 0.16 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.867 0.365 . . . . 0.0 110.791 -179.624 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -120.0 16.96 10.05 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.936 -0.649 . . . . 0.0 112.467 179.714 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 6.6 pt20 -77.29 154.79 82.12 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 120.734 0.302 . . . . 0.0 110.801 -179.965 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 32.7 Cg_endo -64.57 154.56 71.42 Favored 'Trans proline' 0 C--N 1.344 0.32 0 C-N-CA 122.465 2.11 . . . . 0.0 112.264 179.879 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 2.1 t60 -102.85 -30.38 10.88 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.829 179.871 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -148.98 27.74 1.27 Allowed Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.431 179.991 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 162.48 -108.64 0.35 Allowed Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.487 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -123.26 -158.44 10.18 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.561 179.975 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 81' ' ' TRP . . . . . 0.477 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -147.7 -78.36 0.16 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.847 0.356 . . . . 0.0 110.748 -179.574 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -111.2 -18.36 8.24 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.928 -0.653 . . . . 0.0 112.523 179.908 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 4.6 pt20 -58.03 154.0 31.59 Favored Pre-proline 0 C--N 1.331 -0.232 0 CA-C-O 120.732 0.301 . . . . 0.0 110.931 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 84' ' ' PRO . . . . . 0.416 ' HB2' ' N ' ' A' ' 88' ' ' GLY . 28.1 Cg_endo -63.47 161.44 31.35 Favored 'Trans proline' 0 C--N 1.344 0.329 0 C-N-CA 122.581 2.188 . . . . 0.0 112.335 179.942 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 1.7 m80 -118.32 106.15 12.47 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.674 179.694 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 94.43 -26.51 17.37 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.452 -179.801 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 150.06 92.43 0.1 OUTLIER Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.51 -179.98 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 88' ' ' GLY . . . . . 0.416 ' N ' ' HB2' ' A' ' 84' ' ' PRO . . . 59.1 -156.78 24.36 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.591 -179.968 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 89' ' ' TRP . . . . . 0.501 ' N ' ' CD1' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -142.58 -78.5 0.24 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.959 0.409 . . . . 0.0 110.666 -179.656 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -134.84 16.53 4.24 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.907 -0.663 . . . . 0.0 112.54 179.902 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 3.6 pt20 . . . . . 0 C--O 1.249 1.063 0 CA-C-O 118.2 -0.905 . . . . 0.0 110.927 179.996 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.306 0 N-CA-C 112.496 -0.241 . . . . 0.0 112.496 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 73' ' ' TRP . . . . . 0.493 ' N ' ' CD1' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -146.2 -77.97 0.18 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.939 0.399 . . . . 0.0 110.794 -179.672 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -104.74 -21.17 9.32 Favored Glycine 0 N--CA 1.45 -0.416 0 C-N-CA 120.888 -0.673 . . . . 0.0 112.485 179.755 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 17.6 pt20 -65.74 154.0 89.74 Favored Pre-proline 0 C--N 1.331 -0.225 0 CA-C-O 120.751 0.31 . . . . 0.0 110.861 179.971 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 33.7 Cg_endo -65.32 149.04 88.8 Favored 'Trans proline' 0 C--N 1.345 0.342 0 C-N-CA 122.535 2.156 . . . . 0.0 112.227 179.951 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 4.2 t-160 -102.82 6.56 39.31 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.369 179.93 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 158.39 -26.43 0.41 Allowed Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.64 -0.791 . . . . 0.0 112.536 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -113.64 -82.1 1.09 Allowed Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.545 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -171.16 -157.86 13.94 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.673 -0.775 . . . . 0.0 112.504 -179.961 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 81' ' ' TRP . . . . . 0.498 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -145.18 -78.6 0.19 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.949 0.404 . . . . 0.0 110.682 -179.574 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -112.85 10.87 25.24 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.87 -0.681 . . . . 0.0 112.574 179.829 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 19.0 pt20 -96.32 154.56 38.66 Favored Pre-proline 0 C--N 1.332 -0.164 0 CA-C-O 120.747 0.308 . . . . 0.0 110.878 179.933 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 42.3 Cg_endo -67.71 141.39 54.48 Favored 'Trans proline' 0 C--N 1.345 0.364 0 C-N-CA 122.486 2.124 . . . . 0.0 112.244 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 45.5 m-70 -95.89 -30.65 13.53 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.853 -179.973 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -118.92 -52.19 0.29 Allowed Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.515 -179.939 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -172.38 88.63 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.539 179.973 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 69.55 -170.68 42.22 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.604 -179.961 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 89' ' ' TRP . . . . . 0.482 ' N ' ' CD1' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -147.3 -78.74 0.16 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.946 0.403 . . . . 0.0 110.735 -179.641 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -138.49 22.19 3.04 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.96 -0.638 . . . . 0.0 112.194 179.749 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 6.2 mt-30 . . . . . 0 C--O 1.25 1.087 0 CA-C-O 118.19 -0.91 . . . . 0.0 110.911 -179.85 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.254 0 N-CA-C 112.464 -0.254 . . . . 0.0 112.464 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 73' ' ' TRP . . . . . 0.492 ' N ' ' CD1' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -146.75 -78.53 0.17 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.917 0.389 . . . . 0.0 110.77 -179.601 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -103.93 -20.65 10.37 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.927 -0.654 . . . . 0.0 112.477 179.823 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 17.9 pt20 -65.1 153.91 88.09 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-O 120.682 0.277 . . . . 0.0 110.852 -179.984 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 76' ' ' PRO . . . . . 0.401 ' HB3' ' CA ' ' A' ' 80' ' ' GLY . 51.6 Cg_endo -69.69 140.09 42.07 Favored 'Trans proline' 0 C--N 1.343 0.283 0 C-N-CA 122.502 2.134 . . . . 0.0 112.414 179.947 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 25.3 p80 -92.23 -31.43 15.44 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.653 179.757 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -120.6 -35.69 0.83 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.845 -0.693 . . . . 0.0 112.411 179.981 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -155.12 -78.0 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.5 -179.952 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 80' ' ' GLY . . . . . 0.401 ' CA ' ' HB3' ' A' ' 76' ' ' PRO . . . -130.62 -157.67 9.03 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.575 -179.951 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 81' ' ' TRP . . . . . 0.48 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -146.75 -78.06 0.17 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.857 0.36 . . . . 0.0 110.731 -179.646 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -105.96 -20.06 9.65 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.886 -0.673 . . . . 0.0 112.532 179.898 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 11.1 pt20 -59.72 154.2 48.0 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-O 120.699 0.285 . . . . 0.0 110.895 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.9 140.57 42.47 Favored 'Trans proline' 0 C--N 1.343 0.263 0 C-N-CA 122.551 2.167 . . . . 0.0 112.314 179.913 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 7.8 m-70 -93.53 -30.46 14.99 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.892 179.925 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -147.38 27.8 1.52 Allowed Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.522 -179.97 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 163.25 -102.27 0.2 Allowed Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.53 179.933 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -130.93 -156.89 8.7 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.552 -179.934 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 89' ' ' TRP . . . . . 0.479 ' CD1' ' N ' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -147.18 -77.99 0.17 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.934 0.397 . . . . 0.0 110.779 -179.65 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -134.78 17.67 4.14 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.923 -0.656 . . . . 0.0 112.528 179.823 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 5.9 pt20 . . . . . 0 C--O 1.249 1.074 0 CA-C-O 118.193 -0.908 . . . . 0.0 110.849 -179.964 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.254 0 N-CA-C 112.495 -0.242 . . . . 0.0 112.495 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 73' ' ' TRP . . . . . 0.488 ' CD1' ' N ' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -146.86 -78.89 0.16 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.942 0.401 . . . . 0.0 110.811 -179.648 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -117.79 14.43 12.83 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.964 -0.636 . . . . 0.0 112.585 179.782 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 8.6 pt20 -84.21 154.36 63.3 Favored Pre-proline 0 C--N 1.331 -0.2 0 CA-C-O 120.684 0.278 . . . . 0.0 110.847 -179.972 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -66.43 146.88 81.64 Favored 'Trans proline' 0 C--N 1.344 0.317 0 C-N-CA 122.557 2.171 . . . . 0.0 112.253 179.89 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 49.0 t-80 -98.68 -31.01 12.14 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.917 179.902 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -128.38 -42.18 0.26 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.435 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -172.76 94.15 0.1 OUTLIER Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.556 -179.967 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 62.01 -170.29 11.48 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.545 -179.926 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 81' ' ' TRP . . . . . 0.491 ' CD1' ' N ' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -147.16 -78.65 0.16 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.93 0.395 . . . . 0.0 110.713 -179.552 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -117.85 14.03 12.85 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.86 -0.686 . . . . 0.0 112.505 179.857 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 21.5 pt20 -81.34 154.62 71.86 Favored Pre-proline 0 C--N 1.331 -0.214 0 CA-C-O 120.736 0.303 . . . . 0.0 110.857 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 40.3 Cg_endo -67.12 143.39 65.03 Favored 'Trans proline' 0 C--N 1.344 0.322 0 C-N-CA 122.541 2.161 . . . . 0.0 112.265 179.967 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 45.2 m-70 -97.43 -30.84 12.68 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.882 179.983 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -126.31 -41.49 0.32 Allowed Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.457 -179.947 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -175.23 96.18 0.1 Allowed Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.672 -0.775 . . . . 0.0 112.471 179.986 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 59.64 -169.51 6.82 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.557 -179.982 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 89' ' ' TRP . . . . . 0.481 ' N ' ' CD1' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -148.26 -76.62 0.17 Allowed 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.961 0.41 . . . . 0.0 110.763 -179.632 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -112.88 -22.12 5.78 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.92 -0.657 . . . . 0.0 112.537 179.88 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 1.1 pt20 . . . . . 0 C--O 1.248 1.008 0 CA-C-O 118.27 -0.871 . . . . 0.0 110.9 179.991 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.3 0 N-CA-C 112.533 -0.227 . . . . 0.0 112.533 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 73' ' ' TRP . . . . . 0.483 ' N ' ' CD1' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -146.46 -78.96 0.17 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.92 0.39 . . . . 0.0 110.705 -179.628 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -113.96 10.61 22.9 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.845 -0.693 . . . . 0.0 112.662 179.845 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 13.6 pt20 -93.16 153.35 41.68 Favored Pre-proline 0 C--N 1.331 -0.216 0 CA-C-O 120.704 0.288 . . . . 0.0 110.889 179.973 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 28.8 Cg_endo -64.08 151.96 83.06 Favored 'Trans proline' 0 C--N 1.344 0.322 0 C-N-CA 122.529 2.153 . . . . 0.0 112.31 -179.989 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 15.7 t-160 -107.68 -28.62 9.61 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.821 179.902 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -157.02 25.6 0.49 Allowed Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.552 -179.998 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 134.86 89.32 0.31 Allowed Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.664 -0.779 . . . . 0.0 112.595 179.867 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 56.92 -176.34 1.17 Allowed Glycine 0 N--CA 1.452 -0.237 0 C-N-CA 120.807 -0.711 . . . . 0.0 112.645 179.888 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 81' ' ' TRP . . . . . 0.527 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -142.14 -79.22 0.24 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.908 0.385 . . . . 0.0 110.819 -179.48 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -118.45 19.28 10.72 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.834 -0.698 . . . . 0.0 112.551 179.797 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 24.4 pt20 -85.08 154.38 60.47 Favored Pre-proline 0 C--N 1.331 -0.228 0 CA-C-O 120.702 0.287 . . . . 0.0 110.827 179.977 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -66.54 158.55 55.07 Favored 'Trans proline' 0 C--N 1.344 0.31 0 C-N-CA 122.56 2.174 . . . . 0.0 112.329 179.903 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 29.1 m80 -107.99 -30.79 8.26 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.916 179.968 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -133.72 27.7 3.32 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.72 -0.753 . . . . 0.0 112.503 -179.999 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 104.5 93.56 2.3 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.523 179.921 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 59.36 -169.86 6.16 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.547 179.938 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 89' ' ' TRP . . . . . 0.484 ' N ' ' CD1' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -147.5 -77.79 0.17 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.942 0.401 . . . . 0.0 110.751 -179.626 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -134.8 17.99 4.11 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.918 -0.658 . . . . 0.0 112.574 179.871 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 2.0 pt20 . . . . . 0 C--O 1.248 1.017 0 CA-C-O 118.233 -0.889 . . . . 0.0 110.868 -179.97 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.31 0 N-CA-C 112.507 -0.237 . . . . 0.0 112.507 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 73' ' ' TRP . . . . . 0.6 ' N ' ' CD1' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -123.06 -78.42 0.6 Allowed 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.896 0.379 . . . . 0.0 110.709 -179.639 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -109.86 -19.15 8.35 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.947 -0.644 . . . . 0.0 112.457 179.799 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 13.8 pt20 -59.34 153.87 45.83 Favored Pre-proline 0 C--N 1.33 -0.249 0 CA-C-O 120.722 0.296 . . . . 0.0 110.894 -179.99 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 30.6 Cg_endo -64.07 153.55 75.49 Favored 'Trans proline' 0 C--N 1.344 0.334 0 C-N-CA 122.568 2.179 . . . . 0.0 112.321 179.956 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 13.2 p80 -107.25 -30.66 8.6 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.817 179.931 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -108.09 -62.83 0.56 Allowed Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.51 179.949 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -164.41 29.26 0.22 Allowed Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.564 -179.981 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 136.16 -164.52 25.04 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.575 179.984 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 81' ' ' TRP . . . . . 0.497 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -146.1 -78.69 0.17 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.941 0.401 . . . . 0.0 110.788 -179.621 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -116.74 13.89 14.78 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.851 -0.69 . . . . 0.0 112.573 179.807 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 18.8 pt20 -86.21 154.31 57.26 Favored Pre-proline 0 C--N 1.331 -0.204 0 CA-C-O 120.688 0.28 . . . . 0.0 110.879 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 38.9 Cg_endo -66.89 153.4 78.04 Favored 'Trans proline' 0 C--N 1.344 0.301 0 C-N-CA 122.565 2.177 . . . . 0.0 112.277 -179.995 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 3.5 t-80 -107.76 -31.1 8.19 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.9 179.928 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -129.61 27.91 4.08 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.51 179.949 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 101.33 96.02 2.25 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.55 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 59.51 -169.45 6.64 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.548 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 89' ' ' TRP . . . . . 0.47 ' N ' ' CD1' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -147.38 -77.61 0.17 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.938 0.399 . . . . 0.0 110.82 -179.612 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -134.69 18.19 4.11 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.907 -0.663 . . . . 0.0 112.556 179.872 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 2.9 pt20 . . . . . 0 C--O 1.249 1.065 0 CA-C-O 118.282 -0.866 . . . . 0.0 110.92 179.995 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.341 0 N-CA-C 112.472 -0.251 . . . . 0.0 112.472 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 73' ' ' TRP . . . . . 0.487 ' N ' ' CD1' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -147.71 -77.95 0.16 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.993 0.425 . . . . 0.0 110.708 -179.583 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -105.53 -20.48 9.51 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.912 -0.661 . . . . 0.0 112.347 179.861 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 13.5 pt20 -65.47 154.43 87.97 Favored Pre-proline 0 C--N 1.33 -0.241 0 CA-C-O 120.652 0.263 . . . . 0.0 110.898 -179.954 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 40.1 Cg_endo -67.14 154.8 73.22 Favored 'Trans proline' 0 C--N 1.343 0.257 0 C-N-CA 122.536 2.157 . . . . 0.0 112.256 179.937 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 15.4 p80 -100.55 -31.67 11.15 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.912 179.99 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -125.24 -47.36 0.22 Allowed Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.457 179.985 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -171.82 87.38 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.459 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 72.67 -169.54 52.12 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.546 179.987 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 81' ' ' TRP . . . . . 0.482 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -148.12 -76.14 0.17 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.921 0.391 . . . . 0.0 110.785 -179.649 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -107.05 -21.73 7.94 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.935 -0.65 . . . . 0.0 112.455 179.833 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 15.6 pt20 -60.1 154.4 50.99 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 120.677 0.275 . . . . 0.0 110.865 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 44.5 Cg_endo -68.34 141.13 50.58 Favored 'Trans proline' 0 C--N 1.344 0.331 0 C-N-CA 122.539 2.159 . . . . 0.0 112.248 179.958 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 13.7 m-70 -95.17 -31.14 13.67 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.934 179.966 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -125.2 -40.99 0.38 Allowed Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.821 -0.704 . . . . 0.0 112.437 -179.959 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -176.92 96.55 0.1 Allowed Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.509 -179.946 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 59.64 -170.36 6.3 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.55 -179.986 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 89' ' ' TRP . . . . . 0.483 ' N ' ' CD1' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -147.58 -77.82 0.16 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.901 0.381 . . . . 0.0 110.831 -179.664 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -133.66 18.55 4.32 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.853 -0.689 . . . . 0.0 112.514 179.776 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 6.5 pt20 . . . . . 0 C--O 1.249 1.052 0 CA-C-O 118.179 -0.915 . . . . 0.0 110.949 -179.998 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.353 0 N-CA-C 112.5 -0.24 . . . . 0.0 112.5 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 73' ' ' TRP . . . . . 0.486 ' N ' ' CD1' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -147.38 -77.66 0.17 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.931 0.396 . . . . 0.0 110.715 -179.563 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -107.89 -20.15 8.62 Favored Glycine 0 N--CA 1.45 -0.413 0 C-N-CA 120.901 -0.666 . . . . 0.0 112.463 179.856 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 11.6 pt20 -59.62 154.32 46.2 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-O 120.701 0.286 . . . . 0.0 110.904 -179.988 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 40.9 Cg_endo -67.33 152.76 78.67 Favored 'Trans proline' 0 C--N 1.345 0.356 0 C-N-CA 122.564 2.176 . . . . 0.0 112.26 179.941 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 6.0 t-160 -105.72 -31.24 8.97 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.875 179.967 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -128.57 29.36 4.04 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.453 -179.996 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 97.48 94.71 1.92 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.467 179.959 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 61.64 -170.07 10.66 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.505 179.966 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 81' ' ' TRP . . . . . 0.488 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -147.02 -78.29 0.17 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.901 0.381 . . . . 0.0 110.736 -179.558 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -115.17 12.97 19.38 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.907 -0.663 . . . . 0.0 112.618 179.748 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 13.1 pt20 -93.43 154.17 41.33 Favored Pre-proline 0 C--N 1.332 -0.186 0 CA-C-O 120.649 0.262 . . . . 0.0 110.889 179.973 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -65.93 148.89 86.5 Favored 'Trans proline' 0 C--N 1.343 0.268 0 C-N-CA 122.629 2.22 . . . . 0.0 112.274 179.944 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 7.7 m170 -100.33 -30.57 11.79 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.776 179.877 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -110.63 -27.93 4.18 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.489 179.935 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 173.91 -43.28 0.15 Allowed Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.641 179.997 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -154.39 -160.12 9.64 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.61 179.985 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 89' ' ' TRP . . . . . 0.488 ' N ' ' CD1' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -146.89 -78.84 0.16 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.879 0.371 . . . . 0.0 110.644 -179.541 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -138.48 22.04 3.05 Favored Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.946 -0.645 . . . . 0.0 112.211 179.764 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 6.0 mt-30 . . . . . 0 C--O 1.25 1.118 0 CA-C-O 118.209 -0.9 . . . . 0.0 110.929 -179.875 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.345 0 N-CA-C 112.6 -0.2 . . . . 0.0 112.6 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 73' ' ' TRP . . . . . 0.493 ' CD1' ' N ' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -147.4 -77.49 0.17 Allowed 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.903 0.382 . . . . 0.0 110.696 -179.53 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -101.84 -19.67 14.73 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.964 -0.636 . . . . 0.0 112.522 179.851 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 4.7 pt20 -59.03 153.97 41.91 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 120.734 0.302 . . . . 0.0 110.891 179.983 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -66.64 154.06 75.77 Favored 'Trans proline' 0 C--N 1.345 0.369 0 C-N-CA 122.524 2.149 . . . . 0.0 112.329 179.992 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 19.8 p-80 -109.51 -30.31 8.0 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.867 -179.933 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -132.13 27.07 3.67 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.545 -179.982 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 104.5 96.45 2.42 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.668 -0.777 . . . . 0.0 112.563 179.925 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 58.84 -170.85 4.9 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.824 -0.703 . . . . 0.0 112.615 179.968 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 81' ' ' TRP . . . . . 0.49 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -147.03 -77.02 0.18 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.884 0.373 . . . . 0.0 110.71 -179.563 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -104.18 -20.86 9.94 Favored Glycine 0 N--CA 1.452 -0.248 0 C-N-CA 120.861 -0.685 . . . . 0.0 112.548 179.86 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 8.3 pt20 -58.84 153.84 40.74 Favored Pre-proline 0 C--N 1.331 -0.221 0 CA-C-O 120.686 0.279 . . . . 0.0 110.917 179.997 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 84' ' ' PRO . . . . . 0.413 ' HB3' ' CA ' ' A' ' 88' ' ' GLY . 18.9 Cg_endo -59.77 160.75 20.26 Favored 'Trans proline' 0 C--N 1.343 0.283 0 C-N-CA 122.584 2.189 . . . . 0.0 112.352 -179.979 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 7.8 p-80 -113.15 -30.87 6.82 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.822 179.873 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -116.8 20.81 11.64 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.648 179.93 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 102.56 9.72 40.17 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.939 179.847 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 88' ' ' GLY . . . . . 0.413 ' CA ' ' HB3' ' A' ' 84' ' ' PRO . . . 161.67 -170.75 37.47 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.633 -0.794 . . . . 0.0 112.635 -179.987 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 89' ' ' TRP . . . . . 0.522 ' N ' ' CD1' ' A' ' 89' ' ' TRP . 0.1 OUTLIER -150.78 -60.05 0.18 Allowed 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 121.278 0.561 . . . . 0.0 110.559 -179.256 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -153.18 -44.86 0.02 OUTLIER Glycine 0 N--CA 1.45 -0.433 0 CA-C-N 115.264 -0.88 . . . . 0.0 111.499 179.636 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 4.6 mt-30 . . . . . 0 C--O 1.248 1.004 0 CA-C-O 118.22 -0.895 . . . . 0.0 111.363 179.326 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.324 0 N-CA-C 112.539 -0.224 . . . . 0.0 112.539 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 73' ' ' TRP . . . . . 0.485 ' N ' ' CD1' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -147.16 -77.04 0.18 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.956 0.408 . . . . 0.0 110.785 -179.555 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -106.76 -21.26 8.32 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.805 -0.712 . . . . 0.0 112.5 179.867 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 3.0 pt20 -59.94 153.84 52.38 Favored Pre-proline 0 C--N 1.331 -0.223 0 CA-C-O 120.663 0.268 . . . . 0.0 110.915 179.947 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_endo -66.06 153.93 76.11 Favored 'Trans proline' 0 C--N 1.344 0.321 0 C-N-CA 122.481 2.121 . . . . 0.0 112.389 179.938 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 23.3 t-160 -109.7 -29.76 8.19 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.811 179.956 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -134.39 26.7 3.33 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.549 179.952 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 106.88 97.63 2.52 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.53 179.888 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 58.45 -172.7 3.59 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.58 179.909 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 81' ' ' TRP . . . . . 0.486 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -146.21 -77.84 0.18 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.96 0.41 . . . . 0.0 110.845 -179.603 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -106.46 -20.81 8.76 Favored Glycine 0 N--CA 1.45 -0.419 0 C-N-CA 120.848 -0.692 . . . . 0.0 112.553 179.895 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 12.5 pt20 -58.89 153.68 42.17 Favored Pre-proline 0 C--N 1.33 -0.254 0 CA-C-O 120.694 0.283 . . . . 0.0 110.933 179.966 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 84' ' ' PRO . . . . . 0.416 ' HB2' ' N ' ' A' ' 88' ' ' GLY . 30.3 Cg_endo -64.37 159.99 41.29 Favored 'Trans proline' 0 C--N 1.344 0.326 0 C-N-CA 122.522 2.148 . . . . 0.0 112.321 -179.977 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 2.3 m80 -117.72 106.34 12.95 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.092 -0.503 . . . . 0.0 110.645 179.665 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 94.93 -26.85 16.7 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.444 -179.797 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 150.01 92.8 0.1 Allowed Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.549 -179.966 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 88' ' ' GLY . . . . . 0.416 ' N ' ' HB2' ' A' ' 84' ' ' PRO . . . 58.46 -157.5 19.53 Favored Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.593 179.988 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 89' ' ' TRP . . . . . 0.509 ' N ' ' CD1' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -142.02 -78.46 0.25 Allowed 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.981 0.42 . . . . 0.0 110.701 -179.636 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -134.68 17.29 4.21 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.908 -0.663 . . . . 0.0 112.507 179.816 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 6.0 pt20 . . . . . 0 C--O 1.249 1.072 0 CA-C-O 118.228 -0.891 . . . . 0.0 110.943 179.963 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.394 0 N-CA-C 112.571 -0.212 . . . . 0.0 112.571 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 73' ' ' TRP . . . . . 0.489 ' N ' ' CD1' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -145.62 -78.83 0.18 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.872 0.368 . . . . 0.0 110.804 -179.606 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -105.93 -20.93 8.91 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.868 -0.682 . . . . 0.0 112.446 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 16.7 pt20 -59.81 154.16 49.2 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 120.742 0.306 . . . . 0.0 110.891 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 76' ' ' PRO . . . . . 0.404 ' HB3' ' CA ' ' A' ' 80' ' ' GLY . 50.0 Cg_endo -69.31 139.75 42.59 Favored 'Trans proline' 0 C--N 1.344 0.326 0 C-N-CA 122.548 2.165 . . . . 0.0 112.333 179.965 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 1.1 t60 -93.73 -31.22 14.51 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.86 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -125.89 -40.82 0.36 Allowed Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.801 -0.714 . . . . 0.0 112.485 -180.0 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -176.48 97.16 0.11 Allowed Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.567 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 80' ' ' GLY . . . . . 0.404 ' CA ' ' HB3' ' A' ' 76' ' ' PRO . . . 59.91 -171.82 5.78 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.563 179.971 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 81' ' ' TRP . . . . . 0.474 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -147.09 -77.34 0.17 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.902 0.382 . . . . 0.0 110.757 -179.66 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -106.6 -21.63 8.18 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.919 -0.658 . . . . 0.0 112.493 179.934 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 20.7 pt20 -59.96 154.03 51.52 Favored Pre-proline 0 C--N 1.33 -0.24 0 CA-C-O 120.702 0.287 . . . . 0.0 110.902 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 84' ' ' PRO . . . . . 0.404 ' HB3' ' CA ' ' A' ' 88' ' ' GLY . 39.0 Cg_endo -67.13 158.1 58.52 Favored 'Trans proline' 0 C--N 1.344 0.335 0 C-N-CA 122.567 2.178 . . . . 0.0 112.296 179.955 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 8.8 m170 -97.67 -30.94 12.54 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.774 179.986 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -113.75 -29.09 2.97 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.506 179.97 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 172.38 -33.6 0.13 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.524 179.991 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 88' ' ' GLY . . . . . 0.404 ' CA ' ' HB3' ' A' ' 84' ' ' PRO . . . -157.85 -161.2 10.74 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.68 -0.771 . . . . 0.0 112.558 -179.968 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 89' ' ' TRP . . . . . 0.489 ' N ' ' CD1' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -147.17 -77.98 0.17 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.969 0.414 . . . . 0.0 110.756 -179.636 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -133.79 17.87 4.36 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.909 -0.662 . . . . 0.0 112.484 179.816 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 13.8 pt20 . . . . . 0 C--O 1.25 1.095 0 CA-C-O 118.164 -0.922 . . . . 0.0 110.896 179.982 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.267 0 N-CA-C 112.469 -0.252 . . . . 0.0 112.469 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 73' ' ' TRP . . . . . 0.509 ' N ' ' CD1' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -144.61 -79.79 0.18 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.944 0.402 . . . . 0.0 110.72 -179.546 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -112.27 15.16 25.4 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.81 -0.71 . . . . 0.0 112.436 179.706 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 3.5 pt20 -107.39 154.07 40.86 Favored Pre-proline 0 C--N 1.33 -0.252 0 CA-C-O 120.713 0.292 . . . . 0.0 110.901 179.989 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_endo -66.0 146.73 83.26 Favored 'Trans proline' 0 C--N 1.344 0.299 0 C-N-CA 122.481 2.121 . . . . 0.0 112.305 179.988 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 6.3 t-160 -100.03 -31.16 11.58 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.794 179.813 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -118.83 -34.59 1.04 Allowed Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.812 -0.709 . . . . 0.0 112.436 179.907 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -161.53 -64.96 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.558 -179.996 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -138.57 -158.95 7.9 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.599 -179.957 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 81' ' ' TRP . . . . . 0.501 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -145.94 -77.99 0.18 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.9 0.381 . . . . 0.0 110.778 -179.594 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -104.18 -21.88 9.14 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.903 -0.665 . . . . 0.0 112.54 179.896 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 16.9 pt20 -61.13 151.7 74.48 Favored Pre-proline 0 C--N 1.331 -0.224 0 CA-C-O 120.719 0.295 . . . . 0.0 110.93 -179.98 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 84' ' ' PRO . . . . . 0.41 ' HB2' ' N ' ' A' ' 88' ' ' GLY . 30.7 Cg_endo -64.63 160.82 38.23 Favored 'Trans proline' 0 C--N 1.344 0.328 0 C-N-CA 122.511 2.141 . . . . 0.0 112.358 179.968 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 16.6 p-80 -118.47 106.57 12.82 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.599 179.644 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 94.42 -26.08 19.52 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.513 -179.797 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 149.29 92.53 0.1 Allowed Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.498 179.937 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 88' ' ' GLY . . . . . 0.41 ' N ' ' HB2' ' A' ' 84' ' ' PRO . . . 58.93 -157.37 22.33 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.548 179.985 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 89' ' ' TRP . . . . . 0.511 ' N ' ' CD1' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -142.55 -78.7 0.24 Allowed 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 121.002 0.429 . . . . 0.0 110.829 -179.676 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -113.15 -20.71 6.2 Favored Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 120.904 -0.665 . . . . 0.0 112.473 179.888 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 2.0 pt20 . . . . . 0 C--O 1.248 1.024 0 CA-C-O 118.333 -0.841 . . . . 0.0 110.862 -179.982 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 57' ' ' TRP . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.489 1.478 0 CA-C-O 120.831 0.348 . . . . 0.0 111.316 . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -166.08 30.61 0.21 Allowed Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.535 -179.96 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 13.0 pt20 -71.12 154.21 94.1 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 120.789 0.328 . . . . 0.0 110.837 -179.954 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 44.7 Cg_endo -68.14 153.79 73.94 Favored 'Trans proline' 0 C--N 1.345 0.345 0 C-N-CA 122.518 2.145 . . . . 0.0 112.314 179.945 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 61' ' ' HIS . . . . . . . . . . . . . 16.6 p-80 -101.89 -31.17 10.84 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.885 179.934 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -126.54 -41.53 0.32 Allowed Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.462 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -176.38 90.26 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.441 179.963 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 62.31 -170.81 11.31 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.679 -0.772 . . . . 0.0 112.603 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 65' ' ' TRP . . . . . 0.492 ' N ' ' CD1' ' A' ' 65' ' ' TRP . 0.0 OUTLIER -147.06 -78.6 0.16 Allowed 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.864 0.364 . . . . 0.0 110.823 -179.673 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -118.5 14.67 11.82 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.941 -0.647 . . . . 0.0 112.538 179.732 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 20.6 pt20 -80.32 154.5 74.4 Favored Pre-proline 0 C--N 1.33 -0.241 0 CA-C-O 120.656 0.265 . . . . 0.0 110.91 -179.988 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -66.35 160.26 46.26 Favored 'Trans proline' 0 C--N 1.344 0.312 0 C-N-CA 122.56 2.173 . . . . 0.0 112.291 179.982 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 27.8 p-80 -106.76 -31.36 8.44 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.828 -179.897 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . -135.14 28.07 3.08 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.515 -179.964 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 105.04 93.48 2.31 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.512 -179.952 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 59.39 -171.12 5.49 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.561 179.967 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 73' ' ' TRP . . . . . 0.481 ' N ' ' CD1' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -146.76 -78.9 0.16 Allowed 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 120.97 0.415 . . . . 0.0 110.746 -179.573 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -114.39 13.23 21.13 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.843 -0.694 . . . . 0.0 112.54 179.83 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 23.9 pt20 -97.38 154.48 38.02 Favored Pre-proline 0 C--N 1.332 -0.192 0 CA-C-O 120.722 0.296 . . . . 0.0 110.888 179.983 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 39.4 Cg_endo -67.29 147.3 78.0 Favored 'Trans proline' 0 C--N 1.344 0.303 0 C-N-CA 122.543 2.162 . . . . 0.0 112.27 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 8.4 t-160 -97.26 -30.62 12.87 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.865 179.893 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -113.17 -27.95 3.5 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.893 -0.67 . . . . 0.0 112.565 179.941 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 179.37 -54.52 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.596 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -145.71 -158.64 7.79 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.521 -179.924 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 81' ' ' TRP . . . . . 0.478 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -147.56 -77.11 0.17 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.97 0.414 . . . . 0.0 110.698 -179.556 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -106.85 -20.93 8.47 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.903 -0.665 . . . . 0.0 112.473 179.868 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 17.8 pt20 -60.18 154.45 51.54 Favored Pre-proline 0 C--N 1.331 -0.216 0 CA-C-O 120.735 0.302 . . . . 0.0 110.856 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_endo -68.72 140.53 47.05 Favored 'Trans proline' 0 C--N 1.345 0.378 0 C-N-CA 122.525 2.15 . . . . 0.0 112.251 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 7.5 m170 -94.89 -30.99 13.89 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.846 -179.956 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -125.22 -40.79 0.39 Allowed Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.496 179.98 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -177.18 96.9 0.11 Allowed Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.468 179.942 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 59.59 -170.71 6.01 Favored Glycine 0 N--CA 1.452 -0.268 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.55 179.947 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 89' ' ' TRP . . . . . 0.478 ' CD1' ' N ' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -147.52 -77.78 0.17 Allowed 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.919 0.39 . . . . 0.0 110.795 -179.638 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -134.69 18.32 4.1 Favored Glycine 0 N--CA 1.449 -0.445 0 C-N-CA 120.894 -0.669 . . . . 0.0 112.504 179.843 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 7.2 pt20 . . . . . 0 C--O 1.249 1.052 0 CA-C-O 118.173 -0.918 . . . . 0.0 110.864 -179.944 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 57' ' ' TRP . . . . . . . . . . . . . 30.1 t-105 . . . . . 0 N--CA 1.486 1.367 0 CA-C-O 120.709 0.29 . . . . 0.0 111.207 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 58' ' ' GLY . . . . . 0.465 ' O ' ' CG ' ' A' ' 59' ' ' GLN . . . -60.31 -40.7 97.81 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.541 179.948 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.465 ' CG ' ' O ' ' A' ' 58' ' ' GLY . 2.6 pt20 54.74 155.08 0.05 OUTLIER Pre-proline 0 N--CA 1.464 0.256 0 CA-C-O 120.948 0.404 . . . . 0.0 111.527 179.958 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 58.5 Cg_endo -72.01 142.4 38.46 Favored 'Trans proline' 0 C--N 1.344 0.328 0 C-N-CA 122.556 2.171 . . . . 0.0 112.302 -179.891 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 61' ' ' HIS . . . . . . . . . . . . . 8.7 t-160 -90.29 -31.11 17.09 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.937 179.924 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -126.22 -42.14 0.31 Allowed Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.41 -179.951 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -176.14 97.81 0.12 Allowed Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.501 -179.899 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 59.61 -170.86 5.94 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.541 179.94 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 65' ' ' TRP . . . . . 0.474 ' CD1' ' N ' ' A' ' 65' ' ' TRP . 0.0 OUTLIER -147.91 -76.82 0.17 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.934 0.397 . . . . 0.0 110.751 -179.621 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -108.23 -19.72 8.75 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.937 -0.649 . . . . 0.0 112.574 179.9 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 18.1 pt20 -58.56 154.14 36.2 Favored Pre-proline 0 C--N 1.33 -0.246 0 CA-C-O 120.682 0.277 . . . . 0.0 110.95 -179.99 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo -69.06 151.39 73.08 Favored 'Trans proline' 0 C--N 1.343 0.287 0 C-N-CA 122.591 2.194 . . . . 0.0 112.309 179.967 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 27.6 p-80 -95.38 -31.01 13.61 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.83 179.933 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . -151.87 27.66 0.92 Allowed Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.502 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 167.41 -107.97 0.3 Allowed Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.524 -179.995 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -126.46 -158.08 9.76 Favored Glycine 0 N--CA 1.452 -0.268 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.56 -179.968 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 73' ' ' TRP . . . . . 0.467 ' CD1' ' N ' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -147.69 -78.02 0.16 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.927 0.394 . . . . 0.0 110.799 -179.598 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -111.34 -15.26 10.66 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.883 -0.675 . . . . 0.0 112.632 179.917 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 18.9 pt20 -56.74 154.08 19.49 Favored Pre-proline 0 C--N 1.331 -0.201 0 CA-C-O 120.699 0.285 . . . . 0.0 111.028 -179.974 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 41.2 Cg_endo -67.32 161.29 43.76 Favored 'Trans proline' 0 C--N 1.343 0.28 0 C-N-CA 122.597 2.198 . . . . 0.0 112.314 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 48.8 t-80 -109.32 -30.5 7.96 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.966 179.865 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -135.16 27.09 3.18 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.468 179.982 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 106.28 92.9 2.29 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.476 179.939 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 58.92 -170.88 4.98 Favored Glycine 0 N--CA 1.452 -0.268 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.535 179.936 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 81' ' ' TRP . . . . . 0.489 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -146.81 -78.88 0.16 Allowed 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.832 0.348 . . . . 0.0 110.76 -179.604 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -119.98 15.89 10.22 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.863 -0.684 . . . . 0.0 112.547 179.733 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 8.2 pt20 -82.11 154.2 69.65 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-O 120.723 0.297 . . . . 0.0 110.903 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 27.6 Cg_endo -62.72 156.47 53.03 Favored 'Trans proline' 0 C--N 1.345 0.365 0 C-N-CA 122.535 2.156 . . . . 0.0 112.273 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 0.7 OUTLIER -109.38 -31.08 7.67 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.815 179.94 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -108.26 -61.71 0.55 Allowed Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.436 -179.984 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -165.77 30.1 0.21 Allowed Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.709 -0.757 . . . . 0.0 112.523 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 136.1 -164.33 25.04 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.581 -179.971 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 89' ' ' TRP . . . . . 0.491 ' CD1' ' N ' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -146.85 -77.92 0.17 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.897 0.379 . . . . 0.0 110.735 -179.634 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -133.04 18.69 4.45 Favored Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.907 -0.663 . . . . 0.0 112.511 179.793 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 15.3 pt20 . . . . . 0 C--O 1.249 1.056 0 CA-C-O 118.203 -0.903 . . . . 0.0 110.89 -179.968 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 57' ' ' TRP . . . . . . . . . . . . . 31.0 t-105 . . . . . 0 N--CA 1.487 1.387 0 CA-C-O 120.848 0.356 . . . . 0.0 111.21 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 58' ' ' GLY . . . . . 0.468 ' O ' ' CG ' ' A' ' 59' ' ' GLN . . . -60.85 -50.83 63.25 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.512 -179.983 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.468 ' CG ' ' O ' ' A' ' 58' ' ' GLY . 5.4 pt20 54.62 155.55 0.05 OUTLIER Pre-proline 0 CA--C 1.531 0.213 0 CA-C-O 121.01 0.433 . . . . 0.0 111.517 179.949 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 60.5 Cg_endo -73.52 147.39 40.83 Favored 'Trans proline' 0 C--N 1.346 0.418 0 C-N-CA 122.446 2.098 . . . . 0.0 112.335 -179.867 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 61' ' ' HIS . . . . . . . . . . . . . 1.8 t60 -89.33 -30.63 18.28 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.905 179.97 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -165.77 31.45 0.22 Allowed Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.527 179.941 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -178.37 -91.22 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.458 179.965 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -155.56 -158.52 8.82 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.62 -179.964 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 65' ' ' TRP . . . . . 0.476 ' N ' ' CD1' ' A' ' 65' ' ' TRP . 0.0 OUTLIER -147.13 -77.61 0.17 Allowed 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 120.973 0.416 . . . . 0.0 110.826 -179.584 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -108.18 -21.07 7.9 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.901 -0.666 . . . . 0.0 112.455 179.827 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 3.2 pt20 -60.05 153.95 53.0 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 120.639 0.257 . . . . 0.0 110.868 -179.969 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 30.2 Cg_endo -64.01 154.13 72.04 Favored 'Trans proline' 0 C--N 1.343 0.289 0 C-N-CA 122.478 2.118 . . . . 0.0 112.304 179.952 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 12.1 t-160 -107.78 -30.6 8.45 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.87 179.923 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . -108.28 -62.69 0.55 Allowed Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.454 -179.976 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -164.28 29.29 0.23 Allowed Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.57 -179.975 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 135.82 -164.02 24.98 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.561 -180.0 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 73' ' ' TRP . . . . . 0.496 ' CD1' ' N ' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -146.31 -78.6 0.17 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.857 0.36 . . . . 0.0 110.76 -179.616 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -116.64 13.72 15.1 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.953 -0.641 . . . . 0.0 112.599 179.73 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 3.9 pt20 -91.02 154.13 45.05 Favored Pre-proline 0 C--N 1.331 -0.238 0 CA-C-O 120.708 0.289 . . . . 0.0 110.942 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 76' ' ' PRO . . . . . 0.403 ' HB3' ' CA ' ' A' ' 80' ' ' GLY . 36.0 Cg_endo -65.33 151.01 86.56 Favored 'Trans proline' 0 C--N 1.344 0.324 0 C-N-CA 122.495 2.13 . . . . 0.0 112.27 179.971 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 17.2 t-160 -101.07 -30.72 11.44 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.796 179.916 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -109.17 -27.77 4.67 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.528 179.95 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 168.11 -31.38 0.18 Allowed Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.598 179.953 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 80' ' ' GLY . . . . . 0.403 ' CA ' ' HB3' ' A' ' 76' ' ' PRO . . . -162.3 -162.17 13.05 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.555 -179.987 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 81' ' ' TRP . . . . . 0.49 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -146.28 -78.54 0.17 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.92 0.391 . . . . 0.0 110.748 -179.657 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -116.99 13.25 14.3 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.903 -0.665 . . . . 0.0 112.555 179.806 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 13.9 pt20 -86.09 154.29 57.58 Favored Pre-proline 0 C--N 1.332 -0.193 0 CA-C-O 120.628 0.251 . . . . 0.0 110.917 179.966 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 84' ' ' PRO . . . . . 0.401 ' HB3' ' CA ' ' A' ' 88' ' ' GLY . 37.3 Cg_endo -66.12 157.41 59.85 Favored 'Trans proline' 0 C--N 1.344 0.296 0 C-N-CA 122.538 2.159 . . . . 0.0 112.32 179.914 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 3.5 t-80 -98.95 -30.79 12.16 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.854 179.861 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -113.03 -27.73 3.61 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.481 -179.995 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 169.91 -32.39 0.16 Allowed Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.711 -0.756 . . . . 0.0 112.551 179.979 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 88' ' ' GLY . . . . . 0.401 ' CA ' ' HB3' ' A' ' 84' ' ' PRO . . . -159.08 -161.48 11.18 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.509 -179.966 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 89' ' ' TRP . . . . . 0.485 ' CD1' ' N ' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -147.14 -77.98 0.17 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.826 0.346 . . . . 0.0 110.826 -179.669 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -134.71 17.76 4.15 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.921 -0.657 . . . . 0.0 112.523 179.863 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 7.6 pt20 . . . . . 0 C--O 1.248 1.023 0 CA-C-O 118.242 -0.885 . . . . 0.0 110.944 -180.0 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 57' ' ' TRP . . . . . . . . . . . . . 6.1 t90 . . . . . 0 N--CA 1.487 1.412 0 CA-C-O 120.797 0.332 . . . . 0.0 111.197 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -59.87 -75.23 0.29 Allowed Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.545 -179.996 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 9.1 pt20 -87.54 153.79 53.27 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 120.714 0.292 . . . . 0.0 110.922 179.969 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 32.5 Cg_endo -64.62 150.56 87.99 Favored 'Trans proline' 0 C--N 1.344 0.337 0 C-N-CA 122.566 2.178 . . . . 0.0 112.342 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 61' ' ' HIS . . . . . . . . . . . . . 9.0 t-160 -103.18 6.27 38.23 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.221 179.931 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 137.68 43.76 0.09 OUTLIER Glycine 0 C--N 1.331 0.298 0 C-N-CA 120.617 -0.802 . . . . 0.0 112.522 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 158.74 42.53 0.02 OUTLIER Glycine 0 N--CA 1.45 -0.419 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.681 179.882 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 56.0 -157.35 9.48 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.748 179.893 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 65' ' ' TRP . . . . . 0.488 ' N ' ' CD1' ' A' ' 65' ' ' TRP . 0.0 OUTLIER -147.33 -77.68 0.17 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.911 0.386 . . . . 0.0 110.743 -179.623 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -109.08 -19.17 8.68 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.869 -0.681 . . . . 0.0 112.483 179.901 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 9.1 pt20 -58.55 154.19 35.84 Favored Pre-proline 0 C--N 1.331 -0.208 0 CA-C-O 120.674 0.273 . . . . 0.0 110.954 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo -66.02 157.83 57.44 Favored 'Trans proline' 0 C--N 1.344 0.309 0 C-N-CA 122.572 2.182 . . . . 0.0 112.28 179.913 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 10.7 p80 -108.09 -31.18 8.04 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.899 179.948 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . -130.57 28.55 3.75 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.456 -179.955 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 100.19 95.93 2.17 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.559 179.988 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 60.37 -169.61 7.93 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.56 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 73' ' ' TRP . . . . . 0.485 ' N ' ' CD1' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -147.82 -77.25 0.17 Allowed 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.936 0.398 . . . . 0.0 110.787 -179.603 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -105.39 -21.67 8.67 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.888 -0.672 . . . . 0.0 112.446 179.832 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 16.3 pt20 -63.66 154.48 80.04 Favored Pre-proline 0 C--N 1.331 -0.2 0 CA-C-O 120.677 0.275 . . . . 0.0 110.879 -180.0 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 41.6 Cg_endo -67.7 142.06 56.9 Favored 'Trans proline' 0 C--N 1.344 0.311 0 C-N-CA 122.518 2.145 . . . . 0.0 112.239 -179.998 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 3.5 t-80 -96.05 -31.0 13.25 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.918 179.994 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -124.78 -41.77 0.37 Allowed Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.463 -179.986 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -177.02 94.58 0.1 OUTLIER Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.531 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 62.84 -170.66 13.08 Favored Glycine 0 N--CA 1.45 -0.416 0 C-N-CA 120.667 -0.778 . . . . 0.0 112.607 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 81' ' ' TRP . . . . . 0.477 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -148.24 -75.59 0.18 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.942 0.401 . . . . 0.0 110.742 -179.634 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -107.45 -22.09 7.61 Favored Glycine 0 N--CA 1.449 -0.436 0 C-N-CA 120.869 -0.682 . . . . 0.0 112.463 179.831 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 14.6 pt20 -60.17 154.11 53.32 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-O 120.646 0.26 . . . . 0.0 110.876 179.961 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 34.8 Cg_endo -65.35 153.46 78.15 Favored 'Trans proline' 0 C--N 1.344 0.308 0 C-N-CA 122.515 2.143 . . . . 0.0 112.255 179.963 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 57.5 m80 -100.63 -31.74 11.09 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.672 179.831 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -116.69 -31.65 1.74 Allowed Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.834 -0.698 . . . . 0.0 112.447 179.971 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -165.87 -69.25 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.59 -180.0 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -135.66 -147.84 5.51 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.616 179.98 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 89' ' ' TRP . . . . . 0.432 ' CH2' ' HB3' ' A' ' 91' ' ' GLN . 0.4 OUTLIER -161.11 23.57 0.13 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.765 0.317 . . . . 0.0 111.119 -179.342 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 103.03 -14.34 55.77 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.668 -0.777 . . . . 0.0 112.402 -179.644 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 91' ' ' GLN . . . . . 0.432 ' HB3' ' CH2' ' A' ' 89' ' ' TRP . 4.3 pt20 . . . . . 0 C--O 1.249 1.074 0 CA-C-O 118.229 -0.891 . . . . 0.0 110.919 -179.984 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 57' ' ' TRP . . . . . 0.451 ' CZ2' ' HG2' ' A' ' 59' ' ' GLN . 3.5 p-90 . . . . . 0 N--CA 1.488 1.429 0 CA-C-O 120.493 0.187 . . . . 0.0 111.021 . . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -43.68 -75.46 0.15 Allowed Glycine 0 C--N 1.332 0.319 0 C-N-CA 121.094 -0.574 . . . . 0.0 113.194 -179.567 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.451 ' HG2' ' CZ2' ' A' ' 57' ' ' TRP . 5.6 pt20 -96.48 154.6 38.53 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 120.705 0.288 . . . . 0.0 110.95 -179.934 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -66.1 151.02 84.81 Favored 'Trans proline' 0 C--N 1.344 0.321 0 C-N-CA 122.527 2.151 . . . . 0.0 112.32 179.968 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 61' ' ' HIS . . . . . . . . . . . . . 17.9 t-160 -104.79 -31.18 9.44 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.871 179.983 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -125.32 -40.85 0.38 Allowed Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.543 179.946 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -176.54 91.06 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.652 -0.785 . . . . 0.0 112.445 179.94 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 59.63 -169.0 7.12 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.51 179.961 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 65' ' ' TRP . . . . . 0.467 ' CD1' ' N ' ' A' ' 65' ' ' TRP . 0.0 OUTLIER -148.46 -75.88 0.17 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.905 0.383 . . . . 0.0 110.794 -179.643 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -110.22 -19.55 7.97 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.9 -0.667 . . . . 0.0 112.496 179.932 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 11.2 pt20 -58.4 153.74 36.77 Favored Pre-proline 0 C--N 1.331 -0.2 0 CA-C-O 120.744 0.307 . . . . 0.0 110.956 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 27.6 Cg_endo -63.25 157.86 47.6 Favored 'Trans proline' 0 C--N 1.344 0.329 0 C-N-CA 122.601 2.201 . . . . 0.0 112.355 179.977 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 15.2 p-80 -116.6 105.28 12.27 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.6 179.556 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 94.29 -25.92 20.05 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.531 -179.728 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -172.17 -92.77 0.08 OUTLIER Glycine 0 N--CA 1.453 -0.216 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.612 -179.983 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -133.55 -146.45 5.52 Favored Glycine 0 N--CA 1.453 -0.229 0 C-N-CA 120.85 -0.69 . . . . 0.0 112.57 -179.876 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 73' ' ' TRP . . . . . 0.557 ' N ' ' CD1' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -136.21 -78.33 0.42 Allowed 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.954 0.407 . . . . 0.0 110.629 -179.654 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -113.33 -9.09 18.34 Favored Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 120.907 -0.663 . . . . 0.0 112.625 179.758 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 14.3 pt20 -58.37 154.22 33.79 Favored Pre-proline 0 C--N 1.331 -0.237 0 CA-C-O 120.751 0.31 . . . . 0.0 110.957 179.933 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 76' ' ' PRO . . . . . 0.426 ' HB2' ' N ' ' A' ' 80' ' ' GLY . 55.0 Cg_endo -70.58 137.9 34.06 Favored 'Trans proline' 0 C--N 1.344 0.32 0 C-N-CA 122.431 2.088 . . . . 0.0 112.199 179.796 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 18.4 m-70 -107.66 105.38 15.21 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.985 0.421 . . . . 0.0 110.709 179.657 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 104.74 -31.5 8.53 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.868 -0.682 . . . . 0.0 112.433 -179.886 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 152.04 93.28 0.1 OUTLIER Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.576 -179.986 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 80' ' ' GLY . . . . . 0.426 ' N ' ' HB2' ' A' ' 76' ' ' PRO . . . 52.8 -161.79 2.54 Favored Glycine 0 C--N 1.33 0.229 0 C-N-CA 120.883 -0.675 . . . . 0.0 112.781 179.983 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 81' ' ' TRP . . . . . 0.549 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -137.09 -78.27 0.4 Allowed 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.935 0.398 . . . . 0.0 110.694 -179.665 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -107.33 -20.28 8.76 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.89 -0.672 . . . . 0.0 112.483 179.853 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 15.6 pt20 -59.9 154.42 48.66 Favored Pre-proline 0 C--N 1.331 -0.223 0 CA-C-O 120.631 0.253 . . . . 0.0 110.923 -179.946 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 44.0 Cg_endo -68.04 141.39 52.85 Favored 'Trans proline' 0 C--N 1.344 0.306 0 C-N-CA 122.558 2.172 . . . . 0.0 112.277 179.912 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 4.7 t-160 -95.5 -31.07 13.52 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.886 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -120.55 -41.37 0.53 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.518 179.966 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 179.22 96.13 0.1 Allowed Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.68 -0.772 . . . . 0.0 112.434 179.958 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 59.7 -170.07 6.55 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.542 -179.998 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 89' ' ' TRP . . . . . 0.482 ' N ' ' CD1' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -148.31 -76.18 0.17 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.998 0.428 . . . . 0.0 110.828 -179.634 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -112.89 -22.22 5.74 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.86 -0.686 . . . . 0.0 112.435 179.879 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 2.8 pp0? . . . . . 0 C--O 1.249 1.03 0 CA-C-O 118.257 -0.877 . . . . 0.0 110.904 -179.914 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 57' ' ' TRP . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.486 1.357 0 CA-C-O 120.815 0.34 . . . . 0.0 111.254 . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 161.24 -28.24 0.29 Allowed Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.493 179.97 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 14.1 pt20 -69.35 154.08 95.26 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 120.7 0.286 . . . . 0.0 110.92 179.999 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_endo -68.21 147.52 72.77 Favored 'Trans proline' 0 C--N 1.344 0.33 0 C-N-CA 122.54 2.16 . . . . 0.0 112.317 179.961 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 61' ' ' HIS . . . . . . . . . . . . . 21.9 t-160 -96.04 -31.02 13.25 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.858 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -127.66 -41.79 0.28 Allowed Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.848 -0.691 . . . . 0.0 112.516 179.928 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -174.52 94.91 0.1 Allowed Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.686 -0.768 . . . . 0.0 112.507 179.969 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 59.37 -169.32 6.49 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.535 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 65' ' ' TRP . . . . . 0.46 ' CD1' ' N ' ' A' ' 65' ' ' TRP . 0.0 OUTLIER -148.69 -75.97 0.17 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.876 0.369 . . . . 0.0 110.786 -179.683 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -111.86 -13.72 12.17 Favored Glycine 0 N--CA 1.452 -0.248 0 C-N-CA 120.886 -0.674 . . . . 0.0 112.698 -179.99 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 6.6 pt20 -56.68 154.32 18.25 Favored Pre-proline 0 C--N 1.332 -0.157 0 CA-C-O 120.708 0.29 . . . . 0.0 110.958 -179.943 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -70.72 152.48 64.36 Favored 'Trans proline' 0 C--N 1.343 0.254 0 C-N-CA 122.57 2.18 . . . . 0.0 112.313 179.878 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 1.6 t60 -97.02 -29.8 13.43 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.853 179.894 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . -151.21 27.56 0.99 Allowed Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.569 179.931 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 165.86 -107.04 0.28 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.542 179.958 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -126.9 -156.63 9.24 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.805 -0.712 . . . . 0.0 112.517 179.982 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 73' ' ' TRP . . . . . 0.454 ' CD1' ' N ' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -148.04 -79.36 0.15 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.885 0.374 . . . . 0.0 110.845 -179.667 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -115.99 -2.82 20.2 Favored Glycine 0 CA--C 1.519 0.311 0 C-N-CA 120.815 -0.707 . . . . 0.0 112.663 179.911 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 9.7 pt20 -58.04 154.41 29.58 Favored Pre-proline 0 C--N 1.33 -0.263 0 CA-C-O 120.728 0.299 . . . . 0.0 110.942 179.985 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -66.32 153.47 77.91 Favored 'Trans proline' 0 C--N 1.344 0.318 0 C-N-CA 122.553 2.169 . . . . 0.0 112.287 179.991 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 2.2 t60 -100.23 -30.33 11.97 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.785 179.896 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -151.04 27.46 1.01 Allowed Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.478 -179.99 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 165.49 -109.59 0.37 Allowed Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.541 -179.932 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -123.7 -158.94 10.3 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.829 -0.701 . . . . 0.0 112.518 -179.945 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 81' ' ' TRP . . . . . 0.481 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -147.42 -78.6 0.16 Allowed 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.971 0.415 . . . . 0.0 110.873 -179.637 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -111.9 -15.22 10.23 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.959 -0.639 . . . . 0.0 112.577 179.898 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 16.2 pt20 -56.36 154.33 16.68 Favored Pre-proline 0 C--N 1.331 -0.211 0 CA-C-O 120.706 0.288 . . . . 0.0 111.006 179.969 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 40.9 Cg_endo -67.35 169.22 15.91 Favored 'Trans proline' 0 C--N 1.344 0.299 0 C-N-CA 122.604 2.202 . . . . 0.0 112.287 179.936 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 3.6 m-70 -110.15 -31.34 7.38 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.898 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -136.75 27.93 2.89 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.556 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 105.22 98.4 2.54 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.46 179.928 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 59.09 -170.81 5.24 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.511 179.925 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 89' ' ' TRP . . . . . 0.475 ' CD1' ' N ' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -147.92 -77.51 0.16 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.936 0.398 . . . . 0.0 110.88 -179.605 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -113.56 -22.06 5.57 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.87 -0.681 . . . . 0.0 112.486 179.823 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.249 1.034 0 CA-C-O 118.173 -0.918 . . . . 0.0 110.939 -179.993 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 57' ' ' TRP . . . . . . . . . . . . . 2.2 t90 . . . . . 0 N--CA 1.487 1.376 0 CA-C-O 120.847 0.356 . . . . 0.0 111.208 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -59.75 -51.18 60.53 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.492 179.981 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER 57.53 165.03 0.07 OUTLIER Pre-proline 0 C--N 1.33 -0.271 0 CA-C-O 120.755 0.312 . . . . 0.0 111.005 -179.928 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -70.05 126.2 12.85 Favored 'Trans proline' 0 C--N 1.344 0.317 0 C-N-CA 122.548 2.166 . . . . 0.0 112.267 -179.928 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 61' ' ' HIS . . . . . . . . . . . . . 5.4 m170 -89.81 6.05 43.42 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.377 179.908 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 173.25 39.37 0.04 OUTLIER Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.515 -179.993 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 151.47 -102.41 0.23 Allowed Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.68 -0.772 . . . . 0.0 112.48 179.929 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -139.54 -159.22 7.91 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.511 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 65' ' ' TRP . . . . . 0.488 ' N ' ' CD1' ' A' ' 65' ' ' TRP . 0.0 OUTLIER -146.88 -78.62 0.16 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.889 0.376 . . . . 0.0 110.725 -179.573 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -119.12 14.01 11.18 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.907 -0.663 . . . . 0.0 112.56 179.77 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 17.9 pt20 -78.56 154.19 78.75 Favored Pre-proline 0 C--N 1.331 -0.198 0 CA-C-O 120.75 0.31 . . . . 0.0 110.906 179.932 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 68' ' ' PRO . . . . . 0.413 ' HB2' ' N ' ' A' ' 72' ' ' GLY . 29.3 Cg_endo -63.83 160.68 35.88 Favored 'Trans proline' 0 C--N 1.345 0.378 0 C-N-CA 122.541 2.161 . . . . 0.0 112.31 -179.972 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 6.1 p80 -117.9 106.34 12.87 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.649 179.707 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 94.46 -26.52 17.36 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.452 -179.812 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 149.69 92.7 0.1 Allowed Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.497 179.99 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 72' ' ' GLY . . . . . 0.413 ' N ' ' HB2' ' A' ' 68' ' ' PRO . . . 58.88 -158.43 20.0 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.676 -0.773 . . . . 0.0 112.56 179.965 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 73' ' ' TRP . . . . . 0.528 ' N ' ' CD1' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -141.31 -79.08 0.26 Allowed 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.928 0.394 . . . . 0.0 110.627 -179.601 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -116.99 13.93 14.09 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.83 -0.7 . . . . 0.0 112.47 179.842 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 21.2 pt20 -89.55 154.52 48.46 Favored Pre-proline 0 C--N 1.331 -0.197 0 CA-C-O 120.661 0.267 . . . . 0.0 110.881 -179.966 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 39.8 Cg_endo -67.06 148.38 81.33 Favored 'Trans proline' 0 C--N 1.344 0.319 0 C-N-CA 122.485 2.123 . . . . 0.0 112.26 179.921 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 0.8 OUTLIER -97.54 6.22 48.42 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.379 179.956 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 150.81 44.57 0.02 OUTLIER Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.524 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 168.37 -82.92 0.1 OUTLIER Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.52 -179.973 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -169.64 -160.8 18.77 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.516 -179.941 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 81' ' ' TRP . . . . . 0.472 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -147.53 -77.96 0.16 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.901 0.381 . . . . 0.0 110.747 -179.613 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -105.86 -20.9 8.97 Favored Glycine 0 N--CA 1.45 -0.398 0 C-N-CA 120.915 -0.66 . . . . 0.0 112.46 179.807 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 20.8 pt20 -63.98 154.2 82.45 Favored Pre-proline 0 C--N 1.33 -0.25 0 CA-C-O 120.71 0.29 . . . . 0.0 110.887 179.935 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo -66.27 177.58 3.08 Favored 'Trans proline' 0 C--N 1.344 0.338 0 C-N-CA 122.62 2.213 . . . . 0.0 112.293 179.9 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 27.4 p-80 -99.96 -30.99 11.69 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.887 179.93 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -162.66 28.78 0.26 Allowed Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.461 179.949 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 170.12 -92.3 0.1 OUTLIER Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.599 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -138.74 -156.5 7.05 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.589 179.953 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 89' ' ' TRP . . . . . 0.478 ' N ' ' CD1' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -147.8 -78.01 0.16 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.908 0.385 . . . . 0.0 110.707 -179.576 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -134.98 16.92 4.17 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.904 -0.665 . . . . 0.0 112.59 179.849 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 7.0 pt20 . . . . . 0 C--O 1.249 1.069 0 CA-C-O 118.238 -0.887 . . . . 0.0 110.93 -179.991 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 57' ' ' TRP . . . . . . . . . . . . . 6.9 t90 . . . . . 0 N--CA 1.487 1.394 0 CA-C-O 120.771 0.32 . . . . 0.0 111.214 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 58' ' ' GLY . . . . . 0.473 ' O ' ' CG ' ' A' ' 59' ' ' GLN . . . -58.45 -28.31 62.02 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.586 179.977 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.473 ' CG ' ' O ' ' A' ' 58' ' ' GLY . 3.0 pt20 54.92 154.32 0.05 OUTLIER Pre-proline 0 N--CA 1.463 0.206 0 CA-C-O 121.01 0.433 . . . . 0.0 111.558 179.994 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_endo -64.36 155.83 63.56 Favored 'Trans proline' 0 C--N 1.345 0.376 0 C-N-CA 122.55 2.166 . . . . 0.0 112.295 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 61' ' ' HIS . . . . . . . . . . . . . 1.6 t60 -103.07 -30.2 10.89 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.859 179.944 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 175.27 38.33 0.05 OUTLIER Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.665 -0.779 . . . . 0.0 112.54 179.988 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 170.02 39.73 0.03 OUTLIER Glycine 0 N--CA 1.452 -0.248 0 C-N-CA 120.604 -0.808 . . . . 0.0 112.576 179.918 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 56.37 -154.15 16.66 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.674 179.856 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 65' ' ' TRP . . . . . 0.475 ' CD1' ' N ' ' A' ' 65' ' ' TRP . 0.0 OUTLIER -147.39 -77.94 0.17 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.959 0.409 . . . . 0.0 110.676 -179.613 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -108.91 -19.61 8.5 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.953 -0.642 . . . . 0.0 112.425 179.866 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 14.5 pt20 -61.42 152.91 71.72 Favored Pre-proline 0 C--N 1.33 -0.258 0 CA-C-O 120.728 0.299 . . . . 0.0 110.908 -179.965 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 21.4 Cg_endo -62.06 137.76 68.75 Favored 'Trans proline' 0 C--N 1.345 0.367 0 C-N-CA 122.599 2.199 . . . . 0.0 112.343 -179.948 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 3.2 t-80 -113.46 6.15 17.02 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.281 179.883 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . -174.45 33.87 0.11 Allowed Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.566 -179.982 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 105.39 88.09 2.03 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.578 179.906 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 58.31 -170.85 4.32 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.599 179.881 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 73' ' ' TRP . . . . . 0.499 ' N ' ' CD1' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -144.78 -77.79 0.2 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.921 0.391 . . . . 0.0 110.8 -179.607 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -103.39 -23.06 8.64 Favored Glycine 0 N--CA 1.449 -0.437 0 C-N-CA 120.954 -0.641 . . . . 0.0 112.517 179.884 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 3.1 pt20 -62.35 151.29 82.76 Favored Pre-proline 0 C--N 1.33 -0.249 0 CA-C-O 120.717 0.294 . . . . 0.0 110.907 -179.986 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 76' ' ' PRO . . . . . 0.405 ' HB3' ' CA ' ' A' ' 80' ' ' GLY . 23.9 Cg_endo -62.36 155.48 57.11 Favored 'Trans proline' 0 C--N 1.344 0.337 0 C-N-CA 122.587 2.191 . . . . 0.0 112.386 179.939 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 8.3 p80 -109.55 -29.92 8.16 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.84 179.817 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -112.35 -57.06 0.44 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.8 -0.715 . . . . 0.0 112.488 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -169.86 32.16 0.16 Allowed Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.649 179.965 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 80' ' ' GLY . . . . . 0.405 ' CA ' ' HB3' ' A' ' 76' ' ' PRO . . . 138.75 -169.3 24.44 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.646 -0.788 . . . . 0.0 112.611 -179.973 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 81' ' ' TRP . . . . . 0.491 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -145.65 -77.98 0.19 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.919 0.39 . . . . 0.0 110.781 -179.681 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -102.69 -20.3 11.99 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.87 -0.681 . . . . 0.0 112.558 179.927 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 13.2 pt20 -58.71 153.78 39.68 Favored Pre-proline 0 C--N 1.332 -0.195 0 CA-C-O 120.784 0.326 . . . . 0.0 110.952 -179.963 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 30.5 Cg_endo -64.2 154.13 72.55 Favored 'Trans proline' 0 C--N 1.345 0.361 0 C-N-CA 122.542 2.162 . . . . 0.0 112.267 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 1.6 t-80 -108.96 -29.82 8.4 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.82 179.872 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -108.5 -61.46 0.54 Allowed Glycine 0 N--CA 1.45 -0.406 0 C-N-CA 120.821 -0.704 . . . . 0.0 112.469 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -166.75 30.6 0.19 Allowed Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.569 179.946 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 135.31 -165.78 24.62 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.586 179.919 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 89' ' ' TRP . . . . . 0.489 ' N ' ' CD1' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -146.1 -79.36 0.17 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.902 0.382 . . . . 0.0 110.727 -179.626 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -139.13 22.67 2.92 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.99 -0.624 . . . . 0.0 112.175 179.779 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 20.2 mt-30 . . . . . 0 C--O 1.249 1.03 0 CA-C-O 118.223 -0.894 . . . . 0.0 110.933 -179.923 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 57' ' ' TRP . . . . . . . . . . . . . 5.4 t-105 . . . . . 0 N--CA 1.487 1.383 0 CA-C-O 120.896 0.379 . . . . 0.0 111.169 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -160.57 28.51 0.32 Allowed Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.496 179.972 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 4.2 pt20 -168.03 154.4 7.26 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 120.691 0.281 . . . . 0.0 110.878 179.969 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo -68.84 142.58 52.54 Favored 'Trans proline' 0 C--N 1.344 0.309 0 C-N-CA 122.57 2.18 . . . . 0.0 112.295 179.933 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 61' ' ' HIS . . . . . . . . . . . . . 1.2 t-160 -94.82 6.42 49.03 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.322 179.966 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 156.39 43.68 0.02 OUTLIER Glycine 0 C--N 1.332 0.327 0 C-N-CA 120.619 -0.8 . . . . 0.0 112.474 -179.973 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 163.79 -92.94 0.11 Allowed Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.613 -0.803 . . . . 0.0 112.475 -179.994 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -156.23 -162.34 11.35 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.816 -0.707 . . . . 0.0 112.581 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 65' ' ' TRP . . . . . 0.498 ' N ' ' CD1' ' A' ' 65' ' ' TRP . 0.0 OUTLIER -146.33 -79.04 0.17 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.898 0.38 . . . . 0.0 110.795 -179.665 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -119.28 15.14 10.88 Favored Glycine 0 N--CA 1.452 -0.268 0 C-N-CA 120.857 -0.687 . . . . 0.0 112.468 179.761 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 14.3 pt20 -76.57 154.16 83.64 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-O 120.645 0.26 . . . . 0.0 110.907 179.975 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 28.7 Cg_endo -63.32 158.13 46.49 Favored 'Trans proline' 0 C--N 1.343 0.244 0 C-N-CA 122.629 2.219 . . . . 0.0 112.307 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 1.7 t60 -109.59 -30.55 7.86 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.82 179.902 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . -139.08 26.45 2.72 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.573 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 111.75 94.41 2.2 Favored Glycine 0 N--CA 1.453 -0.232 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.519 179.967 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 57.99 -174.19 2.58 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.584 179.879 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 73' ' ' TRP . . . . . 0.494 ' CD1' ' N ' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -146.25 -79.72 0.16 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.867 0.365 . . . . 0.0 110.791 -179.624 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -120.0 16.96 10.05 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.936 -0.649 . . . . 0.0 112.467 179.714 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 6.6 pt20 -77.29 154.79 82.12 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 120.734 0.302 . . . . 0.0 110.801 -179.965 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 32.7 Cg_endo -64.57 154.56 71.42 Favored 'Trans proline' 0 C--N 1.344 0.32 0 C-N-CA 122.465 2.11 . . . . 0.0 112.264 179.879 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 2.1 t60 -102.85 -30.38 10.88 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.829 179.871 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -148.98 27.74 1.27 Allowed Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.431 179.991 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 162.48 -108.64 0.35 Allowed Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.487 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -123.26 -158.44 10.18 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.561 179.975 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 81' ' ' TRP . . . . . 0.477 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -147.7 -78.36 0.16 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.847 0.356 . . . . 0.0 110.748 -179.574 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -111.2 -18.36 8.24 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.928 -0.653 . . . . 0.0 112.523 179.908 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 4.6 pt20 -58.03 154.0 31.59 Favored Pre-proline 0 C--N 1.331 -0.232 0 CA-C-O 120.732 0.301 . . . . 0.0 110.931 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 84' ' ' PRO . . . . . 0.416 ' HB2' ' N ' ' A' ' 88' ' ' GLY . 28.1 Cg_endo -63.47 161.44 31.35 Favored 'Trans proline' 0 C--N 1.344 0.329 0 C-N-CA 122.581 2.188 . . . . 0.0 112.335 179.942 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 1.7 m80 -118.32 106.15 12.47 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.674 179.694 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 94.43 -26.51 17.37 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.452 -179.801 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 150.06 92.43 0.1 OUTLIER Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.51 -179.98 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 88' ' ' GLY . . . . . 0.416 ' N ' ' HB2' ' A' ' 84' ' ' PRO . . . 59.1 -156.78 24.36 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.591 -179.968 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 89' ' ' TRP . . . . . 0.501 ' N ' ' CD1' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -142.58 -78.5 0.24 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.959 0.409 . . . . 0.0 110.666 -179.656 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -134.84 16.53 4.24 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.907 -0.663 . . . . 0.0 112.54 179.902 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 3.6 pt20 . . . . . 0 C--O 1.249 1.063 0 CA-C-O 118.2 -0.905 . . . . 0.0 110.927 179.996 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 57' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.487 1.402 0 CA-C-O 120.884 0.373 . . . . 0.0 111.134 . . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 150.21 -32.04 1.05 Allowed Glycine 0 N--CA 1.452 -0.254 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.455 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 14.2 pt20 -132.36 153.58 81.28 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 120.668 0.271 . . . . 0.0 110.854 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 60' ' ' PRO . . . . . 0.428 ' HB2' ' N ' ' A' ' 64' ' ' GLY . 55.2 Cg_endo -70.69 138.22 34.39 Favored 'Trans proline' 0 C--N 1.343 0.284 0 C-N-CA 122.44 2.093 . . . . 0.0 112.224 179.829 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 61' ' ' HIS . . . . . . . . . . . . . 4.2 m-70 -107.97 105.43 15.21 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.728 179.643 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 104.58 -30.92 9.24 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.455 -179.848 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 151.24 93.4 0.1 Allowed Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.609 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 64' ' ' GLY . . . . . 0.428 ' N ' ' HB2' ' A' ' 60' ' ' PRO . . . 52.93 -162.11 2.53 Favored Glycine 0 CA--C 1.518 0.226 0 C-N-CA 120.854 -0.689 . . . . 0.0 112.732 179.979 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 65' ' ' TRP . . . . . 0.539 ' N ' ' CD1' ' A' ' 65' ' ' TRP . 0.0 OUTLIER -137.41 -78.61 0.39 Allowed 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 120.912 0.387 . . . . 0.0 110.718 -179.691 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -106.48 -21.88 8.09 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.945 -0.645 . . . . 0.0 112.404 179.87 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 16.8 pt20 -61.17 154.07 63.85 Favored Pre-proline 0 C--N 1.33 -0.251 0 CA-C-O 120.626 0.251 . . . . 0.0 110.896 -179.996 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 34.7 Cg_endo -65.58 153.13 79.55 Favored 'Trans proline' 0 C--N 1.344 0.311 0 C-N-CA 122.504 2.136 . . . . 0.0 112.272 179.997 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 19.9 p-80 -101.72 -30.5 11.28 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.825 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . -178.23 36.14 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.468 -179.931 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -171.74 -65.03 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.559 179.989 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 167.34 -159.67 33.08 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.496 -179.946 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 73' ' ' TRP . . . . . 0.493 ' N ' ' CD1' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -146.2 -77.97 0.18 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.939 0.399 . . . . 0.0 110.794 -179.672 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -104.74 -21.17 9.32 Favored Glycine 0 N--CA 1.45 -0.416 0 C-N-CA 120.888 -0.673 . . . . 0.0 112.485 179.755 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 17.6 pt20 -65.74 154.0 89.74 Favored Pre-proline 0 C--N 1.331 -0.225 0 CA-C-O 120.751 0.31 . . . . 0.0 110.861 179.971 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 33.7 Cg_endo -65.32 149.04 88.8 Favored 'Trans proline' 0 C--N 1.345 0.342 0 C-N-CA 122.535 2.156 . . . . 0.0 112.227 179.951 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 4.2 t-160 -102.82 6.56 39.31 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.369 179.93 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 158.39 -26.43 0.41 Allowed Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.64 -0.791 . . . . 0.0 112.536 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -113.64 -82.1 1.09 Allowed Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.545 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -171.16 -157.86 13.94 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.673 -0.775 . . . . 0.0 112.504 -179.961 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 81' ' ' TRP . . . . . 0.498 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -145.18 -78.6 0.19 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.949 0.404 . . . . 0.0 110.682 -179.574 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -112.85 10.87 25.24 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.87 -0.681 . . . . 0.0 112.574 179.829 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 19.0 pt20 -96.32 154.56 38.66 Favored Pre-proline 0 C--N 1.332 -0.164 0 CA-C-O 120.747 0.308 . . . . 0.0 110.878 179.933 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 42.3 Cg_endo -67.71 141.39 54.48 Favored 'Trans proline' 0 C--N 1.345 0.364 0 C-N-CA 122.486 2.124 . . . . 0.0 112.244 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 45.5 m-70 -95.89 -30.65 13.53 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.853 -179.973 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -118.92 -52.19 0.29 Allowed Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.515 -179.939 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -172.38 88.63 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.539 179.973 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 69.55 -170.68 42.22 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.604 -179.961 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 89' ' ' TRP . . . . . 0.482 ' N ' ' CD1' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -147.3 -78.74 0.16 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.946 0.403 . . . . 0.0 110.735 -179.641 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -138.49 22.19 3.04 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.96 -0.638 . . . . 0.0 112.194 179.749 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 6.2 mt-30 . . . . . 0 C--O 1.25 1.087 0 CA-C-O 118.19 -0.91 . . . . 0.0 110.911 -179.85 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 57' ' ' TRP . . . . . . . . . . . . . 30.8 t-105 . . . . . 0 N--CA 1.486 1.342 0 CA-C-O 120.798 0.333 . . . . 0.0 111.2 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -69.09 -61.51 4.53 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.481 -179.989 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 10.1 pt20 -176.57 154.34 1.26 Allowed Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 120.766 0.317 . . . . 0.0 110.834 179.941 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -68.91 123.86 10.83 Favored 'Trans proline' 0 C--N 1.344 0.301 0 C-N-CA 122.525 2.15 . . . . 0.0 112.355 179.908 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 61' ' ' HIS . . . . . . . . . . . . . 8.2 m170 -89.94 6.18 43.22 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.34 179.977 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 179.29 37.04 0.07 OUTLIER Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.69 -0.766 . . . . 0.0 112.511 179.968 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 146.71 -101.85 0.24 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.5 -179.933 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -136.38 -157.43 7.76 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.506 -179.93 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 65' ' ' TRP . . . . . 0.475 ' CD1' ' N ' ' A' ' 65' ' ' TRP . 0.0 OUTLIER -147.52 -78.09 0.16 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.912 0.387 . . . . 0.0 110.725 -179.597 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -108.17 -19.88 8.68 Favored Glycine 0 N--CA 1.45 -0.419 0 C-N-CA 120.905 -0.664 . . . . 0.0 112.524 179.766 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 13.6 pt20 -60.07 154.2 51.71 Favored Pre-proline 0 C--N 1.331 -0.237 0 CA-C-O 120.661 0.267 . . . . 0.0 110.902 -179.993 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 42.3 Cg_endo -68.32 150.34 76.15 Favored 'Trans proline' 0 C--N 1.343 0.262 0 C-N-CA 122.478 2.119 . . . . 0.0 112.338 179.935 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 1.7 t60 -96.29 -29.92 13.73 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.803 179.902 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . -152.41 26.83 0.87 Allowed Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.504 179.864 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 166.33 -94.11 0.11 Allowed Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.682 -0.77 . . . . 0.0 112.519 -179.957 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -133.91 -158.69 8.68 Favored Glycine 0 N--CA 1.452 -0.254 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.464 -179.904 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 73' ' ' TRP . . . . . 0.492 ' N ' ' CD1' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -146.75 -78.53 0.17 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.917 0.389 . . . . 0.0 110.77 -179.601 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -103.93 -20.65 10.37 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.927 -0.654 . . . . 0.0 112.477 179.823 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 17.9 pt20 -65.1 153.91 88.09 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-O 120.682 0.277 . . . . 0.0 110.852 -179.984 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 76' ' ' PRO . . . . . 0.401 ' HB3' ' CA ' ' A' ' 80' ' ' GLY . 51.6 Cg_endo -69.69 140.09 42.07 Favored 'Trans proline' 0 C--N 1.343 0.283 0 C-N-CA 122.502 2.134 . . . . 0.0 112.414 179.947 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 25.3 p80 -92.23 -31.43 15.44 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.653 179.757 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -120.6 -35.69 0.83 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.845 -0.693 . . . . 0.0 112.411 179.981 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -155.12 -78.0 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.5 -179.952 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 80' ' ' GLY . . . . . 0.401 ' CA ' ' HB3' ' A' ' 76' ' ' PRO . . . -130.62 -157.67 9.03 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.575 -179.951 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 81' ' ' TRP . . . . . 0.48 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -146.75 -78.06 0.17 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.857 0.36 . . . . 0.0 110.731 -179.646 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -105.96 -20.06 9.65 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.886 -0.673 . . . . 0.0 112.532 179.898 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 11.1 pt20 -59.72 154.2 48.0 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-O 120.699 0.285 . . . . 0.0 110.895 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.9 140.57 42.47 Favored 'Trans proline' 0 C--N 1.343 0.263 0 C-N-CA 122.551 2.167 . . . . 0.0 112.314 179.913 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 7.8 m-70 -93.53 -30.46 14.99 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.892 179.925 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -147.38 27.8 1.52 Allowed Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.522 -179.97 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 163.25 -102.27 0.2 Allowed Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.53 179.933 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -130.93 -156.89 8.7 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.552 -179.934 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 89' ' ' TRP . . . . . 0.479 ' CD1' ' N ' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -147.18 -77.99 0.17 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.934 0.397 . . . . 0.0 110.779 -179.65 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -134.78 17.67 4.14 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.923 -0.656 . . . . 0.0 112.528 179.823 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 5.9 pt20 . . . . . 0 C--O 1.249 1.074 0 CA-C-O 118.193 -0.908 . . . . 0.0 110.849 -179.964 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 57' ' ' TRP . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 N--CA 1.489 1.5 0 CA-C-O 120.75 0.309 . . . . 0.0 111.421 . . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 58' ' ' GLY . . . . . 0.403 ' O ' ' CG ' ' A' ' 59' ' ' GLN . . . -95.0 -29.17 9.27 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.543 179.997 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.403 ' CG ' ' O ' ' A' ' 58' ' ' GLY . 0.0 OUTLIER 56.19 156.42 0.07 OUTLIER Pre-proline 0 CA--C 1.53 0.201 0 CA-C-O 120.776 0.322 . . . . 0.0 111.48 -179.947 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -72.57 128.77 13.85 Favored 'Trans proline' 0 C--N 1.343 0.265 0 C-N-CA 122.62 2.213 . . . . 0.0 112.212 -179.851 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 61' ' ' HIS . . . . . . . . . . . . . 8.8 m170 -90.06 6.06 44.0 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.408 179.897 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 164.28 42.26 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.579 -0.819 . . . . 0.0 112.462 179.98 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 160.14 -96.52 0.15 Allowed Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.472 179.966 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -152.2 -159.78 9.17 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.558 -179.947 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 65' ' ' TRP . . . . . 0.486 ' N ' ' CD1' ' A' ' 65' ' ' TRP . 0.0 OUTLIER -147.13 -77.6 0.17 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.947 0.403 . . . . 0.0 110.734 -179.617 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -108.98 -19.01 8.83 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.978 -0.63 . . . . 0.0 112.582 179.908 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 15.0 pt20 -58.61 154.37 35.44 Favored Pre-proline 0 C--N 1.331 -0.209 0 CA-C-O 120.659 0.266 . . . . 0.0 110.891 -179.931 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 41.8 Cg_endo -67.76 154.02 74.28 Favored 'Trans proline' 0 C--N 1.343 0.271 0 C-N-CA 122.576 2.184 . . . . 0.0 112.249 179.925 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 2.1 t60 -101.3 -31.33 11.02 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.85 179.994 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . -124.11 -40.16 0.46 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.822 -0.704 . . . . 0.0 112.54 179.949 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -179.29 92.47 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.583 -179.979 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 60.93 -170.71 7.93 Favored Glycine 0 N--CA 1.452 -0.254 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.495 179.999 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 73' ' ' TRP . . . . . 0.488 ' CD1' ' N ' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -146.86 -78.89 0.16 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.942 0.401 . . . . 0.0 110.811 -179.648 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -117.79 14.43 12.83 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.964 -0.636 . . . . 0.0 112.585 179.782 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 8.6 pt20 -84.21 154.36 63.3 Favored Pre-proline 0 C--N 1.331 -0.2 0 CA-C-O 120.684 0.278 . . . . 0.0 110.847 -179.972 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -66.43 146.88 81.64 Favored 'Trans proline' 0 C--N 1.344 0.317 0 C-N-CA 122.557 2.171 . . . . 0.0 112.253 179.89 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 49.0 t-80 -98.68 -31.01 12.14 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.917 179.902 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -128.38 -42.18 0.26 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.435 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -172.76 94.15 0.1 OUTLIER Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.556 -179.967 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 62.01 -170.29 11.48 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.545 -179.926 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 81' ' ' TRP . . . . . 0.491 ' CD1' ' N ' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -147.16 -78.65 0.16 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.93 0.395 . . . . 0.0 110.713 -179.552 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -117.85 14.03 12.85 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.86 -0.686 . . . . 0.0 112.505 179.857 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 21.5 pt20 -81.34 154.62 71.86 Favored Pre-proline 0 C--N 1.331 -0.214 0 CA-C-O 120.736 0.303 . . . . 0.0 110.857 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 40.3 Cg_endo -67.12 143.39 65.03 Favored 'Trans proline' 0 C--N 1.344 0.322 0 C-N-CA 122.541 2.161 . . . . 0.0 112.265 179.967 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 45.2 m-70 -97.43 -30.84 12.68 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.882 179.983 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -126.31 -41.49 0.32 Allowed Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.457 -179.947 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -175.23 96.18 0.1 Allowed Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.672 -0.775 . . . . 0.0 112.471 179.986 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 59.64 -169.51 6.82 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.557 -179.982 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 89' ' ' TRP . . . . . 0.481 ' N ' ' CD1' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -148.26 -76.62 0.17 Allowed 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.961 0.41 . . . . 0.0 110.763 -179.632 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -112.88 -22.12 5.78 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.92 -0.657 . . . . 0.0 112.537 179.88 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 1.1 pt20 . . . . . 0 C--O 1.248 1.008 0 CA-C-O 118.27 -0.871 . . . . 0.0 110.9 179.991 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 57' ' ' TRP . . . . . 0.409 ' CH2' ' HB3' ' A' ' 59' ' ' GLN . 0.0 OUTLIER . . . . . 0 N--CA 1.486 1.354 0 CA-C-O 120.864 0.364 . . . . 0.0 111.134 . . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 58' ' ' GLY . . . . . 0.465 ' O ' ' CG ' ' A' ' 59' ' ' GLN . . . 167.22 -31.62 0.19 Allowed Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.496 179.974 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.465 ' CG ' ' O ' ' A' ' 58' ' ' GLY . 7.1 pt20 54.74 154.83 0.05 OUTLIER Pre-proline 0 CA--C 1.53 0.208 0 CA-C-O 120.94 0.4 . . . . 0.0 111.586 -179.994 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -70.98 148.84 58.06 Favored 'Trans proline' 0 C--N 1.345 0.348 0 C-N-CA 122.459 2.106 . . . . 0.0 112.307 -179.835 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 61' ' ' HIS . . . . . . . . . . . . . 1.5 t60 -92.11 -30.79 15.79 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.803 179.915 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -113.26 -28.04 3.45 Favored Glycine 0 N--CA 1.45 -0.39 0 C-N-CA 120.806 -0.711 . . . . 0.0 112.453 179.961 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 175.3 -47.62 0.13 Allowed Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.529 179.987 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -148.14 -161.53 9.61 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.502 -179.896 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 65' ' ' TRP . . . . . 0.491 ' N ' ' CD1' ' A' ' 65' ' ' TRP . 0.0 OUTLIER -145.97 -79.33 0.17 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.93 0.395 . . . . 0.0 110.755 -179.614 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -111.77 12.3 27.44 Favored Glycine 0 N--CA 1.45 -0.417 0 C-N-CA 120.887 -0.673 . . . . 0.0 112.585 179.785 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 14.9 pt20 -101.39 154.19 37.38 Favored Pre-proline 0 C--N 1.332 -0.19 0 CA-C-O 120.657 0.265 . . . . 0.0 110.836 -179.932 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 39.6 Cg_endo -67.45 152.33 78.84 Favored 'Trans proline' 0 C--N 1.343 0.275 0 C-N-CA 122.531 2.154 . . . . 0.0 112.289 179.934 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 15.8 p80 -97.28 -30.08 13.18 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.776 179.881 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . -152.67 26.69 0.84 Allowed Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.81 -0.709 . . . . 0.0 112.485 179.948 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 166.09 -92.87 0.11 Allowed Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.459 179.965 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -133.98 -158.82 8.71 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.533 -179.897 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 73' ' ' TRP . . . . . 0.483 ' N ' ' CD1' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -146.46 -78.96 0.17 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.92 0.39 . . . . 0.0 110.705 -179.628 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -113.96 10.61 22.9 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.845 -0.693 . . . . 0.0 112.662 179.845 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 13.6 pt20 -93.16 153.35 41.68 Favored Pre-proline 0 C--N 1.331 -0.216 0 CA-C-O 120.704 0.288 . . . . 0.0 110.889 179.973 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 28.8 Cg_endo -64.08 151.96 83.06 Favored 'Trans proline' 0 C--N 1.344 0.322 0 C-N-CA 122.529 2.153 . . . . 0.0 112.31 -179.989 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 15.7 t-160 -107.68 -28.62 9.61 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.821 179.902 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -157.02 25.6 0.49 Allowed Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.552 -179.998 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 134.86 89.32 0.31 Allowed Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.664 -0.779 . . . . 0.0 112.595 179.867 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 56.92 -176.34 1.17 Allowed Glycine 0 N--CA 1.452 -0.237 0 C-N-CA 120.807 -0.711 . . . . 0.0 112.645 179.888 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 81' ' ' TRP . . . . . 0.527 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -142.14 -79.22 0.24 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.908 0.385 . . . . 0.0 110.819 -179.48 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -118.45 19.28 10.72 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.834 -0.698 . . . . 0.0 112.551 179.797 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 24.4 pt20 -85.08 154.38 60.47 Favored Pre-proline 0 C--N 1.331 -0.228 0 CA-C-O 120.702 0.287 . . . . 0.0 110.827 179.977 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -66.54 158.55 55.07 Favored 'Trans proline' 0 C--N 1.344 0.31 0 C-N-CA 122.56 2.174 . . . . 0.0 112.329 179.903 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 29.1 m80 -107.99 -30.79 8.26 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.916 179.968 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -133.72 27.7 3.32 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.72 -0.753 . . . . 0.0 112.503 -179.999 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 104.5 93.56 2.3 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.523 179.921 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 59.36 -169.86 6.16 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.547 179.938 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 89' ' ' TRP . . . . . 0.484 ' N ' ' CD1' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -147.5 -77.79 0.17 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.942 0.401 . . . . 0.0 110.751 -179.626 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -134.8 17.99 4.11 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.918 -0.658 . . . . 0.0 112.574 179.871 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 2.0 pt20 . . . . . 0 C--O 1.248 1.017 0 CA-C-O 118.233 -0.889 . . . . 0.0 110.868 -179.97 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 57' ' ' TRP . . . . . 0.425 ' CZ2' ' HB3' ' A' ' 59' ' ' GLN . 30.4 t-105 . . . . . 0 N--CA 1.487 1.383 0 CA-C-O 120.828 0.346 . . . . 0.0 111.209 . . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -158.07 61.1 0.32 Allowed Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.45 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.425 ' HB3' ' CZ2' ' A' ' 57' ' ' TRP . 6.6 pm0 -58.66 154.38 35.85 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 120.729 0.3 . . . . 0.0 111.011 179.897 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 38.5 Cg_endo -66.67 128.06 18.31 Favored 'Trans proline' 0 C--N 1.345 0.351 0 C-N-CA 122.527 2.151 . . . . 0.0 112.264 179.938 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 61' ' ' HIS . . . . . . . . . . . . . 3.8 t-160 -94.93 6.51 48.84 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.323 179.878 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -154.83 -43.81 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.448 179.956 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -150.06 -70.28 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.57 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -147.16 -157.53 7.43 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.544 -179.961 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 65' ' ' TRP . . . . . 0.493 ' N ' ' CD1' ' A' ' 65' ' ' TRP . 0.0 OUTLIER -147.05 -78.68 0.16 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.872 0.367 . . . . 0.0 110.714 -179.588 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -115.18 10.9 20.09 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.894 -0.67 . . . . 0.0 112.586 179.821 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 21.2 pt20 -82.03 157.01 69.29 Favored Pre-proline 0 C--N 1.332 -0.175 0 CA-C-O 120.636 0.255 . . . . 0.0 110.899 179.994 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 68' ' ' PRO . . . . . 0.465 ' HB3' ' HA2' ' A' ' 72' ' ' GLY . 73.2 Cg_endo -77.76 147.79 24.92 Favored 'Trans proline' 0 C--N 1.343 0.288 0 C-N-CA 122.45 2.1 . . . . 0.0 112.313 179.954 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 16.6 p-80 -114.02 108.39 16.95 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.0 -179.964 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 57.73 28.93 60.8 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.8 -0.714 . . . . 0.0 112.614 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 161.14 -109.63 0.4 Allowed Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.523 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 72' ' ' GLY . . . . . 0.465 ' HA2' ' HB3' ' A' ' 68' ' ' PRO . . . -151.68 -178.8 26.79 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.68 -0.772 . . . . 0.0 112.507 -179.854 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 73' ' ' TRP . . . . . 0.6 ' N ' ' CD1' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -123.06 -78.42 0.6 Allowed 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.896 0.379 . . . . 0.0 110.709 -179.639 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -109.86 -19.15 8.35 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.947 -0.644 . . . . 0.0 112.457 179.799 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 13.8 pt20 -59.34 153.87 45.83 Favored Pre-proline 0 C--N 1.33 -0.249 0 CA-C-O 120.722 0.296 . . . . 0.0 110.894 -179.99 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 30.6 Cg_endo -64.07 153.55 75.49 Favored 'Trans proline' 0 C--N 1.344 0.334 0 C-N-CA 122.568 2.179 . . . . 0.0 112.321 179.956 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 13.2 p80 -107.25 -30.66 8.6 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.817 179.931 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -108.09 -62.83 0.56 Allowed Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.51 179.949 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -164.41 29.26 0.22 Allowed Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.564 -179.981 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 136.16 -164.52 25.04 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.575 179.984 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 81' ' ' TRP . . . . . 0.497 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -146.1 -78.69 0.17 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.941 0.401 . . . . 0.0 110.788 -179.621 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -116.74 13.89 14.78 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.851 -0.69 . . . . 0.0 112.573 179.807 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 18.8 pt20 -86.21 154.31 57.26 Favored Pre-proline 0 C--N 1.331 -0.204 0 CA-C-O 120.688 0.28 . . . . 0.0 110.879 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 38.9 Cg_endo -66.89 153.4 78.04 Favored 'Trans proline' 0 C--N 1.344 0.301 0 C-N-CA 122.565 2.177 . . . . 0.0 112.277 -179.995 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 3.5 t-80 -107.76 -31.1 8.19 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.9 179.928 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -129.61 27.91 4.08 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.51 179.949 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 101.33 96.02 2.25 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.55 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 59.51 -169.45 6.64 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.548 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 89' ' ' TRP . . . . . 0.47 ' N ' ' CD1' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -147.38 -77.61 0.17 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.938 0.399 . . . . 0.0 110.82 -179.612 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -134.69 18.19 4.11 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.907 -0.663 . . . . 0.0 112.556 179.872 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 2.9 pt20 . . . . . 0 C--O 1.249 1.065 0 CA-C-O 118.282 -0.866 . . . . 0.0 110.92 179.995 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 57' ' ' TRP . . . . . . . . . . . . . 1.2 t90 . . . . . 0 N--CA 1.485 1.319 0 CA-C-O 120.788 0.328 . . . . 0.0 111.244 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -177.62 48.55 0.1 OUTLIER Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.718 -0.754 . . . . 0.0 112.507 -179.987 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 3.2 pt20 -171.96 154.33 3.45 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 120.68 0.276 . . . . 0.0 110.883 -179.956 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo -68.88 149.86 72.84 Favored 'Trans proline' 0 C--N 1.344 0.299 0 C-N-CA 122.528 2.152 . . . . 0.0 112.284 179.892 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 61' ' ' HIS . . . . . . . . . . . . . 1.9 t60 -95.51 -30.5 13.81 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.871 -179.988 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -170.83 36.29 0.17 Allowed Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.503 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -178.67 -81.24 0.06 OUTLIER Glycine 0 N--CA 1.452 -0.247 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.58 -179.998 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -170.4 -158.76 14.84 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.536 -180.0 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 65' ' ' TRP . . . . . 0.494 ' N ' ' CD1' ' A' ' 65' ' ' TRP . 0.0 OUTLIER -146.45 -78.41 0.17 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.921 0.391 . . . . 0.0 110.745 -179.655 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -118.25 13.11 12.5 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.88 -0.676 . . . . 0.0 112.554 179.797 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -78.85 154.59 78.07 Favored Pre-proline 0 C--N 1.332 -0.193 0 CA-C-O 120.709 0.29 . . . . 0.0 110.878 -179.98 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -66.43 149.15 84.77 Favored 'Trans proline' 0 C--N 1.344 0.316 0 C-N-CA 122.493 2.129 . . . . 0.0 112.255 179.94 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 0.8 OUTLIER -98.33 6.16 47.59 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.335 179.956 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 172.38 39.61 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.626 -0.797 . . . . 0.0 112.491 179.945 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 148.12 -97.79 0.18 Allowed Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.67 -0.776 . . . . 0.0 112.501 179.958 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -139.2 -157.18 7.22 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.472 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 73' ' ' TRP . . . . . 0.487 ' N ' ' CD1' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -147.71 -77.95 0.16 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.993 0.425 . . . . 0.0 110.708 -179.583 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -105.53 -20.48 9.51 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.912 -0.661 . . . . 0.0 112.347 179.861 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 13.5 pt20 -65.47 154.43 87.97 Favored Pre-proline 0 C--N 1.33 -0.241 0 CA-C-O 120.652 0.263 . . . . 0.0 110.898 -179.954 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 40.1 Cg_endo -67.14 154.8 73.22 Favored 'Trans proline' 0 C--N 1.343 0.257 0 C-N-CA 122.536 2.157 . . . . 0.0 112.256 179.937 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 15.4 p80 -100.55 -31.67 11.15 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.912 179.99 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -125.24 -47.36 0.22 Allowed Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.457 179.985 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -171.82 87.38 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.459 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 72.67 -169.54 52.12 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.546 179.987 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 81' ' ' TRP . . . . . 0.482 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -148.12 -76.14 0.17 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.921 0.391 . . . . 0.0 110.785 -179.649 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -107.05 -21.73 7.94 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.935 -0.65 . . . . 0.0 112.455 179.833 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 15.6 pt20 -60.1 154.4 50.99 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 120.677 0.275 . . . . 0.0 110.865 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 44.5 Cg_endo -68.34 141.13 50.58 Favored 'Trans proline' 0 C--N 1.344 0.331 0 C-N-CA 122.539 2.159 . . . . 0.0 112.248 179.958 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 13.7 m-70 -95.17 -31.14 13.67 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.934 179.966 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -125.2 -40.99 0.38 Allowed Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.821 -0.704 . . . . 0.0 112.437 -179.959 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -176.92 96.55 0.1 Allowed Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.509 -179.946 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 59.64 -170.36 6.3 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.55 -179.986 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 89' ' ' TRP . . . . . 0.483 ' N ' ' CD1' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -147.58 -77.82 0.16 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.901 0.381 . . . . 0.0 110.831 -179.664 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -133.66 18.55 4.32 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.853 -0.689 . . . . 0.0 112.514 179.776 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 6.5 pt20 . . . . . 0 C--O 1.249 1.052 0 CA-C-O 118.179 -0.915 . . . . 0.0 110.949 -179.998 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 57' ' ' TRP . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.485 1.312 0 CA-C-O 120.782 0.325 . . . . 0.0 111.245 . . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -172.71 45.39 0.17 Allowed Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.501 -179.956 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 12.2 pt20 -160.72 154.4 18.83 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-O 120.716 0.293 . . . . 0.0 110.91 -179.971 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_endo -69.56 150.5 69.52 Favored 'Trans proline' 0 C--N 1.344 0.329 0 C-N-CA 122.529 2.153 . . . . 0.0 112.243 179.934 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 61' ' ' HIS . . . . . . . . . . . . . 14.2 p80 -94.17 -30.97 14.34 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.865 179.963 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -169.27 33.84 0.18 Allowed Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.808 -0.711 . . . . 0.0 112.542 179.943 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -177.01 -84.0 0.06 OUTLIER Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.496 -179.978 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -166.2 -158.71 11.22 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.53 -179.879 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 65' ' ' TRP . . . . . 0.488 ' N ' ' CD1' ' A' ' 65' ' ' TRP . 0.0 OUTLIER -146.72 -78.95 0.16 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.853 0.359 . . . . 0.0 110.75 -179.629 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -117.53 13.19 13.54 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.877 -0.678 . . . . 0.0 112.482 179.765 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 3.9 pt20 -79.69 154.49 75.98 Favored Pre-proline 0 C--N 1.331 -0.226 0 CA-C-O 120.711 0.291 . . . . 0.0 110.872 -179.968 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_endo -68.48 150.86 75.8 Favored 'Trans proline' 0 C--N 1.344 0.31 0 C-N-CA 122.552 2.168 . . . . 0.0 112.228 179.852 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 1.9 t60 -95.96 -30.18 13.75 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.927 179.884 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . -170.27 37.8 0.19 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.499 -179.963 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 178.36 -82.11 0.06 OUTLIER Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.505 179.984 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -168.74 -157.65 11.74 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.5 -179.927 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 73' ' ' TRP . . . . . 0.486 ' N ' ' CD1' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -147.38 -77.66 0.17 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.931 0.396 . . . . 0.0 110.715 -179.563 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -107.89 -20.15 8.62 Favored Glycine 0 N--CA 1.45 -0.413 0 C-N-CA 120.901 -0.666 . . . . 0.0 112.463 179.856 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 11.6 pt20 -59.62 154.32 46.2 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-O 120.701 0.286 . . . . 0.0 110.904 -179.988 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 40.9 Cg_endo -67.33 152.76 78.67 Favored 'Trans proline' 0 C--N 1.345 0.356 0 C-N-CA 122.564 2.176 . . . . 0.0 112.26 179.941 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 6.0 t-160 -105.72 -31.24 8.97 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.875 179.967 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -128.57 29.36 4.04 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.453 -179.996 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 97.48 94.71 1.92 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.467 179.959 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 61.64 -170.07 10.66 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.505 179.966 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 81' ' ' TRP . . . . . 0.488 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -147.02 -78.29 0.17 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.901 0.381 . . . . 0.0 110.736 -179.558 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -115.17 12.97 19.38 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.907 -0.663 . . . . 0.0 112.618 179.748 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 13.1 pt20 -93.43 154.17 41.33 Favored Pre-proline 0 C--N 1.332 -0.186 0 CA-C-O 120.649 0.262 . . . . 0.0 110.889 179.973 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -65.93 148.89 86.5 Favored 'Trans proline' 0 C--N 1.343 0.268 0 C-N-CA 122.629 2.22 . . . . 0.0 112.274 179.944 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 7.7 m170 -100.33 -30.57 11.79 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.776 179.877 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -110.63 -27.93 4.18 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.489 179.935 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 173.91 -43.28 0.15 Allowed Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.641 179.997 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -154.39 -160.12 9.64 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.61 179.985 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 89' ' ' TRP . . . . . 0.488 ' N ' ' CD1' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -146.89 -78.84 0.16 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.879 0.371 . . . . 0.0 110.644 -179.541 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -138.48 22.04 3.05 Favored Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.946 -0.645 . . . . 0.0 112.211 179.764 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 6.0 mt-30 . . . . . 0 C--O 1.25 1.118 0 CA-C-O 118.209 -0.9 . . . . 0.0 110.929 -179.875 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 57' ' ' TRP . . . . . . . . . . . . . 1.8 t-105 . . . . . 0 N--CA 1.486 1.351 0 CA-C-O 120.764 0.316 . . . . 0.0 111.199 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -119.04 -35.62 0.94 Allowed Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.522 -179.956 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 22.7 pt20 -145.9 154.23 50.92 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 120.691 0.281 . . . . 0.0 110.874 -179.909 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_endo -67.56 152.7 78.0 Favored 'Trans proline' 0 C--N 1.344 0.322 0 C-N-CA 122.501 2.134 . . . . 0.0 112.276 179.907 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 61' ' ' HIS . . . . . . . . . . . . . 13.8 p80 -98.06 -30.74 12.51 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.837 -179.982 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -174.08 34.72 0.11 Allowed Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.508 -179.98 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -173.84 -74.52 0.05 OUTLIER Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.697 -0.764 . . . . 0.0 112.555 -179.949 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -179.23 -159.18 22.91 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.515 -179.948 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 65' ' ' TRP . . . . . 0.487 ' CD1' ' N ' ' A' ' 65' ' ' TRP . 0.0 OUTLIER -146.56 -77.81 0.18 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.905 0.383 . . . . 0.0 110.748 -179.68 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -103.85 -21.22 9.81 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.853 -0.689 . . . . 0.0 112.459 179.794 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 13.0 pt20 -64.81 154.28 86.04 Favored Pre-proline 0 C--N 1.331 -0.219 0 CA-C-O 120.727 0.298 . . . . 0.0 110.865 -179.934 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -69.1 136.88 35.95 Favored 'Trans proline' 0 C--N 1.345 0.349 0 C-N-CA 122.603 2.202 . . . . 0.0 112.309 179.992 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 14.6 p80 -92.73 -30.17 15.67 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.766 179.839 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . -123.02 -38.6 0.56 Allowed Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.849 -0.691 . . . . 0.0 112.515 179.974 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -147.17 -85.96 0.06 OUTLIER Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.633 -0.794 . . . . 0.0 112.541 179.987 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -130.68 -155.68 8.34 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.6 -179.887 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 73' ' ' TRP . . . . . 0.493 ' CD1' ' N ' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -147.4 -77.49 0.17 Allowed 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.903 0.382 . . . . 0.0 110.696 -179.53 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -101.84 -19.67 14.73 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.964 -0.636 . . . . 0.0 112.522 179.851 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 4.7 pt20 -59.03 153.97 41.91 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 120.734 0.302 . . . . 0.0 110.891 179.983 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -66.64 154.06 75.77 Favored 'Trans proline' 0 C--N 1.345 0.369 0 C-N-CA 122.524 2.149 . . . . 0.0 112.329 179.992 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 19.8 p-80 -109.51 -30.31 8.0 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.867 -179.933 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -132.13 27.07 3.67 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.545 -179.982 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 104.5 96.45 2.42 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.668 -0.777 . . . . 0.0 112.563 179.925 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 58.84 -170.85 4.9 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.824 -0.703 . . . . 0.0 112.615 179.968 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 81' ' ' TRP . . . . . 0.49 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -147.03 -77.02 0.18 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.884 0.373 . . . . 0.0 110.71 -179.563 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -104.18 -20.86 9.94 Favored Glycine 0 N--CA 1.452 -0.248 0 C-N-CA 120.861 -0.685 . . . . 0.0 112.548 179.86 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 8.3 pt20 -58.84 153.84 40.74 Favored Pre-proline 0 C--N 1.331 -0.221 0 CA-C-O 120.686 0.279 . . . . 0.0 110.917 179.997 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 84' ' ' PRO . . . . . 0.413 ' HB3' ' CA ' ' A' ' 88' ' ' GLY . 18.9 Cg_endo -59.77 160.75 20.26 Favored 'Trans proline' 0 C--N 1.343 0.283 0 C-N-CA 122.584 2.189 . . . . 0.0 112.352 -179.979 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 7.8 p-80 -113.15 -30.87 6.82 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.822 179.873 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -116.8 20.81 11.64 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.648 179.93 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 102.56 9.72 40.17 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.939 179.847 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 88' ' ' GLY . . . . . 0.413 ' CA ' ' HB3' ' A' ' 84' ' ' PRO . . . 161.67 -170.75 37.47 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.633 -0.794 . . . . 0.0 112.635 -179.987 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 89' ' ' TRP . . . . . 0.522 ' N ' ' CD1' ' A' ' 89' ' ' TRP . 0.1 OUTLIER -150.78 -60.05 0.18 Allowed 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 121.278 0.561 . . . . 0.0 110.559 -179.256 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -153.18 -44.86 0.02 OUTLIER Glycine 0 N--CA 1.45 -0.433 0 CA-C-N 115.264 -0.88 . . . . 0.0 111.499 179.636 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 4.6 mt-30 . . . . . 0 C--O 1.248 1.004 0 CA-C-O 118.22 -0.895 . . . . 0.0 111.363 179.326 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 57' ' ' TRP . . . . . . . . . . . . . 10.2 t-105 . . . . . 0 N--CA 1.486 1.371 0 CA-C-O 120.826 0.346 . . . . 0.0 111.186 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -104.41 -44.92 1.51 Allowed Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.545 -179.981 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 19.5 pt20 -169.67 154.32 5.39 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 120.75 0.309 . . . . 0.0 110.906 -179.99 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -67.8 154.87 71.96 Favored 'Trans proline' 0 C--N 1.344 0.311 0 C-N-CA 122.57 2.18 . . . . 0.0 112.263 179.971 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 61' ' ' HIS . . . . . . . . . . . . . 1.8 t60 -103.5 -31.32 10.02 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.903 179.99 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -123.89 -43.29 0.34 Allowed Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.426 179.974 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -177.32 94.98 0.1 OUTLIER Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.514 179.993 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 62.3 -170.2 12.54 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.452 179.926 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 65' ' ' TRP . . . . . 0.481 ' N ' ' CD1' ' A' ' 65' ' ' TRP . 0.0 OUTLIER -148.32 -76.1 0.17 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.955 0.407 . . . . 0.0 110.753 -179.542 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -107.15 -21.7 7.92 Favored Glycine 0 N--CA 1.45 -0.414 0 C-N-CA 120.89 -0.672 . . . . 0.0 112.473 179.904 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 18.0 pt20 -60.05 154.19 51.55 Favored Pre-proline 0 C--N 1.33 -0.253 0 CA-C-O 120.726 0.298 . . . . 0.0 110.9 179.984 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 42.2 Cg_endo -68.0 151.76 77.4 Favored 'Trans proline' 0 C--N 1.343 0.282 0 C-N-CA 122.571 2.18 . . . . 0.0 112.257 179.968 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 11.4 p80 -96.65 -30.85 13.02 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.835 179.894 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . -153.46 27.6 0.77 Allowed Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.491 179.968 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 168.94 -102.11 0.18 Allowed Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.524 179.985 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -131.7 -158.94 9.26 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.539 -179.996 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 73' ' ' TRP . . . . . 0.485 ' N ' ' CD1' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -147.16 -77.04 0.18 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.956 0.408 . . . . 0.0 110.785 -179.555 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -106.76 -21.26 8.32 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.805 -0.712 . . . . 0.0 112.5 179.867 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 3.0 pt20 -59.94 153.84 52.38 Favored Pre-proline 0 C--N 1.331 -0.223 0 CA-C-O 120.663 0.268 . . . . 0.0 110.915 179.947 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_endo -66.06 153.93 76.11 Favored 'Trans proline' 0 C--N 1.344 0.321 0 C-N-CA 122.481 2.121 . . . . 0.0 112.389 179.938 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 23.3 t-160 -109.7 -29.76 8.19 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.811 179.956 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -134.39 26.7 3.33 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.549 179.952 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 106.88 97.63 2.52 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.53 179.888 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 58.45 -172.7 3.59 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.58 179.909 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 81' ' ' TRP . . . . . 0.486 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -146.21 -77.84 0.18 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.96 0.41 . . . . 0.0 110.845 -179.603 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -106.46 -20.81 8.76 Favored Glycine 0 N--CA 1.45 -0.419 0 C-N-CA 120.848 -0.692 . . . . 0.0 112.553 179.895 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 12.5 pt20 -58.89 153.68 42.17 Favored Pre-proline 0 C--N 1.33 -0.254 0 CA-C-O 120.694 0.283 . . . . 0.0 110.933 179.966 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 84' ' ' PRO . . . . . 0.416 ' HB2' ' N ' ' A' ' 88' ' ' GLY . 30.3 Cg_endo -64.37 159.99 41.29 Favored 'Trans proline' 0 C--N 1.344 0.326 0 C-N-CA 122.522 2.148 . . . . 0.0 112.321 -179.977 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 2.3 m80 -117.72 106.34 12.95 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.092 -0.503 . . . . 0.0 110.645 179.665 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 94.93 -26.85 16.7 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.444 -179.797 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 150.01 92.8 0.1 Allowed Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.549 -179.966 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 88' ' ' GLY . . . . . 0.416 ' N ' ' HB2' ' A' ' 84' ' ' PRO . . . 58.46 -157.5 19.53 Favored Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.593 179.988 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 89' ' ' TRP . . . . . 0.509 ' N ' ' CD1' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -142.02 -78.46 0.25 Allowed 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.981 0.42 . . . . 0.0 110.701 -179.636 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -134.68 17.29 4.21 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.908 -0.663 . . . . 0.0 112.507 179.816 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 6.0 pt20 . . . . . 0 C--O 1.249 1.072 0 CA-C-O 118.228 -0.891 . . . . 0.0 110.943 179.963 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 57' ' ' TRP . . . . . . . . . . . . . 21.3 t-105 . . . . . 0 N--CA 1.485 1.299 0 CA-C-O 120.766 0.317 . . . . 0.0 111.223 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 58' ' ' GLY . . . . . 0.47 ' O ' ' CG ' ' A' ' 59' ' ' GLN . . . -67.33 -30.78 75.74 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.532 179.986 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.47 ' CG ' ' O ' ' A' ' 58' ' ' GLY . 3.2 pt20 54.76 154.92 0.05 OUTLIER Pre-proline 0 N--CA 1.463 0.205 0 CA-C-O 120.951 0.405 . . . . 0.0 111.515 -179.954 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 60' ' ' PRO . . . . . 0.408 ' HB3' ' CA ' ' A' ' 64' ' ' GLY . 56.2 Cg_endo -70.97 142.36 42.42 Favored 'Trans proline' 0 C--N 1.345 0.379 0 C-N-CA 122.513 2.142 . . . . 0.0 112.288 -179.869 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 61' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -100.15 -28.89 12.79 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.933 179.921 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -128.98 27.55 4.28 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.688 -0.768 . . . . 0.0 112.472 -179.995 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 99.42 97.0 2.12 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.55 -179.996 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 64' ' ' GLY . . . . . 0.408 ' CA ' ' HB3' ' A' ' 60' ' ' PRO . . . 57.86 -170.88 3.81 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.812 -0.708 . . . . 0.0 112.554 179.96 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 65' ' ' TRP . . . . . 0.491 ' N ' ' CD1' ' A' ' 65' ' ' TRP . 0.0 OUTLIER -146.51 -78.96 0.17 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.905 0.383 . . . . 0.0 110.791 -179.628 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -113.19 12.49 24.07 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.883 -0.675 . . . . 0.0 112.559 179.757 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 21.7 pt20 -98.63 153.94 37.71 Favored Pre-proline 0 C--N 1.331 -0.214 0 CA-C-O 120.777 0.322 . . . . 0.0 110.888 179.955 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_endo -65.58 155.13 70.6 Favored 'Trans proline' 0 C--N 1.344 0.337 0 C-N-CA 122.523 2.149 . . . . 0.0 112.272 179.95 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 3.5 t-80 -109.59 -30.68 7.8 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.862 179.899 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . -134.44 26.55 3.34 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.557 -179.996 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 107.37 98.24 2.55 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.55 179.924 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 58.75 -173.76 3.38 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.82 -0.705 . . . . 0.0 112.571 179.961 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 73' ' ' TRP . . . . . 0.489 ' N ' ' CD1' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -145.62 -78.83 0.18 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.872 0.368 . . . . 0.0 110.804 -179.606 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -105.93 -20.93 8.91 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.868 -0.682 . . . . 0.0 112.446 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 16.7 pt20 -59.81 154.16 49.2 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 120.742 0.306 . . . . 0.0 110.891 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 76' ' ' PRO . . . . . 0.404 ' HB3' ' CA ' ' A' ' 80' ' ' GLY . 50.0 Cg_endo -69.31 139.75 42.59 Favored 'Trans proline' 0 C--N 1.344 0.326 0 C-N-CA 122.548 2.165 . . . . 0.0 112.333 179.965 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 1.1 t60 -93.73 -31.22 14.51 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.86 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -125.89 -40.82 0.36 Allowed Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.801 -0.714 . . . . 0.0 112.485 -180.0 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -176.48 97.16 0.11 Allowed Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.567 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 80' ' ' GLY . . . . . 0.404 ' CA ' ' HB3' ' A' ' 76' ' ' PRO . . . 59.91 -171.82 5.78 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.563 179.971 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 81' ' ' TRP . . . . . 0.474 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -147.09 -77.34 0.17 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.902 0.382 . . . . 0.0 110.757 -179.66 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -106.6 -21.63 8.18 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.919 -0.658 . . . . 0.0 112.493 179.934 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 20.7 pt20 -59.96 154.03 51.52 Favored Pre-proline 0 C--N 1.33 -0.24 0 CA-C-O 120.702 0.287 . . . . 0.0 110.902 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 84' ' ' PRO . . . . . 0.404 ' HB3' ' CA ' ' A' ' 88' ' ' GLY . 39.0 Cg_endo -67.13 158.1 58.52 Favored 'Trans proline' 0 C--N 1.344 0.335 0 C-N-CA 122.567 2.178 . . . . 0.0 112.296 179.955 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 8.8 m170 -97.67 -30.94 12.54 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.774 179.986 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -113.75 -29.09 2.97 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.506 179.97 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 172.38 -33.6 0.13 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.524 179.991 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 88' ' ' GLY . . . . . 0.404 ' CA ' ' HB3' ' A' ' 84' ' ' PRO . . . -157.85 -161.2 10.74 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.68 -0.771 . . . . 0.0 112.558 -179.968 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 89' ' ' TRP . . . . . 0.489 ' N ' ' CD1' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -147.17 -77.98 0.17 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.969 0.414 . . . . 0.0 110.756 -179.636 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -133.79 17.87 4.36 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.909 -0.662 . . . . 0.0 112.484 179.816 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 13.8 pt20 . . . . . 0 C--O 1.25 1.095 0 CA-C-O 118.164 -0.922 . . . . 0.0 110.896 179.982 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 57' ' ' TRP . . . . . 0.446 ' CD1' ' HG2' ' A' ' 59' ' ' GLN . 26.3 t-105 . . . . . 0 N--CA 1.487 1.381 0 CA-C-O 120.753 0.311 . . . . 0.0 111.191 . . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -56.49 -27.14 53.54 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.629 -179.998 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.446 ' HG2' ' CD1' ' A' ' 57' ' ' TRP . 9.6 pt20 -133.62 154.31 80.63 Favored Pre-proline 0 C--N 1.33 -0.251 0 CA-C-O 120.828 0.346 . . . . 0.0 110.838 179.971 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 60' ' ' PRO . . . . . 0.4 ' HB3' ' CA ' ' A' ' 64' ' ' GLY . 39.0 Cg_endo -67.15 149.47 81.96 Favored 'Trans proline' 0 C--N 1.346 0.417 0 C-N-CA 122.519 2.146 . . . . 0.0 112.302 -179.997 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 61' ' ' HIS . . . . . . . . . . . . . 48.6 t-80 -97.85 -30.67 12.63 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.806 179.941 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -113.46 -28.07 3.39 Favored Glycine 0 N--CA 1.45 -0.398 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.495 179.988 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 178.85 -52.24 0.09 OUTLIER Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.585 179.952 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 64' ' ' GLY . . . . . 0.4 ' CA ' ' HB3' ' A' ' 60' ' ' PRO . . . -147.53 -158.84 8.07 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.563 -179.957 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 65' ' ' TRP . . . . . 0.481 ' N ' ' CD1' ' A' ' 65' ' ' TRP . 0.0 OUTLIER -147.37 -78.03 0.17 Allowed 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.903 0.382 . . . . 0.0 110.712 -179.604 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -110.39 -21.15 7.04 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.908 -0.663 . . . . 0.0 112.446 179.832 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 9.4 pt20 -61.02 153.79 64.21 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 120.782 0.325 . . . . 0.0 110.9 179.976 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 12.8 Cg_endo -57.06 150.73 54.61 Favored 'Trans proline' 0 C--N 1.344 0.334 0 C-N-CA 122.727 2.285 . . . . 0.0 112.219 179.97 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 19.5 t-160 -128.75 6.0 5.55 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.351 179.942 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . -147.88 25.48 1.46 Allowed Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.64 -0.791 . . . . 0.0 112.6 179.933 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 96.77 24.53 13.22 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.636 179.95 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 127.35 -161.98 21.41 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.469 179.889 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 73' ' ' TRP . . . . . 0.509 ' N ' ' CD1' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -144.61 -79.79 0.18 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.944 0.402 . . . . 0.0 110.72 -179.546 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -112.27 15.16 25.4 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.81 -0.71 . . . . 0.0 112.436 179.706 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 3.5 pt20 -107.39 154.07 40.86 Favored Pre-proline 0 C--N 1.33 -0.252 0 CA-C-O 120.713 0.292 . . . . 0.0 110.901 179.989 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_endo -66.0 146.73 83.26 Favored 'Trans proline' 0 C--N 1.344 0.299 0 C-N-CA 122.481 2.121 . . . . 0.0 112.305 179.988 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 6.3 t-160 -100.03 -31.16 11.58 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.794 179.813 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -118.83 -34.59 1.04 Allowed Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.812 -0.709 . . . . 0.0 112.436 179.907 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -161.53 -64.96 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.558 -179.996 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -138.57 -158.95 7.9 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.599 -179.957 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 81' ' ' TRP . . . . . 0.501 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -145.94 -77.99 0.18 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.9 0.381 . . . . 0.0 110.778 -179.594 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -104.18 -21.88 9.14 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.903 -0.665 . . . . 0.0 112.54 179.896 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 16.9 pt20 -61.13 151.7 74.48 Favored Pre-proline 0 C--N 1.331 -0.224 0 CA-C-O 120.719 0.295 . . . . 0.0 110.93 -179.98 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 84' ' ' PRO . . . . . 0.41 ' HB2' ' N ' ' A' ' 88' ' ' GLY . 30.7 Cg_endo -64.63 160.82 38.23 Favored 'Trans proline' 0 C--N 1.344 0.328 0 C-N-CA 122.511 2.141 . . . . 0.0 112.358 179.968 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 16.6 p-80 -118.47 106.57 12.82 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.599 179.644 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 94.42 -26.08 19.52 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.513 -179.797 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 149.29 92.53 0.1 Allowed Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.498 179.937 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 88' ' ' GLY . . . . . 0.41 ' N ' ' HB2' ' A' ' 84' ' ' PRO . . . 58.93 -157.37 22.33 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.548 179.985 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 89' ' ' TRP . . . . . 0.511 ' N ' ' CD1' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -142.55 -78.7 0.24 Allowed 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 121.002 0.429 . . . . 0.0 110.829 -179.676 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -113.15 -20.71 6.2 Favored Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 120.904 -0.665 . . . . 0.0 112.473 179.888 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 2.0 pt20 . . . . . 0 C--O 1.248 1.024 0 CA-C-O 118.333 -0.841 . . . . 0.0 110.862 -179.982 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.361 0 N-CA-C 112.561 -0.216 . . . . 0.0 112.561 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 73' ' ' TRP . . . . . 0.481 ' N ' ' CD1' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -146.76 -78.9 0.16 Allowed 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 120.97 0.415 . . . . 0.0 110.746 -179.573 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -114.39 13.23 21.13 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.843 -0.694 . . . . 0.0 112.54 179.83 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 23.9 pt20 -97.38 154.48 38.02 Favored Pre-proline 0 C--N 1.332 -0.192 0 CA-C-O 120.722 0.296 . . . . 0.0 110.888 179.983 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 39.4 Cg_endo -67.29 147.3 78.0 Favored 'Trans proline' 0 C--N 1.344 0.303 0 C-N-CA 122.543 2.162 . . . . 0.0 112.27 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 8.4 t-160 -97.26 -30.62 12.87 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.865 179.893 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -113.17 -27.95 3.5 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.893 -0.67 . . . . 0.0 112.565 179.941 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 179.37 -54.52 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.596 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -145.71 -158.64 7.79 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.521 -179.924 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 81' ' ' TRP . . . . . 0.478 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -147.56 -77.11 0.17 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.97 0.414 . . . . 0.0 110.698 -179.556 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -106.85 -20.93 8.47 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.903 -0.665 . . . . 0.0 112.473 179.868 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 17.8 pt20 -60.18 154.45 51.54 Favored Pre-proline 0 C--N 1.331 -0.216 0 CA-C-O 120.735 0.302 . . . . 0.0 110.856 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_endo -68.72 140.53 47.05 Favored 'Trans proline' 0 C--N 1.345 0.378 0 C-N-CA 122.525 2.15 . . . . 0.0 112.251 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 7.5 m170 -94.89 -30.99 13.89 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.846 -179.956 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -125.22 -40.79 0.39 Allowed Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.496 179.98 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -177.18 96.9 0.11 Allowed Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.468 179.942 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 59.59 -170.71 6.01 Favored Glycine 0 N--CA 1.452 -0.268 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.55 179.947 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 89' ' ' TRP . . . . . 0.478 ' CD1' ' N ' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -147.52 -77.78 0.17 Allowed 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.919 0.39 . . . . 0.0 110.795 -179.638 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -134.69 18.32 4.1 Favored Glycine 0 N--CA 1.449 -0.445 0 C-N-CA 120.894 -0.669 . . . . 0.0 112.504 179.843 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 7.2 pt20 . . . . . 0 C--O 1.249 1.052 0 CA-C-O 118.173 -0.918 . . . . 0.0 110.864 -179.944 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.268 0 N-CA-C 112.56 -0.216 . . . . 0.0 112.56 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 73' ' ' TRP . . . . . 0.467 ' CD1' ' N ' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -147.69 -78.02 0.16 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.927 0.394 . . . . 0.0 110.799 -179.598 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -111.34 -15.26 10.66 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.883 -0.675 . . . . 0.0 112.632 179.917 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 18.9 pt20 -56.74 154.08 19.49 Favored Pre-proline 0 C--N 1.331 -0.201 0 CA-C-O 120.699 0.285 . . . . 0.0 111.028 -179.974 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 41.2 Cg_endo -67.32 161.29 43.76 Favored 'Trans proline' 0 C--N 1.343 0.28 0 C-N-CA 122.597 2.198 . . . . 0.0 112.314 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 12.6 t60 -109.32 -30.5 7.96 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.966 179.865 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -135.16 27.09 3.18 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.468 179.982 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 106.28 92.9 2.29 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.476 179.939 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 58.92 -170.88 4.98 Favored Glycine 0 N--CA 1.452 -0.268 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.535 179.936 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 81' ' ' TRP . . . . . 0.489 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -146.81 -78.88 0.16 Allowed 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.832 0.348 . . . . 0.0 110.76 -179.604 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -119.98 15.89 10.22 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.863 -0.684 . . . . 0.0 112.547 179.733 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 8.2 pt20 -82.11 154.2 69.65 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-O 120.723 0.297 . . . . 0.0 110.903 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 27.6 Cg_endo -62.72 156.47 53.03 Favored 'Trans proline' 0 C--N 1.345 0.365 0 C-N-CA 122.535 2.156 . . . . 0.0 112.273 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 0.7 OUTLIER -109.38 -31.08 7.67 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.815 179.94 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -108.26 -61.71 0.55 Allowed Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.436 -179.984 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -165.77 30.1 0.21 Allowed Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.709 -0.757 . . . . 0.0 112.523 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 136.1 -164.33 25.04 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.581 -179.971 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 89' ' ' TRP . . . . . 0.491 ' CD1' ' N ' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -146.85 -77.92 0.17 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.897 0.379 . . . . 0.0 110.735 -179.634 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -133.04 18.69 4.45 Favored Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.907 -0.663 . . . . 0.0 112.511 179.793 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 15.3 pt20 . . . . . 0 C--O 1.249 1.056 0 CA-C-O 118.203 -0.903 . . . . 0.0 110.89 -179.968 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.329 0 N-CA-C 112.561 -0.216 . . . . 0.0 112.561 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 73' ' ' TRP . . . . . 0.496 ' CD1' ' N ' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -146.31 -78.6 0.17 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.857 0.36 . . . . 0.0 110.76 -179.616 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -116.64 13.72 15.1 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.953 -0.641 . . . . 0.0 112.599 179.73 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 3.9 pt20 -91.02 154.13 45.05 Favored Pre-proline 0 C--N 1.331 -0.238 0 CA-C-O 120.708 0.289 . . . . 0.0 110.942 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . 0.403 ' HB3' ' CA ' ' A' ' 80' ' ' GLY . 36.0 Cg_endo -65.33 151.01 86.56 Favored 'Trans proline' 0 C--N 1.344 0.324 0 C-N-CA 122.495 2.13 . . . . 0.0 112.27 179.971 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 17.2 t-160 -101.07 -30.72 11.44 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.796 179.916 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -109.17 -27.77 4.67 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.528 179.95 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 168.11 -31.38 0.18 Allowed Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.598 179.953 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . 0.403 ' CA ' ' HB3' ' A' ' 76' ' ' PRO . . . -162.3 -162.17 13.05 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.555 -179.987 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 81' ' ' TRP . . . . . 0.49 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -146.28 -78.54 0.17 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.92 0.391 . . . . 0.0 110.748 -179.657 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -116.99 13.25 14.3 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.903 -0.665 . . . . 0.0 112.555 179.806 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 13.9 pt20 -86.09 154.29 57.58 Favored Pre-proline 0 C--N 1.332 -0.193 0 CA-C-O 120.628 0.251 . . . . 0.0 110.917 179.966 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . 0.401 ' HB3' ' CA ' ' A' ' 88' ' ' GLY . 37.3 Cg_endo -66.12 157.41 59.85 Favored 'Trans proline' 0 C--N 1.344 0.296 0 C-N-CA 122.538 2.159 . . . . 0.0 112.32 179.914 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 3.5 t-80 -98.95 -30.79 12.16 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.854 179.861 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -113.03 -27.73 3.61 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.481 -179.995 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 169.91 -32.39 0.16 Allowed Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.711 -0.756 . . . . 0.0 112.551 179.979 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . 0.401 ' CA ' ' HB3' ' A' ' 84' ' ' PRO . . . -159.08 -161.48 11.18 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.509 -179.966 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 89' ' ' TRP . . . . . 0.485 ' CD1' ' N ' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -147.14 -77.98 0.17 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.826 0.346 . . . . 0.0 110.826 -179.669 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -134.71 17.76 4.15 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.921 -0.657 . . . . 0.0 112.523 179.863 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 7.6 pt20 . . . . . 0 C--O 1.248 1.023 0 CA-C-O 118.242 -0.885 . . . . 0.0 110.944 -180.0 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.349 0 N-CA-C 112.56 -0.216 . . . . 0.0 112.56 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 73' ' ' TRP . . . . . 0.485 ' N ' ' CD1' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -147.82 -77.25 0.17 Allowed 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.936 0.398 . . . . 0.0 110.787 -179.603 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -105.39 -21.67 8.67 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.888 -0.672 . . . . 0.0 112.446 179.832 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 16.3 pt20 -63.66 154.48 80.04 Favored Pre-proline 0 C--N 1.331 -0.2 0 CA-C-O 120.677 0.275 . . . . 0.0 110.879 -180.0 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 41.6 Cg_endo -67.7 142.06 56.9 Favored 'Trans proline' 0 C--N 1.344 0.311 0 C-N-CA 122.518 2.145 . . . . 0.0 112.239 -179.998 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 3.5 t-80 -96.05 -31.0 13.25 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.918 179.994 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -124.78 -41.77 0.37 Allowed Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.463 -179.986 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -177.02 94.58 0.1 OUTLIER Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.531 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 62.84 -170.66 13.08 Favored Glycine 0 N--CA 1.45 -0.416 0 C-N-CA 120.667 -0.778 . . . . 0.0 112.607 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 81' ' ' TRP . . . . . 0.477 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -148.24 -75.59 0.18 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.942 0.401 . . . . 0.0 110.742 -179.634 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -107.45 -22.09 7.61 Favored Glycine 0 N--CA 1.449 -0.436 0 C-N-CA 120.869 -0.682 . . . . 0.0 112.463 179.831 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 14.6 pt20 -60.17 154.11 53.32 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-O 120.646 0.26 . . . . 0.0 110.876 179.961 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 34.8 Cg_endo -65.35 153.46 78.15 Favored 'Trans proline' 0 C--N 1.344 0.308 0 C-N-CA 122.515 2.143 . . . . 0.0 112.255 179.963 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 57.5 m80 -100.63 -31.74 11.09 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.672 179.831 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -116.69 -31.65 1.74 Allowed Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.834 -0.698 . . . . 0.0 112.447 179.971 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -165.87 -69.25 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.59 -180.0 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -135.66 -147.84 5.51 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.616 179.98 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 89' ' ' TRP . . . . . 0.432 ' CH2' ' HB3' ' A' ' 91' ' ' GLN . 0.4 OUTLIER -161.11 23.57 0.13 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.765 0.317 . . . . 0.0 111.119 -179.342 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 103.03 -14.34 55.77 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.668 -0.777 . . . . 0.0 112.402 -179.644 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 91' ' ' GLN . . . . . 0.432 ' HB3' ' CH2' ' A' ' 89' ' ' TRP . 4.3 pt20 . . . . . 0 C--O 1.249 1.074 0 CA-C-O 118.229 -0.891 . . . . 0.0 110.919 -179.984 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.453 -0.229 0 N-CA-C 112.57 -0.212 . . . . 0.0 112.57 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 73' ' ' TRP . . . . . 0.557 ' N ' ' CD1' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -136.21 -78.33 0.42 Allowed 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.954 0.407 . . . . 0.0 110.629 -179.654 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -113.33 -9.09 18.34 Favored Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 120.907 -0.663 . . . . 0.0 112.625 179.758 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 14.3 pt20 -58.37 154.22 33.79 Favored Pre-proline 0 C--N 1.331 -0.237 0 CA-C-O 120.751 0.31 . . . . 0.0 110.957 179.933 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . 0.426 ' HB2' ' N ' ' A' ' 80' ' ' GLY . 55.0 Cg_endo -70.58 137.9 34.06 Favored 'Trans proline' 0 C--N 1.344 0.32 0 C-N-CA 122.431 2.088 . . . . 0.0 112.199 179.796 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 18.4 m-70 -107.66 105.38 15.21 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.985 0.421 . . . . 0.0 110.709 179.657 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 104.74 -31.5 8.53 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.868 -0.682 . . . . 0.0 112.433 -179.886 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 152.04 93.28 0.1 OUTLIER Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.576 -179.986 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . 0.426 ' N ' ' HB2' ' A' ' 76' ' ' PRO . . . 52.8 -161.79 2.54 Favored Glycine 0 C--N 1.33 0.229 0 C-N-CA 120.883 -0.675 . . . . 0.0 112.781 179.983 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 81' ' ' TRP . . . . . 0.549 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -137.09 -78.27 0.4 Allowed 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.935 0.398 . . . . 0.0 110.694 -179.665 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -107.33 -20.28 8.76 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.89 -0.672 . . . . 0.0 112.483 179.853 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 15.6 pt20 -59.9 154.42 48.66 Favored Pre-proline 0 C--N 1.331 -0.223 0 CA-C-O 120.631 0.253 . . . . 0.0 110.923 -179.946 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 44.0 Cg_endo -68.04 141.39 52.85 Favored 'Trans proline' 0 C--N 1.344 0.306 0 C-N-CA 122.558 2.172 . . . . 0.0 112.277 179.912 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 4.7 t-160 -95.5 -31.07 13.52 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.886 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -120.55 -41.37 0.53 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.518 179.966 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 179.22 96.13 0.1 Allowed Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.68 -0.772 . . . . 0.0 112.434 179.958 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 59.7 -170.07 6.55 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.542 -179.998 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 89' ' ' TRP . . . . . 0.482 ' N ' ' CD1' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -148.31 -76.18 0.17 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.998 0.428 . . . . 0.0 110.828 -179.634 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -112.89 -22.22 5.74 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.86 -0.686 . . . . 0.0 112.435 179.879 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 2.8 pp0? . . . . . 0 C--O 1.249 1.03 0 CA-C-O 118.257 -0.877 . . . . 0.0 110.904 -179.914 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.27 0 N-CA-C 112.517 -0.233 . . . . 0.0 112.517 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 73' ' ' TRP . . . . . 0.454 ' CD1' ' N ' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -148.04 -79.36 0.15 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.885 0.374 . . . . 0.0 110.845 -179.667 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -115.99 -2.82 20.2 Favored Glycine 0 CA--C 1.519 0.311 0 C-N-CA 120.815 -0.707 . . . . 0.0 112.663 179.911 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 9.7 pt20 -58.04 154.41 29.58 Favored Pre-proline 0 C--N 1.33 -0.263 0 CA-C-O 120.728 0.299 . . . . 0.0 110.942 179.985 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -66.32 153.47 77.91 Favored 'Trans proline' 0 C--N 1.344 0.318 0 C-N-CA 122.553 2.169 . . . . 0.0 112.287 179.991 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 22.9 t-160 -100.23 -30.33 11.97 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.785 179.896 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -151.04 27.46 1.01 Allowed Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.478 -179.99 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 165.49 -109.59 0.37 Allowed Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.541 -179.932 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -123.7 -158.94 10.3 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.829 -0.701 . . . . 0.0 112.518 -179.945 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 81' ' ' TRP . . . . . 0.481 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -147.42 -78.6 0.16 Allowed 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.971 0.415 . . . . 0.0 110.873 -179.637 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -111.9 -15.22 10.23 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.959 -0.639 . . . . 0.0 112.577 179.898 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 16.2 pt20 -56.36 154.33 16.68 Favored Pre-proline 0 C--N 1.331 -0.211 0 CA-C-O 120.706 0.288 . . . . 0.0 111.006 179.969 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 40.9 Cg_endo -67.35 169.22 15.91 Favored 'Trans proline' 0 C--N 1.344 0.299 0 C-N-CA 122.604 2.202 . . . . 0.0 112.287 179.936 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 3.6 m-70 -110.15 -31.34 7.38 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.898 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -136.75 27.93 2.89 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.556 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 105.22 98.4 2.54 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.46 179.928 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 59.09 -170.81 5.24 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.511 179.925 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 89' ' ' TRP . . . . . 0.475 ' CD1' ' N ' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -147.92 -77.51 0.16 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.936 0.398 . . . . 0.0 110.88 -179.605 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -113.56 -22.06 5.57 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.87 -0.681 . . . . 0.0 112.486 179.823 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.249 1.034 0 CA-C-O 118.173 -0.918 . . . . 0.0 110.939 -179.993 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.267 0 N-CA-C 112.56 -0.216 . . . . 0.0 112.56 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 73' ' ' TRP . . . . . 0.528 ' N ' ' CD1' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -141.31 -79.08 0.26 Allowed 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.928 0.394 . . . . 0.0 110.627 -179.601 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -116.99 13.93 14.09 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.83 -0.7 . . . . 0.0 112.47 179.842 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 21.2 pt20 -89.55 154.52 48.46 Favored Pre-proline 0 C--N 1.331 -0.197 0 CA-C-O 120.661 0.267 . . . . 0.0 110.881 -179.966 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 39.8 Cg_endo -67.06 148.38 81.33 Favored 'Trans proline' 0 C--N 1.344 0.319 0 C-N-CA 122.485 2.123 . . . . 0.0 112.26 179.921 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 77' ' ' HIS . . . . . 0.4 ' CD2' ' O ' ' A' ' 77' ' ' HIS . 9.5 t-160 -97.54 6.22 48.42 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.379 179.956 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 150.81 44.57 0.02 OUTLIER Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.524 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 168.37 -82.92 0.1 OUTLIER Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.52 -179.973 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -169.64 -160.8 18.77 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.516 -179.941 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 81' ' ' TRP . . . . . 0.472 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -147.53 -77.96 0.16 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.901 0.381 . . . . 0.0 110.747 -179.613 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -105.86 -20.9 8.97 Favored Glycine 0 N--CA 1.45 -0.398 0 C-N-CA 120.915 -0.66 . . . . 0.0 112.46 179.807 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 20.8 pt20 -63.98 154.2 82.45 Favored Pre-proline 0 C--N 1.33 -0.25 0 CA-C-O 120.71 0.29 . . . . 0.0 110.887 179.935 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo -66.27 177.58 3.08 Favored 'Trans proline' 0 C--N 1.344 0.338 0 C-N-CA 122.62 2.213 . . . . 0.0 112.293 179.9 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 27.4 p-80 -99.96 -30.99 11.69 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.887 179.93 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -162.66 28.78 0.26 Allowed Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.461 179.949 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 170.12 -92.3 0.1 OUTLIER Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.599 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -138.74 -156.5 7.05 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.589 179.953 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 89' ' ' TRP . . . . . 0.478 ' N ' ' CD1' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -147.8 -78.01 0.16 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.908 0.385 . . . . 0.0 110.707 -179.576 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -134.98 16.92 4.17 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.904 -0.665 . . . . 0.0 112.59 179.849 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 7.0 pt20 . . . . . 0 C--O 1.249 1.069 0 CA-C-O 118.238 -0.887 . . . . 0.0 110.93 -179.991 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.326 0 N-CA-C 112.599 -0.201 . . . . 0.0 112.599 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 73' ' ' TRP . . . . . 0.499 ' N ' ' CD1' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -144.78 -77.79 0.2 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.921 0.391 . . . . 0.0 110.8 -179.607 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -103.39 -23.06 8.64 Favored Glycine 0 N--CA 1.449 -0.437 0 C-N-CA 120.954 -0.641 . . . . 0.0 112.517 179.884 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 3.1 pt20 -62.35 151.29 82.76 Favored Pre-proline 0 C--N 1.33 -0.249 0 CA-C-O 120.717 0.294 . . . . 0.0 110.907 -179.986 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . 0.405 ' HB3' ' CA ' ' A' ' 80' ' ' GLY . 23.9 Cg_endo -62.36 155.48 57.11 Favored 'Trans proline' 0 C--N 1.344 0.337 0 C-N-CA 122.587 2.191 . . . . 0.0 112.386 179.939 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 8.3 p80 -109.55 -29.92 8.16 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.84 179.817 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -112.35 -57.06 0.44 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.8 -0.715 . . . . 0.0 112.488 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -169.86 32.16 0.16 Allowed Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.649 179.965 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . 0.405 ' CA ' ' HB3' ' A' ' 76' ' ' PRO . . . 138.75 -169.3 24.44 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.646 -0.788 . . . . 0.0 112.611 -179.973 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 81' ' ' TRP . . . . . 0.491 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -145.65 -77.98 0.19 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.919 0.39 . . . . 0.0 110.781 -179.681 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -102.69 -20.3 11.99 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.87 -0.681 . . . . 0.0 112.558 179.927 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 12.5 pt20 -58.71 153.78 39.68 Favored Pre-proline 0 C--N 1.332 -0.195 0 CA-C-O 120.784 0.326 . . . . 0.0 110.952 -179.963 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 30.5 Cg_endo -64.2 154.13 72.55 Favored 'Trans proline' 0 C--N 1.345 0.361 0 C-N-CA 122.542 2.162 . . . . 0.0 112.267 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 1.6 t-80 -108.96 -29.82 8.4 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.82 179.872 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -108.5 -61.46 0.54 Allowed Glycine 0 N--CA 1.45 -0.406 0 C-N-CA 120.821 -0.704 . . . . 0.0 112.469 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -166.75 30.6 0.19 Allowed Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.569 179.946 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 135.31 -165.78 24.62 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.586 179.919 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 89' ' ' TRP . . . . . 0.489 ' N ' ' CD1' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -146.1 -79.36 0.17 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.902 0.382 . . . . 0.0 110.727 -179.626 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -139.13 22.67 2.92 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.99 -0.624 . . . . 0.0 112.175 179.779 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 20.2 mt-30 . . . . . 0 C--O 1.249 1.03 0 CA-C-O 118.223 -0.894 . . . . 0.0 110.933 -179.923 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.284 0 N-CA-C 112.584 -0.206 . . . . 0.0 112.584 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 73' ' ' TRP . . . . . 0.494 ' CD1' ' N ' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -146.25 -79.72 0.16 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.867 0.365 . . . . 0.0 110.791 -179.624 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -120.0 16.96 10.05 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.936 -0.649 . . . . 0.0 112.467 179.714 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 6.6 pt20 -77.29 154.79 82.12 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 120.734 0.302 . . . . 0.0 110.801 -179.965 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 32.7 Cg_endo -64.57 154.56 71.42 Favored 'Trans proline' 0 C--N 1.344 0.32 0 C-N-CA 122.465 2.11 . . . . 0.0 112.264 179.879 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 23.1 t-160 -102.85 -30.38 10.88 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.829 179.871 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -148.98 27.74 1.27 Allowed Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.431 179.991 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 162.48 -108.64 0.35 Allowed Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.487 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -123.26 -158.44 10.18 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.561 179.975 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 81' ' ' TRP . . . . . 0.477 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -147.7 -78.36 0.16 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.847 0.356 . . . . 0.0 110.748 -179.574 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -111.2 -18.36 8.24 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.928 -0.653 . . . . 0.0 112.523 179.908 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 4.6 pt20 -58.03 154.0 31.59 Favored Pre-proline 0 C--N 1.331 -0.232 0 CA-C-O 120.732 0.301 . . . . 0.0 110.931 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . 0.416 ' HB2' ' N ' ' A' ' 88' ' ' GLY . 28.1 Cg_endo -63.47 161.44 31.35 Favored 'Trans proline' 0 C--N 1.344 0.329 0 C-N-CA 122.581 2.188 . . . . 0.0 112.335 179.942 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 85' ' ' HIS . . . . . 0.401 ' CD2' ' N ' ' A' ' 85' ' ' HIS . 3.5 m-70 -118.32 106.15 12.47 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.674 179.694 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 94.43 -26.51 17.37 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.452 -179.801 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 150.06 92.43 0.1 OUTLIER Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.51 -179.98 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . 0.416 ' N ' ' HB2' ' A' ' 84' ' ' PRO . . . 59.1 -156.78 24.36 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.591 -179.968 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 89' ' ' TRP . . . . . 0.501 ' N ' ' CD1' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -142.58 -78.5 0.24 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.959 0.409 . . . . 0.0 110.666 -179.656 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -134.84 16.53 4.24 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.907 -0.663 . . . . 0.0 112.54 179.902 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 3.6 pt20 . . . . . 0 C--O 1.249 1.063 0 CA-C-O 118.2 -0.905 . . . . 0.0 110.927 179.996 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.306 0 N-CA-C 112.496 -0.241 . . . . 0.0 112.496 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 73' ' ' TRP . . . . . 0.493 ' N ' ' CD1' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -146.2 -77.97 0.18 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.939 0.399 . . . . 0.0 110.794 -179.672 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -104.74 -21.17 9.32 Favored Glycine 0 N--CA 1.45 -0.416 0 C-N-CA 120.888 -0.673 . . . . 0.0 112.485 179.755 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 17.6 pt20 -65.74 154.0 89.74 Favored Pre-proline 0 C--N 1.331 -0.225 0 CA-C-O 120.751 0.31 . . . . 0.0 110.861 179.971 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 33.7 Cg_endo -65.32 149.04 88.8 Favored 'Trans proline' 0 C--N 1.345 0.342 0 C-N-CA 122.535 2.156 . . . . 0.0 112.227 179.951 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 4.2 t-160 -102.82 6.56 39.31 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.369 179.93 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 158.39 -26.43 0.41 Allowed Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.64 -0.791 . . . . 0.0 112.536 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -113.64 -82.1 1.09 Allowed Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.545 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -171.16 -157.86 13.94 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.673 -0.775 . . . . 0.0 112.504 -179.961 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 81' ' ' TRP . . . . . 0.498 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -145.18 -78.6 0.19 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.949 0.404 . . . . 0.0 110.682 -179.574 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -112.85 10.87 25.24 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.87 -0.681 . . . . 0.0 112.574 179.829 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 19.0 pt20 -96.32 154.56 38.66 Favored Pre-proline 0 C--N 1.332 -0.164 0 CA-C-O 120.747 0.308 . . . . 0.0 110.878 179.933 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 42.3 Cg_endo -67.71 141.39 54.48 Favored 'Trans proline' 0 C--N 1.345 0.364 0 C-N-CA 122.486 2.124 . . . . 0.0 112.244 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 45.5 m-70 -95.89 -30.65 13.53 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.853 -179.973 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -118.92 -52.19 0.29 Allowed Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.515 -179.939 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -172.38 88.63 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.539 179.973 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 69.55 -170.68 42.22 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.604 -179.961 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 89' ' ' TRP . . . . . 0.482 ' N ' ' CD1' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -147.3 -78.74 0.16 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.946 0.403 . . . . 0.0 110.735 -179.641 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -138.49 22.19 3.04 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.96 -0.638 . . . . 0.0 112.194 179.749 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 6.2 mt-30 . . . . . 0 C--O 1.25 1.087 0 CA-C-O 118.19 -0.91 . . . . 0.0 110.911 -179.85 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.254 0 N-CA-C 112.464 -0.254 . . . . 0.0 112.464 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 73' ' ' TRP . . . . . 0.492 ' N ' ' CD1' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -146.75 -78.53 0.17 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.917 0.389 . . . . 0.0 110.77 -179.601 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -103.93 -20.65 10.37 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.927 -0.654 . . . . 0.0 112.477 179.823 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 17.9 pt20 -65.1 153.91 88.09 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-O 120.682 0.277 . . . . 0.0 110.852 -179.984 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . 0.401 ' HB3' ' CA ' ' A' ' 80' ' ' GLY . 51.6 Cg_endo -69.69 140.09 42.07 Favored 'Trans proline' 0 C--N 1.343 0.283 0 C-N-CA 122.502 2.134 . . . . 0.0 112.414 179.947 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 25.3 p80 -92.23 -31.43 15.44 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.653 179.757 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -120.6 -35.69 0.83 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.845 -0.693 . . . . 0.0 112.411 179.981 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -155.12 -78.0 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.5 -179.952 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . 0.401 ' CA ' ' HB3' ' A' ' 76' ' ' PRO . . . -130.62 -157.67 9.03 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.575 -179.951 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 81' ' ' TRP . . . . . 0.48 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -146.75 -78.06 0.17 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.857 0.36 . . . . 0.0 110.731 -179.646 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -105.96 -20.06 9.65 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.886 -0.673 . . . . 0.0 112.532 179.898 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 11.1 pt20 -59.72 154.2 48.0 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-O 120.699 0.285 . . . . 0.0 110.895 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.9 140.57 42.47 Favored 'Trans proline' 0 C--N 1.343 0.263 0 C-N-CA 122.551 2.167 . . . . 0.0 112.314 179.913 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 7.8 m-70 -93.53 -30.46 14.99 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.892 179.925 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -147.38 27.8 1.52 Allowed Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.522 -179.97 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 163.25 -102.27 0.2 Allowed Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.53 179.933 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -130.93 -156.89 8.7 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.552 -179.934 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 89' ' ' TRP . . . . . 0.479 ' CD1' ' N ' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -147.18 -77.99 0.17 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.934 0.397 . . . . 0.0 110.779 -179.65 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -134.78 17.67 4.14 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.923 -0.656 . . . . 0.0 112.528 179.823 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 5.9 pt20 . . . . . 0 C--O 1.249 1.074 0 CA-C-O 118.193 -0.908 . . . . 0.0 110.849 -179.964 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.254 0 N-CA-C 112.495 -0.242 . . . . 0.0 112.495 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 73' ' ' TRP . . . . . 0.488 ' CD1' ' N ' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -146.86 -78.89 0.16 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.942 0.401 . . . . 0.0 110.811 -179.648 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -117.79 14.43 12.83 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.964 -0.636 . . . . 0.0 112.585 179.782 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 8.6 pt20 -84.21 154.36 63.3 Favored Pre-proline 0 C--N 1.331 -0.2 0 CA-C-O 120.684 0.278 . . . . 0.0 110.847 -179.972 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -66.43 146.88 81.64 Favored 'Trans proline' 0 C--N 1.344 0.317 0 C-N-CA 122.557 2.171 . . . . 0.0 112.253 179.89 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 7.8 t60 -98.68 -31.01 12.14 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.917 179.902 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -128.38 -42.18 0.26 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.435 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -172.76 94.15 0.1 OUTLIER Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.556 -179.967 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 62.01 -170.29 11.48 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.545 -179.926 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 81' ' ' TRP . . . . . 0.491 ' CD1' ' N ' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -147.16 -78.65 0.16 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.93 0.395 . . . . 0.0 110.713 -179.552 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -117.85 14.03 12.85 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.86 -0.686 . . . . 0.0 112.505 179.857 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 21.5 pt20 -81.34 154.62 71.86 Favored Pre-proline 0 C--N 1.331 -0.214 0 CA-C-O 120.736 0.303 . . . . 0.0 110.857 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 40.3 Cg_endo -67.12 143.39 65.03 Favored 'Trans proline' 0 C--N 1.344 0.322 0 C-N-CA 122.541 2.161 . . . . 0.0 112.265 179.967 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 45.2 m-70 -97.43 -30.84 12.68 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.882 179.983 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -126.31 -41.49 0.32 Allowed Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.457 -179.947 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -175.23 96.18 0.1 Allowed Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.672 -0.775 . . . . 0.0 112.471 179.986 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 59.64 -169.51 6.82 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.557 -179.982 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 89' ' ' TRP . . . . . 0.481 ' N ' ' CD1' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -148.26 -76.62 0.17 Allowed 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.961 0.41 . . . . 0.0 110.763 -179.632 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -112.88 -22.12 5.78 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.92 -0.657 . . . . 0.0 112.537 179.88 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 1.1 pt20 . . . . . 0 C--O 1.248 1.008 0 CA-C-O 118.27 -0.871 . . . . 0.0 110.9 179.991 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.3 0 N-CA-C 112.533 -0.227 . . . . 0.0 112.533 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 73' ' ' TRP . . . . . 0.483 ' N ' ' CD1' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -146.46 -78.96 0.17 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.92 0.39 . . . . 0.0 110.705 -179.628 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -113.96 10.61 22.9 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.845 -0.693 . . . . 0.0 112.662 179.845 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 13.6 pt20 -93.16 153.35 41.68 Favored Pre-proline 0 C--N 1.331 -0.216 0 CA-C-O 120.704 0.288 . . . . 0.0 110.889 179.973 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 28.8 Cg_endo -64.08 151.96 83.06 Favored 'Trans proline' 0 C--N 1.344 0.322 0 C-N-CA 122.529 2.153 . . . . 0.0 112.31 -179.989 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 15.7 t-160 -107.68 -28.62 9.61 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.821 179.902 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -157.02 25.6 0.49 Allowed Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.552 -179.998 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 134.86 89.32 0.31 Allowed Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.664 -0.779 . . . . 0.0 112.595 179.867 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 56.92 -176.34 1.17 Allowed Glycine 0 N--CA 1.452 -0.237 0 C-N-CA 120.807 -0.711 . . . . 0.0 112.645 179.888 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 81' ' ' TRP . . . . . 0.527 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -142.14 -79.22 0.24 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.908 0.385 . . . . 0.0 110.819 -179.48 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -118.45 19.28 10.72 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.834 -0.698 . . . . 0.0 112.551 179.797 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 24.4 pt20 -85.08 154.38 60.47 Favored Pre-proline 0 C--N 1.331 -0.228 0 CA-C-O 120.702 0.287 . . . . 0.0 110.827 179.977 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -66.54 158.55 55.07 Favored 'Trans proline' 0 C--N 1.344 0.31 0 C-N-CA 122.56 2.174 . . . . 0.0 112.329 179.903 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 29.1 m80 -107.99 -30.79 8.26 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.916 179.968 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -133.72 27.7 3.32 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.72 -0.753 . . . . 0.0 112.503 -179.999 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 104.5 93.56 2.3 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.523 179.921 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 59.36 -169.86 6.16 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.547 179.938 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 89' ' ' TRP . . . . . 0.484 ' N ' ' CD1' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -147.5 -77.79 0.17 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.942 0.401 . . . . 0.0 110.751 -179.626 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -134.8 17.99 4.11 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.918 -0.658 . . . . 0.0 112.574 179.871 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 2.0 pt20 . . . . . 0 C--O 1.248 1.017 0 CA-C-O 118.233 -0.889 . . . . 0.0 110.868 -179.97 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.31 0 N-CA-C 112.507 -0.237 . . . . 0.0 112.507 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 73' ' ' TRP . . . . . 0.6 ' N ' ' CD1' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -123.06 -78.42 0.6 Allowed 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.896 0.379 . . . . 0.0 110.709 -179.639 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -109.86 -19.15 8.35 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.947 -0.644 . . . . 0.0 112.457 179.799 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 13.8 pt20 -59.34 153.87 45.83 Favored Pre-proline 0 C--N 1.33 -0.249 0 CA-C-O 120.722 0.296 . . . . 0.0 110.894 -179.99 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 30.6 Cg_endo -64.07 153.55 75.49 Favored 'Trans proline' 0 C--N 1.344 0.334 0 C-N-CA 122.568 2.179 . . . . 0.0 112.321 179.956 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 13.2 p80 -107.25 -30.66 8.6 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.817 179.931 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -108.09 -62.83 0.56 Allowed Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.51 179.949 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -164.41 29.26 0.22 Allowed Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.564 -179.981 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 136.16 -164.52 25.04 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.575 179.984 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 81' ' ' TRP . . . . . 0.497 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -146.1 -78.69 0.17 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.941 0.401 . . . . 0.0 110.788 -179.621 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -116.74 13.89 14.78 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.851 -0.69 . . . . 0.0 112.573 179.807 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 18.8 pt20 -86.21 154.31 57.26 Favored Pre-proline 0 C--N 1.331 -0.204 0 CA-C-O 120.688 0.28 . . . . 0.0 110.879 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 38.9 Cg_endo -66.89 153.4 78.04 Favored 'Trans proline' 0 C--N 1.344 0.301 0 C-N-CA 122.565 2.177 . . . . 0.0 112.277 -179.995 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 3.5 t-80 -107.76 -31.1 8.19 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.9 179.928 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -129.61 27.91 4.08 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.51 179.949 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 101.33 96.02 2.25 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.55 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 59.51 -169.45 6.64 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.548 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 89' ' ' TRP . . . . . 0.47 ' N ' ' CD1' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -147.38 -77.61 0.17 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.938 0.399 . . . . 0.0 110.82 -179.612 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -134.69 18.19 4.11 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.907 -0.663 . . . . 0.0 112.556 179.872 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 2.9 pt20 . . . . . 0 C--O 1.249 1.065 0 CA-C-O 118.282 -0.866 . . . . 0.0 110.92 179.995 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.341 0 N-CA-C 112.472 -0.251 . . . . 0.0 112.472 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 73' ' ' TRP . . . . . 0.487 ' N ' ' CD1' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -147.71 -77.95 0.16 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.993 0.425 . . . . 0.0 110.708 -179.583 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -105.53 -20.48 9.51 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.912 -0.661 . . . . 0.0 112.347 179.861 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 13.5 pt20 -65.47 154.43 87.97 Favored Pre-proline 0 C--N 1.33 -0.241 0 CA-C-O 120.652 0.263 . . . . 0.0 110.898 -179.954 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 40.1 Cg_endo -67.14 154.8 73.22 Favored 'Trans proline' 0 C--N 1.343 0.257 0 C-N-CA 122.536 2.157 . . . . 0.0 112.256 179.937 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 5.3 p-80 -100.55 -31.67 11.15 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.912 179.99 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -125.24 -47.36 0.22 Allowed Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.457 179.985 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -171.82 87.38 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.459 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 72.67 -169.54 52.12 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.546 179.987 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 81' ' ' TRP . . . . . 0.482 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -148.12 -76.14 0.17 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.921 0.391 . . . . 0.0 110.785 -179.649 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -107.05 -21.73 7.94 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.935 -0.65 . . . . 0.0 112.455 179.833 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 15.6 pt20 -60.1 154.4 50.99 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 120.677 0.275 . . . . 0.0 110.865 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 44.5 Cg_endo -68.34 141.13 50.58 Favored 'Trans proline' 0 C--N 1.344 0.331 0 C-N-CA 122.539 2.159 . . . . 0.0 112.248 179.958 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 13.7 m-70 -95.17 -31.14 13.67 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.934 179.966 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -125.2 -40.99 0.38 Allowed Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.821 -0.704 . . . . 0.0 112.437 -179.959 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -176.92 96.55 0.1 Allowed Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.509 -179.946 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 59.64 -170.36 6.3 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.55 -179.986 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 89' ' ' TRP . . . . . 0.483 ' N ' ' CD1' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -147.58 -77.82 0.16 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.901 0.381 . . . . 0.0 110.831 -179.664 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -133.66 18.55 4.32 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.853 -0.689 . . . . 0.0 112.514 179.776 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 6.5 pt20 . . . . . 0 C--O 1.249 1.052 0 CA-C-O 118.179 -0.915 . . . . 0.0 110.949 -179.998 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.353 0 N-CA-C 112.5 -0.24 . . . . 0.0 112.5 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 73' ' ' TRP . . . . . 0.486 ' N ' ' CD1' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -147.38 -77.66 0.17 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.931 0.396 . . . . 0.0 110.715 -179.563 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -107.89 -20.15 8.62 Favored Glycine 0 N--CA 1.45 -0.413 0 C-N-CA 120.901 -0.666 . . . . 0.0 112.463 179.856 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 11.6 pt20 -59.62 154.32 46.2 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-O 120.701 0.286 . . . . 0.0 110.904 -179.988 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 40.9 Cg_endo -67.33 152.76 78.67 Favored 'Trans proline' 0 C--N 1.345 0.356 0 C-N-CA 122.564 2.176 . . . . 0.0 112.26 179.941 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 6.0 t-160 -105.72 -31.24 8.97 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.875 179.967 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -128.57 29.36 4.04 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.453 -179.996 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 97.48 94.71 1.92 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.467 179.959 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 61.64 -170.07 10.66 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.505 179.966 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 81' ' ' TRP . . . . . 0.488 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -147.02 -78.29 0.17 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.901 0.381 . . . . 0.0 110.736 -179.558 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -115.17 12.97 19.38 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.907 -0.663 . . . . 0.0 112.618 179.748 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 13.1 pt20 -93.43 154.17 41.33 Favored Pre-proline 0 C--N 1.332 -0.186 0 CA-C-O 120.649 0.262 . . . . 0.0 110.889 179.973 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -65.93 148.89 86.5 Favored 'Trans proline' 0 C--N 1.343 0.268 0 C-N-CA 122.629 2.22 . . . . 0.0 112.274 179.944 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 7.7 m170 -100.33 -30.57 11.79 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.776 179.877 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -110.63 -27.93 4.18 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.489 179.935 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 173.91 -43.28 0.15 Allowed Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.641 179.997 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -154.39 -160.12 9.64 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.61 179.985 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 89' ' ' TRP . . . . . 0.488 ' N ' ' CD1' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -146.89 -78.84 0.16 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.879 0.371 . . . . 0.0 110.644 -179.541 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -138.48 22.04 3.05 Favored Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.946 -0.645 . . . . 0.0 112.211 179.764 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 6.0 mt-30 . . . . . 0 C--O 1.25 1.118 0 CA-C-O 118.209 -0.9 . . . . 0.0 110.929 -179.875 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.345 0 N-CA-C 112.6 -0.2 . . . . 0.0 112.6 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 73' ' ' TRP . . . . . 0.493 ' CD1' ' N ' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -147.4 -77.49 0.17 Allowed 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.903 0.382 . . . . 0.0 110.696 -179.53 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -101.84 -19.67 14.73 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.964 -0.636 . . . . 0.0 112.522 179.851 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 4.7 pt20 -59.03 153.97 41.91 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 120.734 0.302 . . . . 0.0 110.891 179.983 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -66.64 154.06 75.77 Favored 'Trans proline' 0 C--N 1.345 0.369 0 C-N-CA 122.524 2.149 . . . . 0.0 112.329 179.992 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 19.8 p-80 -109.51 -30.31 8.0 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.867 -179.933 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -132.13 27.07 3.67 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.545 -179.982 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 104.5 96.45 2.42 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.668 -0.777 . . . . 0.0 112.563 179.925 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 58.84 -170.85 4.9 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.824 -0.703 . . . . 0.0 112.615 179.968 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 81' ' ' TRP . . . . . 0.49 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -147.03 -77.02 0.18 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.884 0.373 . . . . 0.0 110.71 -179.563 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -104.18 -20.86 9.94 Favored Glycine 0 N--CA 1.452 -0.248 0 C-N-CA 120.861 -0.685 . . . . 0.0 112.548 179.86 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 8.3 pt20 -58.84 153.84 40.74 Favored Pre-proline 0 C--N 1.331 -0.221 0 CA-C-O 120.686 0.279 . . . . 0.0 110.917 179.997 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . 0.413 ' HB3' ' CA ' ' A' ' 88' ' ' GLY . 18.9 Cg_endo -59.77 160.75 20.26 Favored 'Trans proline' 0 C--N 1.343 0.283 0 C-N-CA 122.584 2.189 . . . . 0.0 112.352 -179.979 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 7.8 p-80 -113.15 -30.87 6.82 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.822 179.873 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -116.8 20.81 11.64 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.648 179.93 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 102.56 9.72 40.17 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.939 179.847 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . 0.413 ' CA ' ' HB3' ' A' ' 84' ' ' PRO . . . 161.67 -170.75 37.47 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.633 -0.794 . . . . 0.0 112.635 -179.987 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 89' ' ' TRP . . . . . 0.522 ' N ' ' CD1' ' A' ' 89' ' ' TRP . 0.1 OUTLIER -150.78 -60.05 0.18 Allowed 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 121.278 0.561 . . . . 0.0 110.559 -179.256 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -153.18 -44.86 0.02 OUTLIER Glycine 0 N--CA 1.45 -0.433 0 CA-C-N 115.264 -0.88 . . . . 0.0 111.499 179.636 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 4.6 mt-30 . . . . . 0 C--O 1.248 1.004 0 CA-C-O 118.22 -0.895 . . . . 0.0 111.363 179.326 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.324 0 N-CA-C 112.539 -0.224 . . . . 0.0 112.539 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 73' ' ' TRP . . . . . 0.485 ' N ' ' CD1' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -147.16 -77.04 0.18 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.956 0.408 . . . . 0.0 110.785 -179.555 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -106.76 -21.26 8.32 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.805 -0.712 . . . . 0.0 112.5 179.867 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 3.0 pt20 -59.94 153.84 52.38 Favored Pre-proline 0 C--N 1.331 -0.223 0 CA-C-O 120.663 0.268 . . . . 0.0 110.915 179.947 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_endo -66.06 153.93 76.11 Favored 'Trans proline' 0 C--N 1.344 0.321 0 C-N-CA 122.481 2.121 . . . . 0.0 112.389 179.938 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 23.3 t-160 -109.7 -29.76 8.19 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.811 179.956 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -134.39 26.7 3.33 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.549 179.952 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 106.88 97.63 2.52 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.53 179.888 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 58.45 -172.7 3.59 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.58 179.909 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 81' ' ' TRP . . . . . 0.486 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -146.21 -77.84 0.18 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.96 0.41 . . . . 0.0 110.845 -179.603 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -106.46 -20.81 8.76 Favored Glycine 0 N--CA 1.45 -0.419 0 C-N-CA 120.848 -0.692 . . . . 0.0 112.553 179.895 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 12.5 pt20 -58.89 153.68 42.17 Favored Pre-proline 0 C--N 1.33 -0.254 0 CA-C-O 120.694 0.283 . . . . 0.0 110.933 179.966 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . 0.416 ' HB2' ' N ' ' A' ' 88' ' ' GLY . 30.3 Cg_endo -64.37 159.99 41.29 Favored 'Trans proline' 0 C--N 1.344 0.326 0 C-N-CA 122.522 2.148 . . . . 0.0 112.321 -179.977 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 4.1 m-70 -117.72 106.34 12.95 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.092 -0.503 . . . . 0.0 110.645 179.665 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 94.93 -26.85 16.7 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.444 -179.797 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 150.01 92.8 0.1 Allowed Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.549 -179.966 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . 0.416 ' N ' ' HB2' ' A' ' 84' ' ' PRO . . . 58.46 -157.5 19.53 Favored Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.593 179.988 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 89' ' ' TRP . . . . . 0.509 ' N ' ' CD1' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -142.02 -78.46 0.25 Allowed 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.981 0.42 . . . . 0.0 110.701 -179.636 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -134.68 17.29 4.21 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.908 -0.663 . . . . 0.0 112.507 179.816 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 6.0 pt20 . . . . . 0 C--O 1.249 1.072 0 CA-C-O 118.228 -0.891 . . . . 0.0 110.943 179.963 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.394 0 N-CA-C 112.571 -0.212 . . . . 0.0 112.571 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 73' ' ' TRP . . . . . 0.489 ' N ' ' CD1' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -145.62 -78.83 0.18 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.872 0.368 . . . . 0.0 110.804 -179.606 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -105.93 -20.93 8.91 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.868 -0.682 . . . . 0.0 112.446 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 16.7 pt20 -59.81 154.16 49.2 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 120.742 0.306 . . . . 0.0 110.891 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . 0.404 ' HB3' ' CA ' ' A' ' 80' ' ' GLY . 50.0 Cg_endo -69.31 139.75 42.59 Favored 'Trans proline' 0 C--N 1.344 0.326 0 C-N-CA 122.548 2.165 . . . . 0.0 112.333 179.965 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 19.9 t-160 -93.73 -31.22 14.51 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.86 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -125.89 -40.82 0.36 Allowed Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.801 -0.714 . . . . 0.0 112.485 -180.0 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -176.48 97.16 0.11 Allowed Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.567 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . 0.404 ' CA ' ' HB3' ' A' ' 76' ' ' PRO . . . 59.91 -171.82 5.78 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.563 179.971 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 81' ' ' TRP . . . . . 0.474 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -147.09 -77.34 0.17 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.902 0.382 . . . . 0.0 110.757 -179.66 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -106.6 -21.63 8.18 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.919 -0.658 . . . . 0.0 112.493 179.934 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 20.7 pt20 -59.96 154.03 51.52 Favored Pre-proline 0 C--N 1.33 -0.24 0 CA-C-O 120.702 0.287 . . . . 0.0 110.902 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . 0.404 ' HB3' ' CA ' ' A' ' 88' ' ' GLY . 39.0 Cg_endo -67.13 158.1 58.52 Favored 'Trans proline' 0 C--N 1.344 0.335 0 C-N-CA 122.567 2.178 . . . . 0.0 112.296 179.955 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 8.8 m170 -97.67 -30.94 12.54 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.774 179.986 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -113.75 -29.09 2.97 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.506 179.97 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 172.38 -33.6 0.13 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.524 179.991 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . 0.404 ' CA ' ' HB3' ' A' ' 84' ' ' PRO . . . -157.85 -161.2 10.74 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.68 -0.771 . . . . 0.0 112.558 -179.968 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 89' ' ' TRP . . . . . 0.489 ' N ' ' CD1' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -147.17 -77.98 0.17 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.969 0.414 . . . . 0.0 110.756 -179.636 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -133.79 17.87 4.36 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.909 -0.662 . . . . 0.0 112.484 179.816 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 13.8 pt20 . . . . . 0 C--O 1.25 1.095 0 CA-C-O 118.164 -0.922 . . . . 0.0 110.896 179.982 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.267 0 N-CA-C 112.469 -0.252 . . . . 0.0 112.469 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 73' ' ' TRP . . . . . 0.509 ' N ' ' CD1' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -144.61 -79.79 0.18 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.944 0.402 . . . . 0.0 110.72 -179.546 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -112.27 15.16 25.4 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.81 -0.71 . . . . 0.0 112.436 179.706 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 3.5 pt20 -107.39 154.07 40.86 Favored Pre-proline 0 C--N 1.33 -0.252 0 CA-C-O 120.713 0.292 . . . . 0.0 110.901 179.989 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_endo -66.0 146.73 83.26 Favored 'Trans proline' 0 C--N 1.344 0.299 0 C-N-CA 122.481 2.121 . . . . 0.0 112.305 179.988 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 6.3 t-160 -100.03 -31.16 11.58 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.794 179.813 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -118.83 -34.59 1.04 Allowed Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.812 -0.709 . . . . 0.0 112.436 179.907 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -161.53 -64.96 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.558 -179.996 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -138.57 -158.95 7.9 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.599 -179.957 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 81' ' ' TRP . . . . . 0.501 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -145.94 -77.99 0.18 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.9 0.381 . . . . 0.0 110.778 -179.594 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -104.18 -21.88 9.14 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.903 -0.665 . . . . 0.0 112.54 179.896 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 16.9 pt20 -61.13 151.7 74.48 Favored Pre-proline 0 C--N 1.331 -0.224 0 CA-C-O 120.719 0.295 . . . . 0.0 110.93 -179.98 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . 0.41 ' HB2' ' N ' ' A' ' 88' ' ' GLY . 30.7 Cg_endo -64.63 160.82 38.23 Favored 'Trans proline' 0 C--N 1.344 0.328 0 C-N-CA 122.511 2.141 . . . . 0.0 112.358 179.968 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 16.6 p-80 -118.47 106.57 12.82 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.599 179.644 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 94.42 -26.08 19.52 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.513 -179.797 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 149.29 92.53 0.1 Allowed Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.498 179.937 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . 0.41 ' N ' ' HB2' ' A' ' 84' ' ' PRO . . . 58.93 -157.37 22.33 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.548 179.985 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 89' ' ' TRP . . . . . 0.511 ' N ' ' CD1' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -142.55 -78.7 0.24 Allowed 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 121.002 0.429 . . . . 0.0 110.829 -179.676 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -113.15 -20.71 6.2 Favored Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 120.904 -0.665 . . . . 0.0 112.473 179.888 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 2.0 pt20 . . . . . 0 C--O 1.248 1.024 0 CA-C-O 118.333 -0.841 . . . . 0.0 110.862 -179.982 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' TRP . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.489 1.478 0 CA-C-O 120.831 0.348 . . . . 0.0 111.316 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -166.08 30.61 0.21 Allowed Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.535 -179.96 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 13.0 pt20 -71.12 154.21 94.1 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 120.789 0.328 . . . . 0.0 110.837 -179.954 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 44.7 Cg_endo -68.14 153.79 73.94 Favored 'Trans proline' 0 C--N 1.345 0.345 0 C-N-CA 122.518 2.145 . . . . 0.0 112.314 179.945 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' HIS . . . . . . . . . . . . . 16.6 p-80 -101.89 -31.17 10.84 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.885 179.934 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -126.54 -41.53 0.32 Allowed Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.462 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -176.38 90.26 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.441 179.963 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 62.31 -170.81 11.31 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.679 -0.772 . . . . 0.0 112.603 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' TRP . . . . . 0.492 ' N ' ' CD1' ' A' ' 65' ' ' TRP . 0.0 OUTLIER -147.06 -78.6 0.16 Allowed 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.864 0.364 . . . . 0.0 110.823 -179.673 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -118.5 14.67 11.82 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.941 -0.647 . . . . 0.0 112.538 179.732 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 20.6 pt20 -80.32 154.5 74.4 Favored Pre-proline 0 C--N 1.33 -0.241 0 CA-C-O 120.656 0.265 . . . . 0.0 110.91 -179.988 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -66.35 160.26 46.26 Favored 'Trans proline' 0 C--N 1.344 0.312 0 C-N-CA 122.56 2.173 . . . . 0.0 112.291 179.982 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 27.8 p-80 -106.76 -31.36 8.44 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.828 -179.897 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . -135.14 28.07 3.08 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.515 -179.964 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 105.04 93.48 2.31 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.512 -179.952 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 59.39 -171.12 5.49 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.561 179.967 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' TRP . . . . . 0.481 ' N ' ' CD1' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -146.76 -78.9 0.16 Allowed 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 120.97 0.415 . . . . 0.0 110.746 -179.573 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -114.39 13.23 21.13 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.843 -0.694 . . . . 0.0 112.54 179.83 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 23.9 pt20 -97.38 154.48 38.02 Favored Pre-proline 0 C--N 1.332 -0.192 0 CA-C-O 120.722 0.296 . . . . 0.0 110.888 179.983 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 39.4 Cg_endo -67.29 147.3 78.0 Favored 'Trans proline' 0 C--N 1.344 0.303 0 C-N-CA 122.543 2.162 . . . . 0.0 112.27 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 8.4 t-160 -97.26 -30.62 12.87 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.865 179.893 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -113.17 -27.95 3.5 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.893 -0.67 . . . . 0.0 112.565 179.941 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 179.37 -54.52 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.596 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -145.71 -158.64 7.79 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.521 -179.924 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' TRP . . . . . 0.478 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -147.56 -77.11 0.17 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.97 0.414 . . . . 0.0 110.698 -179.556 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -106.85 -20.93 8.47 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.903 -0.665 . . . . 0.0 112.473 179.868 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 17.8 pt20 -60.18 154.45 51.54 Favored Pre-proline 0 C--N 1.331 -0.216 0 CA-C-O 120.735 0.302 . . . . 0.0 110.856 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_endo -68.72 140.53 47.05 Favored 'Trans proline' 0 C--N 1.345 0.378 0 C-N-CA 122.525 2.15 . . . . 0.0 112.251 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 7.5 m170 -94.89 -30.99 13.89 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.846 -179.956 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -125.22 -40.79 0.39 Allowed Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.496 179.98 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -177.18 96.9 0.11 Allowed Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.468 179.942 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 59.59 -170.71 6.01 Favored Glycine 0 N--CA 1.452 -0.268 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.55 179.947 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' TRP . . . . . 0.478 ' CD1' ' N ' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -147.52 -77.78 0.17 Allowed 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.919 0.39 . . . . 0.0 110.795 -179.638 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -134.69 18.32 4.1 Favored Glycine 0 N--CA 1.449 -0.445 0 C-N-CA 120.894 -0.669 . . . . 0.0 112.504 179.843 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 7.2 pt20 . . . . . 0 C--O 1.249 1.052 0 CA-C-O 118.173 -0.918 . . . . 0.0 110.864 -179.944 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' TRP . . . . . . . . . . . . . 30.1 t-105 . . . . . 0 N--CA 1.486 1.367 0 CA-C-O 120.709 0.29 . . . . 0.0 111.207 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . 0.465 ' O ' ' CG ' ' A' ' 59' ' ' GLN . . . -60.31 -40.7 97.81 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.541 179.948 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.465 ' CG ' ' O ' ' A' ' 58' ' ' GLY . 2.6 pt20 54.74 155.08 0.05 OUTLIER Pre-proline 0 N--CA 1.464 0.256 0 CA-C-O 120.948 0.404 . . . . 0.0 111.527 179.958 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 58.5 Cg_endo -72.01 142.4 38.46 Favored 'Trans proline' 0 C--N 1.344 0.328 0 C-N-CA 122.556 2.171 . . . . 0.0 112.302 -179.891 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' HIS . . . . . . . . . . . . . 8.7 t-160 -90.29 -31.11 17.09 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.937 179.924 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -126.22 -42.14 0.31 Allowed Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.41 -179.951 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -176.14 97.81 0.12 Allowed Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.501 -179.899 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 59.61 -170.86 5.94 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.541 179.94 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' TRP . . . . . 0.474 ' CD1' ' N ' ' A' ' 65' ' ' TRP . 0.0 OUTLIER -147.91 -76.82 0.17 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.934 0.397 . . . . 0.0 110.751 -179.621 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -108.23 -19.72 8.75 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.937 -0.649 . . . . 0.0 112.574 179.9 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 18.1 pt20 -58.56 154.14 36.2 Favored Pre-proline 0 C--N 1.33 -0.246 0 CA-C-O 120.682 0.277 . . . . 0.0 110.95 -179.99 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo -69.06 151.39 73.08 Favored 'Trans proline' 0 C--N 1.343 0.287 0 C-N-CA 122.591 2.194 . . . . 0.0 112.309 179.967 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 27.6 p-80 -95.38 -31.01 13.61 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.83 179.933 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . -151.87 27.66 0.92 Allowed Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.502 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 167.41 -107.97 0.3 Allowed Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.524 -179.995 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -126.46 -158.08 9.76 Favored Glycine 0 N--CA 1.452 -0.268 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.56 -179.968 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' TRP . . . . . 0.467 ' CD1' ' N ' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -147.69 -78.02 0.16 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.927 0.394 . . . . 0.0 110.799 -179.598 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -111.34 -15.26 10.66 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.883 -0.675 . . . . 0.0 112.632 179.917 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 18.9 pt20 -56.74 154.08 19.49 Favored Pre-proline 0 C--N 1.331 -0.201 0 CA-C-O 120.699 0.285 . . . . 0.0 111.028 -179.974 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 41.2 Cg_endo -67.32 161.29 43.76 Favored 'Trans proline' 0 C--N 1.343 0.28 0 C-N-CA 122.597 2.198 . . . . 0.0 112.314 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 12.6 t60 -109.32 -30.5 7.96 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.966 179.865 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -135.16 27.09 3.18 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.468 179.982 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 106.28 92.9 2.29 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.476 179.939 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 58.92 -170.88 4.98 Favored Glycine 0 N--CA 1.452 -0.268 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.535 179.936 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' TRP . . . . . 0.489 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -146.81 -78.88 0.16 Allowed 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.832 0.348 . . . . 0.0 110.76 -179.604 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -119.98 15.89 10.22 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.863 -0.684 . . . . 0.0 112.547 179.733 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 8.2 pt20 -82.11 154.2 69.65 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-O 120.723 0.297 . . . . 0.0 110.903 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 27.6 Cg_endo -62.72 156.47 53.03 Favored 'Trans proline' 0 C--N 1.345 0.365 0 C-N-CA 122.535 2.156 . . . . 0.0 112.273 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 0.7 OUTLIER -109.38 -31.08 7.67 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.815 179.94 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -108.26 -61.71 0.55 Allowed Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.436 -179.984 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -165.77 30.1 0.21 Allowed Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.709 -0.757 . . . . 0.0 112.523 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 136.1 -164.33 25.04 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.581 -179.971 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' TRP . . . . . 0.491 ' CD1' ' N ' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -146.85 -77.92 0.17 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.897 0.379 . . . . 0.0 110.735 -179.634 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -133.04 18.69 4.45 Favored Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.907 -0.663 . . . . 0.0 112.511 179.793 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 15.3 pt20 . . . . . 0 C--O 1.249 1.056 0 CA-C-O 118.203 -0.903 . . . . 0.0 110.89 -179.968 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' TRP . . . . . . . . . . . . . 31.0 t-105 . . . . . 0 N--CA 1.487 1.387 0 CA-C-O 120.848 0.356 . . . . 0.0 111.21 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . 0.468 ' O ' ' CG ' ' A' ' 59' ' ' GLN . . . -60.85 -50.83 63.25 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.512 -179.983 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.468 ' CG ' ' O ' ' A' ' 58' ' ' GLY . 5.4 pt20 54.62 155.55 0.05 OUTLIER Pre-proline 0 CA--C 1.531 0.213 0 CA-C-O 121.01 0.433 . . . . 0.0 111.517 179.949 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 60.5 Cg_endo -73.52 147.39 40.83 Favored 'Trans proline' 0 C--N 1.346 0.418 0 C-N-CA 122.446 2.098 . . . . 0.0 112.335 -179.867 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' HIS . . . . . . . . . . . . . 23.8 t-160 -89.33 -30.63 18.28 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.905 179.97 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -165.77 31.45 0.22 Allowed Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.527 179.941 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -178.37 -91.22 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.458 179.965 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -155.56 -158.52 8.82 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.62 -179.964 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' TRP . . . . . 0.476 ' N ' ' CD1' ' A' ' 65' ' ' TRP . 0.0 OUTLIER -147.13 -77.61 0.17 Allowed 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 120.973 0.416 . . . . 0.0 110.826 -179.584 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -108.18 -21.07 7.9 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.901 -0.666 . . . . 0.0 112.455 179.827 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 3.2 pt20 -60.05 153.95 53.0 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 120.639 0.257 . . . . 0.0 110.868 -179.969 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 30.2 Cg_endo -64.01 154.13 72.04 Favored 'Trans proline' 0 C--N 1.343 0.289 0 C-N-CA 122.478 2.118 . . . . 0.0 112.304 179.952 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 12.1 t-160 -107.78 -30.6 8.45 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.87 179.923 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . -108.28 -62.69 0.55 Allowed Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.454 -179.976 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -164.28 29.29 0.23 Allowed Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.57 -179.975 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 135.82 -164.02 24.98 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.561 -180.0 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' TRP . . . . . 0.496 ' CD1' ' N ' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -146.31 -78.6 0.17 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.857 0.36 . . . . 0.0 110.76 -179.616 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -116.64 13.72 15.1 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.953 -0.641 . . . . 0.0 112.599 179.73 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 3.9 pt20 -91.02 154.13 45.05 Favored Pre-proline 0 C--N 1.331 -0.238 0 CA-C-O 120.708 0.289 . . . . 0.0 110.942 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . 0.403 ' HB3' ' CA ' ' A' ' 80' ' ' GLY . 36.0 Cg_endo -65.33 151.01 86.56 Favored 'Trans proline' 0 C--N 1.344 0.324 0 C-N-CA 122.495 2.13 . . . . 0.0 112.27 179.971 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 17.2 t-160 -101.07 -30.72 11.44 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.796 179.916 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -109.17 -27.77 4.67 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.528 179.95 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 168.11 -31.38 0.18 Allowed Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.598 179.953 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . 0.403 ' CA ' ' HB3' ' A' ' 76' ' ' PRO . . . -162.3 -162.17 13.05 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.555 -179.987 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' TRP . . . . . 0.49 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -146.28 -78.54 0.17 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.92 0.391 . . . . 0.0 110.748 -179.657 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -116.99 13.25 14.3 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.903 -0.665 . . . . 0.0 112.555 179.806 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 13.9 pt20 -86.09 154.29 57.58 Favored Pre-proline 0 C--N 1.332 -0.193 0 CA-C-O 120.628 0.251 . . . . 0.0 110.917 179.966 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . 0.401 ' HB3' ' CA ' ' A' ' 88' ' ' GLY . 37.3 Cg_endo -66.12 157.41 59.85 Favored 'Trans proline' 0 C--N 1.344 0.296 0 C-N-CA 122.538 2.159 . . . . 0.0 112.32 179.914 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 3.5 t-80 -98.95 -30.79 12.16 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.854 179.861 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -113.03 -27.73 3.61 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.481 -179.995 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 169.91 -32.39 0.16 Allowed Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.711 -0.756 . . . . 0.0 112.551 179.979 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . 0.401 ' CA ' ' HB3' ' A' ' 84' ' ' PRO . . . -159.08 -161.48 11.18 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.509 -179.966 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' TRP . . . . . 0.485 ' CD1' ' N ' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -147.14 -77.98 0.17 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.826 0.346 . . . . 0.0 110.826 -179.669 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -134.71 17.76 4.15 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.921 -0.657 . . . . 0.0 112.523 179.863 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 7.6 pt20 . . . . . 0 C--O 1.248 1.023 0 CA-C-O 118.242 -0.885 . . . . 0.0 110.944 -180.0 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' TRP . . . . . . . . . . . . . 6.1 t90 . . . . . 0 N--CA 1.487 1.412 0 CA-C-O 120.797 0.332 . . . . 0.0 111.197 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -59.87 -75.23 0.29 Allowed Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.545 -179.996 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 9.1 pt20 -87.54 153.79 53.27 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 120.714 0.292 . . . . 0.0 110.922 179.969 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 32.5 Cg_endo -64.62 150.56 87.99 Favored 'Trans proline' 0 C--N 1.344 0.337 0 C-N-CA 122.566 2.178 . . . . 0.0 112.342 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' HIS . . . . . . . . . . . . . 9.0 t-160 -103.18 6.27 38.23 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.221 179.931 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 137.68 43.76 0.09 OUTLIER Glycine 0 C--N 1.331 0.298 0 C-N-CA 120.617 -0.802 . . . . 0.0 112.522 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 158.74 42.53 0.02 OUTLIER Glycine 0 N--CA 1.45 -0.419 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.681 179.882 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 56.0 -157.35 9.48 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.748 179.893 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' TRP . . . . . 0.488 ' N ' ' CD1' ' A' ' 65' ' ' TRP . 0.0 OUTLIER -147.33 -77.68 0.17 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.911 0.386 . . . . 0.0 110.743 -179.623 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -109.08 -19.17 8.68 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.869 -0.681 . . . . 0.0 112.483 179.901 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 9.1 pt20 -58.55 154.19 35.84 Favored Pre-proline 0 C--N 1.331 -0.208 0 CA-C-O 120.674 0.273 . . . . 0.0 110.954 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo -66.02 157.83 57.44 Favored 'Trans proline' 0 C--N 1.344 0.309 0 C-N-CA 122.572 2.182 . . . . 0.0 112.28 179.913 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 3.7 p-80 -108.09 -31.18 8.04 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.899 179.948 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . -130.57 28.55 3.75 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.456 -179.955 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 100.19 95.93 2.17 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.559 179.988 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 60.37 -169.61 7.93 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.56 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' TRP . . . . . 0.485 ' N ' ' CD1' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -147.82 -77.25 0.17 Allowed 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.936 0.398 . . . . 0.0 110.787 -179.603 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -105.39 -21.67 8.67 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.888 -0.672 . . . . 0.0 112.446 179.832 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 16.3 pt20 -63.66 154.48 80.04 Favored Pre-proline 0 C--N 1.331 -0.2 0 CA-C-O 120.677 0.275 . . . . 0.0 110.879 -180.0 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 41.6 Cg_endo -67.7 142.06 56.9 Favored 'Trans proline' 0 C--N 1.344 0.311 0 C-N-CA 122.518 2.145 . . . . 0.0 112.239 -179.998 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 3.5 t-80 -96.05 -31.0 13.25 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.918 179.994 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -124.78 -41.77 0.37 Allowed Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.463 -179.986 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -177.02 94.58 0.1 OUTLIER Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.531 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 62.84 -170.66 13.08 Favored Glycine 0 N--CA 1.45 -0.416 0 C-N-CA 120.667 -0.778 . . . . 0.0 112.607 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' TRP . . . . . 0.477 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -148.24 -75.59 0.18 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.942 0.401 . . . . 0.0 110.742 -179.634 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -107.45 -22.09 7.61 Favored Glycine 0 N--CA 1.449 -0.436 0 C-N-CA 120.869 -0.682 . . . . 0.0 112.463 179.831 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 14.6 pt20 -60.17 154.11 53.32 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-O 120.646 0.26 . . . . 0.0 110.876 179.961 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 34.8 Cg_endo -65.35 153.46 78.15 Favored 'Trans proline' 0 C--N 1.344 0.308 0 C-N-CA 122.515 2.143 . . . . 0.0 112.255 179.963 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 57.5 m80 -100.63 -31.74 11.09 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.672 179.831 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -116.69 -31.65 1.74 Allowed Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.834 -0.698 . . . . 0.0 112.447 179.971 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -165.87 -69.25 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.59 -180.0 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -135.66 -147.84 5.51 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.616 179.98 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' TRP . . . . . 0.432 ' CH2' ' HB3' ' A' ' 91' ' ' GLN . 0.4 OUTLIER -161.11 23.57 0.13 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.765 0.317 . . . . 0.0 111.119 -179.342 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 103.03 -14.34 55.77 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.668 -0.777 . . . . 0.0 112.402 -179.644 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 91' ' ' GLN . . . . . 0.432 ' HB3' ' CH2' ' A' ' 89' ' ' TRP . 4.3 pt20 . . . . . 0 C--O 1.249 1.074 0 CA-C-O 118.229 -0.891 . . . . 0.0 110.919 -179.984 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' TRP . . . . . 0.451 ' CZ2' ' HG2' ' A' ' 59' ' ' GLN . 3.5 p-90 . . . . . 0 N--CA 1.488 1.429 0 CA-C-O 120.493 0.187 . . . . 0.0 111.021 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -43.68 -75.46 0.15 Allowed Glycine 0 C--N 1.332 0.319 0 C-N-CA 121.094 -0.574 . . . . 0.0 113.194 -179.567 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.451 ' HG2' ' CZ2' ' A' ' 57' ' ' TRP . 5.6 pt20 -96.48 154.6 38.53 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 120.705 0.288 . . . . 0.0 110.95 -179.934 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -66.1 151.02 84.81 Favored 'Trans proline' 0 C--N 1.344 0.321 0 C-N-CA 122.527 2.151 . . . . 0.0 112.32 179.968 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' HIS . . . . . . . . . . . . . 17.9 t-160 -104.79 -31.18 9.44 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.871 179.983 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -125.32 -40.85 0.38 Allowed Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.543 179.946 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -176.54 91.06 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.652 -0.785 . . . . 0.0 112.445 179.94 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 59.63 -169.0 7.12 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.51 179.961 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' TRP . . . . . 0.467 ' CD1' ' N ' ' A' ' 65' ' ' TRP . 0.0 OUTLIER -148.46 -75.88 0.17 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.905 0.383 . . . . 0.0 110.794 -179.643 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -110.22 -19.55 7.97 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.9 -0.667 . . . . 0.0 112.496 179.932 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 11.2 pt20 -58.4 153.74 36.77 Favored Pre-proline 0 C--N 1.331 -0.2 0 CA-C-O 120.744 0.307 . . . . 0.0 110.956 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 27.6 Cg_endo -63.25 157.86 47.6 Favored 'Trans proline' 0 C--N 1.344 0.329 0 C-N-CA 122.601 2.201 . . . . 0.0 112.355 179.977 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 15.2 p-80 -116.6 105.28 12.27 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.6 179.556 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 94.29 -25.92 20.05 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.531 -179.728 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -172.17 -92.77 0.08 OUTLIER Glycine 0 N--CA 1.453 -0.216 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.612 -179.983 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -133.55 -146.45 5.52 Favored Glycine 0 N--CA 1.453 -0.229 0 C-N-CA 120.85 -0.69 . . . . 0.0 112.57 -179.876 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' TRP . . . . . 0.557 ' N ' ' CD1' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -136.21 -78.33 0.42 Allowed 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.954 0.407 . . . . 0.0 110.629 -179.654 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -113.33 -9.09 18.34 Favored Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 120.907 -0.663 . . . . 0.0 112.625 179.758 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 14.3 pt20 -58.37 154.22 33.79 Favored Pre-proline 0 C--N 1.331 -0.237 0 CA-C-O 120.751 0.31 . . . . 0.0 110.957 179.933 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . 0.426 ' HB2' ' N ' ' A' ' 80' ' ' GLY . 55.0 Cg_endo -70.58 137.9 34.06 Favored 'Trans proline' 0 C--N 1.344 0.32 0 C-N-CA 122.431 2.088 . . . . 0.0 112.199 179.796 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 18.4 m-70 -107.66 105.38 15.21 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.985 0.421 . . . . 0.0 110.709 179.657 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 104.74 -31.5 8.53 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.868 -0.682 . . . . 0.0 112.433 -179.886 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 152.04 93.28 0.1 OUTLIER Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.576 -179.986 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . 0.426 ' N ' ' HB2' ' A' ' 76' ' ' PRO . . . 52.8 -161.79 2.54 Favored Glycine 0 C--N 1.33 0.229 0 C-N-CA 120.883 -0.675 . . . . 0.0 112.781 179.983 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' TRP . . . . . 0.549 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -137.09 -78.27 0.4 Allowed 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.935 0.398 . . . . 0.0 110.694 -179.665 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -107.33 -20.28 8.76 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.89 -0.672 . . . . 0.0 112.483 179.853 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 15.6 pt20 -59.9 154.42 48.66 Favored Pre-proline 0 C--N 1.331 -0.223 0 CA-C-O 120.631 0.253 . . . . 0.0 110.923 -179.946 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 44.0 Cg_endo -68.04 141.39 52.85 Favored 'Trans proline' 0 C--N 1.344 0.306 0 C-N-CA 122.558 2.172 . . . . 0.0 112.277 179.912 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 4.7 t-160 -95.5 -31.07 13.52 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.886 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -120.55 -41.37 0.53 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.518 179.966 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 179.22 96.13 0.1 Allowed Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.68 -0.772 . . . . 0.0 112.434 179.958 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 59.7 -170.07 6.55 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.542 -179.998 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' TRP . . . . . 0.482 ' N ' ' CD1' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -148.31 -76.18 0.17 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.998 0.428 . . . . 0.0 110.828 -179.634 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -112.89 -22.22 5.74 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.86 -0.686 . . . . 0.0 112.435 179.879 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 2.8 pp0? . . . . . 0 C--O 1.249 1.03 0 CA-C-O 118.257 -0.877 . . . . 0.0 110.904 -179.914 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' TRP . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.486 1.357 0 CA-C-O 120.815 0.34 . . . . 0.0 111.254 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 161.24 -28.24 0.29 Allowed Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.493 179.97 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 14.1 pt20 -69.35 154.08 95.26 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 120.7 0.286 . . . . 0.0 110.92 179.999 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_endo -68.21 147.52 72.77 Favored 'Trans proline' 0 C--N 1.344 0.33 0 C-N-CA 122.54 2.16 . . . . 0.0 112.317 179.961 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' HIS . . . . . . . . . . . . . 21.9 t-160 -96.04 -31.02 13.25 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.858 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -127.66 -41.79 0.28 Allowed Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.848 -0.691 . . . . 0.0 112.516 179.928 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -174.52 94.91 0.1 Allowed Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.686 -0.768 . . . . 0.0 112.507 179.969 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 59.37 -169.32 6.49 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.535 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' TRP . . . . . 0.46 ' CD1' ' N ' ' A' ' 65' ' ' TRP . 0.0 OUTLIER -148.69 -75.97 0.17 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.876 0.369 . . . . 0.0 110.786 -179.683 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -111.86 -13.72 12.17 Favored Glycine 0 N--CA 1.452 -0.248 0 C-N-CA 120.886 -0.674 . . . . 0.0 112.698 -179.99 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 6.6 pt20 -56.68 154.32 18.25 Favored Pre-proline 0 C--N 1.332 -0.157 0 CA-C-O 120.708 0.29 . . . . 0.0 110.958 -179.943 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -70.72 152.48 64.36 Favored 'Trans proline' 0 C--N 1.343 0.254 0 C-N-CA 122.57 2.18 . . . . 0.0 112.313 179.878 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 23.7 t-160 -97.02 -29.8 13.43 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.853 179.894 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . -151.21 27.56 0.99 Allowed Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.569 179.931 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 165.86 -107.04 0.28 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.542 179.958 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -126.9 -156.63 9.24 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.805 -0.712 . . . . 0.0 112.517 179.982 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' TRP . . . . . 0.454 ' CD1' ' N ' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -148.04 -79.36 0.15 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.885 0.374 . . . . 0.0 110.845 -179.667 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -115.99 -2.82 20.2 Favored Glycine 0 CA--C 1.519 0.311 0 C-N-CA 120.815 -0.707 . . . . 0.0 112.663 179.911 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 9.7 pt20 -58.04 154.41 29.58 Favored Pre-proline 0 C--N 1.33 -0.263 0 CA-C-O 120.728 0.299 . . . . 0.0 110.942 179.985 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -66.32 153.47 77.91 Favored 'Trans proline' 0 C--N 1.344 0.318 0 C-N-CA 122.553 2.169 . . . . 0.0 112.287 179.991 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 22.9 t-160 -100.23 -30.33 11.97 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.785 179.896 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -151.04 27.46 1.01 Allowed Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.478 -179.99 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 165.49 -109.59 0.37 Allowed Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.541 -179.932 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -123.7 -158.94 10.3 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.829 -0.701 . . . . 0.0 112.518 -179.945 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' TRP . . . . . 0.481 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -147.42 -78.6 0.16 Allowed 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.971 0.415 . . . . 0.0 110.873 -179.637 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -111.9 -15.22 10.23 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.959 -0.639 . . . . 0.0 112.577 179.898 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 16.2 pt20 -56.36 154.33 16.68 Favored Pre-proline 0 C--N 1.331 -0.211 0 CA-C-O 120.706 0.288 . . . . 0.0 111.006 179.969 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 40.9 Cg_endo -67.35 169.22 15.91 Favored 'Trans proline' 0 C--N 1.344 0.299 0 C-N-CA 122.604 2.202 . . . . 0.0 112.287 179.936 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 3.6 m-70 -110.15 -31.34 7.38 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.898 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -136.75 27.93 2.89 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.556 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 105.22 98.4 2.54 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.46 179.928 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 59.09 -170.81 5.24 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.511 179.925 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' TRP . . . . . 0.475 ' CD1' ' N ' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -147.92 -77.51 0.16 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.936 0.398 . . . . 0.0 110.88 -179.605 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -113.56 -22.06 5.57 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.87 -0.681 . . . . 0.0 112.486 179.823 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.249 1.034 0 CA-C-O 118.173 -0.918 . . . . 0.0 110.939 -179.993 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' TRP . . . . . . . . . . . . . 2.2 t90 . . . . . 0 N--CA 1.487 1.376 0 CA-C-O 120.847 0.356 . . . . 0.0 111.208 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -59.75 -51.18 60.53 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.492 179.981 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER 57.53 165.03 0.07 OUTLIER Pre-proline 0 C--N 1.33 -0.271 0 CA-C-O 120.755 0.312 . . . . 0.0 111.005 -179.928 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -70.05 126.2 12.85 Favored 'Trans proline' 0 C--N 1.344 0.317 0 C-N-CA 122.548 2.166 . . . . 0.0 112.267 -179.928 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' HIS . . . . . . . . . . . . . 5.4 m170 -89.81 6.05 43.42 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.377 179.908 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 173.25 39.37 0.04 OUTLIER Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.515 -179.993 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 151.47 -102.41 0.23 Allowed Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.68 -0.772 . . . . 0.0 112.48 179.929 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -139.54 -159.22 7.91 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.511 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' TRP . . . . . 0.488 ' N ' ' CD1' ' A' ' 65' ' ' TRP . 0.0 OUTLIER -146.88 -78.62 0.16 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.889 0.376 . . . . 0.0 110.725 -179.573 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -119.12 14.01 11.18 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.907 -0.663 . . . . 0.0 112.56 179.77 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 17.9 pt20 -78.56 154.19 78.75 Favored Pre-proline 0 C--N 1.331 -0.198 0 CA-C-O 120.75 0.31 . . . . 0.0 110.906 179.932 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . 0.413 ' HB2' ' N ' ' A' ' 72' ' ' GLY . 29.3 Cg_endo -63.83 160.68 35.88 Favored 'Trans proline' 0 C--N 1.345 0.378 0 C-N-CA 122.541 2.161 . . . . 0.0 112.31 -179.972 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 6.1 p80 -117.9 106.34 12.87 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.649 179.707 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 94.46 -26.52 17.36 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.452 -179.812 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 149.69 92.7 0.1 Allowed Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.497 179.99 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . 0.413 ' N ' ' HB2' ' A' ' 68' ' ' PRO . . . 58.88 -158.43 20.0 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.676 -0.773 . . . . 0.0 112.56 179.965 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' TRP . . . . . 0.528 ' N ' ' CD1' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -141.31 -79.08 0.26 Allowed 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.928 0.394 . . . . 0.0 110.627 -179.601 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -116.99 13.93 14.09 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.83 -0.7 . . . . 0.0 112.47 179.842 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 21.2 pt20 -89.55 154.52 48.46 Favored Pre-proline 0 C--N 1.331 -0.197 0 CA-C-O 120.661 0.267 . . . . 0.0 110.881 -179.966 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 39.8 Cg_endo -67.06 148.38 81.33 Favored 'Trans proline' 0 C--N 1.344 0.319 0 C-N-CA 122.485 2.123 . . . . 0.0 112.26 179.921 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' HIS . . . . . 0.4 ' CD2' ' O ' ' A' ' 77' ' ' HIS . 9.5 t-160 -97.54 6.22 48.42 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.379 179.956 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 150.81 44.57 0.02 OUTLIER Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.524 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 168.37 -82.92 0.1 OUTLIER Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.52 -179.973 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -169.64 -160.8 18.77 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.516 -179.941 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' TRP . . . . . 0.472 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -147.53 -77.96 0.16 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.901 0.381 . . . . 0.0 110.747 -179.613 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -105.86 -20.9 8.97 Favored Glycine 0 N--CA 1.45 -0.398 0 C-N-CA 120.915 -0.66 . . . . 0.0 112.46 179.807 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 20.8 pt20 -63.98 154.2 82.45 Favored Pre-proline 0 C--N 1.33 -0.25 0 CA-C-O 120.71 0.29 . . . . 0.0 110.887 179.935 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo -66.27 177.58 3.08 Favored 'Trans proline' 0 C--N 1.344 0.338 0 C-N-CA 122.62 2.213 . . . . 0.0 112.293 179.9 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 27.4 p-80 -99.96 -30.99 11.69 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.887 179.93 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -162.66 28.78 0.26 Allowed Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.461 179.949 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 170.12 -92.3 0.1 OUTLIER Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.599 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -138.74 -156.5 7.05 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.589 179.953 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' TRP . . . . . 0.478 ' N ' ' CD1' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -147.8 -78.01 0.16 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.908 0.385 . . . . 0.0 110.707 -179.576 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -134.98 16.92 4.17 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.904 -0.665 . . . . 0.0 112.59 179.849 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 7.0 pt20 . . . . . 0 C--O 1.249 1.069 0 CA-C-O 118.238 -0.887 . . . . 0.0 110.93 -179.991 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' TRP . . . . . . . . . . . . . 6.9 t90 . . . . . 0 N--CA 1.487 1.394 0 CA-C-O 120.771 0.32 . . . . 0.0 111.214 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . 0.473 ' O ' ' CG ' ' A' ' 59' ' ' GLN . . . -58.45 -28.31 62.02 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.586 179.977 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.473 ' CG ' ' O ' ' A' ' 58' ' ' GLY . 3.0 pt20 54.92 154.32 0.05 OUTLIER Pre-proline 0 N--CA 1.463 0.206 0 CA-C-O 121.01 0.433 . . . . 0.0 111.558 179.994 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_endo -64.36 155.83 63.56 Favored 'Trans proline' 0 C--N 1.345 0.376 0 C-N-CA 122.55 2.166 . . . . 0.0 112.295 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' HIS . . . . . . . . . . . . . 23.8 t-160 -103.07 -30.2 10.89 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.859 179.944 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 175.27 38.33 0.05 OUTLIER Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.665 -0.779 . . . . 0.0 112.54 179.988 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 170.02 39.73 0.03 OUTLIER Glycine 0 N--CA 1.452 -0.248 0 C-N-CA 120.604 -0.808 . . . . 0.0 112.576 179.918 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 56.37 -154.15 16.66 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.674 179.856 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' TRP . . . . . 0.475 ' CD1' ' N ' ' A' ' 65' ' ' TRP . 0.0 OUTLIER -147.39 -77.94 0.17 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.959 0.409 . . . . 0.0 110.676 -179.613 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -108.91 -19.61 8.5 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.953 -0.642 . . . . 0.0 112.425 179.866 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 14.5 pt20 -61.42 152.91 71.72 Favored Pre-proline 0 C--N 1.33 -0.258 0 CA-C-O 120.728 0.299 . . . . 0.0 110.908 -179.965 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 21.4 Cg_endo -62.06 137.76 68.75 Favored 'Trans proline' 0 C--N 1.345 0.367 0 C-N-CA 122.599 2.199 . . . . 0.0 112.343 -179.948 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 3.2 t-80 -113.46 6.15 17.02 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.281 179.883 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . -174.45 33.87 0.11 Allowed Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.566 -179.982 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 105.39 88.09 2.03 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.578 179.906 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 58.31 -170.85 4.32 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.599 179.881 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' TRP . . . . . 0.499 ' N ' ' CD1' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -144.78 -77.79 0.2 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.921 0.391 . . . . 0.0 110.8 -179.607 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -103.39 -23.06 8.64 Favored Glycine 0 N--CA 1.449 -0.437 0 C-N-CA 120.954 -0.641 . . . . 0.0 112.517 179.884 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 3.1 pt20 -62.35 151.29 82.76 Favored Pre-proline 0 C--N 1.33 -0.249 0 CA-C-O 120.717 0.294 . . . . 0.0 110.907 -179.986 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . 0.405 ' HB3' ' CA ' ' A' ' 80' ' ' GLY . 23.9 Cg_endo -62.36 155.48 57.11 Favored 'Trans proline' 0 C--N 1.344 0.337 0 C-N-CA 122.587 2.191 . . . . 0.0 112.386 179.939 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 8.3 p80 -109.55 -29.92 8.16 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.84 179.817 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -112.35 -57.06 0.44 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.8 -0.715 . . . . 0.0 112.488 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -169.86 32.16 0.16 Allowed Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.649 179.965 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . 0.405 ' CA ' ' HB3' ' A' ' 76' ' ' PRO . . . 138.75 -169.3 24.44 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.646 -0.788 . . . . 0.0 112.611 -179.973 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' TRP . . . . . 0.491 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -145.65 -77.98 0.19 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.919 0.39 . . . . 0.0 110.781 -179.681 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -102.69 -20.3 11.99 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.87 -0.681 . . . . 0.0 112.558 179.927 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 12.5 pt20 -58.71 153.78 39.68 Favored Pre-proline 0 C--N 1.332 -0.195 0 CA-C-O 120.784 0.326 . . . . 0.0 110.952 -179.963 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 30.5 Cg_endo -64.2 154.13 72.55 Favored 'Trans proline' 0 C--N 1.345 0.361 0 C-N-CA 122.542 2.162 . . . . 0.0 112.267 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 1.6 t-80 -108.96 -29.82 8.4 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.82 179.872 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -108.5 -61.46 0.54 Allowed Glycine 0 N--CA 1.45 -0.406 0 C-N-CA 120.821 -0.704 . . . . 0.0 112.469 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -166.75 30.6 0.19 Allowed Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.569 179.946 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 135.31 -165.78 24.62 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.586 179.919 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' TRP . . . . . 0.489 ' N ' ' CD1' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -146.1 -79.36 0.17 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.902 0.382 . . . . 0.0 110.727 -179.626 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -139.13 22.67 2.92 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.99 -0.624 . . . . 0.0 112.175 179.779 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 20.2 mt-30 . . . . . 0 C--O 1.249 1.03 0 CA-C-O 118.223 -0.894 . . . . 0.0 110.933 -179.923 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' TRP . . . . . . . . . . . . . 5.4 t-105 . . . . . 0 N--CA 1.487 1.383 0 CA-C-O 120.896 0.379 . . . . 0.0 111.169 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -160.57 28.51 0.32 Allowed Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.496 179.972 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 4.2 pt20 -168.03 154.4 7.26 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 120.691 0.281 . . . . 0.0 110.878 179.969 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo -68.84 142.58 52.54 Favored 'Trans proline' 0 C--N 1.344 0.309 0 C-N-CA 122.57 2.18 . . . . 0.0 112.295 179.933 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' HIS . . . . . . . . . . . . . 1.2 t-160 -94.82 6.42 49.03 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.322 179.966 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 156.39 43.68 0.02 OUTLIER Glycine 0 C--N 1.332 0.327 0 C-N-CA 120.619 -0.8 . . . . 0.0 112.474 -179.973 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 163.79 -92.94 0.11 Allowed Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.613 -0.803 . . . . 0.0 112.475 -179.994 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -156.23 -162.34 11.35 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.816 -0.707 . . . . 0.0 112.581 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' TRP . . . . . 0.498 ' N ' ' CD1' ' A' ' 65' ' ' TRP . 0.0 OUTLIER -146.33 -79.04 0.17 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.898 0.38 . . . . 0.0 110.795 -179.665 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -119.28 15.14 10.88 Favored Glycine 0 N--CA 1.452 -0.268 0 C-N-CA 120.857 -0.687 . . . . 0.0 112.468 179.761 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 14.3 pt20 -76.57 154.16 83.64 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-O 120.645 0.26 . . . . 0.0 110.907 179.975 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 28.7 Cg_endo -63.32 158.13 46.49 Favored 'Trans proline' 0 C--N 1.343 0.244 0 C-N-CA 122.629 2.219 . . . . 0.0 112.307 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 23.7 t-160 -109.59 -30.55 7.86 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.82 179.902 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . -139.08 26.45 2.72 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.573 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 111.75 94.41 2.2 Favored Glycine 0 N--CA 1.453 -0.232 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.519 179.967 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 57.99 -174.19 2.58 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.584 179.879 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' TRP . . . . . 0.494 ' CD1' ' N ' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -146.25 -79.72 0.16 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.867 0.365 . . . . 0.0 110.791 -179.624 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -120.0 16.96 10.05 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.936 -0.649 . . . . 0.0 112.467 179.714 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 6.6 pt20 -77.29 154.79 82.12 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 120.734 0.302 . . . . 0.0 110.801 -179.965 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 32.7 Cg_endo -64.57 154.56 71.42 Favored 'Trans proline' 0 C--N 1.344 0.32 0 C-N-CA 122.465 2.11 . . . . 0.0 112.264 179.879 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 23.1 t-160 -102.85 -30.38 10.88 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.829 179.871 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -148.98 27.74 1.27 Allowed Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.431 179.991 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 162.48 -108.64 0.35 Allowed Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.487 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -123.26 -158.44 10.18 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.561 179.975 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' TRP . . . . . 0.477 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -147.7 -78.36 0.16 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.847 0.356 . . . . 0.0 110.748 -179.574 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -111.2 -18.36 8.24 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.928 -0.653 . . . . 0.0 112.523 179.908 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 4.6 pt20 -58.03 154.0 31.59 Favored Pre-proline 0 C--N 1.331 -0.232 0 CA-C-O 120.732 0.301 . . . . 0.0 110.931 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . 0.416 ' HB2' ' N ' ' A' ' 88' ' ' GLY . 28.1 Cg_endo -63.47 161.44 31.35 Favored 'Trans proline' 0 C--N 1.344 0.329 0 C-N-CA 122.581 2.188 . . . . 0.0 112.335 179.942 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' HIS . . . . . 0.401 ' CD2' ' N ' ' A' ' 85' ' ' HIS . 3.5 m-70 -118.32 106.15 12.47 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.674 179.694 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 94.43 -26.51 17.37 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.452 -179.801 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 150.06 92.43 0.1 OUTLIER Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.51 -179.98 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . 0.416 ' N ' ' HB2' ' A' ' 84' ' ' PRO . . . 59.1 -156.78 24.36 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.591 -179.968 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' TRP . . . . . 0.501 ' N ' ' CD1' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -142.58 -78.5 0.24 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.959 0.409 . . . . 0.0 110.666 -179.656 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -134.84 16.53 4.24 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.907 -0.663 . . . . 0.0 112.54 179.902 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 3.6 pt20 . . . . . 0 C--O 1.249 1.063 0 CA-C-O 118.2 -0.905 . . . . 0.0 110.927 179.996 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.487 1.402 0 CA-C-O 120.884 0.373 . . . . 0.0 111.134 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 150.21 -32.04 1.05 Allowed Glycine 0 N--CA 1.452 -0.254 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.455 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 14.2 pt20 -132.36 153.58 81.28 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 120.668 0.271 . . . . 0.0 110.854 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' PRO . . . . . 0.428 ' HB2' ' N ' ' A' ' 64' ' ' GLY . 55.2 Cg_endo -70.69 138.22 34.39 Favored 'Trans proline' 0 C--N 1.343 0.284 0 C-N-CA 122.44 2.093 . . . . 0.0 112.224 179.829 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' HIS . . . . . . . . . . . . . 5.4 m170 -107.97 105.43 15.21 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.728 179.643 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 104.58 -30.92 9.24 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.455 -179.848 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 151.24 93.4 0.1 Allowed Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.609 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . 0.428 ' N ' ' HB2' ' A' ' 60' ' ' PRO . . . 52.93 -162.11 2.53 Favored Glycine 0 CA--C 1.518 0.226 0 C-N-CA 120.854 -0.689 . . . . 0.0 112.732 179.979 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' TRP . . . . . 0.539 ' N ' ' CD1' ' A' ' 65' ' ' TRP . 0.0 OUTLIER -137.41 -78.61 0.39 Allowed 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 120.912 0.387 . . . . 0.0 110.718 -179.691 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -106.48 -21.88 8.09 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.945 -0.645 . . . . 0.0 112.404 179.87 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 16.8 pt20 -61.17 154.07 63.85 Favored Pre-proline 0 C--N 1.33 -0.251 0 CA-C-O 120.626 0.251 . . . . 0.0 110.896 -179.996 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 34.7 Cg_endo -65.58 153.13 79.55 Favored 'Trans proline' 0 C--N 1.344 0.311 0 C-N-CA 122.504 2.136 . . . . 0.0 112.272 179.997 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 19.9 p-80 -101.72 -30.5 11.28 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.825 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . -178.23 36.14 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.468 -179.931 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -171.74 -65.03 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.559 179.989 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 167.34 -159.67 33.08 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.496 -179.946 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' TRP . . . . . 0.493 ' N ' ' CD1' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -146.2 -77.97 0.18 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.939 0.399 . . . . 0.0 110.794 -179.672 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -104.74 -21.17 9.32 Favored Glycine 0 N--CA 1.45 -0.416 0 C-N-CA 120.888 -0.673 . . . . 0.0 112.485 179.755 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 17.6 pt20 -65.74 154.0 89.74 Favored Pre-proline 0 C--N 1.331 -0.225 0 CA-C-O 120.751 0.31 . . . . 0.0 110.861 179.971 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 33.7 Cg_endo -65.32 149.04 88.8 Favored 'Trans proline' 0 C--N 1.345 0.342 0 C-N-CA 122.535 2.156 . . . . 0.0 112.227 179.951 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 4.2 t-160 -102.82 6.56 39.31 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.369 179.93 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 158.39 -26.43 0.41 Allowed Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.64 -0.791 . . . . 0.0 112.536 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -113.64 -82.1 1.09 Allowed Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.545 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -171.16 -157.86 13.94 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.673 -0.775 . . . . 0.0 112.504 -179.961 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' TRP . . . . . 0.498 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -145.18 -78.6 0.19 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.949 0.404 . . . . 0.0 110.682 -179.574 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -112.85 10.87 25.24 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.87 -0.681 . . . . 0.0 112.574 179.829 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 19.0 pt20 -96.32 154.56 38.66 Favored Pre-proline 0 C--N 1.332 -0.164 0 CA-C-O 120.747 0.308 . . . . 0.0 110.878 179.933 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 42.3 Cg_endo -67.71 141.39 54.48 Favored 'Trans proline' 0 C--N 1.345 0.364 0 C-N-CA 122.486 2.124 . . . . 0.0 112.244 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 45.5 m-70 -95.89 -30.65 13.53 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.853 -179.973 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -118.92 -52.19 0.29 Allowed Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.515 -179.939 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -172.38 88.63 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.539 179.973 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 69.55 -170.68 42.22 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.604 -179.961 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' TRP . . . . . 0.482 ' N ' ' CD1' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -147.3 -78.74 0.16 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.946 0.403 . . . . 0.0 110.735 -179.641 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -138.49 22.19 3.04 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.96 -0.638 . . . . 0.0 112.194 179.749 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 6.2 mt-30 . . . . . 0 C--O 1.25 1.087 0 CA-C-O 118.19 -0.91 . . . . 0.0 110.911 -179.85 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' TRP . . . . . . . . . . . . . 30.8 t-105 . . . . . 0 N--CA 1.486 1.342 0 CA-C-O 120.798 0.333 . . . . 0.0 111.2 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -69.09 -61.51 4.53 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.481 -179.989 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 10.1 pt20 -176.57 154.34 1.26 Allowed Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 120.766 0.317 . . . . 0.0 110.834 179.941 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -68.91 123.86 10.83 Favored 'Trans proline' 0 C--N 1.344 0.301 0 C-N-CA 122.525 2.15 . . . . 0.0 112.355 179.908 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' HIS . . . . . . . . . . . . . 8.2 m170 -89.94 6.18 43.22 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.34 179.977 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 179.29 37.04 0.07 OUTLIER Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.69 -0.766 . . . . 0.0 112.511 179.968 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 146.71 -101.85 0.24 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.5 -179.933 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -136.38 -157.43 7.76 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.506 -179.93 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' TRP . . . . . 0.475 ' CD1' ' N ' ' A' ' 65' ' ' TRP . 0.0 OUTLIER -147.52 -78.09 0.16 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.912 0.387 . . . . 0.0 110.725 -179.597 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -108.17 -19.88 8.68 Favored Glycine 0 N--CA 1.45 -0.419 0 C-N-CA 120.905 -0.664 . . . . 0.0 112.524 179.766 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 13.6 pt20 -60.07 154.2 51.71 Favored Pre-proline 0 C--N 1.331 -0.237 0 CA-C-O 120.661 0.267 . . . . 0.0 110.902 -179.993 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 42.3 Cg_endo -68.32 150.34 76.15 Favored 'Trans proline' 0 C--N 1.343 0.262 0 C-N-CA 122.478 2.119 . . . . 0.0 112.338 179.935 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 23.8 t-160 -96.29 -29.92 13.73 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.803 179.902 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . -152.41 26.83 0.87 Allowed Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.504 179.864 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 166.33 -94.11 0.11 Allowed Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.682 -0.77 . . . . 0.0 112.519 -179.957 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -133.91 -158.69 8.68 Favored Glycine 0 N--CA 1.452 -0.254 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.464 -179.904 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' TRP . . . . . 0.492 ' N ' ' CD1' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -146.75 -78.53 0.17 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.917 0.389 . . . . 0.0 110.77 -179.601 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -103.93 -20.65 10.37 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.927 -0.654 . . . . 0.0 112.477 179.823 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 17.9 pt20 -65.1 153.91 88.09 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-O 120.682 0.277 . . . . 0.0 110.852 -179.984 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . 0.401 ' HB3' ' CA ' ' A' ' 80' ' ' GLY . 51.6 Cg_endo -69.69 140.09 42.07 Favored 'Trans proline' 0 C--N 1.343 0.283 0 C-N-CA 122.502 2.134 . . . . 0.0 112.414 179.947 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 25.3 p80 -92.23 -31.43 15.44 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.653 179.757 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -120.6 -35.69 0.83 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.845 -0.693 . . . . 0.0 112.411 179.981 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -155.12 -78.0 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.5 -179.952 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . 0.401 ' CA ' ' HB3' ' A' ' 76' ' ' PRO . . . -130.62 -157.67 9.03 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.575 -179.951 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 81' ' ' TRP . . . . . 0.48 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -146.75 -78.06 0.17 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.857 0.36 . . . . 0.0 110.731 -179.646 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -105.96 -20.06 9.65 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.886 -0.673 . . . . 0.0 112.532 179.898 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 11.1 pt20 -59.72 154.2 48.0 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-O 120.699 0.285 . . . . 0.0 110.895 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.9 140.57 42.47 Favored 'Trans proline' 0 C--N 1.343 0.263 0 C-N-CA 122.551 2.167 . . . . 0.0 112.314 179.913 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 7.8 m-70 -93.53 -30.46 14.99 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.892 179.925 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -147.38 27.8 1.52 Allowed Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.522 -179.97 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 163.25 -102.27 0.2 Allowed Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.53 179.933 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -130.93 -156.89 8.7 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.552 -179.934 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 89' ' ' TRP . . . . . 0.479 ' CD1' ' N ' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -147.18 -77.99 0.17 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.934 0.397 . . . . 0.0 110.779 -179.65 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -134.78 17.67 4.14 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.923 -0.656 . . . . 0.0 112.528 179.823 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 5.9 pt20 . . . . . 0 C--O 1.249 1.074 0 CA-C-O 118.193 -0.908 . . . . 0.0 110.849 -179.964 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' TRP . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 N--CA 1.489 1.5 0 CA-C-O 120.75 0.309 . . . . 0.0 111.421 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . 0.403 ' O ' ' CG ' ' A' ' 59' ' ' GLN . . . -95.0 -29.17 9.27 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.543 179.997 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.403 ' CG ' ' O ' ' A' ' 58' ' ' GLY . 0.0 OUTLIER 56.19 156.42 0.07 OUTLIER Pre-proline 0 CA--C 1.53 0.201 0 CA-C-O 120.776 0.322 . . . . 0.0 111.48 -179.947 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -72.57 128.77 13.85 Favored 'Trans proline' 0 C--N 1.343 0.265 0 C-N-CA 122.62 2.213 . . . . 0.0 112.212 -179.851 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' HIS . . . . . . . . . . . . . 8.8 m170 -90.06 6.06 44.0 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.408 179.897 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 164.28 42.26 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.579 -0.819 . . . . 0.0 112.462 179.98 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 160.14 -96.52 0.15 Allowed Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.472 179.966 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -152.2 -159.78 9.17 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.558 -179.947 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' TRP . . . . . 0.486 ' N ' ' CD1' ' A' ' 65' ' ' TRP . 0.0 OUTLIER -147.13 -77.6 0.17 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.947 0.403 . . . . 0.0 110.734 -179.617 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -108.98 -19.01 8.83 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.978 -0.63 . . . . 0.0 112.582 179.908 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 15.0 pt20 -58.61 154.37 35.44 Favored Pre-proline 0 C--N 1.331 -0.209 0 CA-C-O 120.659 0.266 . . . . 0.0 110.891 -179.931 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 41.8 Cg_endo -67.76 154.02 74.28 Favored 'Trans proline' 0 C--N 1.343 0.271 0 C-N-CA 122.576 2.184 . . . . 0.0 112.249 179.925 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 23.1 t-160 -101.3 -31.33 11.02 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.85 179.994 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . -124.11 -40.16 0.46 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.822 -0.704 . . . . 0.0 112.54 179.949 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -179.29 92.47 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.583 -179.979 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 60.93 -170.71 7.93 Favored Glycine 0 N--CA 1.452 -0.254 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.495 179.999 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' TRP . . . . . 0.488 ' CD1' ' N ' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -146.86 -78.89 0.16 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.942 0.401 . . . . 0.0 110.811 -179.648 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -117.79 14.43 12.83 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.964 -0.636 . . . . 0.0 112.585 179.782 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 8.6 pt20 -84.21 154.36 63.3 Favored Pre-proline 0 C--N 1.331 -0.2 0 CA-C-O 120.684 0.278 . . . . 0.0 110.847 -179.972 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -66.43 146.88 81.64 Favored 'Trans proline' 0 C--N 1.344 0.317 0 C-N-CA 122.557 2.171 . . . . 0.0 112.253 179.89 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 7.8 t60 -98.68 -31.01 12.14 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.917 179.902 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -128.38 -42.18 0.26 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.435 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -172.76 94.15 0.1 OUTLIER Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.556 -179.967 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 62.01 -170.29 11.48 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.545 -179.926 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 81' ' ' TRP . . . . . 0.491 ' CD1' ' N ' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -147.16 -78.65 0.16 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.93 0.395 . . . . 0.0 110.713 -179.552 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -117.85 14.03 12.85 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.86 -0.686 . . . . 0.0 112.505 179.857 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 21.5 pt20 -81.34 154.62 71.86 Favored Pre-proline 0 C--N 1.331 -0.214 0 CA-C-O 120.736 0.303 . . . . 0.0 110.857 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 40.3 Cg_endo -67.12 143.39 65.03 Favored 'Trans proline' 0 C--N 1.344 0.322 0 C-N-CA 122.541 2.161 . . . . 0.0 112.265 179.967 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 45.2 m-70 -97.43 -30.84 12.68 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.882 179.983 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -126.31 -41.49 0.32 Allowed Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.457 -179.947 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -175.23 96.18 0.1 Allowed Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.672 -0.775 . . . . 0.0 112.471 179.986 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 59.64 -169.51 6.82 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.557 -179.982 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 89' ' ' TRP . . . . . 0.481 ' N ' ' CD1' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -148.26 -76.62 0.17 Allowed 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.961 0.41 . . . . 0.0 110.763 -179.632 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -112.88 -22.12 5.78 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.92 -0.657 . . . . 0.0 112.537 179.88 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 1.1 pt20 . . . . . 0 C--O 1.248 1.008 0 CA-C-O 118.27 -0.871 . . . . 0.0 110.9 179.991 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' TRP . . . . . 0.409 ' CH2' ' HB3' ' A' ' 59' ' ' GLN . 0.0 OUTLIER . . . . . 0 N--CA 1.486 1.354 0 CA-C-O 120.864 0.364 . . . . 0.0 111.134 . . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . 0.465 ' O ' ' CG ' ' A' ' 59' ' ' GLN . . . 167.22 -31.62 0.19 Allowed Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.496 179.974 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.465 ' CG ' ' O ' ' A' ' 58' ' ' GLY . 7.1 pt20 54.74 154.83 0.05 OUTLIER Pre-proline 0 CA--C 1.53 0.208 0 CA-C-O 120.94 0.4 . . . . 0.0 111.586 -179.994 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -70.98 148.84 58.06 Favored 'Trans proline' 0 C--N 1.345 0.348 0 C-N-CA 122.459 2.106 . . . . 0.0 112.307 -179.835 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' HIS . . . . . . . . . . . . . 23.7 t-160 -92.11 -30.79 15.79 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.803 179.915 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -113.26 -28.04 3.45 Favored Glycine 0 N--CA 1.45 -0.39 0 C-N-CA 120.806 -0.711 . . . . 0.0 112.453 179.961 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 175.3 -47.62 0.13 Allowed Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.529 179.987 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -148.14 -161.53 9.61 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.502 -179.896 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' TRP . . . . . 0.491 ' N ' ' CD1' ' A' ' 65' ' ' TRP . 0.0 OUTLIER -145.97 -79.33 0.17 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.93 0.395 . . . . 0.0 110.755 -179.614 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -111.77 12.3 27.44 Favored Glycine 0 N--CA 1.45 -0.417 0 C-N-CA 120.887 -0.673 . . . . 0.0 112.585 179.785 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 14.9 pt20 -101.39 154.19 37.38 Favored Pre-proline 0 C--N 1.332 -0.19 0 CA-C-O 120.657 0.265 . . . . 0.0 110.836 -179.932 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 39.6 Cg_endo -67.45 152.33 78.84 Favored 'Trans proline' 0 C--N 1.343 0.275 0 C-N-CA 122.531 2.154 . . . . 0.0 112.289 179.934 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 15.8 p80 -97.28 -30.08 13.18 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.776 179.881 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . -152.67 26.69 0.84 Allowed Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.81 -0.709 . . . . 0.0 112.485 179.948 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 166.09 -92.87 0.11 Allowed Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.459 179.965 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -133.98 -158.82 8.71 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.533 -179.897 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 73' ' ' TRP . . . . . 0.483 ' N ' ' CD1' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -146.46 -78.96 0.17 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.92 0.39 . . . . 0.0 110.705 -179.628 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -113.96 10.61 22.9 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.845 -0.693 . . . . 0.0 112.662 179.845 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 13.6 pt20 -93.16 153.35 41.68 Favored Pre-proline 0 C--N 1.331 -0.216 0 CA-C-O 120.704 0.288 . . . . 0.0 110.889 179.973 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 28.8 Cg_endo -64.08 151.96 83.06 Favored 'Trans proline' 0 C--N 1.344 0.322 0 C-N-CA 122.529 2.153 . . . . 0.0 112.31 -179.989 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 15.7 t-160 -107.68 -28.62 9.61 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.821 179.902 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -157.02 25.6 0.49 Allowed Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.552 -179.998 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 134.86 89.32 0.31 Allowed Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.664 -0.779 . . . . 0.0 112.595 179.867 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 56.92 -176.34 1.17 Allowed Glycine 0 N--CA 1.452 -0.237 0 C-N-CA 120.807 -0.711 . . . . 0.0 112.645 179.888 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 81' ' ' TRP . . . . . 0.527 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -142.14 -79.22 0.24 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.908 0.385 . . . . 0.0 110.819 -179.48 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -118.45 19.28 10.72 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.834 -0.698 . . . . 0.0 112.551 179.797 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 24.4 pt20 -85.08 154.38 60.47 Favored Pre-proline 0 C--N 1.331 -0.228 0 CA-C-O 120.702 0.287 . . . . 0.0 110.827 179.977 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -66.54 158.55 55.07 Favored 'Trans proline' 0 C--N 1.344 0.31 0 C-N-CA 122.56 2.174 . . . . 0.0 112.329 179.903 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 29.1 m80 -107.99 -30.79 8.26 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.916 179.968 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -133.72 27.7 3.32 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.72 -0.753 . . . . 0.0 112.503 -179.999 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 104.5 93.56 2.3 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.523 179.921 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 59.36 -169.86 6.16 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.547 179.938 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 89' ' ' TRP . . . . . 0.484 ' N ' ' CD1' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -147.5 -77.79 0.17 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.942 0.401 . . . . 0.0 110.751 -179.626 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -134.8 17.99 4.11 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.918 -0.658 . . . . 0.0 112.574 179.871 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 2.0 pt20 . . . . . 0 C--O 1.248 1.017 0 CA-C-O 118.233 -0.889 . . . . 0.0 110.868 -179.97 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' TRP . . . . . 0.425 ' CZ2' ' HB3' ' A' ' 59' ' ' GLN . 30.4 t-105 . . . . . 0 N--CA 1.487 1.383 0 CA-C-O 120.828 0.346 . . . . 0.0 111.209 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -158.07 61.1 0.32 Allowed Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.45 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.425 ' HB3' ' CZ2' ' A' ' 57' ' ' TRP . 6.6 pm0 -58.66 154.38 35.85 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 120.729 0.3 . . . . 0.0 111.011 179.897 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 38.5 Cg_endo -66.67 128.06 18.31 Favored 'Trans proline' 0 C--N 1.345 0.351 0 C-N-CA 122.527 2.151 . . . . 0.0 112.264 179.938 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' HIS . . . . . . . . . . . . . 3.8 t-160 -94.93 6.51 48.84 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.323 179.878 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -154.83 -43.81 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.448 179.956 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -150.06 -70.28 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.57 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -147.16 -157.53 7.43 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.544 -179.961 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' TRP . . . . . 0.493 ' N ' ' CD1' ' A' ' 65' ' ' TRP . 0.0 OUTLIER -147.05 -78.68 0.16 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.872 0.367 . . . . 0.0 110.714 -179.588 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -115.18 10.9 20.09 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.894 -0.67 . . . . 0.0 112.586 179.821 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 21.2 pt20 -82.03 157.01 69.29 Favored Pre-proline 0 C--N 1.332 -0.175 0 CA-C-O 120.636 0.255 . . . . 0.0 110.899 179.994 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . 0.465 ' HB3' ' HA2' ' A' ' 72' ' ' GLY . 73.2 Cg_endo -77.76 147.79 24.92 Favored 'Trans proline' 0 C--N 1.343 0.288 0 C-N-CA 122.45 2.1 . . . . 0.0 112.313 179.954 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 16.6 p-80 -114.02 108.39 16.95 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.0 -179.964 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 57.73 28.93 60.8 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.8 -0.714 . . . . 0.0 112.614 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 161.14 -109.63 0.4 Allowed Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.523 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . 0.465 ' HA2' ' HB3' ' A' ' 68' ' ' PRO . . . -151.68 -178.8 26.79 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.68 -0.772 . . . . 0.0 112.507 -179.854 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 73' ' ' TRP . . . . . 0.6 ' N ' ' CD1' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -123.06 -78.42 0.6 Allowed 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.896 0.379 . . . . 0.0 110.709 -179.639 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -109.86 -19.15 8.35 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.947 -0.644 . . . . 0.0 112.457 179.799 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 13.8 pt20 -59.34 153.87 45.83 Favored Pre-proline 0 C--N 1.33 -0.249 0 CA-C-O 120.722 0.296 . . . . 0.0 110.894 -179.99 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 30.6 Cg_endo -64.07 153.55 75.49 Favored 'Trans proline' 0 C--N 1.344 0.334 0 C-N-CA 122.568 2.179 . . . . 0.0 112.321 179.956 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 13.2 p80 -107.25 -30.66 8.6 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.817 179.931 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -108.09 -62.83 0.56 Allowed Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.51 179.949 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -164.41 29.26 0.22 Allowed Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.564 -179.981 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 136.16 -164.52 25.04 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.575 179.984 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 81' ' ' TRP . . . . . 0.497 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -146.1 -78.69 0.17 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.941 0.401 . . . . 0.0 110.788 -179.621 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -116.74 13.89 14.78 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.851 -0.69 . . . . 0.0 112.573 179.807 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 18.8 pt20 -86.21 154.31 57.26 Favored Pre-proline 0 C--N 1.331 -0.204 0 CA-C-O 120.688 0.28 . . . . 0.0 110.879 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 38.9 Cg_endo -66.89 153.4 78.04 Favored 'Trans proline' 0 C--N 1.344 0.301 0 C-N-CA 122.565 2.177 . . . . 0.0 112.277 -179.995 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 3.5 t-80 -107.76 -31.1 8.19 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.9 179.928 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -129.61 27.91 4.08 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.51 179.949 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 101.33 96.02 2.25 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.55 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 59.51 -169.45 6.64 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.548 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 89' ' ' TRP . . . . . 0.47 ' N ' ' CD1' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -147.38 -77.61 0.17 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.938 0.399 . . . . 0.0 110.82 -179.612 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -134.69 18.19 4.11 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.907 -0.663 . . . . 0.0 112.556 179.872 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 2.9 pt20 . . . . . 0 C--O 1.249 1.065 0 CA-C-O 118.282 -0.866 . . . . 0.0 110.92 179.995 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' TRP . . . . . . . . . . . . . 1.2 t90 . . . . . 0 N--CA 1.485 1.319 0 CA-C-O 120.788 0.328 . . . . 0.0 111.244 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -177.62 48.55 0.1 OUTLIER Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.718 -0.754 . . . . 0.0 112.507 -179.987 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 3.2 pt20 -171.96 154.33 3.45 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 120.68 0.276 . . . . 0.0 110.883 -179.956 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo -68.88 149.86 72.84 Favored 'Trans proline' 0 C--N 1.344 0.299 0 C-N-CA 122.528 2.152 . . . . 0.0 112.284 179.892 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' HIS . . . . . . . . . . . . . 23.8 t-160 -95.51 -30.5 13.81 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.871 -179.988 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -170.83 36.29 0.17 Allowed Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.503 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -178.67 -81.24 0.06 OUTLIER Glycine 0 N--CA 1.452 -0.247 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.58 -179.998 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -170.4 -158.76 14.84 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.536 -180.0 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' TRP . . . . . 0.494 ' N ' ' CD1' ' A' ' 65' ' ' TRP . 0.0 OUTLIER -146.45 -78.41 0.17 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.921 0.391 . . . . 0.0 110.745 -179.655 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -118.25 13.11 12.5 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.88 -0.676 . . . . 0.0 112.554 179.797 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -78.85 154.59 78.07 Favored Pre-proline 0 C--N 1.332 -0.193 0 CA-C-O 120.709 0.29 . . . . 0.0 110.878 -179.98 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -66.43 149.15 84.77 Favored 'Trans proline' 0 C--N 1.344 0.316 0 C-N-CA 122.493 2.129 . . . . 0.0 112.255 179.94 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 12.6 t-160 -98.33 6.16 47.59 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.335 179.956 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 172.38 39.61 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.626 -0.797 . . . . 0.0 112.491 179.945 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 148.12 -97.79 0.18 Allowed Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.67 -0.776 . . . . 0.0 112.501 179.958 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -139.2 -157.18 7.22 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.472 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 73' ' ' TRP . . . . . 0.487 ' N ' ' CD1' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -147.71 -77.95 0.16 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.993 0.425 . . . . 0.0 110.708 -179.583 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -105.53 -20.48 9.51 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.912 -0.661 . . . . 0.0 112.347 179.861 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 13.5 pt20 -65.47 154.43 87.97 Favored Pre-proline 0 C--N 1.33 -0.241 0 CA-C-O 120.652 0.263 . . . . 0.0 110.898 -179.954 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 40.1 Cg_endo -67.14 154.8 73.22 Favored 'Trans proline' 0 C--N 1.343 0.257 0 C-N-CA 122.536 2.157 . . . . 0.0 112.256 179.937 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 5.3 p-80 -100.55 -31.67 11.15 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.912 179.99 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -125.24 -47.36 0.22 Allowed Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.457 179.985 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -171.82 87.38 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.459 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 72.67 -169.54 52.12 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.546 179.987 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 81' ' ' TRP . . . . . 0.482 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -148.12 -76.14 0.17 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.921 0.391 . . . . 0.0 110.785 -179.649 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -107.05 -21.73 7.94 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.935 -0.65 . . . . 0.0 112.455 179.833 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 15.6 pt20 -60.1 154.4 50.99 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 120.677 0.275 . . . . 0.0 110.865 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 44.5 Cg_endo -68.34 141.13 50.58 Favored 'Trans proline' 0 C--N 1.344 0.331 0 C-N-CA 122.539 2.159 . . . . 0.0 112.248 179.958 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 13.7 m-70 -95.17 -31.14 13.67 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.934 179.966 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -125.2 -40.99 0.38 Allowed Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.821 -0.704 . . . . 0.0 112.437 -179.959 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -176.92 96.55 0.1 Allowed Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.509 -179.946 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 59.64 -170.36 6.3 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.55 -179.986 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 89' ' ' TRP . . . . . 0.483 ' N ' ' CD1' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -147.58 -77.82 0.16 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.901 0.381 . . . . 0.0 110.831 -179.664 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -133.66 18.55 4.32 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.853 -0.689 . . . . 0.0 112.514 179.776 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 6.5 pt20 . . . . . 0 C--O 1.249 1.052 0 CA-C-O 118.179 -0.915 . . . . 0.0 110.949 -179.998 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' TRP . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.485 1.312 0 CA-C-O 120.782 0.325 . . . . 0.0 111.245 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -172.71 45.39 0.17 Allowed Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.501 -179.956 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 12.2 pt20 -160.72 154.4 18.83 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-O 120.716 0.293 . . . . 0.0 110.91 -179.971 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_endo -69.56 150.5 69.52 Favored 'Trans proline' 0 C--N 1.344 0.329 0 C-N-CA 122.529 2.153 . . . . 0.0 112.243 179.934 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' HIS . . . . . . . . . . . . . 14.2 p80 -94.17 -30.97 14.34 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.865 179.963 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -169.27 33.84 0.18 Allowed Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.808 -0.711 . . . . 0.0 112.542 179.943 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -177.01 -84.0 0.06 OUTLIER Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.496 -179.978 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -166.2 -158.71 11.22 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.53 -179.879 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 65' ' ' TRP . . . . . 0.488 ' N ' ' CD1' ' A' ' 65' ' ' TRP . 0.0 OUTLIER -146.72 -78.95 0.16 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.853 0.359 . . . . 0.0 110.75 -179.629 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -117.53 13.19 13.54 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.877 -0.678 . . . . 0.0 112.482 179.765 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 3.9 pt20 -79.69 154.49 75.98 Favored Pre-proline 0 C--N 1.331 -0.226 0 CA-C-O 120.711 0.291 . . . . 0.0 110.872 -179.968 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_endo -68.48 150.86 75.8 Favored 'Trans proline' 0 C--N 1.344 0.31 0 C-N-CA 122.552 2.168 . . . . 0.0 112.228 179.852 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 23.8 t-160 -95.96 -30.18 13.75 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.927 179.884 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . -170.27 37.8 0.19 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.499 -179.963 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 178.36 -82.11 0.06 OUTLIER Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.505 179.984 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -168.74 -157.65 11.74 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.5 -179.927 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 73' ' ' TRP . . . . . 0.486 ' N ' ' CD1' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -147.38 -77.66 0.17 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.931 0.396 . . . . 0.0 110.715 -179.563 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -107.89 -20.15 8.62 Favored Glycine 0 N--CA 1.45 -0.413 0 C-N-CA 120.901 -0.666 . . . . 0.0 112.463 179.856 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 11.6 pt20 -59.62 154.32 46.2 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-O 120.701 0.286 . . . . 0.0 110.904 -179.988 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 40.9 Cg_endo -67.33 152.76 78.67 Favored 'Trans proline' 0 C--N 1.345 0.356 0 C-N-CA 122.564 2.176 . . . . 0.0 112.26 179.941 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 6.0 t-160 -105.72 -31.24 8.97 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.875 179.967 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -128.57 29.36 4.04 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.453 -179.996 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 97.48 94.71 1.92 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.467 179.959 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 61.64 -170.07 10.66 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.505 179.966 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 81' ' ' TRP . . . . . 0.488 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -147.02 -78.29 0.17 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.901 0.381 . . . . 0.0 110.736 -179.558 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -115.17 12.97 19.38 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.907 -0.663 . . . . 0.0 112.618 179.748 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 13.1 pt20 -93.43 154.17 41.33 Favored Pre-proline 0 C--N 1.332 -0.186 0 CA-C-O 120.649 0.262 . . . . 0.0 110.889 179.973 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -65.93 148.89 86.5 Favored 'Trans proline' 0 C--N 1.343 0.268 0 C-N-CA 122.629 2.22 . . . . 0.0 112.274 179.944 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 7.7 m170 -100.33 -30.57 11.79 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.776 179.877 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -110.63 -27.93 4.18 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.489 179.935 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 173.91 -43.28 0.15 Allowed Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.641 179.997 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -154.39 -160.12 9.64 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.61 179.985 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 89' ' ' TRP . . . . . 0.488 ' N ' ' CD1' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -146.89 -78.84 0.16 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.879 0.371 . . . . 0.0 110.644 -179.541 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -138.48 22.04 3.05 Favored Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.946 -0.645 . . . . 0.0 112.211 179.764 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 6.0 mt-30 . . . . . 0 C--O 1.25 1.118 0 CA-C-O 118.209 -0.9 . . . . 0.0 110.929 -179.875 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 57' ' ' TRP . . . . . . . . . . . . . 1.8 t-105 . . . . . 0 N--CA 1.486 1.351 0 CA-C-O 120.764 0.316 . . . . 0.0 111.199 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -119.04 -35.62 0.94 Allowed Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.522 -179.956 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 22.7 pt20 -145.9 154.23 50.92 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 120.691 0.281 . . . . 0.0 110.874 -179.909 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_endo -67.56 152.7 78.0 Favored 'Trans proline' 0 C--N 1.344 0.322 0 C-N-CA 122.501 2.134 . . . . 0.0 112.276 179.907 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 61' ' ' HIS . . . . . . . . . . . . . 13.8 p80 -98.06 -30.74 12.51 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.837 -179.982 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -174.08 34.72 0.11 Allowed Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.508 -179.98 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -173.84 -74.52 0.05 OUTLIER Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.697 -0.764 . . . . 0.0 112.555 -179.949 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -179.23 -159.18 22.91 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.515 -179.948 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 65' ' ' TRP . . . . . 0.487 ' CD1' ' N ' ' A' ' 65' ' ' TRP . 0.0 OUTLIER -146.56 -77.81 0.18 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.905 0.383 . . . . 0.0 110.748 -179.68 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -103.85 -21.22 9.81 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.853 -0.689 . . . . 0.0 112.459 179.794 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 13.0 pt20 -64.81 154.28 86.04 Favored Pre-proline 0 C--N 1.331 -0.219 0 CA-C-O 120.727 0.298 . . . . 0.0 110.865 -179.934 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -69.1 136.88 35.95 Favored 'Trans proline' 0 C--N 1.345 0.349 0 C-N-CA 122.603 2.202 . . . . 0.0 112.309 179.992 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 14.6 p80 -92.73 -30.17 15.67 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.766 179.839 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . -123.02 -38.6 0.56 Allowed Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.849 -0.691 . . . . 0.0 112.515 179.974 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -147.17 -85.96 0.06 OUTLIER Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.633 -0.794 . . . . 0.0 112.541 179.987 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -130.68 -155.68 8.34 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.6 -179.887 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 73' ' ' TRP . . . . . 0.493 ' CD1' ' N ' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -147.4 -77.49 0.17 Allowed 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.903 0.382 . . . . 0.0 110.696 -179.53 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -101.84 -19.67 14.73 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.964 -0.636 . . . . 0.0 112.522 179.851 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 4.7 pt20 -59.03 153.97 41.91 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 120.734 0.302 . . . . 0.0 110.891 179.983 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -66.64 154.06 75.77 Favored 'Trans proline' 0 C--N 1.345 0.369 0 C-N-CA 122.524 2.149 . . . . 0.0 112.329 179.992 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 19.8 p-80 -109.51 -30.31 8.0 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.867 -179.933 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -132.13 27.07 3.67 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.545 -179.982 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 104.5 96.45 2.42 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.668 -0.777 . . . . 0.0 112.563 179.925 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 58.84 -170.85 4.9 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.824 -0.703 . . . . 0.0 112.615 179.968 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 81' ' ' TRP . . . . . 0.49 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -147.03 -77.02 0.18 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.884 0.373 . . . . 0.0 110.71 -179.563 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -104.18 -20.86 9.94 Favored Glycine 0 N--CA 1.452 -0.248 0 C-N-CA 120.861 -0.685 . . . . 0.0 112.548 179.86 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 8.3 pt20 -58.84 153.84 40.74 Favored Pre-proline 0 C--N 1.331 -0.221 0 CA-C-O 120.686 0.279 . . . . 0.0 110.917 179.997 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . 0.413 ' HB3' ' CA ' ' A' ' 88' ' ' GLY . 18.9 Cg_endo -59.77 160.75 20.26 Favored 'Trans proline' 0 C--N 1.343 0.283 0 C-N-CA 122.584 2.189 . . . . 0.0 112.352 -179.979 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 7.8 p-80 -113.15 -30.87 6.82 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.822 179.873 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -116.8 20.81 11.64 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.648 179.93 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 102.56 9.72 40.17 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.939 179.847 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . 0.413 ' CA ' ' HB3' ' A' ' 84' ' ' PRO . . . 161.67 -170.75 37.47 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.633 -0.794 . . . . 0.0 112.635 -179.987 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 89' ' ' TRP . . . . . 0.522 ' N ' ' CD1' ' A' ' 89' ' ' TRP . 0.1 OUTLIER -150.78 -60.05 0.18 Allowed 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 121.278 0.561 . . . . 0.0 110.559 -179.256 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -153.18 -44.86 0.02 OUTLIER Glycine 0 N--CA 1.45 -0.433 0 CA-C-N 115.264 -0.88 . . . . 0.0 111.499 179.636 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 4.6 mt-30 . . . . . 0 C--O 1.248 1.004 0 CA-C-O 118.22 -0.895 . . . . 0.0 111.363 179.326 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 57' ' ' TRP . . . . . . . . . . . . . 10.2 t-105 . . . . . 0 N--CA 1.486 1.371 0 CA-C-O 120.826 0.346 . . . . 0.0 111.186 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -104.41 -44.92 1.51 Allowed Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.545 -179.981 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 19.5 pt20 -169.67 154.32 5.39 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 120.75 0.309 . . . . 0.0 110.906 -179.99 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -67.8 154.87 71.96 Favored 'Trans proline' 0 C--N 1.344 0.311 0 C-N-CA 122.57 2.18 . . . . 0.0 112.263 179.971 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 61' ' ' HIS . . . . . . . . . . . . . 23.8 t-160 -103.5 -31.32 10.02 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.903 179.99 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -123.89 -43.29 0.34 Allowed Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.426 179.974 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -177.32 94.98 0.1 OUTLIER Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.514 179.993 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 62.3 -170.2 12.54 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.452 179.926 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 65' ' ' TRP . . . . . 0.481 ' N ' ' CD1' ' A' ' 65' ' ' TRP . 0.0 OUTLIER -148.32 -76.1 0.17 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.955 0.407 . . . . 0.0 110.753 -179.542 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -107.15 -21.7 7.92 Favored Glycine 0 N--CA 1.45 -0.414 0 C-N-CA 120.89 -0.672 . . . . 0.0 112.473 179.904 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 18.0 pt20 -60.05 154.19 51.55 Favored Pre-proline 0 C--N 1.33 -0.253 0 CA-C-O 120.726 0.298 . . . . 0.0 110.9 179.984 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 42.2 Cg_endo -68.0 151.76 77.4 Favored 'Trans proline' 0 C--N 1.343 0.282 0 C-N-CA 122.571 2.18 . . . . 0.0 112.257 179.968 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 3.9 p-80 -96.65 -30.85 13.02 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.835 179.894 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . -153.46 27.6 0.77 Allowed Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.491 179.968 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 168.94 -102.11 0.18 Allowed Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.524 179.985 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -131.7 -158.94 9.26 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.539 -179.996 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 73' ' ' TRP . . . . . 0.485 ' N ' ' CD1' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -147.16 -77.04 0.18 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.956 0.408 . . . . 0.0 110.785 -179.555 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -106.76 -21.26 8.32 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.805 -0.712 . . . . 0.0 112.5 179.867 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 3.0 pt20 -59.94 153.84 52.38 Favored Pre-proline 0 C--N 1.331 -0.223 0 CA-C-O 120.663 0.268 . . . . 0.0 110.915 179.947 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_endo -66.06 153.93 76.11 Favored 'Trans proline' 0 C--N 1.344 0.321 0 C-N-CA 122.481 2.121 . . . . 0.0 112.389 179.938 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 23.3 t-160 -109.7 -29.76 8.19 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.811 179.956 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -134.39 26.7 3.33 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.549 179.952 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 106.88 97.63 2.52 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.53 179.888 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 58.45 -172.7 3.59 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.58 179.909 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 81' ' ' TRP . . . . . 0.486 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -146.21 -77.84 0.18 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.96 0.41 . . . . 0.0 110.845 -179.603 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -106.46 -20.81 8.76 Favored Glycine 0 N--CA 1.45 -0.419 0 C-N-CA 120.848 -0.692 . . . . 0.0 112.553 179.895 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 12.5 pt20 -58.89 153.68 42.17 Favored Pre-proline 0 C--N 1.33 -0.254 0 CA-C-O 120.694 0.283 . . . . 0.0 110.933 179.966 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . 0.416 ' HB2' ' N ' ' A' ' 88' ' ' GLY . 30.3 Cg_endo -64.37 159.99 41.29 Favored 'Trans proline' 0 C--N 1.344 0.326 0 C-N-CA 122.522 2.148 . . . . 0.0 112.321 -179.977 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 4.1 m-70 -117.72 106.34 12.95 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.092 -0.503 . . . . 0.0 110.645 179.665 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 94.93 -26.85 16.7 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.444 -179.797 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 150.01 92.8 0.1 Allowed Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.549 -179.966 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . 0.416 ' N ' ' HB2' ' A' ' 84' ' ' PRO . . . 58.46 -157.5 19.53 Favored Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.593 179.988 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 89' ' ' TRP . . . . . 0.509 ' N ' ' CD1' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -142.02 -78.46 0.25 Allowed 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.981 0.42 . . . . 0.0 110.701 -179.636 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -134.68 17.29 4.21 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.908 -0.663 . . . . 0.0 112.507 179.816 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 6.0 pt20 . . . . . 0 C--O 1.249 1.072 0 CA-C-O 118.228 -0.891 . . . . 0.0 110.943 179.963 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 57' ' ' TRP . . . . . . . . . . . . . 21.3 t-105 . . . . . 0 N--CA 1.485 1.299 0 CA-C-O 120.766 0.317 . . . . 0.0 111.223 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . 0.47 ' O ' ' CG ' ' A' ' 59' ' ' GLN . . . -67.33 -30.78 75.74 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.532 179.986 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.47 ' CG ' ' O ' ' A' ' 58' ' ' GLY . 3.2 pt20 54.76 154.92 0.05 OUTLIER Pre-proline 0 N--CA 1.463 0.205 0 CA-C-O 120.951 0.405 . . . . 0.0 111.515 -179.954 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 60' ' ' PRO . . . . . 0.408 ' HB3' ' CA ' ' A' ' 64' ' ' GLY . 56.2 Cg_endo -70.97 142.36 42.42 Favored 'Trans proline' 0 C--N 1.345 0.379 0 C-N-CA 122.513 2.142 . . . . 0.0 112.288 -179.869 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 61' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -100.15 -28.89 12.79 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.933 179.921 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -128.98 27.55 4.28 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.688 -0.768 . . . . 0.0 112.472 -179.995 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 99.42 97.0 2.12 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.55 -179.996 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . 0.408 ' CA ' ' HB3' ' A' ' 60' ' ' PRO . . . 57.86 -170.88 3.81 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.812 -0.708 . . . . 0.0 112.554 179.96 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 65' ' ' TRP . . . . . 0.491 ' N ' ' CD1' ' A' ' 65' ' ' TRP . 0.0 OUTLIER -146.51 -78.96 0.17 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.905 0.383 . . . . 0.0 110.791 -179.628 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -113.19 12.49 24.07 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.883 -0.675 . . . . 0.0 112.559 179.757 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 21.7 pt20 -98.63 153.94 37.71 Favored Pre-proline 0 C--N 1.331 -0.214 0 CA-C-O 120.777 0.322 . . . . 0.0 110.888 179.955 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_endo -65.58 155.13 70.6 Favored 'Trans proline' 0 C--N 1.344 0.337 0 C-N-CA 122.523 2.149 . . . . 0.0 112.272 179.95 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 3.5 t-80 -109.59 -30.68 7.8 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.862 179.899 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . -134.44 26.55 3.34 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.557 -179.996 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 107.37 98.24 2.55 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.55 179.924 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 58.75 -173.76 3.38 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.82 -0.705 . . . . 0.0 112.571 179.961 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 73' ' ' TRP . . . . . 0.489 ' N ' ' CD1' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -145.62 -78.83 0.18 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.872 0.368 . . . . 0.0 110.804 -179.606 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -105.93 -20.93 8.91 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.868 -0.682 . . . . 0.0 112.446 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 16.7 pt20 -59.81 154.16 49.2 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 120.742 0.306 . . . . 0.0 110.891 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . 0.404 ' HB3' ' CA ' ' A' ' 80' ' ' GLY . 50.0 Cg_endo -69.31 139.75 42.59 Favored 'Trans proline' 0 C--N 1.344 0.326 0 C-N-CA 122.548 2.165 . . . . 0.0 112.333 179.965 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 19.9 t-160 -93.73 -31.22 14.51 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.86 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -125.89 -40.82 0.36 Allowed Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.801 -0.714 . . . . 0.0 112.485 -180.0 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -176.48 97.16 0.11 Allowed Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.567 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . 0.404 ' CA ' ' HB3' ' A' ' 76' ' ' PRO . . . 59.91 -171.82 5.78 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.563 179.971 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 81' ' ' TRP . . . . . 0.474 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -147.09 -77.34 0.17 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.902 0.382 . . . . 0.0 110.757 -179.66 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -106.6 -21.63 8.18 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.919 -0.658 . . . . 0.0 112.493 179.934 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 20.7 pt20 -59.96 154.03 51.52 Favored Pre-proline 0 C--N 1.33 -0.24 0 CA-C-O 120.702 0.287 . . . . 0.0 110.902 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . 0.404 ' HB3' ' CA ' ' A' ' 88' ' ' GLY . 39.0 Cg_endo -67.13 158.1 58.52 Favored 'Trans proline' 0 C--N 1.344 0.335 0 C-N-CA 122.567 2.178 . . . . 0.0 112.296 179.955 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 8.8 m170 -97.67 -30.94 12.54 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.774 179.986 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -113.75 -29.09 2.97 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.506 179.97 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 172.38 -33.6 0.13 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.524 179.991 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . 0.404 ' CA ' ' HB3' ' A' ' 84' ' ' PRO . . . -157.85 -161.2 10.74 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.68 -0.771 . . . . 0.0 112.558 -179.968 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 89' ' ' TRP . . . . . 0.489 ' N ' ' CD1' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -147.17 -77.98 0.17 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.969 0.414 . . . . 0.0 110.756 -179.636 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -133.79 17.87 4.36 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.909 -0.662 . . . . 0.0 112.484 179.816 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 13.8 pt20 . . . . . 0 C--O 1.25 1.095 0 CA-C-O 118.164 -0.922 . . . . 0.0 110.896 179.982 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 57' ' ' TRP . . . . . 0.446 ' CD1' ' HG2' ' A' ' 59' ' ' GLN . 26.3 t-105 . . . . . 0 N--CA 1.487 1.381 0 CA-C-O 120.753 0.311 . . . . 0.0 111.191 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -56.49 -27.14 53.54 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.629 -179.998 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.446 ' HG2' ' CD1' ' A' ' 57' ' ' TRP . 9.6 pt20 -133.62 154.31 80.63 Favored Pre-proline 0 C--N 1.33 -0.251 0 CA-C-O 120.828 0.346 . . . . 0.0 110.838 179.971 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 60' ' ' PRO . . . . . 0.4 ' HB3' ' CA ' ' A' ' 64' ' ' GLY . 39.0 Cg_endo -67.15 149.47 81.96 Favored 'Trans proline' 0 C--N 1.346 0.417 0 C-N-CA 122.519 2.146 . . . . 0.0 112.302 -179.997 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 61' ' ' HIS . . . . . . . . . . . . . 7.9 t60 -97.85 -30.67 12.63 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.806 179.941 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -113.46 -28.07 3.39 Favored Glycine 0 N--CA 1.45 -0.398 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.495 179.988 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 178.85 -52.24 0.09 OUTLIER Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.585 179.952 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . 0.4 ' CA ' ' HB3' ' A' ' 60' ' ' PRO . . . -147.53 -158.84 8.07 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.563 -179.957 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 65' ' ' TRP . . . . . 0.481 ' N ' ' CD1' ' A' ' 65' ' ' TRP . 0.0 OUTLIER -147.37 -78.03 0.17 Allowed 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.903 0.382 . . . . 0.0 110.712 -179.604 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -110.39 -21.15 7.04 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.908 -0.663 . . . . 0.0 112.446 179.832 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 9.4 pt20 -61.02 153.79 64.21 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 120.782 0.325 . . . . 0.0 110.9 179.976 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 12.8 Cg_endo -57.06 150.73 54.61 Favored 'Trans proline' 0 C--N 1.344 0.334 0 C-N-CA 122.727 2.285 . . . . 0.0 112.219 179.97 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 19.5 t-160 -128.75 6.0 5.55 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.351 179.942 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . -147.88 25.48 1.46 Allowed Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.64 -0.791 . . . . 0.0 112.6 179.933 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 96.77 24.53 13.22 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.636 179.95 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 127.35 -161.98 21.41 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.469 179.889 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 73' ' ' TRP . . . . . 0.509 ' N ' ' CD1' ' A' ' 73' ' ' TRP . 0.0 OUTLIER -144.61 -79.79 0.18 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.944 0.402 . . . . 0.0 110.72 -179.546 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -112.27 15.16 25.4 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.81 -0.71 . . . . 0.0 112.436 179.706 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 3.5 pt20 -107.39 154.07 40.86 Favored Pre-proline 0 C--N 1.33 -0.252 0 CA-C-O 120.713 0.292 . . . . 0.0 110.901 179.989 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_endo -66.0 146.73 83.26 Favored 'Trans proline' 0 C--N 1.344 0.299 0 C-N-CA 122.481 2.121 . . . . 0.0 112.305 179.988 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 6.3 t-160 -100.03 -31.16 11.58 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.794 179.813 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -118.83 -34.59 1.04 Allowed Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.812 -0.709 . . . . 0.0 112.436 179.907 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -161.53 -64.96 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.558 -179.996 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -138.57 -158.95 7.9 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.599 -179.957 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 81' ' ' TRP . . . . . 0.501 ' N ' ' CD1' ' A' ' 81' ' ' TRP . 0.0 OUTLIER -145.94 -77.99 0.18 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.9 0.381 . . . . 0.0 110.778 -179.594 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -104.18 -21.88 9.14 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.903 -0.665 . . . . 0.0 112.54 179.896 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 83' ' ' GLN . . . . . . . . . . . . . 16.9 pt20 -61.13 151.7 74.48 Favored Pre-proline 0 C--N 1.331 -0.224 0 CA-C-O 120.719 0.295 . . . . 0.0 110.93 -179.98 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . 0.41 ' HB2' ' N ' ' A' ' 88' ' ' GLY . 30.7 Cg_endo -64.63 160.82 38.23 Favored 'Trans proline' 0 C--N 1.344 0.328 0 C-N-CA 122.511 2.141 . . . . 0.0 112.358 179.968 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 16.6 p-80 -118.47 106.57 12.82 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.599 179.644 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 94.42 -26.08 19.52 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.513 -179.797 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 149.29 92.53 0.1 Allowed Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.498 179.937 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . 0.41 ' N ' ' HB2' ' A' ' 84' ' ' PRO . . . 58.93 -157.37 22.33 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.548 179.985 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 89' ' ' TRP . . . . . 0.511 ' N ' ' CD1' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -142.55 -78.7 0.24 Allowed 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 121.002 0.429 . . . . 0.0 110.829 -179.676 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -113.15 -20.71 6.2 Favored Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 120.904 -0.665 . . . . 0.0 112.473 179.888 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 91' ' ' GLN . . . . . . . . . . . . . 2.0 pt20 . . . . . 0 C--O 1.248 1.024 0 CA-C-O 118.333 -0.841 . . . . 0.0 110.862 -179.982 . . . . . . . . 0 0 . 1 stop_ save_